<SEC-DOCUMENT>0001811884-20-000015.txt : 20201106
<SEC-HEADER>0001811884-20-000015.hdr.sgml : 20201106
<ACCEPTANCE-DATETIME>20201106154615
ACCESSION NUMBER:		0001811884-20-000015
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		53
CONFORMED PERIOD OF REPORT:	20200930
FILED AS OF DATE:		20201106
DATE AS OF CHANGE:		20201106

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			UTAH MEDICAL PRODUCTS INC
		CENTRAL INDEX KEY:			0000706698
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				870342734
		STATE OF INCORPORATION:			UT
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12575
		FILM NUMBER:		201294243

	BUSINESS ADDRESS:	
		STREET 1:		7043 S 300 WEST
		CITY:			MIDVALE
		STATE:			UT
		ZIP:			84047
		BUSINESS PHONE:		8015661200
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>utmd-20200930.htm
<DESCRIPTION>UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING
<TEXT>
<XBRL>
<?xml version='1.0' encoding='us-ascii' standalone='no'?>
<html xmlns='http://www.w3.org/1999/xhtml' xmlns:xbrli='http://www.xbrl.org/2003/instance' xmlns:us-gaap='http://fasb.org/us-gaap/2020-01-31' xmlns:nonnum='http://www.xbrl.org/dtr/type/non-numeric' xmlns:dei='http://xbrl.sec.gov/dei/2020-01-31' xmlns:srt='http://fasb.org/srt/2020-01-31' xmlns:fil='http://www.utahmed.com/20200930' xmlns:i='http://www.xbrl.org/2003/instance' xmlns:xbrldi='http://xbrl.org/2006/xbrldi' xmlns:iso4217='http://www.xbrl.org/2003/iso4217' xmlns:ix='http://www.xbrl.org/2013/inlineXBRL' xmlns:ixt='http://www.xbrl.org/inlineXBRL/transformation/2015-02-26' xmlns:ixt-sec='http://www.sec.gov/inlineXBRL/transformation/2015-08-31' xmlns:utr='http://www.xbrl.org/2009/utr' xmlns:link='http://www.xbrl.org/2003/linkbase' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance'>
<head>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2020 [PPXK9NDL3JZWVJK4T7A6]. www.edgarsuite.com -->
<title>UTAH MEDICAL PRODUCTS INC - Form 10-Q SEC filing</title>
<meta content='text/html; charset=UTF-8' http-equiv='Content-Type' />
</head>
<body>
<div style='display:none'>
<ix:header>
<ix:hidden>
<ix:nonNumeric name='dei:EntityCentralIndexKey' contextRef='D200101_200930' id='fact1'>0000706698</ix:nonNumeric>
<ix:nonNumeric name='dei:CurrentFiscalYearEndDate' contextRef='D200101_200930' id='fact2'>--12-31</ix:nonNumeric>
<ix:nonNumeric name='dei:EntityCurrentReportingStatus' contextRef='D200101_200930' id='fact3'>Yes</ix:nonNumeric>
<ix:nonNumeric name='dei:AmendmentFlag' contextRef='D200101_200930' id='fact4'>false</ix:nonNumeric>
<ix:nonNumeric name='dei:DocumentFiscalYearFocus' contextRef='D200101_200930' id='fact5'>2020</ix:nonNumeric>
<ix:nonNumeric name='dei:DocumentFiscalPeriodFocus' contextRef='D200101_200930' id='fact6'>Q3</ix:nonNumeric>
</ix:hidden>
<ix:references>
<link:schemaRef xlink:arcrole='http://www.xbrl.org/2003/linkbase' xlink:href='utmd-20200930.xsd' xlink:type='simple'/>
</ix:references>
<ix:resources>
<i:context id='D200101_200930'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2020-01-01</i:startDate>
<i:endDate>2020-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='E20Q3'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2020-09-30</i:instant>
</i:period>
</i:context>
<i:context id='E19Q2'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2019-06-30</i:instant>
</i:period>
</i:context>
<i:context id='I201105'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2020-11-05</i:instant>
</i:period>
</i:context>
<i:context id='D200930'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2020-09-30</i:startDate>
<i:endDate>2020-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='E19'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2019-12-31</i:instant>
</i:period>
</i:context>
<i:context id='Y20Q3'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2020-07-01</i:startDate>
<i:endDate>2020-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y19Q3'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2019-07-01</i:startDate>
<i:endDate>2019-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D190101_190930'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2019-01-01</i:startDate>
<i:endDate>2019-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='E18'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2018-12-31</i:instant>
</i:period>
</i:context>
<i:context id='E19Q3'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2019-09-30</i:instant>
</i:period>
</i:context>
<i:context id='D200101_200930_StEqComps-CommonStock'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2020-01-01</i:startDate>
<i:endDate>2020-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D200101_200930_StEqComps-AddPaidInCap'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2020-01-01</i:startDate>
<i:endDate>2020-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D200101_200930_StEqComps-ComprIncome'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2020-01-01</i:startDate>
<i:endDate>2020-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D200101_200930_StEqComps-RetainedEarnings'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2020-01-01</i:startDate>
<i:endDate>2020-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='E20Q2'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:instant>2020-06-30</i:instant>
</i:period>
</i:context>
<i:context id='E20Q2_StEqComps-CommonStock'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2020-06-30</i:instant>
</i:period>
</i:context>
<i:context id='E20Q2_StEqComps-AddPaidInCap'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2020-06-30</i:instant>
</i:period>
</i:context>
<i:context id='E20Q2_StEqComps-ComprIncome'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2020-06-30</i:instant>
</i:period>
</i:context>
<i:context id='E20Q2_StEqComps-RetainedEarnings'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2020-06-30</i:instant>
</i:period>
</i:context>
<i:context id='Y20Q3_StEqComps-CommonStock'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2020-07-01</i:startDate>
<i:endDate>2020-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y20Q3_StEqComps-AddPaidInCap'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2020-07-01</i:startDate>
<i:endDate>2020-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y20Q3_StEqComps-ComprIncome'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2020-07-01</i:startDate>
<i:endDate>2020-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y20Q3_StEqComps-RetainedEarnings'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2020-07-01</i:startDate>
<i:endDate>2020-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='E20Q3_StEqComps-CommonStock'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2020-09-30</i:instant>
</i:period>
</i:context>
<i:context id='E20Q3_StEqComps-AddPaidInCap'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2020-09-30</i:instant>
</i:period>
</i:context>
<i:context id='E20Q3_StEqComps-ComprIncome'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2020-09-30</i:instant>
</i:period>
</i:context>
<i:context id='E20Q3_StEqComps-RetainedEarnings'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2020-09-30</i:instant>
</i:period>
</i:context>
<i:context id='E19_StEqComps-CommonStock'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2019-12-31</i:instant>
</i:period>
</i:context>
<i:context id='E19_StEqComps-AddPaidInCap'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2019-12-31</i:instant>
</i:period>
</i:context>
<i:context id='E19_StEqComps-ComprIncome'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2019-12-31</i:instant>
</i:period>
</i:context>
<i:context id='E19_StEqComps-RetainedEarnings'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2019-12-31</i:instant>
</i:period>
</i:context>
<i:context id='E19Q2_StEqComps-CommonStock'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2019-06-30</i:instant>
</i:period>
</i:context>
<i:context id='E19Q2_StEqComps-AddPaidInCap'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2019-06-30</i:instant>
</i:period>
</i:context>
<i:context id='E19Q2_StEqComps-ComprIncome'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2019-06-30</i:instant>
</i:period>
</i:context>
<i:context id='E19Q2_StEqComps-RetainedEarnings'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2019-06-30</i:instant>
</i:period>
</i:context>
<i:context id='Y19Q3_StEqComps-CommonStock'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2019-07-01</i:startDate>
<i:endDate>2019-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y19Q3_StEqComps-AddPaidInCap'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2019-07-01</i:startDate>
<i:endDate>2019-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y19Q3_StEqComps-ComprIncome'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2019-07-01</i:startDate>
<i:endDate>2019-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y19Q3_StEqComps-RetainedEarnings'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2019-07-01</i:startDate>
<i:endDate>2019-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='E19Q3_StEqComps-CommonStock'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2019-09-30</i:instant>
</i:period>
</i:context>
<i:context id='E19Q3_StEqComps-AddPaidInCap'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2019-09-30</i:instant>
</i:period>
</i:context>
<i:context id='E19Q3_StEqComps-ComprIncome'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2019-09-30</i:instant>
</i:period>
</i:context>
<i:context id='E19Q3_StEqComps-RetainedEarnings'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2019-09-30</i:instant>
</i:period>
</i:context>
<i:context id='E18_StEqComps-CommonStock'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2018-12-31</i:instant>
</i:period>
</i:context>
<i:context id='E18_StEqComps-AddPaidInCap'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2018-12-31</i:instant>
</i:period>
</i:context>
<i:context id='E18_StEqComps-ComprIncome'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2018-12-31</i:instant>
</i:period>
</i:context>
<i:context id='E18_StEqComps-RetainedEarnings'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:instant>2018-12-31</i:instant>
</i:period>
</i:context>
<i:context id='D190101_190930_StEqComps-CommonStock'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2019-01-01</i:startDate>
<i:endDate>2019-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D190101_190930_StEqComps-AddPaidInCap'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2019-01-01</i:startDate>
<i:endDate>2019-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D190101_190930_StEqComps-ComprIncome'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2019-01-01</i:startDate>
<i:endDate>2019-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D190101_190930_StEqComps-RetainedEarnings'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2019-01-01</i:startDate>
<i:endDate>2019-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y18Q3'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2018-07-01</i:startDate>
<i:endDate>2018-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D180101_180930'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2018-01-01</i:startDate>
<i:endDate>2018-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D200101_200930_StGeo-DomesticUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2020-01-01</i:startDate>
<i:endDate>2020-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D200101_200930_StGeo-OutsideUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2020-01-01</i:startDate>
<i:endDate>2020-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D200101_200930_ProductOrService-Obstetrics'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:ObstetricsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2020-01-01</i:startDate>
<i:endDate>2020-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y20Q3_ProductOrService-Obstetrics_StGeo-DomesticUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:ObstetricsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2020-07-01</i:startDate>
<i:endDate>2020-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y20Q3_ProductOrService-Obstetrics_StGeo-OutsideUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:ObstetricsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2020-07-01</i:startDate>
<i:endDate>2020-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y20Q3_ProductOrService-Obstetrics'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:ObstetricsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2020-07-01</i:startDate>
<i:endDate>2020-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D200101_200930_ProductOrService-GynecologyElectrosurgeryUrology'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2020-01-01</i:startDate>
<i:endDate>2020-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y20Q3_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2020-07-01</i:startDate>
<i:endDate>2020-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y20Q3_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2020-07-01</i:startDate>
<i:endDate>2020-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y20Q3_ProductOrService-GynecologyElectrosurgeryUrology'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2020-07-01</i:startDate>
<i:endDate>2020-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D200101_200930_ProductOrService-Neonatal'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:NeonatalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2020-01-01</i:startDate>
<i:endDate>2020-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y20Q3_ProductOrService-Neonatal_StGeo-DomesticUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:NeonatalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2020-07-01</i:startDate>
<i:endDate>2020-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y20Q3_ProductOrService-Neonatal_StGeo-OutsideUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:NeonatalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2020-07-01</i:startDate>
<i:endDate>2020-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y20Q3_ProductOrService-Neonatal'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:NeonatalMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2020-07-01</i:startDate>
<i:endDate>2020-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D200101_200930_ProductOrService-BloodPressureMonitoringAndAccessories'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2020-01-01</i:startDate>
<i:endDate>2020-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y20Q3_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2020-07-01</i:startDate>
<i:endDate>2020-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y20Q3_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2020-07-01</i:startDate>
<i:endDate>2020-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y20Q3_ProductOrService-BloodPressureMonitoringAndAccessories'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2020-07-01</i:startDate>
<i:endDate>2020-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y20Q3_StGeo-DomesticUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2020-07-01</i:startDate>
<i:endDate>2020-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='Y20Q3_StGeo-OutsideUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2020-07-01</i:startDate>
<i:endDate>2020-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D200101_200930_ProductOrService-Obstetrics_StGeo-DomesticUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:ObstetricsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2020-01-01</i:startDate>
<i:endDate>2020-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D200101_200930_ProductOrService-Obstetrics_StGeo-OutsideUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:ObstetricsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2020-01-01</i:startDate>
<i:endDate>2020-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D200101_200930_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2020-01-01</i:startDate>
<i:endDate>2020-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D200101_200930_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2020-01-01</i:startDate>
<i:endDate>2020-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D200101_200930_ProductOrService-Neonatal_StGeo-DomesticUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:NeonatalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2020-01-01</i:startDate>
<i:endDate>2020-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D200101_200930_ProductOrService-Neonatal_StGeo-OutsideUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:NeonatalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2020-01-01</i:startDate>
<i:endDate>2020-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D200101_200930_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:DomesticUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2020-01-01</i:startDate>
<i:endDate>2020-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D200101_200930_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='srt:ProductOrServiceAxis'>fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension='srt:StatementGeographicalAxis'>fil:OutsideUsMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2020-01-01</i:startDate>
<i:endDate>2020-09-30</i:endDate>
</i:period>
</i:context>
<i:context id='D190101_190930_DistributionRightsAcquisition-CoopersurgicalInc'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
<i:segment><xbrldi:explicitMember dimension='fil:DistributionRightsAcquisitionAxis'>fil:CoopersurgicalIncMember</xbrldi:explicitMember></i:segment>
</i:entity>
<i:period>
<i:startDate>2019-01-01</i:startDate>
<i:endDate>2019-09-30</i:endDate>
</i:period>
</i:context>
<i:unit id='Pure'>
<i:measure>xbrli:pure</i:measure>
</i:unit>
<i:unit id='USD'>
<i:measure>iso4217:USD</i:measure>
</i:unit>
<i:unit id='Shares'>
<i:measure>xbrli:shares</i:measure>
</i:unit>
<i:unit id='UsdPerShare'>
<i:divide>
<i:unitNumerator>
<i:measure>iso4217:USD</i:measure>
</i:unitNumerator>
<i:unitDenominator>
<i:measure>xbrli:shares</i:measure>
</i:unitDenominator>
</i:divide>
</i:unit>
</ix:resources>
</ix:header>
</div>
<div><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'>UNITED STATES</p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'>SECURITIES AND EXCHANGE COMMISSION</p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'>Washington, D.C. &#160;20549</p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'><b>FORM </b><ix:nonNumeric name='dei:DocumentType' contextRef='D200101_200930' escape='true'>10-Q</ix:nonNumeric></p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:100%'><p style='font:10pt Times New Roman;margin:0'><span style='font-family:MS Gothic'><ix:nonNumeric name='dei:DocumentQuarterlyReport' contextRef='D200101_200930' format='ixt-sec:boolballotbox'>&#9746;</ix:nonNumeric></span> &#160;&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p>
</td></tr>
<tr><td valign='top' style='width:100%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>For the quarterly period ended <ix:nonNumeric name='dei:DocumentPeriodEndDate' contextRef='D200101_200930' format='ixt:datemonthdayyearen'> September 30, 2020</ix:nonNumeric></p>
</td></tr>
<tr><td valign='top' style='width:100%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>OR</p>
</td></tr>
<tr><td valign='top' style='width:100%'><p style='font:10pt Times New Roman;margin:0'><span style='font-family:MS Gothic'><ix:nonNumeric name='dei:DocumentTransitionReport' contextRef='D200101_200930' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></span> &#160;&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p>
</td></tr>
<tr><td valign='top' style='width:100%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>For the transition period from  &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</p>
</td></tr>
<tr><td valign='top' style='width:100%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Commission File No. <span style='border-bottom:1px solid #000000'><ix:nonNumeric name='dei:EntityFileNumber' contextRef='D200101_200930' escape='true'>001-12575</ix:nonNumeric></span></p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'><ix:nonNumeric name='dei:EntityRegistrantName' contextRef='D200101_200930' escape='true'>UTAH MEDICAL PRODUCTS INC</ix:nonNumeric></p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'>(Exact name of Registrant as specified in its charter)</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:50%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><ix:nonNumeric name='dei:EntityIncorporationStateCountryCode' contextRef='D200101_200930' format='ixt-sec:stateprovnameen'>Utah</ix:nonNumeric></p>
</td><td valign='top' style='width:50%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><ix:nonNumeric name='dei:EntityTaxIdentificationNumber' contextRef='D200101_200930' escape='true'>87-0342734</ix:nonNumeric></p>
</td></tr>
<tr><td valign='top' style='width:50%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(State or other jurisdiction of incorporation or organization)</p>
</td><td valign='top' style='width:50%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(I.R.S. Employer&#160;Identification No.)</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:100%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><ix:nonNumeric name='dei:EntityAddressAddressLine1' contextRef='D200101_200930' escape='true'>7043 South 300 West</ix:nonNumeric></p>
</td></tr>
<tr><td valign='top' style='width:100%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'><ix:nonNumeric name='dei:EntityAddressCityOrTown' contextRef='D200101_200930' escape='true'>Midvale</ix:nonNumeric>, <ix:nonNumeric name='dei:EntityAddressStateOrProvince' contextRef='D200101_200930' format='ixt-sec:stateprovnameen'>Utah</ix:nonNumeric> &#160;<ix:nonNumeric name='dei:EntityAddressPostalZipCode' contextRef='D200101_200930' escape='true'>84047</ix:nonNumeric></span></p>
</td></tr>
<tr><td valign='top' style='width:100%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(Address of principal executive offices) (Zip Code)</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:100%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>(<ix:nonNumeric name='dei:CityAreaCode' contextRef='D200101_200930' escape='true'>801</ix:nonNumeric>) </span><ix:nonNumeric name='dei:LocalPhoneNumber' contextRef='D200101_200930' escape='true'>566-1200</ix:nonNumeric></p>
</td></tr>
<tr><td valign='top' style='width:100%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(Registrant&#8217;s telephone number, including area code)</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:33.34%'><p style='font:10pt Times New Roman;margin:0'>Securities registered pursuant to Section 12(b) of the Act:</p>
</td><td valign='top' style='width:33.34%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:33.32%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:33.34%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:33.34%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:33.32%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:33.34%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Title of each class:</p>
</td><td valign='top' style='width:33.34%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Trading Symbol:</p>
</td><td valign='top' style='width:33.32%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Name of each exchange on which registered:</p>
</td></tr>
<tr><td valign='top' style='width:33.34%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><ix:nonNumeric name='dei:Security12bTitle' contextRef='D200101_200930' escape='true'>Common stock, $0.01 par value</ix:nonNumeric></p>
</td><td valign='top' style='width:33.34%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><ix:nonNumeric name='dei:TradingSymbol' contextRef='D200101_200930' escape='true'>UTMD</ix:nonNumeric></p>
</td><td valign='top' style='width:33.32%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><ix:nonNumeric name='dei:SecurityExchangeName' contextRef='D200101_200930' escape='true'>NASDAQ</ix:nonNumeric></p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:18pt'></kbd>Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. &#160;&#160;<span style='-sec-ix-hidden:fact3'>Yes</span>&#160;<span style='font-family:MS Gothic'>&#9746;</span> &#160;&#160;No&#160;<span style='font-family:MS Gothic'>&#9744;</span>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:18pt'></kbd>Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). &#160;&#160;<ix:nonNumeric name='dei:EntityInteractiveDataCurrent' contextRef='D200101_200930' escape='true'>Yes</ix:nonNumeric>&#160;<span style='font-family:MS Gothic'>&#9746;</span> &#160;&#160;No&#160;<span style='font-family:MS Gothic'>&#9744;</span>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;text-align:justify'><kbd style='margin-left:18pt'></kbd>Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. &#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:50%'><p style='font:10pt Times New Roman;margin:0'>Large accelerated filer&#160;<span style='font-family:MS Gothic'>&#9744;</span></p>
</td><td valign='top' style='width:50%'><p style='font:10pt Times New Roman;margin:0'><ix:nonNumeric name='dei:EntityFilerCategory' contextRef='D200101_200930' format='ixt-sec:entityfilercategoryen'>Accelerated filer</ix:nonNumeric>&#160;<span style='font-family:MS Gothic'>&#9746;</span></p>
</td></tr>
<tr><td valign='top' style='width:50%'><p style='font:10pt Times New Roman;margin:0'>Non-accelerated filer <span style='font-family:MS Gothic'>&#9744;</span></p>
</td><td valign='top' style='width:50%'><p style='font:10pt Times New Roman;margin:0'>Smaller reporting company <span style='font-family:MS Gothic'><ix:nonNumeric name='dei:EntitySmallBusiness' contextRef='D200101_200930' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></span></p>
</td></tr>
<tr><td valign='top' style='width:50%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:50%'><p style='font:10pt Times New Roman;margin:0'>Emerging growth company <span style='font-family:MS Gothic'><ix:nonNumeric name='dei:EntityEmergingGrowthCompany' contextRef='D200101_200930' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></span></p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:18pt'></kbd>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;<span style='font-family:MS Gothic'>&#9744;</span> &#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:18pt'></kbd>Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). &#160;Yes&#160;<span style='font-family:MS Gothic'><ix:nonNumeric name='dei:EntityShellCompany' contextRef='D200101_200930' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></span> &#160;&#160;No&#160;<span style='font-family:MS Gothic'>&#9746;</span>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt CG Times;margin:0'><kbd style='margin-left:18pt'></kbd><span style='font-family:Times New Roman'>Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock as of November 5, 2020: <ix:nonFraction name='dei:EntityCommonStockSharesOutstanding' contextRef='I201105' unitRef='Shares' decimals='INF' scale='0' format='ixt:numdotdecimal'>3,640,403</ix:nonFraction>.</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<a id='a2'></a><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>UTAH MEDICAL PRODUCTS, INC.</span></p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>INDEX TO FORM 10-Q</span></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>PAGE</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0'><a href='#a3' style='text-decoration:none'><span style='color:#0000FF;border-bottom:1px solid #0000FF'>PART I - FINANCIAL INFORMATION</span></a></p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><a href='#a3' style='text-decoration:none'><span style='color:#0000FF;border-bottom:1px solid #0000FF'>Item 1.</span></a></p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0'><a href='#a3' style='text-decoration:none'><span style='color:#0000FF;border-bottom:1px solid #0000FF'>Financial Statements</span></a></p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0'><a href='#a4' style='text-decoration:none'><span style='color:#0000FF;border-bottom:1px solid #0000FF'>Consolidated Condensed Balance Sheets as of September 30, 2020 and December 31, 2019</span></a></p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0'><a href='#a5' style='text-decoration:none'><span style='color:#0000FF;border-bottom:1px solid #0000FF'>Consolidated Condensed Statements of Income for the three and nine months ended September 30, 2020 and September 30, 2019</span></a></p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>2</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0;margin-right:42.3pt'><a href='#a6' style='text-decoration:none'><span style='color:#0000FF;border-bottom:1px solid #0000FF'>Consolidated Condensed Statements of Cash Flows for the nine months ended September 30, 2020 and September 30, 2019</span></a></p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>3</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0;margin-right:42.3pt'><a href='#a7' style='text-decoration:none'><span style='color:#0000FF;border-bottom:1px solid #0000FF'>Consolidated Condensed Statements of Stockholders&#8217; Equity for the three and nine months ended September 30, 2020 and September 30, 2019</span></a></p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>4</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0'><a href='#a8' style='text-decoration:none'><span style='color:#0000FF;border-bottom:1px solid #0000FF'>Notes to Consolidated Condensed Financial Statements</span></a></p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>5</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><a href='#a9' style='text-decoration:none'><span style='color:#0000FF;border-bottom:1px solid #0000FF'>Item 2.</span></a></p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0;margin-right:42.3pt'><a href='#a9' style='text-decoration:none'><span style='color:#0000FF;border-bottom:1px solid #0000FF'>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>9</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><a href='#a10' style='text-decoration:none'><span style='color:#0000FF;border-bottom:1px solid #0000FF'>Item 3.</span></a></p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0'><a href='#a10' style='text-decoration:none'><span style='color:#0000FF;border-bottom:1px solid #0000FF'>Quantitative and Qualitative Disclosures About Market Risk</span></a></p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>18</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><a href='#a11' style='text-decoration:none'><span style='color:#0000FF;border-bottom:1px solid #0000FF'>Item 4.</span></a></p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0'><a href='#a11' style='text-decoration:none'><span style='color:#0000FF;border-bottom:1px solid #0000FF'>Controls and Procedures</span></a></p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>18</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0'><a href='#a12' style='text-decoration:none'><span style='color:#0000FF;border-bottom:1px solid #0000FF'>PART II &#8211;&#160;OTHER INFORMATION</span></a></p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><a href='#a13' style='text-decoration:none'><span style='color:#0000FF;border-bottom:1px solid #0000FF'>Item 1.</span></a></p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0'><a href='#a13' style='text-decoration:none'><span style='color:#0000FF;border-bottom:1px solid #0000FF'>Legal Proceedings</span></a></p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>19</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><a href='#a14' style='text-decoration:none'><span style='color:#0000FF;border-bottom:1px solid #0000FF'>Item 1A.</span></a></p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0'><a href='#a14' style='text-decoration:none'><span style='color:#0000FF;border-bottom:1px solid #0000FF'>Risk Factors</span></a></p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>19</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><a href='#a15' style='text-decoration:none'><span style='color:#0000FF;border-bottom:1px solid #0000FF'>Item 2.</span></a></p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0'><a href='#a15' style='text-decoration:none'><span style='color:#0000FF;border-bottom:1px solid #0000FF'>Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>20</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0;text-align:center'><a href='#a17' style='text-decoration:none'><span style='color:#0000FF;border-bottom:1px solid #0000FF'>Item 6.</span></a></p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0'><a href='#a17' style='text-decoration:none'><span style='color:#0000FF;border-bottom:1px solid #0000FF'>Exhibits</span></a></p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>20</p>
</td></tr>
<tr><td valign='top' style='width:19.12%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:19.12%'><p style='font:10pt Times New Roman;margin:0'><a href='#a18' style='text-decoration:none'><span style='color:#0000FF;border-bottom:1px solid #0000FF'>SIGNATURES</span></a></p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.14%'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.72%'><p style='font:10pt Times New Roman;margin:0;text-align:center'>21</p>
</td></tr>
</table>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><a href='#a2' style='text-decoration:none'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'>Table of Contents</span></a></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<a id='a3'></a><p style='font:10pt Times New Roman;margin:0;text-align:center'>PART I - FINANCIAL INFORMATION</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><b>Item 1. Financial Statements</b></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<a id='a4'></a><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<table style='border-collapse:collapse;width:100%;margin-left:4.65pt'><tr style='height:12.75pt'><td colspan='4' valign='bottom' style='width:1129.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES</span></p>
</td></tr>
<tr style='height:12.75pt'><td colspan='4' valign='bottom' style='width:1129.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>CONSOLIDATED CONDENSED BALANCE SHEETS AS OF</span></p>
</td></tr>
<tr style='height:8.25pt'><td colspan='4' valign='bottom' style='width:1129.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>SEPTEMBER 30, 2020 AND DECEMBER 31, 2019</span></p>
</td></tr>
<tr style='height:12.75pt'><td colspan='4' valign='bottom' style='width:1129.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(in thousands)</p>
</td></tr>
<tr style='height:21pt'><td valign='bottom' style='width:597.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(unaudited)</p>
</td><td valign='bottom' style='width:27.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(audited)</p>
</td></tr>
<tr style='height:19.5pt'><td valign='bottom' style='width:597.7pt;padding-right:5.75pt'></td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>SEPTEMBER 30, 2020</span></p>
</td><td valign='bottom' style='width:27.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>DECEMBER 31, 2019</span></p>
</td></tr>
<tr style='height:19.5pt'><td valign='bottom' style='width:597.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'><span style='border-bottom:1px solid #000000'>ASSETS</span></p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:27.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='width:597.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Current assets:</p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:27.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;width:597.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Cash &amp; investments</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;<ix:nonFraction name='us-gaap:CashAndCashEquivalentsAtCarryingValue' contextRef='E20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>46,294</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:27.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;<ix:nonFraction name='us-gaap:CashAndCashEquivalentsAtCarryingValue' contextRef='E19' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>42,787</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='width:597.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Accounts &amp; other receivables, net</p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AccountsReceivableNetCurrent' contextRef='E20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,277</ix:nonFraction></p>
</td><td valign='bottom' style='width:27.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AccountsReceivableNetCurrent' contextRef='E19' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,742</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;width:597.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Inventories</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InventoryNet' contextRef='E20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>6,304</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:27.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InventoryNet' contextRef='E19' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>6,913</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='width:597.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Other current assets</p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherAssetsCurrent' contextRef='E20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>385</ix:nonFraction></p>
</td><td valign='bottom' style='width:27.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherAssetsCurrent' contextRef='E19' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>444</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;width:597.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Total current assets</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:252.1pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AssetsCurrent' contextRef='E20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>57,260</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:27.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:252.1pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AssetsCurrent' contextRef='E19' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>54,886</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='width:597.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Property and equipment, net</p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:PropertyPlantAndEquipmentNet' contextRef='E20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>10,650</ix:nonFraction></p>
</td><td valign='bottom' style='width:27.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:PropertyPlantAndEquipmentNet' contextRef='E19' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>10,314</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;width:597.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Operating lease &#8211;&#160;right of use assets, net</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingLeaseRightOfUseAsset' contextRef='E20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>386</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:27.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingLeaseRightOfUseAsset' contextRef='E19' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>414</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='width:597.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Goodwill</p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:Goodwill' contextRef='E20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>13,783</ix:nonFraction></p>
</td><td valign='bottom' style='width:27.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:Goodwill' contextRef='E19' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>13,961</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;width:597.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Other intangible assets</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:FiniteLivedIntangibleAssetsGross' contextRef='E20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>54,362</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:27.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:FiniteLivedIntangibleAssetsGross' contextRef='E19' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>55,205</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='width:597.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Other intangible assets - accumulated amortization</p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization' contextRef='E20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>29,369</ix:nonFraction>)</p>
</td><td valign='bottom' style='width:27.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization' contextRef='E19' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>24,993</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;width:597.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Other intangible assets, net</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:252.1pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IntangibleAssetsNetExcludingGoodwill' contextRef='E20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>24,993</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:27.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:252.1pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IntangibleAssetsNetExcludingGoodwill' contextRef='E19' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>30,212</ix:nonFraction> </p>
</td></tr>
<tr style='height:13.5pt'><td valign='bottom' style='width:597.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Total assets</p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;<ix:nonFraction name='us-gaap:Assets' contextRef='E20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>107,072</ix:nonFraction></p>
</td><td valign='bottom' style='width:27.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;<ix:nonFraction name='us-gaap:Assets' contextRef='E19' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>109,787</ix:nonFraction> </p>
</td></tr>
<tr style='height:13.5pt'><td valign='bottom' style='background-color:#CCEEFF;width:597.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:27.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='width:597.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'><span style='border-bottom:1px solid #000000'>LIABILITIES AND STOCKHOLDERS' EQUITY</span></p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:27.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;width:597.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Current liabilities:</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:27.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='width:597.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Accounts payable</p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:AccountsPayableCurrent' contextRef='E20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>651</ix:nonFraction></p>
</td><td valign='bottom' style='width:27.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:AccountsPayableCurrent' contextRef='E19' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,098</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;width:597.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Accrued expenses</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AccruedLiabilitiesCurrent' contextRef='E20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,976</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:27.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AccruedLiabilitiesCurrent' contextRef='E19' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,350</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='width:597.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Total current liabilities</p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:LiabilitiesCurrent' contextRef='E20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,627</ix:nonFraction></p>
</td><td valign='bottom' style='width:27.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:LiabilitiesCurrent' contextRef='E19' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,448</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;width:597.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Deferred tax liability &#8211; Femcare IIA</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' contextRef='E20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,995</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:27.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' contextRef='E19' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,110</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='width:597.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Other long term liabilities</p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:OtherLiabilitiesNoncurrent' contextRef='E20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,132</ix:nonFraction></p>
</td><td valign='bottom' style='width:27.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:OtherLiabilitiesNoncurrent' contextRef='E19' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,239</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;width:597.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Operating lease liability</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:OperatingLeaseLiabilityNoncurrent' contextRef='E20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>346</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:27.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingLeaseLiabilityNoncurrent' contextRef='E19' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>376</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='width:597.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Deferred income taxes</p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DeferredIncomeTaxLiabilitiesNet' contextRef='E20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>557</ix:nonFraction></p>
</td><td valign='bottom' style='width:27.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DeferredIncomeTaxLiabilitiesNet' contextRef='E19' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>521</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;width:597.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Total liabilities</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:252.1pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:Liabilities' contextRef='E20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>8,657</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:27.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:252.1pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:Liabilities' contextRef='E19' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>8,694</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='width:597.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:27.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;width:597.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Stockholders' equity:</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:27.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='width:597.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Preferred stock - $<ix:nonFraction name='us-gaap:PreferredStockParOrStatedValuePerShare' contextRef='E20Q3' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'><ix:nonFraction name='us-gaap:PreferredStockParOrStatedValuePerShare' contextRef='E19' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>0.01</ix:nonFraction></ix:nonFraction> par value; authorized - <ix:nonFraction name='us-gaap:PreferredStockSharesAuthorized' contextRef='E20Q3' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'><ix:nonFraction name='us-gaap:PreferredStockSharesAuthorized' contextRef='E19' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>5,000</ix:nonFraction></ix:nonFraction> shares; <ix:nonFraction name='us-gaap:PreferredStockSharesIssued' contextRef='E20Q3' unitRef='Shares' decimals='INF' format='ixt-sec:numwordsen'><ix:nonFraction name='us-gaap:PreferredStockSharesIssued' contextRef='E19' unitRef='Shares' decimals='INF' format='ixt-sec:numwordsen'><ix:nonFraction name='us-gaap:PreferredStockSharesOutstanding' contextRef='E20Q3' unitRef='Shares' decimals='INF' format='ixt-sec:numwordsen'><ix:nonFraction name='us-gaap:PreferredStockSharesOutstanding' contextRef='E19' unitRef='Shares' decimals='INF' format='ixt-sec:numwordsen'>no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding</p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:PreferredStockValue' contextRef='E20Q3' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:27.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:PreferredStockValue' contextRef='E19' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;width:597.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Common stock - $<ix:nonFraction name='us-gaap:CommonStockParOrStatedValuePerShare' contextRef='E20Q3' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'><ix:nonFraction name='us-gaap:CommonStockParOrStatedValuePerShare' contextRef='E19' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>0.01</ix:nonFraction></ix:nonFraction> par value; authorized - <ix:nonFraction name='us-gaap:CommonStockSharesAuthorized' contextRef='E20Q3' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'><ix:nonFraction name='us-gaap:CommonStockSharesAuthorized' contextRef='E19' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>50,000</ix:nonFraction></ix:nonFraction> shares; issued - September 30, 2020, <ix:nonFraction name='us-gaap:CommonStockSharesIssued' contextRef='E20Q3' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'><ix:nonFraction name='us-gaap:CommonStockSharesOutstanding' contextRef='E20Q3' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,640</ix:nonFraction></ix:nonFraction> shares and December 31, 2019, <ix:nonFraction name='us-gaap:CommonStockSharesIssued' contextRef='E19' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'><ix:nonFraction name='us-gaap:CommonStockSharesOutstanding' contextRef='E19' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,722</ix:nonFraction></ix:nonFraction> shares</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:CommonStockValue' contextRef='E20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>36</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:27.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:CommonStockValue' contextRef='E19' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>37</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='width:597.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Accumulated other comprehensive income (loss)</p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1' contextRef='E20Q3' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>10,199</ix:nonFraction>)</p>
</td><td valign='bottom' style='width:27.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1' contextRef='E19' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>9,782</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;width:597.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Additional paid-in capital</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AdditionalPaidInCapitalCommonStock' contextRef='E20Q3' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:27.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AdditionalPaidInCapitalCommonStock' contextRef='E19' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>18</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='width:597.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Retained earnings</p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RetainedEarningsAccumulatedDeficit' contextRef='E20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>108,578</ix:nonFraction></p>
</td><td valign='bottom' style='width:27.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RetainedEarningsAccumulatedDeficit' contextRef='E19' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>110,820</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;width:597.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Total stockholders' equity</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:252.1pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockholdersEquity' contextRef='E20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>98,415</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:27.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:252.1pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockholdersEquity' contextRef='E19' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>101,093</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='width:597.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:27.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:13.5pt'><td valign='bottom' style='background-color:#CCEEFF;width:597.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Total liabilities and stockholders' equity</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:252.1pt;padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;<ix:nonFraction name='us-gaap:LiabilitiesAndStockholdersEquity' contextRef='E20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>107,072</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:27.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:252.1pt;padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;<ix:nonFraction name='us-gaap:LiabilitiesAndStockholdersEquity' contextRef='E19' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>109,787</ix:nonFraction> </p>
</td></tr>
<tr style='height:13.5pt'><td valign='bottom' style='width:597.7pt;padding-right:5.75pt'><p style='font:8pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:27.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:13.5pt'><td valign='bottom' style='width:597.7pt;padding-right:5.75pt'><p style='font:8pt Times New Roman;margin:0'><i>see notes to consolidated condensed financial statements</i></p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:27.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:252.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
</table>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>1</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><a href='#a2' style='text-decoration:none'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'>Table of Contents</span></a></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><a id='a5'></a><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<table style='border-collapse:collapse;width:100%;margin-left:4.65pt'><tr style='height:12.75pt'><td colspan='9' valign='bottom' style='width:1129.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES</span></p>
</td></tr>
<tr style='height:12.75pt'><td colspan='9' valign='bottom' style='width:1129.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>CONSOLIDATED CONDENSED STATEMENTS OF INCOME FOR THE</span></p>
</td></tr>
<tr style='height:12.75pt'><td colspan='9' valign='bottom' style='width:1129.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2020 AND SEPTEMBER 30, 2019</span></p>
</td></tr>
<tr style='height:12.75pt'><td colspan='9' valign='bottom' style='width:1129.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(in thousands, except per share amounts - unaudited)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='width:495pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td colspan='3' valign='bottom' style='width:288.65pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Three Months Ended </p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td colspan='3' valign='bottom' style='width:288.65pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Nine Months Ended </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='width:495pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>September 30, 2020</p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>September 30, 2019</p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>September 30, 2020</p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>September 30, 2019</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='width:495pt;padding-right:5.75pt'></td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt;border-top:0.5pt solid #000000'></td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt;border-top:0.5pt solid #000000'></td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt;border-top:0.5pt solid #000000'></td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt;border-top:0.5pt solid #000000'></td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;width:495pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Sales, net</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;<ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>10,479</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;<ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y19Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>12,494</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;<ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D200101_200930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>30,168</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;<ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D190101_190930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>35,073</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='width:495pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;width:495pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Cost of goods sold</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:CostOfGoodsAndServicesSold' contextRef='Y20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,982</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:CostOfGoodsAndServicesSold' contextRef='Y19Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>5,115</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:CostOfGoodsAndServicesSold' contextRef='D200101_200930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>11,885</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:CostOfGoodsAndServicesSold' contextRef='D190101_190930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>13,421</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='width:495pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Gross profit</p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:GrossProfit' contextRef='Y20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>6,497</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:GrossProfit' contextRef='Y19Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>7,379</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:GrossProfit' contextRef='D200101_200930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>18,283</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:GrossProfit' contextRef='D190101_190930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>21,652</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;width:495pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='width:495pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Operating expense</p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;width:495pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Selling, general and administrative</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:SellingGeneralAndAdministrativeExpense' contextRef='Y20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,785</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:SellingGeneralAndAdministrativeExpense' contextRef='Y19Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,878</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:SellingGeneralAndAdministrativeExpense' contextRef='D200101_200930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>8,480</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:SellingGeneralAndAdministrativeExpense' contextRef='D190101_190930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>8,341</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='width:495pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Research &amp; development</p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ResearchAndDevelopmentExpense' contextRef='Y20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>125</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ResearchAndDevelopmentExpense' contextRef='Y19Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>130</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ResearchAndDevelopmentExpense' contextRef='D200101_200930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>375</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ResearchAndDevelopmentExpense' contextRef='D190101_190930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>357</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;width:495pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Total operating expenses</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingExpenses' contextRef='Y20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,910</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingExpenses' contextRef='Y19Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,008</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingExpenses' contextRef='D200101_200930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>8,855</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingExpenses' contextRef='D190101_190930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>8,698</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='width:495pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Operating income</p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingIncomeLoss' contextRef='Y20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,587</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingIncomeLoss' contextRef='Y19Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,371</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingIncomeLoss' contextRef='D200101_200930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>9,428</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingIncomeLoss' contextRef='D190101_190930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>12,954</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;width:495pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='width:495pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Other income (expense)</p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherNonoperatingIncomeExpense' contextRef='Y20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherNonoperatingIncomeExpense' contextRef='Y19Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>76</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherNonoperatingIncomeExpense' contextRef='D200101_200930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>125</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherNonoperatingIncomeExpense' contextRef='D190101_190930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>196</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;width:495pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Income before provision for income taxes</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments' contextRef='Y20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,588</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments' contextRef='Y19Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,447</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments' contextRef='D200101_200930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>9,553</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments' contextRef='D190101_190930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>13,150</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='width:495pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;width:495pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Provision for income taxes</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncomeTaxExpenseBenefit' contextRef='Y20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>655</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncomeTaxExpenseBenefit' contextRef='Y19Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>742</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncomeTaxExpenseBenefit' contextRef='D200101_200930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,167</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncomeTaxExpenseBenefit' contextRef='D190101_190930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,781</ix:nonFraction></p>
</td></tr>
<tr style='height:13.5pt'><td valign='bottom' style='width:495pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Net income</p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,933</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y19Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,705</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;<ix:nonFraction name='us-gaap:ProfitLoss' contextRef='D200101_200930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>7,386</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;<ix:nonFraction name='us-gaap:ProfitLoss' contextRef='D190101_190930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>10,369</ix:nonFraction></p>
</td></tr>
<tr style='height:13.5pt'><td valign='bottom' style='background-color:#CCEEFF;width:495pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='width:495pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Earnings per common share (basic)</p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:EarningsPerShareBasic' contextRef='Y20Q3' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>0.81</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:EarningsPerShareBasic' contextRef='Y19Q3' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>1.00</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:EarningsPerShareBasic' contextRef='D200101_200930' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>2.02</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:EarningsPerShareBasic' contextRef='D190101_190930' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>2.79</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;width:495pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='width:495pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Earnings per common share (diluted)</p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160; &#160;&#160;&#160;<ix:nonFraction name='us-gaap:EarningsPerShareDiluted' contextRef='Y20Q3' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>0.80</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160; &#160;&#160;&#160;<ix:nonFraction name='us-gaap:EarningsPerShareDiluted' contextRef='Y19Q3' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>0.99</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:EarningsPerShareDiluted' contextRef='D200101_200930' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>2.01</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:EarningsPerShareDiluted' contextRef='D190101_190930' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>2.77</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;width:495pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='width:495pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Shares outstanding - basic</p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfSharesOutstandingBasic' contextRef='Y20Q3' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,642</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfSharesOutstandingBasic' contextRef='Y19Q3' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,720</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfSharesOutstandingBasic' contextRef='D200101_200930' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,664</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfSharesOutstandingBasic' contextRef='D190101_190930' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,722</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;width:495pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='width:495pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Shares outstanding - diluted</p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding' contextRef='Y20Q3' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,653</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding' contextRef='Y19Q3' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,737</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding' contextRef='D200101_200930' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,678</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding' contextRef='D190101_190930' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,738</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;width:495pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='width:495pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Other comprehensive income (loss):</p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:23.25pt'><td valign='bottom' style='background-color:#CCEEFF;width:495pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Foreign currency translation net of taxes of $<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' contextRef='Y20Q3' unitRef='USD' decimals='INF' scale='0' format='ixt:numdotdecimal'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' contextRef='Y19Q3' unitRef='USD' decimals='INF' scale='0' format='ixt:numdotdecimal'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' contextRef='D200101_200930' unitRef='USD' decimals='INF' scale='0' format='ixt:numdotdecimal'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' contextRef='D190101_190930' unitRef='USD' decimals='INF' scale='0' format='ixt:numdotdecimal'>0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> in all periods</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,511</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;(<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y19Q3' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,683</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160; &#160;&#160;(<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='D200101_200930' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>416</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:129.95pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;(<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='D190101_190930' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,200</ix:nonFraction>)</p>
</td></tr>
<tr style='height:13.5pt'><td valign='bottom' style='width:495pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Total comprehensive income</p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ComprehensiveIncomeNetOfTax' contextRef='Y20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,444</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ComprehensiveIncomeNetOfTax' contextRef='Y19Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,022</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ComprehensiveIncomeNetOfTax' contextRef='D200101_200930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>6,970</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ComprehensiveIncomeNetOfTax' contextRef='D190101_190930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>9,169</ix:nonFraction></p>
</td></tr>
<tr style='height:13.5pt'><td valign='bottom' style='width:495pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;margin-left:38.9pt'></p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:13.5pt'><td valign='bottom' style='width:495pt;padding-right:5.75pt'><p style='font:8pt Times New Roman;margin:0'><i>see notes to consolidated condensed financial statements</i></p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:28.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:129.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
</table>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>2</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><a href='#a2' style='text-decoration:none'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'>Table of Contents</span></a></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><a id='a6'></a><table style='border-collapse:collapse;width:100%;margin-left:4.3pt'><tr style='height:12.75pt'><td colspan='5' valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES</span></p>
</td></tr>
<tr style='height:12.75pt'><td colspan='5' valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS</span></p>
</td></tr>
<tr style='height:12.75pt'><td colspan='5' valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>FOR THE SIX MONTHS ENDED SEPTEMBER 30, 2020 AND SEPTEMBER 30, 2019</span></p>
</td></tr>
<tr style='height:12.75pt'><td colspan='5' valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(in thousands - unaudited)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td colspan='3' valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Nine Months Ended<br/>September 30,</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'></td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>2020</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>2019</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>CASH FLOWS FROM OPERATING ACTIVITIES:</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Net income</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ProfitLoss' contextRef='D200101_200930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>7,386</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:ProfitLoss' contextRef='D190101_190930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>10,369</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Adjustments to reconcile net income to net<br/> &#160;cash provided by operating activities</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:10.1pt'>Depreciation</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:Depreciation' contextRef='D200101_200930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>495</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:Depreciation' contextRef='D190101_190930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>526</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:10.1pt'>Amortization</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AdjustmentForAmortization' contextRef='D200101_200930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,875</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AdjustmentForAmortization' contextRef='D190101_190930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,512</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;margin-left:10.1pt'><span style='font-family:Times New Roman'>Provision for (recovery of) losses on accounts receivable</span></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>(<ix:nonFraction name='us-gaap:ProvisionForDoubtfulAccounts' contextRef='D200101_200930' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4</ix:nonFraction>)</span></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>(<ix:nonFraction name='us-gaap:ProvisionForDoubtfulAccounts' contextRef='D190101_190930' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2</ix:nonFraction>)</span></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:10.1pt'>Amortization of Right-of-Use Assets</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='fil:OperatingLeaseRightOfUseAssetAmortization' contextRef='D200101_200930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>29</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='fil:OperatingLeaseRightOfUseAssetAmortization' contextRef='D190101_190930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>29</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:10.1pt'>(Gain) loss on disposal of assets</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:GainLossOnDispositionOfAssets' contextRef='D200101_200930' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:GainLossOnDispositionOfAssets' contextRef='D190101_190930' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;margin-left:10.1pt'><span style='font-family:Times New Roman'>Deferred income taxes</span></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:DeferredIncomeTaxExpenseBenefit' contextRef='D200101_200930' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>20</ix:nonFraction>)</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:DeferredIncomeTaxExpenseBenefit' contextRef='D190101_190930' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>398</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:10.1pt'>Stock-based compensation expense</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ShareBasedCompensation' contextRef='D200101_200930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>121</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ShareBasedCompensation' contextRef='D190101_190930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>85</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:10.1pt'>Tax benefit attributable to exercise of stock options</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DeferredTaxExpenseFromStockOptionsExercised' contextRef='D200101_200930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>7</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DeferredTaxExpenseFromStockOptionsExercised' contextRef='D190101_190930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>20</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Changes in operating assets and liabilities:</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Accounts receivable and other receivables</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncreaseDecreaseInAccountsReceivable' contextRef='D200101_200930' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>442</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:IncreaseDecreaseInAccountsReceivable' contextRef='D190101_190930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,139</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Inventories</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncreaseDecreaseInInventories' contextRef='D200101_200930' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>757</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:IncreaseDecreaseInInventories' contextRef='D190101_190930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,449</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Prepaid expenses and other current assets</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' contextRef='D200101_200930' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>58</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' contextRef='D190101_190930' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>73</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Accounts payable</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:IncreaseDecreaseInAccountsPayable' contextRef='D200101_200930' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>439</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:IncreaseDecreaseInAccountsPayable' contextRef='D190101_190930' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>188</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:20.9pt'>Accrued expenses</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:IncreaseDecreaseInAccruedLiabilities' contextRef='D200101_200930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>651</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:IncreaseDecreaseInAccruedLiabilities' contextRef='D190101_190930' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,023</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Total adjustments</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' contextRef='D200101_200930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>6,973</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' contextRef='D190101_190930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,046</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Net cash provided by operating activities</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'><ix:nonFraction name='us-gaap:NetCashProvidedByUsedInOperatingActivities' contextRef='D200101_200930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>14,359</ix:nonFraction></span></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'><ix:nonFraction name='us-gaap:NetCashProvidedByUsedInOperatingActivities' contextRef='D190101_190930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>11,415</ix:nonFraction></span></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>CASH FLOWS FROM INVESTING ACTIVITIES:</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Capital expenditures for:</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:10.1pt'>Property and equipment</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:PaymentsToAcquirePropertyPlantAndEquipment' contextRef='D200101_200930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>806</ix:nonFraction>)</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:PaymentsToAcquirePropertyPlantAndEquipment' contextRef='D190101_190930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>252</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:10.1pt'>Intangible assets</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:PaymentsToAcquireIntangibleAssets' contextRef='D200101_200930' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:PaymentsToAcquireIntangibleAssets' contextRef='D190101_190930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>21,000</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Net cash used in investing activities</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:NetCashProvidedByUsedInInvestingActivities' contextRef='D200101_200930' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>806</ix:nonFraction>)</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:NetCashProvidedByUsedInInvestingActivities' contextRef='D190101_190930' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>21,252</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>CASH FLOWS FROM FINANCING ACTIVITIES:</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Proceeds from issuance of common stock - options</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProceedsFromIssuanceOfCommonStock' contextRef='D200101_200930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>282</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProceedsFromIssuanceOfCommonStock' contextRef='D190101_190930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>223</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Common stock purchased and retired</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:PaymentsForRepurchaseOfCommonStock' contextRef='D200101_200930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>6,977</ix:nonFraction>)</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:PaymentsForRepurchaseOfCommonStock' contextRef='D190101_190930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>398</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Payment of dividends</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:PaymentsOfDividends' contextRef='D200101_200930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,097</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:PaymentsOfDividends' contextRef='D190101_190930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,083</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:38.9pt'>Net cash used in financing activities</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:NetCashProvidedByUsedInFinancingActivities' contextRef='D200101_200930' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>9,792</ix:nonFraction>)</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:NetCashProvidedByUsedInFinancingActivities' contextRef='D190101_190930' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,258</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Effect of exchange rate changes on cash</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' contextRef='D200101_200930' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>254</ix:nonFraction>)</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' contextRef='D190101_190930' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>624</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Net decrease in cash and cash equivalents</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' contextRef='D200101_200930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,507</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' contextRef='D190101_190930' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>13,719</ix:nonFraction>) </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Cash at beginning of period</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:CashAndCashEquivalentsAtCarryingValue' contextRef='E19' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>42,787</ix:nonFraction> </p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:CashAndCashEquivalentsAtCarryingValue' contextRef='E18' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>51,112</ix:nonFraction> </p>
</td></tr>
<tr style='height:13.5pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Cash at end of period</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;<ix:nonFraction name='us-gaap:CashAndCashEquivalentsAtCarryingValue' contextRef='E20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>46,294</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;<ix:nonFraction name='us-gaap:CashAndCashEquivalentsAtCarryingValue' contextRef='E19Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>37,393</ix:nonFraction> </p>
</td></tr>
<tr style='height:13.5pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td colspan='2' valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:10.1pt'>Cash paid during the period for income taxes</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:IncomeTaxesPaid' contextRef='D200101_200930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,153</ix:nonFraction></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:IncomeTaxesPaid' contextRef='D190101_190930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,957</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-left:10.1pt'>Cash paid during the period for interest</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InterestPaid' contextRef='D200101_200930' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InterestPaid' contextRef='D190101_190930' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction> </p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;margin-left:10.1pt'></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='padding-right:5.75pt'><p style='font:8pt Times New Roman;margin:0'><i>see notes to consolidated condensed financial statements</i></p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
</table>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>3</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><a href='#a2' style='text-decoration:none'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'>Table of Contents</span></a></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<a id='a7'></a><table style='border-collapse:collapse;width:100%;margin-left:4.3pt'><tr style='height:12.75pt'><td colspan='12' valign='bottom' style='width:1412.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>UTAH MEDICAL PRODUCTS, INC.</span></p>
</td></tr>
<tr style='height:12.75pt'><td colspan='12' valign='bottom' style='width:1412.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>CONSOLIDATED CONDENSED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY FOR THE</span></p>
</td></tr>
<tr style='height:12.75pt'><td colspan='12' valign='bottom' style='width:1412.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2020 AND SEPTEMBER 30, 2019</span></p>
</td></tr>
<tr style='height:12.75pt'><td colspan='12' valign='bottom' style='width:1412.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(In thousands - unaudited)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='width:345.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:113.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:28.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:121pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:150.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:199.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Accumulated</p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:158.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:180.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='width:345.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:113.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:28.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:121pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:150.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Additional</p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:199.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Other</p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:158.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:180.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Total</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='width:345.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td colspan='3' valign='bottom' style='width:263.15pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Common Stock</p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:150.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Paid-in</p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:199.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Comprehensive</p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:158.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Retained</p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:180.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Stockholders'</p>
</td></tr>
<tr style='height:12.75pt'><td valign='bottom' style='width:345.35pt;padding-right:5.75pt'></td><td valign='bottom' style='width:113.65pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Shares</p>
</td><td valign='bottom' style='width:28.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:121pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Amount</p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:150.8pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Capital</p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:199.4pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Income</p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:158.3pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Earnings</p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:180.65pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Equity</p>
</td></tr>
<tr style='height:18.75pt'><td valign='middle' style='background-color:#CCEEFF;width:345.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Balance at June 30, 2020</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:113.65pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:SharesOutstanding' contextRef='E20Q2_StEqComps-CommonStock' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,643</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:28.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:121pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E20Q2_StEqComps-CommonStock' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>36</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:150.8pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E20Q2_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>80</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:199.4pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E20Q2_StEqComps-ComprIncome' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>11,710</ix:nonFraction>)</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:158.3pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E20Q2_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>106,881</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:180.65pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E20Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>95,288</ix:nonFraction></p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='width:345.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Shares issued upon exercise of employee <br/> &#160;stock options for cash</p>
</td><td valign='bottom' style='width:113.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised' contextRef='Y20Q3_StEqComps-CommonStock' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>4</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:121pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y20Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:150.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y20Q3_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>202</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:199.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y20Q3_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:158.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y20Q3_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:180.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>202</ix:nonFraction></p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='background-color:#CCEEFF;width:345.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Stock option compensation expense</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:113.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y20Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:121pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y20Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:150.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y20Q3_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>49</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:199.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y20Q3_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:158.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y20Q3_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:180.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>49</ix:nonFraction></p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='width:345.35pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman'>Common stock purchased and retired</span></p>
</td><td valign='bottom' style='width:113.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:StockRepurchasedAndRetiredDuringPeriodShares' contextRef='Y20Q3_StEqComps-CommonStock' sign='-' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>7</ix:nonFraction>)</p>
</td><td valign='bottom' style='width:28.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:121pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockRepurchasedAndRetiredDuringPeriodValue' contextRef='Y20Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:150.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:StockRepurchasedAndRetiredDuringPeriodValue' contextRef='Y20Q3_StEqComps-AddPaidInCap' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>332</ix:nonFraction>)</p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:199.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockRepurchasedAndRetiredDuringPeriodValue' contextRef='Y20Q3_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:158.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:StockRepurchasedAndRetiredDuringPeriodValue' contextRef='Y20Q3_StEqComps-RetainedEarnings' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>219</ix:nonFraction>)</p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:180.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:StockRepurchasedAndRetiredDuringPeriodValue' contextRef='Y20Q3' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>551</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='background-color:#CCEEFF;width:345.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Foreign currency translation adjustment</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:113.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y20Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:121pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y20Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:150.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y20Q3_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:199.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y20Q3_StEqComps-ComprIncome' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,511</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:158.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y20Q3_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:180.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> <ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,511</ix:nonFraction></p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='width:345.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Common stock dividends</p>
</td><td valign='bottom' style='width:113.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y20Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:121pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y20Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:150.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y20Q3_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:199.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y20Q3_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:158.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y20Q3_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,018</ix:nonFraction>)</p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:180.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,018</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='background-color:#CCEEFF;width:345.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Net income</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:113.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y20Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:121pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y20Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:150.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y20Q3_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:199.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y20Q3_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:158.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y20Q3_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,933</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:180.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,933</ix:nonFraction></p>
</td></tr>
<tr style='height:18.75pt'><td valign='middle' style='width:345.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Balance at September 30, 2020</p>
</td><td valign='middle' style='width:113.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:SharesOutstanding' contextRef='E20Q3_StEqComps-CommonStock' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,640</ix:nonFraction></p>
</td><td valign='middle' style='width:28.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:121pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E20Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>36</ix:nonFraction></p>
</td><td valign='middle' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:150.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E20Q3_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='middle' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:199.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E20Q3_StEqComps-ComprIncome' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>10,199</ix:nonFraction>)</p>
</td><td valign='middle' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:158.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E20Q3_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>108,578</ix:nonFraction></p>
</td><td valign='middle' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:180.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>98,415</ix:nonFraction></p>
</td></tr>
<tr style='height:25.5pt'><td valign='middle' style='background-color:#CCEEFF;width:345.35pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0'></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:113.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:121pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:150.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:199.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:158.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:180.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:18.75pt'><td valign='middle' style='width:345.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Balance at December 31, 2019 </p>
</td><td valign='middle' style='width:113.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:SharesOutstanding' contextRef='E19_StEqComps-CommonStock' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,722</ix:nonFraction> </p>
</td><td valign='middle' style='width:28.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:121pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E19_StEqComps-CommonStock' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>37</ix:nonFraction></p>
</td><td valign='middle' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:150.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E19_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>18</ix:nonFraction></p>
</td><td valign='middle' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:199.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E19_StEqComps-ComprIncome' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>9,783</ix:nonFraction>)</p>
</td><td valign='middle' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:158.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E19_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>110,820</ix:nonFraction></p>
</td><td valign='middle' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:180.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E19' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>101,092</ix:nonFraction></p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='background-color:#CCEEFF;width:345.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Shares issued upon exercise of employee <br/> &#160;stock options for cash</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:113.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised' contextRef='D200101_200930_StEqComps-CommonStock' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>6</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:121pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='D200101_200930_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:150.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='D200101_200930_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>282</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:199.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='D200101_200930_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:158.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='D200101_200930_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:180.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='D200101_200930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>282</ix:nonFraction></p>
</td></tr>
<tr style='height:12.75pt'><td valign='middle' style='width:345.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Stock option compensation expense</p>
</td><td valign='bottom' style='width:113.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='D200101_200930_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:121pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='D200101_200930_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:150.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='D200101_200930_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>121</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:199.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='D200101_200930_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:158.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='D200101_200930_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:180.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='D200101_200930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>121</ix:nonFraction></p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='background-color:#CCEEFF;width:345.35pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman'>Common stock purchased and retired</span></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:113.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:StockRepurchasedAndRetiredDuringPeriodShares' contextRef='D200101_200930_StEqComps-CommonStock' sign='-' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>87</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:121pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:StockRepurchasedAndRetiredDuringPeriodValue' contextRef='D200101_200930_StEqComps-CommonStock' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:150.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:StockRepurchasedAndRetiredDuringPeriodValue' contextRef='D200101_200930_StEqComps-AddPaidInCap' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>421</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:199.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockRepurchasedAndRetiredDuringPeriodValue' contextRef='D200101_200930_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:158.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:StockRepurchasedAndRetiredDuringPeriodValue' contextRef='D200101_200930_StEqComps-RetainedEarnings' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>6,555</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:180.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:StockRepurchasedAndRetiredDuringPeriodValue' contextRef='D200101_200930' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>6,976</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='middle' style='width:345.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Foreign currency translation adjustment</p>
</td><td valign='bottom' style='width:113.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='D200101_200930_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:121pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='D200101_200930_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:150.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='D200101_200930_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:199.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='D200101_200930_StEqComps-ComprIncome' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>416</ix:nonFraction>)</p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:158.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='D200101_200930_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:180.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='D200101_200930' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>416</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='middle' style='background-color:#CCEEFF;width:345.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Common stock dividends</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:113.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='D200101_200930_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:121pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='D200101_200930_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:150.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='D200101_200930_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:199.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='D200101_200930_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:158.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='D200101_200930_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,074</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:180.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='D200101_200930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,074</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.75pt'><td valign='middle' style='width:345.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Net income</p>
</td><td valign='bottom' style='width:113.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='D200101_200930_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:121pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='D200101_200930_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:150.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='D200101_200930_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:199.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='D200101_200930_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:158.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='D200101_200930_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>7,386</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:180.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='D200101_200930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>7,386</ix:nonFraction></p>
</td></tr>
<tr style='height:18.75pt'><td valign='middle' style='background-color:#CCEEFF;width:345.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Balance at September 30, 2020</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:113.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:SharesOutstanding' contextRef='E20Q3_StEqComps-CommonStock' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,640</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:28.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:121pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E20Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>36</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:150.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E20Q3_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:199.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E20Q3_StEqComps-ComprIncome' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>10,199</ix:nonFraction>)</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:158.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E20Q3_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>108,578</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:180.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>98,415</ix:nonFraction></p>
</td></tr>
<tr style='height:25.5pt'><td valign='middle' style='width:345.35pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0'></p>
</td><td valign='bottom' style='width:113.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:28.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:121pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:150.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:199.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:158.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:180.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:18.75pt'><td valign='middle' style='background-color:#CCEEFF;width:345.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Balance at June 30, 2019</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:113.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:SharesOutstanding' contextRef='E19Q2_StEqComps-CommonStock' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,719</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:28.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:121pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E19Q2_StEqComps-CommonStock' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>37</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:150.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E19Q2_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:199.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E19Q2_StEqComps-ComprIncome' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>10,807</ix:nonFraction>)</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:158.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E19Q2_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>104,682</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:180.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E19Q2' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>93,912</ix:nonFraction></p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='width:345.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Shares issued upon exercise of employee <br/> &#160;stock options for cash</p>
</td><td valign='bottom' style='width:113.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised' contextRef='Y19Q3_StEqComps-CommonStock' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>1</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:121pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y19Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:150.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y19Q3_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>52</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:199.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y19Q3_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:158.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y19Q3_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:180.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='Y19Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>52</ix:nonFraction></p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='background-color:#CCEEFF;width:345.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Stock option compensation expense</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:113.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y19Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:121pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y19Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:150.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y19Q3_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>29</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:199.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y19Q3_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:158.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y19Q3_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:180.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='Y19Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>29</ix:nonFraction></p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='width:345.35pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman'>Common stock purchased and retired</span></p>
</td><td valign='bottom' style='width:113.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockRepurchasedAndRetiredDuringPeriodShares' contextRef='Y19Q3_StEqComps-CommonStock' unitRef='Shares' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:121pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockRepurchasedAndRetiredDuringPeriodValue' contextRef='Y19Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:150.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:StockRepurchasedAndRetiredDuringPeriodValue' contextRef='Y19Q3_StEqComps-AddPaidInCap' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>81</ix:nonFraction>)</p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:199.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockRepurchasedAndRetiredDuringPeriodValue' contextRef='Y19Q3_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:158.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockRepurchasedAndRetiredDuringPeriodValue' contextRef='Y19Q3_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>81</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:180.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockRepurchasedAndRetiredDuringPeriodValue' contextRef='Y19Q3' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='background-color:#CCEEFF;width:345.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Foreign currency translation adjustment</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:113.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y19Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:121pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y19Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:150.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y19Q3_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:199.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y19Q3_StEqComps-ComprIncome' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,683</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:158.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y19Q3_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:180.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> (<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='Y19Q3' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,683</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='width:345.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Common stock dividends</p>
</td><td valign='bottom' style='width:113.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y19Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:121pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y19Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:150.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y19Q3_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:199.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y19Q3_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:158.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y19Q3_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,029</ix:nonFraction>)</p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:180.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='Y19Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,029</ix:nonFraction>)</p>
</td></tr>
<tr style='height:18.75pt'><td valign='middle' style='background-color:#CCEEFF;width:345.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Net income</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:113.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y19Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:121pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y19Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:150.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y19Q3_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:199.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y19Q3_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:158.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y19Q3_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,705</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:180.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y19Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,705</ix:nonFraction></p>
</td></tr>
<tr style='height:18.75pt'><td valign='middle' style='width:345.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Balance at September 30, 2019</p>
</td><td valign='middle' style='width:113.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:SharesOutstanding' contextRef='E19Q3_StEqComps-CommonStock' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,720</ix:nonFraction></p>
</td><td valign='middle' style='width:28.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:121pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E19Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>37</ix:nonFraction></p>
</td><td valign='middle' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:150.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E19Q3_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='middle' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:199.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E19Q3_StEqComps-ComprIncome' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>12,490</ix:nonFraction>)</p>
</td><td valign='middle' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:158.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E19Q3_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>107,439</ix:nonFraction></p>
</td><td valign='middle' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:180.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E19Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>94,986</ix:nonFraction></p>
</td></tr>
<tr style='height:25.2pt'><td valign='middle' style='background-color:#CCEEFF;width:345.35pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0'></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:113.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:28.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:121pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:150.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:199.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:158.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:180.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:18.7pt'><td valign='middle' style='width:345.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Balance at December 31, 2018 </p>
</td><td valign='middle' style='width:113.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:SharesOutstanding' contextRef='E18_StEqComps-CommonStock' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,720</ix:nonFraction> </p>
</td><td valign='middle' style='width:28.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:121pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E18_StEqComps-CommonStock' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>37</ix:nonFraction></p>
</td><td valign='middle' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:150.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E18_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>121</ix:nonFraction></p>
</td><td valign='middle' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:199.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E18_StEqComps-ComprIncome' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>11,290</ix:nonFraction>)</p>
</td><td valign='middle' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:158.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E18_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>100,123</ix:nonFraction></p>
</td><td valign='middle' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:180.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E18' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>88,992</ix:nonFraction></p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='background-color:#CCEEFF;width:345.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Shares issued upon exercise of employee <br/> &#160;stock options for cash</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:113.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised' contextRef='D190101_190930_StEqComps-CommonStock' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>5</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:121pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='D190101_190930_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:150.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='D190101_190930_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>222</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:199.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='D190101_190930_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:158.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='D190101_190930_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:180.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised' contextRef='D190101_190930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>222</ix:nonFraction></p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='width:345.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Stock option compensation expense</p>
</td><td valign='bottom' style='width:113.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='D190101_190930_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:121pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='D190101_190930_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:150.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='D190101_190930_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>85</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:199.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='D190101_190930_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:158.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='D190101_190930_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:180.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockOptionPlanExpense' contextRef='D190101_190930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>85</ix:nonFraction></p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='background-color:#CCEEFF;width:345.35pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0'><span style='font-family:Times New Roman'>Common stock purchased and retired</span></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:113.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:StockRepurchasedAndRetiredDuringPeriodShares' contextRef='D190101_190930_StEqComps-CommonStock' sign='-' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>5</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:121pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockRepurchasedAndRetiredDuringPeriodValue' contextRef='D190101_190930_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:150.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:StockRepurchasedAndRetiredDuringPeriodValue' contextRef='D190101_190930_StEqComps-AddPaidInCap' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>429</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:199.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockRepurchasedAndRetiredDuringPeriodValue' contextRef='D190101_190930_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:158.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:StockRepurchasedAndRetiredDuringPeriodValue' contextRef='D190101_190930_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>31</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:180.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:StockRepurchasedAndRetiredDuringPeriodValue' contextRef='D190101_190930' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>398</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='width:345.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Foreign currency translation adjustment</p>
</td><td valign='bottom' style='width:113.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='D190101_190930_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:121pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='D190101_190930_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:150.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='D190101_190930_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:199.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='D190101_190930_StEqComps-ComprIncome' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,200</ix:nonFraction>)</p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:158.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='D190101_190930_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:180.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' contextRef='D190101_190930' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,200</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='background-color:#CCEEFF;width:345.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Common stock dividends</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:113.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='D190101_190930_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:121pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='D190101_190930_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:150.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='D190101_190930_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:199.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='D190101_190930_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:158.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='D190101_190930_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,084</ix:nonFraction>)</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='background-color:#CCEEFF;width:180.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<ix:nonFraction name='us-gaap:DividendsCommonStockCash' contextRef='D190101_190930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,084</ix:nonFraction>)</p>
</td></tr>
<tr style='height:12.95pt'><td valign='middle' style='width:345.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Net income</p>
</td><td valign='bottom' style='width:113.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='D190101_190930_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:121pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='D190101_190930_StEqComps-CommonStock' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='bottom' style='width:150.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='D190101_190930_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:199.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='D190101_190930_StEqComps-ComprIncome' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:158.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='D190101_190930_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>10,369</ix:nonFraction></p>
</td><td valign='bottom' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='bottom' style='width:180.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='D190101_190930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>10,369</ix:nonFraction></p>
</td></tr>
<tr style='height:18.75pt'><td valign='middle' style='background-color:#CCEEFF;width:345.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'> Balance at September 30, 2019</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:113.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:SharesOutstanding' contextRef='E19Q3_StEqComps-CommonStock' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,720</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:28.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:121pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E19Q3_StEqComps-CommonStock' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>37</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:150.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E19Q3_StEqComps-AddPaidInCap' unitRef='USD' decimals='-3' format='ixt:zerodash'>-</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:199.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E19Q3_StEqComps-ComprIncome' sign='-' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>12,490</ix:nonFraction>)</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:158.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E19Q3_StEqComps-RetainedEarnings' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>107,439</ix:nonFraction></p>
</td><td valign='middle' style='background-color:#CCEEFF;width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:180.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name='us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' contextRef='E19Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>94,986</ix:nonFraction></p>
</td></tr>
<tr style='height:18.75pt'><td valign='middle' style='width:345.35pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0'></p>
</td><td valign='middle' style='width:113.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:28.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:121pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:150.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:199.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:158.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:180.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:13.7pt'><td valign='bottom' style='width:345.35pt;padding-right:5.75pt'><p style='font:8pt Times New Roman;margin:0'><i>see notes to consolidated condensed financial statements</i></p>
</td><td valign='middle' style='width:113.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:28.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:121pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:150.8pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:199.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:158.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:28.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:180.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>4</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><a href='#a2' style='text-decoration:none'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'>Table of Contents</span></a></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><a id='a8'></a><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>UTAH MEDICAL PRODUCTS, INC.</span></p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS</span></p>
<p style='font:10pt Times New Roman;margin:0;text-align:center'>(unaudited)</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<ix:nonNumeric name='us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' contextRef='D200101_200930' escape='true'><p style='font:10pt Times New Roman;margin:0'>(1) The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States. &#160;These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. (&quot;UTMD&quot; or &quot;the Company&quot;) annual report on Form 10-K for the year ended December 31, 2019. &#160;In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. &#160;Currency amounts are in thousands except per-share amounts and where noted.</p>
</ix:nonNumeric><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<ix:nonNumeric name='us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' contextRef='D200101_200930' escape='true'><p style='font:10pt Times New Roman;margin:0'>(2) Recent Accounting Standards. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt CG Times;margin:0'><ix:nonNumeric name='us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock' contextRef='D200101_200930' escape='true'><span style='font-family:Times New Roman'>The Company has determined that other recently issued accounting standards will either have no material impact on its consolidated financial position, results of operations or cash flows, or will not apply to its operations.</span></ix:nonNumeric></p>
</ix:nonNumeric><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<ix:nonNumeric name='us-gaap:InventoryDisclosureTextBlock' contextRef='D200101_200930' escape='true'><p style='font:10pt Times New Roman;margin-top:0pt;margin-bottom:6pt'>(3) Inventories at September 30, 2020, and December 31, 2019, consisted of the following:</p>
<ix:nonNumeric name='us-gaap:ScheduleOfInventoryCurrentTableTextBlock' contextRef='D200101_200930' escape='true'><table style='margin:0 auto;border-collapse:collapse;width:100%'><tr><td valign='top' style='width:144pt'></td><td valign='top' style='width:6.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:108pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'> September 30, 2020</p>
</td><td valign='top' style='width:8.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:6.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:101pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>December 31, 2019</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:144pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Finished goods</p>
</td><td valign='top' style='background-color:#CCEEFF;width:6.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>$</p>
</td><td valign='top' style='background-color:#CCEEFF;width:108pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InventoryFinishedGoodsNetOfReserves' contextRef='E19Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,446</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:6.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>$</p>
</td><td valign='top' style='background-color:#CCEEFF;width:101pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InventoryFinishedGoodsNetOfReserves' contextRef='E18' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,708</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='width:144pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Work-in-process</p>
</td><td valign='top' style='width:6.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:108pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InventoryWorkInProcess' contextRef='E19Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,387</ix:nonFraction></p>
</td><td valign='top' style='width:8.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:6.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:101pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InventoryWorkInProcess' contextRef='E18' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,022</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:144pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Raw materials</p>
</td><td valign='top' style='background-color:#CCEEFF;width:6.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:108pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InventoryRawMaterials' contextRef='E19Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,471</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:6.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:101pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InventoryRawMaterials' contextRef='E18' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,183</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='width:144pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Total</p>
</td><td valign='top' style='width:6.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0'>$</p>
</td><td valign='top' style='width:108pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InventoryNet' contextRef='E19Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>6,304</ix:nonFraction></p>
</td><td valign='top' style='width:8.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:6.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0'>$</p>
</td><td valign='top' style='width:101pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:InventoryNet' contextRef='E18' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>6,913</ix:nonFraction></p>
</td></tr>
</table>
</ix:nonNumeric></ix:nonNumeric><hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>5</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><a href='#a2' style='text-decoration:none'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'>Table of Contents</span></a></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<ix:nonNumeric name='us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' contextRef='D200101_200930' escape='true'><p style='font:10pt Times New Roman;margin:0'>(4) Stock-Based Compensation. At September 30, 2020, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors. &#160;The Company accounts for stock compensation under FASB Accounting Standards Codification (&#8220;ASC&#8221;) 718, <i>Compensation - Stock Compensation</i>. &#160;This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors. &#160;In the quarters ended September 30, 2020, and 2019, the Company recognized $<ix:nonFraction name='us-gaap:AllocatedShareBasedCompensationExpense' contextRef='Y19Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>49</ix:nonFraction> and $<ix:nonFraction name='us-gaap:AllocatedShareBasedCompensationExpense' contextRef='Y18Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>29</ix:nonFraction>, respectively, in stock based compensation cost. &#160;In the nine months ended September 30, 2020, and 2019, the Company recognized $<ix:nonFraction name='us-gaap:AllocatedShareBasedCompensationExpense' contextRef='D190101_190930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>121</ix:nonFraction> and $<ix:nonFraction name='us-gaap:AllocatedShareBasedCompensationExpense' contextRef='D180101_180930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>85</ix:nonFraction>, respectively, in stock based compensation cost.</p>
</ix:nonNumeric><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<ix:nonNumeric name='us-gaap:ProductWarrantyDisclosureTextBlock' contextRef='D200101_200930' escape='true'><p style='font:10pt Times New Roman;margin:0'>(5) Warranty Reserve. &#160;The Company&#8217;s published warranty is: &#8220;UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment. &#160;During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price.&#8221; </p>
<p style='font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, <ix:nonFraction name='us-gaap:ProductWarrantyAccrual' contextRef='E19' unitRef='USD' decimals='INF' format='ixt-sec:numwordsen'><ix:nonFraction name='us-gaap:ProductWarrantyAccrual' contextRef='E20Q3' unitRef='USD' decimals='INF' format='ixt-sec:numwordsen'>no</ix:nonFraction></ix:nonFraction> warranty reserve was made at December 31, 2019, or September 30, 2020. </p>
</ix:nonNumeric><hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>6</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><a href='#a2' style='text-decoration:none'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'>Table of Contents</span></a></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<ix:nonNumeric name='us-gaap:RevenueRecognitionPolicyTextBlock' contextRef='D200101_200930' escape='true'><ix:nonNumeric name='fil:ScheduleOfRevenuesByProductCategoryTextBlock' contextRef='D200101_200930' escape='true'><p style='font:10pt Times New Roman;margin:0;color:#000000'>(6) Global 3Q 2020 revenues (USD) by product category:</p>
<table style='margin:0 auto;border-collapse:collapse;width:100%'><tr><td valign='top' style='width:180pt'></td><td valign='top' style='width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Domestic</p>
</td><td valign='top' style='width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Outside US</p>
</td><td valign='top' style='width:28.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Total</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:180pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Obstetrics</p>
</td><td valign='top' style='background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>$</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y20Q3_ProductOrService-Obstetrics_StGeo-DomesticUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,032</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>$</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y20Q3_ProductOrService-Obstetrics_StGeo-OutsideUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>247</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>$</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y20Q3_ProductOrService-Obstetrics' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,279</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='width:180pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Gynecology/Electrosurgery/Urology</p>
</td><td valign='top' style='width:23.05pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y20Q3_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,847</ix:nonFraction></span></p>
</td><td valign='top' style='width:23.05pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y20Q3_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,202</ix:nonFraction></span></p>
</td><td valign='top' style='width:28.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y20Q3_ProductOrService-GynecologyElectrosurgeryUrology' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>5,049</ix:nonFraction></span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:180pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Neonatal</p>
</td><td valign='top' style='background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y20Q3_ProductOrService-Neonatal_StGeo-DomesticUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,151</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y20Q3_ProductOrService-Neonatal_StGeo-OutsideUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>348</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y20Q3_ProductOrService-Neonatal' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,499</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='width:180pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Blood Pressure Monitoring and Accessories</p>
</td><td valign='top' style='width:23.05pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y20Q3_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,920</ix:nonFraction></span></p>
</td><td valign='top' style='width:23.05pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y20Q3_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>732</ix:nonFraction></span></p>
</td><td valign='top' style='width:28.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y20Q3_ProductOrService-BloodPressureMonitoringAndAccessories' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,652</ix:nonFraction></span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:180pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-indent:-19.8pt;margin-left:19.8pt'><span style='font-family:Times New Roman'>Total</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>$</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y20Q3_StGeo-DomesticUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>6,950</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>$</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y20Q3_StGeo-OutsideUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,529</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>$</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='Y20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>10,479</ix:nonFraction></p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0;color:#000000'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Global 9M 2020 revenues (USD) by product category:</p>
<table style='margin:0 auto;border-collapse:collapse;width:100%'><tr><td valign='top' style='width:180pt'></td><td valign='top' style='width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Domestic</p>
</td><td valign='top' style='width:23.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Outside US</p>
</td><td valign='top' style='width:28.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Total</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:180pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Obstetrics</p>
</td><td valign='top' style='background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>$</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D200101_200930_ProductOrService-Obstetrics_StGeo-DomesticUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,739</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>$</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D200101_200930_ProductOrService-Obstetrics_StGeo-OutsideUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>612</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>$</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D200101_200930_ProductOrService-Obstetrics' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,351</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='width:180pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Gynecology/Electrosurgery/Urology</p>
</td><td valign='top' style='width:23.05pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D200101_200930_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>7,686</ix:nonFraction></span></p>
</td><td valign='top' style='width:23.05pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D200101_200930_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>6,945</ix:nonFraction></span></p>
</td><td valign='top' style='width:28.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D200101_200930_ProductOrService-GynecologyElectrosurgeryUrology' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>14,631</ix:nonFraction></span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:180pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Neonatal</p>
</td><td valign='top' style='background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D200101_200930_ProductOrService-Neonatal_StGeo-DomesticUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,266</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D200101_200930_ProductOrService-Neonatal_StGeo-OutsideUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>1,169</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D200101_200930_ProductOrService-Neonatal' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>4,435</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='width:180pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Blood Pressure Monitoring and Accessories</p>
</td><td valign='top' style='width:23.05pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D200101_200930_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>5,215</ix:nonFraction></span></p>
</td><td valign='top' style='width:23.05pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D200101_200930_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,536</ix:nonFraction></span></p>
</td><td valign='top' style='width:28.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:8.65pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:54pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D200101_200930_ProductOrService-BloodPressureMonitoringAndAccessories' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>7,751</ix:nonFraction></span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:180pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-indent:-19.8pt;margin-left:19.8pt'><span style='font-family:Times New Roman'>Total</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>$</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D200101_200930_StGeo-DomesticUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>18,906</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>$</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D200101_200930_StGeo-OutsideUs' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>11,262</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>$</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:54pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax' contextRef='D200101_200930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>30,168</ix:nonFraction></p>
</td></tr>
</table>
<p style='font:12pt Times New Roman;margin:0'>&#160;</p>
</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric name='us-gaap:LesseeOperatingLeasesTextBlock' contextRef='D200101_200930' escape='true' continuedAt='c1'><p style='font:10pt Times New Roman;margin:0;color:#000000'>(7) Leases</p>
<p style='font:10pt Times New Roman;margin:0;color:#000000'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>UTMD has operating leases for a portion of its parking lot at its Midvale facility and an automobile at its Ireland facility. &#160;The remaining lease term on the parking lot is <ix:nonNumeric name='fil:LesseeOperatingLeaseForParkingLotTermOfContract' contextRef='D200930' format='ixt-sec:duryear'>11</ix:nonNumeric> years and on the automobile it is <ix:nonNumeric name='fil:LesseeOperatingLeaseForAutomobileTermOfContract' contextRef='D200930' format='ixt-sec:durmonth'>16</ix:nonNumeric> months. &#160;There are no options to extend or terminate the leases. &#160;UTMD has no other leases yet to commence. &#160;As neither lease contains implicit rates, UTMD&#8217;s incremental borrowing rate, based on information available at adoption date, was used to determine the present value of the leases.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<ix:nonNumeric name='us-gaap:LeaseCostTableTextBlock' contextRef='D200101_200930' escape='true'><p style='font:10pt Arial Narrow;margin:0;color:#339966'></p>
<table style='border-collapse:collapse;width:100%'><tr style='height:23.85pt'><td valign='top' style='width:311.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>The components of lease cost were as follows:</p>
</td><td valign='top' style='width:112.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>Three Months Ended September 30, 2020</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:311.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Operating Lease Cost (<i>in thousands</i>)</p>
</td><td valign='top' style='background-color:#CCEEFF;width:112.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$<ix:nonFraction name='us-gaap:OperatingLeaseCost' contextRef='Y20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>15</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='width:311.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Right of Use Assets obtained in exchange for new operating lease Obligations</p>
</td><td valign='top' style='width:112.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$<ix:nonFraction name='us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability' contextRef='Y20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>0</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:311.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:112.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'></p>
</td></tr>
<tr><td valign='top' style='width:311.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Other Information</p>
</td><td valign='top' style='width:112.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>Three Months Ended September 30, 2020</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:311.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Weighted Average Remaining Lease Term &#160;- Operating Leases</p>
</td><td valign='top' style='background-color:#CCEEFF;width:112.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonNumeric name='us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1' contextRef='E20Q3' format='ixt-sec:duryear'>11</ix:nonNumeric> years</p>
</td></tr>
<tr><td valign='top' style='width:311.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Weighted Average Discount Rate &#8211;&#160;Operating Leases</p>
</td><td valign='top' style='width:112.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent' contextRef='E20Q3' unitRef='Pure' decimals='INF' scale='-2' format='ixt:numdotdecimal'>5.4</ix:nonFraction>%</p>
</td></tr>
</table>
</ix:nonNumeric><ix:nonNumeric name='us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock' contextRef='D200101_200930' escape='true'><table style='border-collapse:collapse;width:100%'><tr style='height:23.85pt'><td valign='top' style='width:239.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Operating lease liabilities/ payments (<i>in thousands</i>)</p>
</td><td valign='top' style='width:72pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:239.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Operating lease payments, 2020</p>
</td><td valign='top' style='background-color:#CCEEFF;width:72pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$<ix:nonFraction name='us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent' contextRef='E19' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>60</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='width:239.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Operating lease payments, 2021</p>
</td><td valign='top' style='width:72pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$<ix:nonFraction name='us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears' contextRef='E19' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>60</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:239.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Operating lease payments, 2022</p>
</td><td valign='top' style='background-color:#CCEEFF;width:72pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$<ix:nonFraction name='us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears' contextRef='E19' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>45</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='width:239.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Operating lease payments, 2023</p>
</td><td valign='top' style='width:72pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$<ix:nonFraction name='us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears' contextRef='E19' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>45</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:239.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Operating lease payments, 2024</p>
</td><td valign='top' style='background-color:#CCEEFF;width:72pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$<ix:nonFraction name='us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears' contextRef='E19' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>45</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='width:239.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Thereafter</p>
</td><td valign='top' style='width:72pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$<ix:nonFraction name='us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter' contextRef='E19' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>299</ix:nonFraction></p>
</td></tr>
</table>
</ix:nonNumeric><ix:nonNumeric name='fil:ReconciliationOfOperatingLeaseLiabilitiesTableTextBlock' contextRef='D200101_200930' escape='true'><p style='font:10pt Times New Roman;margin-top:0pt;margin-bottom:10pt'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr style='height:23.85pt'><td valign='top' style='width:311.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Reconciliation of operating lease liabilities/ payments to operating lease liabilities</p>
</td><td valign='top' style='width:99pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> (<i>in thousands</i>)</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:311.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Total operating lease liabilities/ payments</p>
</td><td valign='top' style='background-color:#CCEEFF;width:99pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$<ix:nonFraction name='us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue' contextRef='E20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>528</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='width:311.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Operating lease liabilities &#8211;&#160;current (included in Accrued Expenses)</p>
</td><td valign='top' style='width:99pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$<ix:nonFraction name='us-gaap:OperatingLeaseLiabilityCurrent' contextRef='E20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>40</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:311.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Operating lease liabilities &#8211;&#160;long term</p>
</td><td valign='top' style='background-color:#CCEEFF;width:99pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>$<ix:nonFraction name='us-gaap:OperatingLeaseLiabilityNoncurrent' contextRef='E20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>346</ix:nonFraction></span></p>
</td></tr>
<tr><td valign='top' style='width:311.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Present value adjustment</p>
</td><td valign='top' style='width:99pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$<ix:nonFraction name='us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount' contextRef='E20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>142</ix:nonFraction></p>
</td></tr>
</table>
</ix:nonNumeric><p style='font:10pt Times New Roman;margin-top:0pt;margin-bottom:10pt'>&#160;</p>
<span style='font-family:Times New Roman;color:#000000'><b>Maturities of lease liabilities were as follows:</b></span>(<i>in thousands</i>)<br/><ix:nonNumeric name='us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock' contextRef='D200101_200930' escape='true' continuedAt='c2'><p style='font:10pt Arial Narrow;margin-top:0pt;margin-bottom:10pt;color:#339966'></p>
</ix:nonNumeric></ix:nonNumeric><ix:continuation id='c1'><ix:continuation id='c2'><table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:239.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Maturities of lease liabilities were as follows:</p>
</td><td valign='top' style='width:90pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(<i>in thousands</i>)</p>
</td></tr>
<tr><td valign='top' style='width:239.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Year ending December 31,</p>
</td><td valign='top' style='width:90pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:239.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>2020</p>
</td><td valign='top' style='background-color:#CCEEFF;width:90pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$<ix:nonFraction name='us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths' contextRef='E19' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>38</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='width:239.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>2021</p>
</td><td valign='top' style='width:90pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$<ix:nonFraction name='us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo' contextRef='E19' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>40</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:239.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>2022</p>
</td><td valign='top' style='background-color:#CCEEFF;width:90pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$<ix:nonFraction name='us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree' contextRef='E19' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>27</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='width:239.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>2023</p>
</td><td valign='top' style='width:90pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$<ix:nonFraction name='us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour' contextRef='E19' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>29</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:239.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>2024</p>
</td><td valign='top' style='background-color:#CCEEFF;width:90pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$<ix:nonFraction name='us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive' contextRef='E19' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>30</ix:nonFraction></p>
</td></tr>
<tr><td valign='top' style='width:239.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Thereafter</p>
</td><td valign='top' style='width:90pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$<ix:nonFraction name='us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive' contextRef='E19' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>248</ix:nonFraction></p>
</td></tr>
</table>
<p style='font:12pt Times New Roman;margin:0'>&#160;</p>
</ix:continuation></ix:continuation><hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>7</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><a href='#a2' style='text-decoration:none'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'>Table of Contents</span></a></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<ix:nonNumeric name='us-gaap:IntangibleAssetsDisclosureTextBlock' contextRef='D200101_200930' escape='true'><p style='font:12pt Times New Roman;margin:0;color:#000000'><span style='font-size:10pt'>(8) Distribution Agreement Purchase. UTMD completed the purchase of exclusive U.S. distribution rights for the Filshie Clip System from CooperSurgical, Inc. (CSI) on February 1, 2019. The $<ix:nonFraction name='us-gaap:FinitelivedIntangibleAssetsAcquired1' contextRef='D190101_190930_DistributionRightsAcquisition-CoopersurgicalInc' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>21,000</ix:nonFraction> purchase price represented an identifiable intangible asset which is being straight-line amortized and recognized as part of G&amp;A expenses over a remaining <ix:nonFraction name='fil:RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' contextRef='D190101_190930_DistributionRightsAcquisition-CoopersurgicalInc' unitRef='Pure' decimals='INF' scale='0' format='ixt:numdotdecimal'>3.08</ix:nonFraction> year life as of September 30, 2020 of the prior CSI distribution agreement with Femcare.</span></p>
<p style='font:12pt Times New Roman;margin:0'>&#160;</p>
</ix:nonNumeric><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<span style='font-family:Times New Roman;color:#000000'> </span><ix:nonNumeric name='us-gaap:EarningsPerShareTextBlock' contextRef='D200101_200930' escape='true'><p style='font:10pt Times New Roman;margin:0'>(9) Earnings Per Share. Basic earnings per share is calculated by dividing net income attributable to the common stockholders of the company by the weighted average number of common shares outstanding during the period. &#160;Diluted earnings per share is calculated by assuming the exercise of stock options at the closing price of stock at the end of 3<span style='vertical-align:super'>rd</span> quarter 2020.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<ix:nonNumeric name='us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' contextRef='D200101_200930' escape='true'><p style='font:10pt Times New Roman;margin:0'> The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:</p>
<table style='border-collapse:collapse;width:100%'><tr style='height:12.5pt'><td valign='top' style='width:257.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>(<i>in thousands</i>)</p>
</td><td colspan='3' valign='top' style='width:269.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Three months ended</p>
</td><td valign='top' style='width:36.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td colspan='3' valign='top' style='width:313.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>Nine months ended</p>
</td></tr>
<tr style='height:12.5pt'><td valign='top' style='width:257.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td colspan='3' valign='top' style='width:269.55pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>September 30,</p>
</td><td valign='top' style='width:36.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td colspan='3' valign='top' style='width:313.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>September 30,</p>
</td></tr>
<tr style='height:12.5pt'><td valign='top' style='width:257.15pt;padding-right:5.75pt'></td><td valign='middle' style='width:109.35pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>2020</p>
</td><td valign='top' style='width:31.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:128.9pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>2019</p>
</td><td valign='top' style='width:36.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:147.35pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>2020</p>
</td><td valign='top' style='width:27.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='middle' style='width:138.1pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>2019</p>
</td></tr>
<tr style='height:12.5pt'><td valign='top' style='background-color:#CCEEFF;width:257.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><b>Numerator</b></p>
</td><td valign='top' style='background-color:#CCEEFF;width:109.35pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:31.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:128.9pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:36.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:147.35pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:27.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:138.1pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr style='height:11.2pt'><td valign='top' style='width:257.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Net income</p>
</td><td valign='middle' style='width:109.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y20Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>2,933</ix:nonFraction></p>
</td><td valign='top' style='width:31.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:128.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='Y19Q3' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,705</ix:nonFraction></p>
</td><td valign='top' style='width:36.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:147.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='D200101_200930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>7,386</ix:nonFraction></p>
</td><td valign='top' style='width:27.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:138.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:ProfitLoss' contextRef='D190101_190930' unitRef='USD' decimals='-3' scale='3' format='ixt:numdotdecimal'>10,369</ix:nonFraction></p>
</td></tr>
<tr style='height:12.5pt'><td valign='top' style='background-color:#CCEEFF;width:257.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:109.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:31.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:128.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:36.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:147.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:27.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:138.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr style='height:12pt'><td valign='top' style='width:257.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><b>Denominator</b></p>
</td><td valign='top' style='width:109.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:31.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:128.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:36.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:147.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:27.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:138.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr style='height:12.5pt'><td valign='top' style='background-color:#CCEEFF;width:257.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Weighted average shares, basic</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:109.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfSharesOutstandingBasic' contextRef='Y20Q3' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,642</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:31.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:128.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfSharesOutstandingBasic' contextRef='Y19Q3' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,720</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:36.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:147.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfSharesOutstandingBasic' contextRef='D200101_200930' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,664</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:27.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:138.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfSharesOutstandingBasic' contextRef='D190101_190930' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,722</ix:nonFraction></p>
</td></tr>
<tr style='height:12.5pt'><td valign='top' style='width:257.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Dilutive effect of stock options</p>
</td><td valign='middle' style='width:109.35pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment' contextRef='Y20Q3' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>11</ix:nonFraction></p>
</td><td valign='top' style='width:31.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:128.9pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment' contextRef='Y19Q3' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>17</ix:nonFraction></p>
</td><td valign='top' style='width:36.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:147.35pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment' contextRef='D200101_200930' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>14</ix:nonFraction></p>
</td><td valign='top' style='width:27.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:138.1pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment' contextRef='D190101_190930' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>16</ix:nonFraction></p>
</td></tr>
<tr style='height:12.5pt'><td valign='top' style='background-color:#CCEEFF;width:257.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Diluted shares</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:109.35pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding' contextRef='Y20Q3' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,653</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:31.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:128.9pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding' contextRef='Y19Q3' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,737</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:36.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:147.35pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding' contextRef='D200101_200930' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,678</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:27.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:138.1pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding' contextRef='D190101_190930' unitRef='Shares' decimals='-3' scale='3' format='ixt:numdotdecimal'>3,738</ix:nonFraction></p>
</td></tr>
<tr style='height:12.5pt'><td valign='top' style='width:257.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='middle' style='width:109.35pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:31.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:128.9pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:36.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:147.35pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:27.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:138.1pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:12.5pt'><td valign='top' style='background-color:#CCEEFF;width:257.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Earnings per share, basic</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:109.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:EarningsPerShareBasic' contextRef='Y20Q3' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>0.81</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:31.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:128.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:EarningsPerShareBasic' contextRef='Y19Q3' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>1.00</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:36.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:147.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:EarningsPerShareBasic' contextRef='D200101_200930' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>2.02</ix:nonFraction></p>
</td><td valign='top' style='background-color:#CCEEFF;width:27.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='background-color:#CCEEFF;width:138.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:EarningsPerShareBasic' contextRef='D190101_190930' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>2.79</ix:nonFraction></p>
</td></tr>
<tr style='height:12.5pt'><td valign='top' style='width:257.15pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Earnings per share, diluted</p>
</td><td valign='middle' style='width:109.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:EarningsPerShareDiluted' contextRef='Y20Q3' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>0.80</ix:nonFraction></p>
</td><td valign='top' style='width:31.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:128.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:EarningsPerShareDiluted' contextRef='Y19Q3' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>0.99</ix:nonFraction></p>
</td><td valign='top' style='width:36.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:147.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:EarningsPerShareDiluted' contextRef='D200101_200930' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>2.01</ix:nonFraction></p>
</td><td valign='top' style='width:27.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='middle' style='width:138.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><ix:nonFraction name='us-gaap:EarningsPerShareDiluted' contextRef='D190101_190930' unitRef='UsdPerShare' decimals='INF' scale='0' format='ixt:numdotdecimal'>2.77</ix:nonFraction></p>
</td></tr>
</table>
<p style='font:12pt Times New Roman;margin:0'>&#160;</p>
</ix:nonNumeric></ix:nonNumeric><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
 <ix:nonNumeric name='us-gaap:SubsequentEventsTextBlock' contextRef='D200101_200930' escape='true'><p style='font:10pt Times New Roman;margin:0;color:#000000'>(10) Subsequent Events.<b> &#160;</b>UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its financial statements.</p>
</ix:nonNumeric><hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>8</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><a href='#a2' style='text-decoration:none'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'>Table of Contents</span></a></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><a id='a9'></a><p style='font:10pt Times New Roman;margin:0'><b>Item 2.</b> &#160;<b>Management's Discussion and Analysis of Financial Condition and Results of Operations</b></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>General</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Utah Medical Products, Inc. (UTMD) manufactures and markets a well-established range of specialty medical devices. &#160;The Company&#8217;s Form 10-K Annual Report for the year ended December 31, 2019, provides a detailed description of products, technologies, markets, regulatory issues, business initiatives, resources and business risks, among other details, and should be read in conjunction with this report. &#160;Because of the relatively short span of time, results for any given three month period in comparison with a previous three month period may not be indicative of comparative results for the year as a whole. &#160;Currency amounts in the report are in thousands, except per share amounts or where otherwise noted. &#160;Currencies in this report are denoted as $ or USD = U.S. Dollars; A$ or AUD = Australia Dollars; &#163; or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and &#8364;&#160;or EUR = Euros. &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Analysis of Results of Operations</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:10.8pt'>a)</kbd><kbd style='margin-left:24.3pt'></kbd>Overview &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Income statement results in 3Q and 9M 2020 compared to the same periods of 2019 were as follows:</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:143.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:58.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-0.9pt;text-align:right'><span style='border-bottom:1px solid #000000'>3Q 2020</span></p>
</td><td valign='top' style='width:55.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>3Q 2019</span></p>
</td><td valign='top' style='width:51.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>change</span></p>
</td><td valign='top' style='width:54.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>9M 2020</span></p>
</td><td valign='top' style='width:54.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>9M 2019</span></p>
</td><td valign='top' style='width:50.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>change</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:143.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Net Sales</p>
</td><td valign='top' style='background-color:#CCEEFF;width:58.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 10,479</p>
</td><td valign='top' style='background-color:#CCEEFF;width:55.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 12,494</p>
</td><td valign='top' style='background-color:#CCEEFF;width:51.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(16.1%)</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54.2pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 30,168</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 35,073</p>
</td><td valign='top' style='background-color:#CCEEFF;width:50.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(14.0%)</p>
</td></tr>
<tr><td valign='top' style='width:143.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Gross Profit</p>
</td><td valign='top' style='width:58.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>6,497</p>
</td><td valign='top' style='width:55.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>7,379</p>
</td><td valign='top' style='width:51.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(12.0%)</p>
</td><td valign='top' style='width:54.2pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>18,283</p>
</td><td valign='top' style='width:54.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>21,652</p>
</td><td valign='top' style='width:50.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(15.6%)</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:143.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Operating Income</p>
</td><td valign='top' style='background-color:#CCEEFF;width:58.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>3,588</p>
</td><td valign='top' style='background-color:#CCEEFF;width:55.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>4,371</p>
</td><td valign='top' style='background-color:#CCEEFF;width:51.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(17.9%)</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54.2pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>9,428</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>12,954</p>
</td><td valign='top' style='background-color:#CCEEFF;width:50.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(27.2%)</p>
</td></tr>
<tr><td valign='top' style='width:143.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Income Before Tax</p>
</td><td valign='top' style='width:58.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>3,588</p>
</td><td valign='top' style='width:55.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>4,448</p>
</td><td valign='top' style='width:51.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(19.3%)</p>
</td><td valign='top' style='width:54.2pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>9,553</p>
</td><td valign='top' style='width:54.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>13,150</p>
</td><td valign='top' style='width:50.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(27.4%)</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:143.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Net Income (NI)</p>
</td><td valign='top' style='background-color:#CCEEFF;width:58.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>2,933</p>
</td><td valign='top' style='background-color:#CCEEFF;width:55.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>3,705</p>
</td><td valign='top' style='background-color:#CCEEFF;width:51.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(20.8%)</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54.2pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>7,386</p>
</td><td valign='top' style='background-color:#CCEEFF;width:54.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>10,369</p>
</td><td valign='top' style='background-color:#CCEEFF;width:50.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(28.8%)</p>
</td></tr>
<tr><td valign='top' style='width:143.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Earnings per Diluted Share (EPS)</p>
</td><td valign='top' style='width:58.05pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>0.803</p>
</td><td valign='top' style='width:55.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>0.991</p>
</td><td valign='top' style='width:51.9pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(19.0%)</p>
</td><td valign='top' style='width:54.2pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>2.008</p>
</td><td valign='top' style='width:54.2pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>2.774</p>
</td><td valign='top' style='width:50.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(27.6%)</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>UTMD management believes that the presentation of sequential 2020 quarterly results provides meaningful supplemental information to both management and investors. &#160;Keeping in mind that results for any given three month period in comparison with a previous three month period may not be indicative of comparative results for the year as a whole, the following table shows the percent changes in 2020 quarterly results compared to the same periods of time in 2019: </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:203.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'><span style='border-bottom:1px solid #000000'>Consolidated Income Statement</span></p>
</td><td valign='top' style='width:63pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'><span style='border-bottom:1px solid #000000'>1Q</span></p>
</td><td valign='top' style='width:63pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'><span style='border-bottom:1px solid #000000'>2Q</span></p>
</td><td valign='top' style='width:63pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'><span style='border-bottom:1px solid #000000'>3Q</span></p>
</td><td valign='top' style='width:67.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'><span style='border-bottom:1px solid #000000'>9M</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:203.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'>Worldwide Revenues</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>+  1.6%</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(25.8%)</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(16.1%)</p>
</td><td valign='top' style='background-color:#CCEEFF;width:67.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(14.0%)</p>
</td></tr>
<tr><td valign='top' style='width:203.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'>Gross Profit</p>
</td><td valign='top' style='width:63pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>+  0.9%</p>
</td><td valign='top' style='width:63pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(34.0%)</p>
</td><td valign='top' style='width:63pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(12.0%)</p>
</td><td valign='top' style='width:67.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(15.6%)</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:203.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'>Operating Income</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(  5.8%)</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(55.9%)</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(17.9%)</p>
</td><td valign='top' style='background-color:#CCEEFF;width:67.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(27.2%)</p>
</td></tr>
<tr><td valign='top' style='width:203.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'>Earnings Before Income Tax</p>
</td><td valign='top' style='width:63pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(  3.6%)</p>
</td><td valign='top' style='width:63pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(56.7%)</p>
</td><td valign='top' style='width:63pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(19.3%)</p>
</td><td valign='top' style='width:67.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(27.4%)</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:203.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'>Net Income</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>-</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(62.8%)</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(20.8%)</p>
</td><td valign='top' style='background-color:#CCEEFF;width:67.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(28.8%)</p>
</td></tr>
<tr><td valign='top' style='width:203.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'>Earnings Per Share</p>
</td><td valign='top' style='width:63pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>-</p>
</td><td valign='top' style='width:63pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(62.0%)</p>
</td><td valign='top' style='width:63pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(19.0%)</p>
</td><td valign='top' style='width:67.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(27.6%)</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:203.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'><span style='border-bottom:1px solid #000000'>Revenues [USD denominated]</span></p>
</td><td valign='top' style='width:63pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'><span style='border-bottom:1px solid #000000'>1Q</span></p>
</td><td valign='top' style='width:63pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'><span style='border-bottom:1px solid #000000'>2Q</span></p>
</td><td valign='top' style='width:63pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'><span style='border-bottom:1px solid #000000'>3Q</span></p>
</td><td valign='top' style='width:67.5pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'><span style='border-bottom:1px solid #000000'>9M</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:203.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'>U.S. domestic &#160;(excluding OEM)</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>+ 14.5%</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(29.1%)</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(8.0%)</p>
</td><td valign='top' style='background-color:#CCEEFF;width:67.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>( &#160;9.2%)</p>
</td></tr>
<tr><td valign='top' style='width:203.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'>Canada domestic</p>
</td><td valign='top' style='width:63pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(21.7%)</p>
</td><td valign='top' style='width:63pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(62.9%)</p>
</td><td valign='top' style='width:63pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>( 5.6%)</p>
</td><td valign='top' style='width:67.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(32.0%)</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:203.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'>Ireland domestic</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(26.2%)</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(48.6%)</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(18.1%)</p>
</td><td valign='top' style='background-color:#CCEEFF;width:67.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(30.9%)</p>
</td></tr>
<tr><td valign='top' style='width:203.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'>UK domestic</p>
</td><td valign='top' style='width:63pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(11.2%)</p>
</td><td valign='top' style='width:63pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(72.8%)</p>
</td><td valign='top' style='width:63pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(34.4%)</p>
</td><td valign='top' style='width:67.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(38.7%)</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:203.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'>France domestic</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(11.8%)</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(72.1%)</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(12.3%)</p>
</td><td valign='top' style='background-color:#CCEEFF;width:67.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(32.6%)</p>
</td></tr>
<tr><td valign='top' style='width:203.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'>Australia domestic</p>
</td><td valign='top' style='width:63pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'><span style='border-bottom:1px solid #000000'>( &#160;8.6%)</span></p>
</td><td valign='top' style='width:63pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'><span style='border-bottom:1px solid #000000'>(43.0%)</span></p>
</td><td valign='top' style='width:63pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'><span style='border-bottom:1px solid #000000'>(13.6%)</span></p>
</td><td valign='top' style='width:67.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'><span style='border-bottom:1px solid #000000'>(22.0%)</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:203.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:right'>Subtotal, Direct to End User:</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>+ &#160;4.2%</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(39.1%)</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(11.1%)</p>
</td><td valign='top' style='background-color:#CCEEFF;width:67.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(16.3%)</p>
</td></tr>
<tr><td valign='top' style='width:203.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'>All Other OUS (Sales to Int&#8217;l Distributors)</p>
</td><td valign='top' style='width:63pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'> ( &#160;5.2%)</p>
</td><td valign='top' style='width:63pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>( &#160;4.5%)</p>
</td><td valign='top' style='width:63pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(34.7%)</p>
</td><td valign='top' style='width:67.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(15.6%)</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:203.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'>U.S. OEM Sales</p>
</td><td valign='top' style='background-color:#CCEEFF;width:63pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'><span style='border-bottom:3px double #000000'>+  0.7%</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:63pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'><span style='border-bottom:3px double #000000'>+  9.5%</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:63pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'><span style='border-bottom:3px double #000000'>(  8.9%)</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:67.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'><span style='border-bottom:3px double #000000'>( &#160;0.6%)</span></p>
</td></tr>
<tr><td valign='top' style='width:203.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:right'>Worldwide Revenues</p>
</td><td valign='top' style='width:63pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>+  1.6%</p>
</td><td valign='top' style='width:63pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(25.8%)</p>
</td><td valign='top' style='width:63pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(16.1%)</p>
</td><td valign='top' style='width:67.5pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt;text-align:center'>(14.0%)</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>UTMD subsidiary direct domestic sales in Canada, Ireland, the United Kingdom, France and Australia are invoiced in foreign currencies. Foreign currency exchange (FX) rates for income statement purposes are transaction-weighted averages. The average rates from the applicable foreign currency to USD during 3Q 2020 and 9M 2020 compared to the same periods in 2019 follow:</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:67.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:67.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>3Q 20</span></p>
</td><td valign='top' style='width:67.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>3Q 19</span></p>
</td><td valign='top' style='width:68.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>Change</span></p>
</td><td valign='top' style='width:67.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>9M 20</span></p>
</td><td valign='top' style='width:67.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>9M 19</span></p>
</td><td valign='top' style='width:68.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>Change</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:67.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>GBP</p>
</td><td valign='top' style='background-color:#CCEEFF;width:67.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.295</p>
</td><td valign='top' style='background-color:#CCEEFF;width:67.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.233</p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.6pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>+5.0%</p>
</td><td valign='top' style='background-color:#CCEEFF;width:67.3pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.279</p>
</td><td valign='top' style='background-color:#CCEEFF;width:67.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.273</p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>+0.5%</p>
</td></tr>
<tr><td valign='top' style='width:67.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>EUR</p>
</td><td valign='top' style='width:67.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.173</p>
</td><td valign='top' style='width:67.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.108</p>
</td><td valign='top' style='width:68.6pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>+5.8%</p>
</td><td valign='top' style='width:67.3pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.128</p>
</td><td valign='top' style='width:67.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.123</p>
</td><td valign='top' style='width:68.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>+0.4%</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:67.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>AUD</p>
</td><td valign='top' style='background-color:#CCEEFF;width:67.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.714</p>
</td><td valign='top' style='background-color:#CCEEFF;width:67.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.687</p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.6pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>+4.0%</p>
</td><td valign='top' style='background-color:#CCEEFF;width:67.3pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.677</p>
</td><td valign='top' style='background-color:#CCEEFF;width:67.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.700</p>
</td><td valign='top' style='background-color:#CCEEFF;width:68.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(3.3%)</p>
</td></tr>
<tr><td valign='top' style='width:67.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>CAD</p>
</td><td valign='top' style='width:67.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.751</p>
</td><td valign='top' style='width:67.3pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.758</p>
</td><td valign='top' style='width:68.6pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(0.8%)</p>
</td><td valign='top' style='width:67.3pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.745</p>
</td><td valign='top' style='width:67.35pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.752</p>
</td><td valign='top' style='width:68.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>(1.0%)</p>
</td></tr>
</table>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>9</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><a href='#a2' style='text-decoration:none'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'>Table of Contents</span></a></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Although the volatility of &#160;FX rates for OUS sales when consolidated in USD terms continues to impact period-to-period relative financial results because of UTMD&#8217;s significant percentage of foreign currency sales, the FX rate impact in 9M 2020 was less significant than in the recent past. Except for the CAD FX rate which had not changed as significantly as other currencies, a healthy 3Q 2020 decline in the USD offset its strengthening during the first half of the year. Foreign currency revenues in 3Q 2020 were increased by $85 as a result of a weaker USD compared to 3Q 2019. &#160;In contrast, the difference in period-to-period FX rates reduced revenues by $36 in 9M 2020. &#160;Foreign currency sales as a percentage of total sales were 21.0% of total sales in 3Q 2020 and 22.0% of total sales in 9M 2020. &#160;UTMD&#8217;s 3Q 2019 and 9M 2019 revenues invoiced in foreign currencies represented 23.6% and 27.2% of total consolidated USD sales respectively.</p>
<p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'>Other factors that affected period-to-period revenue comparisons included </p>
<p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'><kbd style='position:absolute;font:10pt Times New Roman;margin-left:0pt'>1)</kbd><kbd style='margin-left:30.6pt'></kbd>International distributors&#8217; quarter-to-quarter orders fluctuate more than domestic end user orders.&#160;</p>
<p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'><kbd style='position:absolute;font:10pt Times New Roman;margin-left:0pt'>2)</kbd><kbd style='margin-left:30.6pt'></kbd>1Q 2019 was a partial quarter of U.S. domestic Filshie Clip System (Filshie device) sales, as the UTMD acquisition of the Cooper Surgical Inc. (CSI) exclusive Filshie device distribution rights took effect February 1, 2019. &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;text-indent:4.3pt;margin-left:-4.3pt'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;text-indent:4.3pt;margin-left:-4.3pt'>UTMD profit margins in 3Q 2020 and 9M 2020 compared to 3Q 2019 and 9M 2019 follow:</p>
<p style='font:10pt Times New Roman;margin:0;text-indent:4.3pt;margin-left:-4.3pt'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:225.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt'>&#160;</p>
</td><td valign='top' style='width:61.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'><span style='border-bottom:1px solid #000000'>3Q 2020 </span></p>
<p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'><span style='border-bottom:1px solid #000000'>(Jul &#8211;&#160;Sep)</span></p>
</td><td valign='top' style='width:61.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt;text-align:center'><span style='border-bottom:1px solid #000000'>3Q &#160;2019</span></p>
<p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt;text-align:center'><span style='border-bottom:1px solid #000000'>(Jul &#8211;&#160;Sep)</span></p>
</td><td valign='top' style='width:61.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt;text-align:center'><span style='border-bottom:1px solid #000000'>9M &#160;2020</span></p>
<p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt;text-align:center'><span style='border-bottom:1px solid #000000'>(Jan &#8211;&#160;Sep)</span></p>
</td><td valign='top' style='width:62.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt;text-align:center'><span style='border-bottom:1px solid #000000'>9M &#160;2019</span></p>
<p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt;text-align:center'><span style='border-bottom:1px solid #000000'>(Jan &#8211;&#160;Sep)</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:225.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'>Gross Profit Margin (gross profits/ sales):</p>
</td><td valign='top' style='background-color:#CCEEFF;width:61.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>62.0%</p>
</td><td valign='top' style='background-color:#CCEEFF;width:61.7pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>59.1%</p>
</td><td valign='top' style='background-color:#CCEEFF;width:61.65pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>60.6%</p>
</td><td valign='top' style='background-color:#CCEEFF;width:62.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>61.7%</p>
</td></tr>
<tr><td valign='top' style='width:225.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'>Operating Income Margin (operating profits/ sales):</p>
</td><td valign='top' style='width:61.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>34.2%</p>
</td><td valign='top' style='width:61.7pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>35.0%</p>
</td><td valign='top' style='width:61.65pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>31.3%</p>
</td><td valign='top' style='width:62.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>36.9%</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:225.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'>Net Income Margin (profit after taxes/ sales):</p>
</td><td valign='top' style='background-color:#CCEEFF;width:61.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>28.0%</p>
</td><td valign='top' style='background-color:#CCEEFF;width:61.7pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>29.7%</p>
</td><td valign='top' style='background-color:#CCEEFF;width:61.65pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>25.2%</p>
</td><td valign='top' style='background-color:#CCEEFF;width:62.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>29.6%</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Gross Profit in 3Q 2020 declined less than the sales decline primarily as a result of sales mix. The 9M 2020 gross profit margin (GPM), gross profit divided by sales, was lower than in 9M 2019 despite the better 3Q GPM because 14% lower sales during 9M 2020 absorbed marginally less of UTMD&#8217;s fixed critical mass of manufacturing overhead. Because UTMD believes that the lower sales are transitory, knows it can remain very profitable even at the lower sales levels experienced during the pandemic and has a significant cash reserve relative to operational needs, management will not cut important resources and sacrifice future capabilities just to maintain short term profit margins. </p>
<p style='font:10pt Times New Roman;margin:0;margin-left:36pt'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Operating Income declined more than gross profit in both 3Q 2020 and 9M 2020 because UTMD&#8217;s non-cash identifiable intangible asset (IIA) amortization expense included in operating expenses was 15.5% of sales in 3Q 2020 compared to 12.8% of sales in 3Q 2019, and 16.0% in 9M 2020 compared to 12.7% in 9M 2019. &#160;This was due not only to the lower sales in 2020 (less absorption of a fixed expense) but also the GBP FX rate difference in the 3Q and the timing of beginning the CSI IIA amortization in 2019.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Earnings before tax (EBT) declined more than operating income simply because UTMD did not receive interest on its cash balances in 2020 like it did in 2019, although average cash balances were about 20% higher during 9M 2020. &#160;Net Income declined slightly more than EBT as a result of the sovereignty mix of taxable profits in 2020 compared to 2019. &#160;The lowest tax regimes of Ireland and the UK had the greatest declines in EBT. Finally, Earnings Per Share (EPS) declined less than net income as a result of the benefit of share repurchases in 2020.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>UTMD&#8217;s FX rates for balance sheet purposes are the applicable rates at the <span style='border-bottom:1px solid #000000'>end</span> of each reporting period. The FX rates from the applicable foreign currency to USD for assets and liabilities at the end of September 2020 and the end of September 2019 follow:</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:260.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'>&#160;</p>
</td><td valign='top' style='width:70.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'><span style='border-bottom:1px solid #000000'>Sep 30, 2020</span></p>
</td><td valign='top' style='width:70.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt;text-align:center'><span style='border-bottom:1px solid #000000'>Sep 30, 2019</span></p>
</td><td valign='top' style='width:72.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt;text-align:center'><span style='border-bottom:1px solid #000000'>Change</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:260.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>GBP</p>
</td><td valign='top' style='background-color:#CCEEFF;width:70.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.292</p>
</td><td valign='top' style='background-color:#CCEEFF;width:70.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.230</p>
</td><td valign='top' style='background-color:#CCEEFF;width:72.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>+5.0%</p>
</td></tr>
<tr><td valign='top' style='width:260.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>EUR</p>
</td><td valign='top' style='width:70.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.172</p>
</td><td valign='top' style='width:70.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>1.091</p>
</td><td valign='top' style='width:72.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>+7.5%</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:260.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>AUD</p>
</td><td valign='top' style='background-color:#CCEEFF;width:70.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.716</p>
</td><td valign='top' style='background-color:#CCEEFF;width:70.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.675</p>
</td><td valign='top' style='background-color:#CCEEFF;width:72.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>+6.1%</p>
</td></tr>
<tr><td valign='top' style='width:260.45pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>CAD</p>
</td><td valign='top' style='width:70.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.751</p>
</td><td valign='top' style='width:70.6pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>0.755</p>
</td><td valign='top' style='width:72.1pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>(0.6%)</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>UTMD&#8217;s September 30, 2020 Balance Sheet remained strong with an absence of debt. During 2020, inventories declined $0.6 million despite much lower sales, which is an indication of good manufacturing planning and control. Due to the increase in value of the GBP, EUR and AUD noted above, despite depreciation of fixed assets, the USD net book value of fixed assets in the UK, Ireland and Australia increased $0.6 million as of September 30, 2020 from September 30, 2019. Over the one year period of time, the intangible asset balance declined $5.5 million, about 12%. &#160;Ending cash and investments were $46.3 million on September 30, 2020 compared to $42.8 million on December 31, 2019, after paying $3.1 million in cash dividends to stockholders and repurchasing $7.0 million in UTMD stock during 9M 2020. &#160;After reducing stockholders&#8217; equity a combined $10.1 million in 9M 2020 stockholder dividends and share repurchases, September 30, 2020 stockholders&#8217; equity was down only $2.7 million from December 31, 2019.</p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>10</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><a href='#a2' style='text-decoration:none'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'>Table of Contents</span></a></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:10.8pt'>b)</kbd><kbd style='margin-left:24.3pt'></kbd>Revenues&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Beginning on January 1, 2018, the Company adopted ASU 2014-09, the new revenue recognition accounting standard. &#160;Management completed an extensive assessment and implementation of the standard, including UTMD&#8217;s various contracts with customers and associated performance obligations and the Company&#8217;s conclusions regarding its revenue recognition practices and procedures. Other items like commissions and rights of return were also evaluated by the Company. Management is confident that the Company has properly evaluated the standard&#8217;s requirements and has arrived at appropriate conclusions in recognizing revenue in accordance with the new standard. &#160;Those practices and procedures the Company will use to recognize revenue under the new standard are not significantly different than the methods used previously since UTMD has traditionally recognized revenue upon shipping a physical product to a customer, which is also when the Company has met its performance obligations under contracts it has with its customers that represent over 99% of its revenue. While the Company&#8217;s revenue not associated with shipping a physical product is immaterial, management believes the Company&#8217;s practices in recognizing that revenue is also in accordance with ASU 2014-09.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Terms of sale are established in advance of UTMD&#8217;s acceptance of customer orders. &#160;In the U.S., Ireland, UK, France, Canada and Australia, UTMD generally accepts orders directly from and ships directly to end user clinical facilities, as well as third party medical/surgical distributors, under UTMD&#8217;s Standard Terms and Conditions (T&amp;C) of Sale. About 14% of UTMD&#8217;s domestic end user sales, excluding Filshie device sales, go through third party med/surg distributors which contract separately with clinical facilities to provide purchasing, storage and scheduled delivery functions for the applicable facility. &#160;UTMD&#8217;s T&amp;C of Sale to end user facilities are substantially the same in the U.S., Ireland, UK, France, Canada and Australia.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>UTMD may have separate discounted pricing agreements with a specific clinical facility or group of affiliated facilities based on volume of purchases. &#160;Pricing agreements which are documented arrangements with clinical facilities, or groups of affiliated facilities, if applicable, are established in advance of orders accepted or shipments made. For existing customers, past actual shipment volumes typically determine the fixed price by part number for the next agreement period of one year. For new customers, the customer&#8217;s best estimate of volume is usually accepted by UTMD for determining the ensuing fixed prices for the agreement period. Prices are not adjusted after an order is accepted. For the sake of clarity, the separate pricing agreements with clinical facilities based on volume of purchases disclosure is not inconsistent with UTMD&#8217;s disclosure that the selling price is fixed prior to the acceptance of a specific customer order. &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Total consolidated 3Q 2020 UTMD sales were $2,016 (16.1%) lower than in 3Q 2019. Constant currency sales were $2,101 (16.8%) lower. Total consolidated 9M 2020 UTMD sales were $4,905 (14.0%) lower than in 9M 2019. &#160;Constant currency sales in 9M 2020 were $4,869 (13.9%) lower than in 9M 2019. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>In 3Q 2020 compared to 3Q 2019, U.S. domestic sales were 8% lower and OUS sales were 28% lower. &#160;&#160;In 9M 2020 compared to 9M 2019, U.S. domestic sales were 7% lower and OUS sales were 23% lower. &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'>Domestic sales in 3Q 2020 were $6,950 compared to $7,575 in 3Q 2019. &#160;Domestic sales in 9M 2020 were $18,906 compared to $20,366 in 9M 2019. &#160;The components of domestic sales include 1) &#8220;direct sales&#8221; of UTMD&#8217;s medical devices to user facilities (and med/surg stocking distributors for hospitals), excluding Filshie Clip System (&#8220;Filshie device&#8221;) sales, 2) &#8220;OEM sales&#8221; of components and other products manufactured by UTMD for other medical device and non-medical device companies, and 3) Filshie device sales direct to U.S. medical facilities starting in February 2019. &#160;</p>
<p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'>Domestic direct sales in 3Q 2020 excluding Filshie devices, representing 50% of total domestic sales, were $178 (5%) lower than in 3Q 2019. &#160;Domestic direct sales in 9M 2020 excluding Filshie devices, representing 51% of total domestic sales, were $1,078 (10%) lower than in 9M 2019. OEM sales in 3Q 2020, representing 25% of total domestic sales, were $172 (9%) lower than in 3Q 2019. OEM sales in 9M 2020, also representing 25% of total domestic sales, were $27 (1%) lower than in 9M 2019. Filshie device sales direct to U.S. domestic end-user facilities were $275 (14%) lower in 3Q 2020 compared to sales in 3Q 2019. &#160;Filshie device sales direct to U.S. domestic end-user facilities were $355 (7%) lower in 9M 2020 compared to Filshie device sales in 9M 2019. &#160;Because Filshie device sales are a significant portion of UTMD&#8217;s domestic business and a UTMD device most affected by the COVID-19 pandemic, management believes the following table might help to see the overall 2020 pandemic impact and recovery trend:</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Filshie device sequential quarterly USD domestic direct sales in the U.S. </p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:225.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'><span style='border-bottom:1px solid #000000'>Year</span></p>
</td><td valign='top' style='width:61.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'><span style='border-bottom:1px solid #000000'>1Q</span></p>
</td><td valign='top' style='width:61.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt;text-align:center'><span style='border-bottom:1px solid #000000'>2Q</span></p>
</td><td valign='top' style='width:61.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt;text-align:center'><span style='border-bottom:1px solid #000000'>3Q</span></p>
</td><td valign='top' style='width:62.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt;text-align:center'><span style='border-bottom:1px solid #000000'>9M</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:225.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'>2020</p>
</td><td valign='top' style='background-color:#CCEEFF;width:61.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>1,689</p>
</td><td valign='top' style='background-color:#CCEEFF;width:61.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>1,135</p>
</td><td valign='top' style='background-color:#CCEEFF;width:61.65pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>1,733</p>
</td><td valign='top' style='background-color:#CCEEFF;width:62.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>4,557</p>
</td></tr>
<tr><td valign='top' style='width:225.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'>2019</p>
</td><td valign='top' style='width:61.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>925</p>
</td><td valign='top' style='width:61.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>1,979</p>
</td><td valign='top' style='width:61.65pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>2,008</p>
</td><td valign='top' style='width:62.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>4,912</p>
</td></tr>
</table>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>11</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><a href='#a2' style='text-decoration:none'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'>Table of Contents</span></a></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0'>OUS sales in 3Q 2020 were $3,528 compared to $4,919 in 3Q 2019. &#160;OUS sales in 9M 2020 were $11,262 compared to $14,707 in 9M 2019. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>OUS sales invoiced in GBP, EUR, AUD and CAD currencies were $85 higher in 3Q 2020 and $36 lower in 9M 2020 as a result of changes in FX rates. Foreign currency OUS sales in 3Q 2020 were $2,205, which was 62% of all OUS sales and 21% of total consolidated sales. &#160;In comparison, foreign currency OUS sales in 3Q 2019 were $2,944, which was 60% of all OUS sales and 24% of total consolidated sales. &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'>The foreign currency OUS sales in 9M 2020 were $6,653, which was 59% of all OUS sales and 22% of total consolidated sales. &#160;In comparison, foreign currency OUS sales in 9M 2019 were $9,534, which was 65% of all OUS sales and 27% of total consolidated sales. &#160;Because Filshie device sales are also a significant portion of UTMD&#8217;s OUS business and an implanted device most affected by the COVID-19 pandemic, management believes the following table might help to see the overall 2020 pandemic impact and recovery trend:</p>
<p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Filshie device OUS sequential quarterly USD-denominated sales:</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:112.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'>&#160;</p>
</td><td valign='top' style='width:112.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'><span style='border-bottom:1px solid #000000'>Year</span></p>
</td><td valign='top' style='width:61.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'><span style='border-bottom:1px solid #000000'>1Q</span></p>
</td><td valign='top' style='width:61.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt;text-align:center'><span style='border-bottom:1px solid #000000'>2Q</span></p>
</td><td valign='top' style='width:61.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt;text-align:center'><span style='border-bottom:1px solid #000000'>3Q</span></p>
</td><td valign='top' style='width:62.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.5pt;text-align:center'><span style='border-bottom:1px solid #000000'>9M</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:112.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'>Direct</p>
</td><td valign='top' style='background-color:#CCEEFF;width:112.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'>2020</p>
</td><td valign='top' style='background-color:#CCEEFF;width:61.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>1,798</p>
</td><td valign='top' style='background-color:#CCEEFF;width:61.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>681</p>
</td><td valign='top' style='background-color:#CCEEFF;width:61.65pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>1,426</p>
</td><td valign='top' style='background-color:#CCEEFF;width:62.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>3,905</p>
</td></tr>
<tr><td valign='top' style='width:112.85pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'>&#160;</p>
</td><td valign='top' style='width:112.9pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'>2019</p>
</td><td valign='top' style='width:61.7pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>2,135</p>
</td><td valign='top' style='width:61.7pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>2,036</p>
</td><td valign='top' style='width:61.65pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>1,810</p>
</td><td valign='top' style='width:62.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>5,981</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:112.85pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'>Distributor</p>
</td><td valign='top' style='background-color:#CCEEFF;width:112.9pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'>2020</p>
</td><td valign='top' style='background-color:#CCEEFF;width:61.7pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>318</p>
</td><td valign='top' style='background-color:#CCEEFF;width:61.7pt;padding-right:5.75pt;border-top:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>323</p>
</td><td valign='top' style='background-color:#CCEEFF;width:61.65pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>133</p>
</td><td valign='top' style='background-color:#CCEEFF;width:62.95pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>774</p>
</td></tr>
<tr><td valign='top' style='width:112.85pt;padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'>&#160;</p>
</td><td valign='top' style='width:112.9pt;padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'>2019</p>
</td><td valign='top' style='width:61.7pt;padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>494</p>
</td><td valign='top' style='width:61.7pt;padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>487</p>
</td><td valign='top' style='width:61.65pt;padding-right:5.75pt;border-bottom:3px double #000000;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>437</p>
</td><td valign='top' style='width:62.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>1,418</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:112.85pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'>Total OUS</p>
</td><td valign='top' style='background-color:#CCEEFF;width:112.9pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'>2020</p>
</td><td valign='top' style='background-color:#CCEEFF;width:61.7pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>2,117</p>
</td><td valign='top' style='background-color:#CCEEFF;width:61.7pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>1,003</p>
</td><td valign='top' style='background-color:#CCEEFF;width:61.65pt;padding-right:5.75pt;border-top:3px double #000000;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>1,559</p>
</td><td valign='top' style='background-color:#CCEEFF;width:62.95pt;padding-right:5.75pt;border-top:3px double #000000;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>4,679</p>
</td></tr>
<tr><td valign='top' style='width:112.85pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'>&#160;</p>
</td><td valign='top' style='width:112.9pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'>2019</p>
</td><td valign='top' style='width:61.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>2,630</p>
</td><td valign='top' style='width:61.7pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>2,523</p>
</td><td valign='top' style='width:61.65pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>2,246</p>
</td><td valign='top' style='width:62.95pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-indent:7.1pt;margin-right:-6.3pt;text-align:center'>7,399</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'> &#160;</p>
<p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'>OUS Filshie sales obviously took a deeper hit from the pandemic than in the U.S. </p>
<p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'>UTMD segments sales into the following general product categories: &#160;gynecology/ electrosurgery, labor &amp; delivery, neonatal, and miscellaneous including blood pressure monitoring kits and accessories as well as related OEM products. &#160;</p>
<p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'>In 3Q 2020 compared to 3Q 2019, worldwide gynecology/ electrosurgery device sales were down 21%, worldwide labor &amp; delivery device sales were essentially the same, worldwide neonatal device sales were down 6% and worldwide blood pressure monitoring and related OEM product sales were down 18%. &#160;Devices in the gynecology/ electrosurgery category were mostly classified as &#8220;nonessential&#8221; during the pandemic. &#160;In the blood pressure monitoring category, UTMD&#8217;s largest OUS distributor took a double quarterly shipment in 3Q 2019.</p>
<p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'>In 9M 2020 compared to 9M 2019, worldwide gynecology/ electrosurgery device sales were down 22%, worldwide labor &amp; delivery device sales were down 13%, worldwide neonatal device sales were down 2% and worldwide blood pressure monitoring and related OEM product sales were down 3%.</p>
<p style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>The following table provides USD sales amounts divided into general product categories for total sales and the subset of OUS sales:</p>
<p style='font:12pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Global 3Q 2020 revenues (USD) by product category:</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:583.25pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>Domestic</span></p>
</td><td valign='top' style='width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>Outside US</span></p>
</td><td valign='top' style='width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>Total</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:583.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Obstetrics</p>
</td><td valign='top' style='background-color:#CCEEFF;width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$  &#160; 1,032</p>
</td><td valign='top' style='background-color:#CCEEFF;width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;  &#160;&#160;&#160;247</p>
</td><td valign='top' style='background-color:#CCEEFF;width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$  &#160;&#160;1,279</p>
</td></tr>
<tr><td valign='top' style='width:583.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Gynecology/Electrosurgery/Urology</p>
</td><td valign='top' style='width:170.75pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>2,847</span></p>
</td><td valign='top' style='width:170.75pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>2,202</span></p>
</td><td valign='top' style='width:170.75pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>5,049</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:583.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Neonatal</p>
</td><td valign='top' style='background-color:#CCEEFF;width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>1,151</p>
</td><td valign='top' style='background-color:#CCEEFF;width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>348</p>
</td><td valign='top' style='background-color:#CCEEFF;width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>1,499</p>
</td></tr>
<tr><td valign='top' style='width:583.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>Blood Pressure Monitoring and Accessories*</span></p>
</td><td valign='top' style='width:170.75pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman;border-bottom:1px solid #000000'>1,920</span></p>
</td><td valign='top' style='width:170.75pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman;border-bottom:1px solid #000000'>732</span></p>
</td><td valign='top' style='width:170.75pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman;border-bottom:1px solid #000000'>2,652</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:583.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Total:</p>
</td><td valign='top' style='background-color:#CCEEFF;width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$  &#160; 6,950</p>
</td><td valign='top' style='background-color:#CCEEFF;width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$  &#160; 3,529</p>
</td><td valign='top' style='background-color:#CCEEFF;width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 10,479</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0;color:#000000'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Global 9M 2020 revenues (USD) by product category:</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:583.25pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>Domestic</span></p>
</td><td valign='top' style='width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>Outside US</span></p>
</td><td valign='top' style='width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>Total</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:583.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Obstetrics</p>
</td><td valign='top' style='background-color:#CCEEFF;width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$  &#160; 2,739</p>
</td><td valign='top' style='background-color:#CCEEFF;width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$  &#160;&#160;&#160;&#160; 612</p>
</td><td valign='top' style='background-color:#CCEEFF;width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$  &#160;&#160;3,351</p>
</td></tr>
<tr><td valign='top' style='width:583.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Gynecology/Electrosurgery/Urology</p>
</td><td valign='top' style='width:170.75pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>7,686</span></p>
</td><td valign='top' style='width:170.75pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>6,945</span></p>
</td><td valign='top' style='width:170.75pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman'>14,631</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:583.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Neonatal</p>
</td><td valign='top' style='background-color:#CCEEFF;width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>3,266</p>
</td><td valign='top' style='background-color:#CCEEFF;width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>1,169</p>
</td><td valign='top' style='background-color:#CCEEFF;width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>4,435</p>
</td></tr>
<tr><td valign='top' style='width:583.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>Blood Pressure Monitoring and Accessories*</span></p>
</td><td valign='top' style='width:170.75pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman;border-bottom:1px solid #000000'>5,215</span></p>
</td><td valign='top' style='width:170.75pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman;border-bottom:1px solid #000000'>2,536</span></p>
</td><td valign='top' style='width:170.75pt;padding-right:5.75pt'><p style='font:10pt CG Times;margin:0;text-align:right'><span style='font-family:Times New Roman;border-bottom:1px solid #000000'>7,751</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:583.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Total:</p>
</td><td valign='top' style='background-color:#CCEEFF;width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 18,906</p>
</td><td valign='top' style='background-color:#CCEEFF;width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 11,262</p>
</td><td valign='top' style='background-color:#CCEEFF;width:170.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 30,168</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:24.3pt'></kbd>*includes molded components sold to OEM customers.&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Looking forward, although an increase in COVID-19 infections is likely in the winter months of 4Q 2020 in the northern hemisphere, assuming no significant new lockdowns or prohibitions of &#8220;nonessential procedures&#8221; are imposed by governments,  UTMD expects that its 4Q 2020 sales will continue to recover and be higher than in 3Q 2020. &#160;</p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>12</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><a href='#a2' style='text-decoration:none'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'>Table of Contents</span></a></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:10.8pt'>c)</kbd><kbd style='margin-left:24.3pt'></kbd>Gross Profit&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Gross Profit results from subtracting the costs of manufacturing and shipping products to customers from revenues. &#160;Gross Profit was $883 (12.0%) lower in 3Q 2020 than in 3Q 2019, and $3,369 (15.6%) lower in 9M 2020 than in 9M 2019. &#160;UTMD&#8217;s 3Q 2020 GPM improved to 62.0% compared to 59.1% in 3Q 2019 so that the decline in 3Q Gross Profit was not as significant as the 3Q decline in sales. Sales to international distributors are at lower prices for the same devices because the distributor incurs direct marketing expenses instead of UTMD. &#160;Sales to international distributors were only 18% of total sales in 3Q 2020 compared to 23% in 3Q 2019. The 3Q 2019 GPM was also exceptionally low because of a &#8220;double&#8221; shipment of blood pressure monitoring kits to UTMD&#8217;s China distributor. For 9M 2020 compared to 9M 2019, Gross Profit declined slightly more than the sales decline as a result of UTMD not cutting critical manufacturing overhead resources, and providing special incentives in 2Q 2020 for employees to come to work. Nevertheless, the 60.6% GPM for the 2020 year to date has met management&#8217;s long term objective. &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:10.8pt'>d)</kbd><kbd style='margin-left:22.5pt'></kbd>Operating Income&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Operating Income results from subtracting Operating Expenses from Gross Profit. Operating Expenses, comprised of general and administrative (G&amp;A) expenses, sales and marketing (S&amp;M) expenses and product development (R&amp;D) expenses, were 27.8% of sales in 3Q 2020 compared to 24.1% of sales in 3Q 2019. &#160;Operating Expenses were 29.4% of sales in 9M 2020 compared to 24.8% of sales in 9M 2019. Although the operating expense percentage of sales increased due to the 2020 short term pandemic reduction in sales, management continued to tightly manage operating expenses without sacrificing resources needed for longer term growth. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Summary comparison of (USD) consolidated operating expenses:</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:157.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>3Q 2020</span></p>
</td><td valign='top' style='width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>3Q 2019</span></p>
</td><td valign='top' style='width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>9M 2020</span></p>
</td><td valign='top' style='width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>9M 2019</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:157.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>S&amp;M Expense</p>
</td><td valign='top' style='background-color:#CCEEFF;width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;352</p>
</td><td valign='top' style='background-color:#CCEEFF;width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;421</p>
</td><td valign='top' style='background-color:#CCEEFF;width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;1,195</p>
</td><td valign='top' style='background-color:#CCEEFF;width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;1,304</p>
</td></tr>
<tr><td valign='top' style='width:157.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>R&amp;D Expense</p>
</td><td valign='top' style='width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>125</p>
</td><td valign='top' style='width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>130</p>
</td><td valign='top' style='width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>375</p>
</td><td valign='top' style='width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>357</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:157.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>G&amp;A Expense</p>
</td><td valign='top' style='background-color:#CCEEFF;width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>2,432</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>2,457</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>7,285</span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>7,037</span></p>
</td></tr>
<tr><td valign='top' style='width:157.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Total Operating Expenses:</p>
</td><td valign='top' style='width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;2,909</p>
</td><td valign='top' style='width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;3,008</p>
</td><td valign='top' style='width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;8,855</p>
</td><td valign='top' style='width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;8,698</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Lower S&amp;M expenses were due primarily to the lack of trade show expenses during the pandemic. S&amp;M expenses were 3.4% of sales in both 3Q 2020 and 3Q 2019. &#160;S&amp;M expenses were 4.0% of sales in 9M 2020 compared to 3.7% of sales in 9M 2019. &#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>R&amp;D expenses were consistent with the prior year&#8217;s same periods of time, varying only by specific project expenses. R&amp;D expenses were 1.2% of sales in 3Q 2020 compared to 1.0% of sales in 3Q 2019. &#160;R&amp;D expenses in 9M 2020 were also 1.2% of sales compared to 1.0% of sales in 9M 2019. &#160;&#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>The higher G&amp;A expense in 9M 2020 was due to amortization expense of the CSI IIA for a full quarter in 1Q 2020 compared to a partial quarter in 1Q 2019. &#160;Consolidated G&amp;A expenses were 23.2% of sales in 3Q 2020 compared to 19.7% of sales in 3Q 2019. &#160;Consolidated G&amp;A expenses were 24.1% of sales in 9M 2020 compared to 20.1% of sales in 9M 2019. &#160;G&amp;A expenses included non-cash expense from the amortization of IIA resulting from the March 2011 Femcare Group Ltd (UK) acquisition and the amortization of IIA from the purchase of the CSI U.S. exclusive Filshie devices distribution rights effective in February 2019. &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>The initial amount of IIA for the 2011 Femcare UK purchase was &#163;23,998. &#160;After 9.5 years of amortization, the IIA balance is &#163;8,686. &#160;For both years of 2020 and 2019, the amortization expense rate was a constant &#163;399 per calendar quarter. The USD amortization expense amount in each period, however, varied according to the USD/GBP FX rate. </p>
<p style='font:10pt Times New Roman;margin:0'> &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>The initial amount of IIA for the 2019 acquisition of 4.75 years&#8217; remaining exclusive U.S. Filshie device distribution rights from CSI was $21,000. &#160;The straight-line amortization of this IIA is $1,105/ calendar quarter over the remaining 4.75 years of the prior distribution agreement. After 20 months of amortization, the CSI IIA balance as of September 30, 2020 is $13,632. &#160;The difference in 9M CSI IIA amortization expense is due to the start of the amortization in February 2019, i.e. 9 months of expense in 2020 through September versus 8 months in 2019. </p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>13</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><a href='#a2' style='text-decoration:none'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'>Table of Contents</span></a></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0'>Because the IIA amortization expenses represent a significant portion of UTMD&#8217;s G&amp;A expenses, UTMD provides the following table that separates the IIA amortization expenses from all other G&amp;A expenses:</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:157.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>3Q 2020</span></p>
</td><td valign='top' style='width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>3Q 2019</span></p>
</td><td valign='top' style='width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>9M 2020</span></p>
</td><td valign='top' style='width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>9M 2019</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:157.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>IIA amortization expense</p>
</td><td valign='top' style='background-color:#CCEEFF;width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;1,621</p>
</td><td valign='top' style='background-color:#CCEEFF;width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;1,597</p>
</td><td valign='top' style='background-color:#CCEEFF;width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;4,839</p>
</td><td valign='top' style='background-color:#CCEEFF;width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;4,471</p>
</td></tr>
<tr><td valign='top' style='width:157.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>All other G&amp;A expense</p>
</td><td valign='top' style='width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>811</span></p>
</td><td valign='top' style='width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>860</span></p>
</td><td valign='top' style='width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>2,445</span></p>
</td><td valign='top' style='width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>2,566</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:157.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Total G&amp;A Expenses:</p>
</td><td valign='top' style='background-color:#CCEEFF;width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;2,432</p>
</td><td valign='top' style='background-color:#CCEEFF;width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;2,457</p>
</td><td valign='top' style='background-color:#CCEEFF;width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;7,284</p>
</td><td valign='top' style='background-color:#CCEEFF;width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;7,037</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:157.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Percent of Sales:</p>
</td><td valign='top' style='width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>3Q 2020</span></p>
</td><td valign='top' style='width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>3Q 2019</span></p>
</td><td valign='top' style='width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>9M 2020</span></p>
</td><td valign='top' style='width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>9M 2019</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:157.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>IIA amortization expense</p>
</td><td valign='top' style='background-color:#CCEEFF;width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>15.5%</p>
</td><td valign='top' style='background-color:#CCEEFF;width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>12.8%</p>
</td><td valign='top' style='background-color:#CCEEFF;width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>16.0%</p>
</td><td valign='top' style='background-color:#CCEEFF;width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>12.8%</p>
</td></tr>
<tr><td valign='top' style='width:157.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>All other G&amp;A expense</p>
</td><td valign='top' style='width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>7.7%</span></p>
</td><td valign='top' style='width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>6.9%</span></p>
</td><td valign='top' style='width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>8.1%</span></p>
</td><td valign='top' style='width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>7.3%</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:157.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Total G&amp;A Expenses:</p>
</td><td valign='top' style='background-color:#CCEEFF;width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>23.2%</p>
</td><td valign='top' style='background-color:#CCEEFF;width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>19.7%</p>
</td><td valign='top' style='background-color:#CCEEFF;width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>24.1%</p>
</td><td valign='top' style='background-color:#CCEEFF;width:78.95pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>20.1%</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'> &#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Eventually, when the two Filshie-related IIA balances are fully amortized, stockholders can look forward to a substantial increase in EBT. The Femcare acquisition IIA amortization expense has 5.5 more years to run at about $516 per quarter using the same 1.295 USD/GBP FX rate as in 3Q 2020. &#160;The CSI IIA amortization expense has 3.1 more years to run at $1,105 per quarter. &#160;Stockholders will appreciate that, although cash flow will not be affected, annualized reported EPS will increase $.90 after another 3.1 years, based on current shares outstanding and if current U.S. and Utah income tax rates remain the same. Similarly, after another 5.5 years annualized EPS would be $1.36 higher based on current shares outstanding and unchanged income tax rates. &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Other G&amp;A expenses were lower in both periods primarily because UTMD&#8217;s CEO has taken 50% salary in 2020 compared to 2019, and 2020 management bonuses based on the projected 2020 annual EBT have been accrued at a lower rate than in 2019. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>In summary, Operating Income in 3Q 2020 was $3,588 (34.2% of sales) compared to $4,371 (35.0% of sales) in 3Q 2019. &#160;Operating Income in 9M 2020 was $9,428 (31.3% of sales) compared to $12,954 (36.9% of sales) in 9M 2019. &#160;Lower gross profits in 2020 were leveraged down further by higher IIA amortization expense absorbed by fewer sales. In any event, the operating income margins achieved in 2020 were excellent compared to industry peers.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:9pt'>e)</kbd><kbd style='margin-left:22.5pt'></kbd>Non-operating expense/ Non-operating income&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Non-operating expense includes 1) bank fees; 2) losses from remeasuring the value of EUR cash bank balances in the UK, and GBP cash balances in Ireland, in USD terms; and 3) losses from disposition of assets. &#160;Non-operating income includes 1) investment income from cash deposit balances; 2) rent of underutilized property; 3) royalties received from licensing the Company&#8217;s technology; 4) gains from dispositions of assets; and 5) gains from remeasuring the value of EUR cash bank balances in the UK, and GBP cash balances in Ireland, in USD terms. &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>UTMD&#8217;s net non-operating income in 3Q 2020 was less than $1 compared to $76 in 3Q 2019. &#160;Net non-operating income in 9M 2020 was $126 compared to $196 in 9M 2019. &#160;&#160;&#160;&#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>In 3Q 2020 and 3Q 2019, gains or losses from remeasurement of the value of foreign currency bank balances were negligible. In 9M 2020, UTMD recognized a $41 gain from remeasurement of the value of foreign currency bank balances compared to a $44 loss in 9M 2019. &#160;Royalties received were $5 in 3Q 2020 compared to $0 in 3Q 2019, and $10 in 9M 2020 compared to $6 in 9M 2019. Interest earned on cash balances were $2 and $64 in 3Q and 9M 2020 respectively, compared to interest of $61 and $199 in 3Q and 9M 2019 respectively. &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:9pt'>f)</kbd><kbd style='margin-left:22.5pt'></kbd>Income Before Income Taxes (EBT)&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>EBT results from subtracting net non-operating expense or adding net non-operating income from or to, as applicable, Operating Income. &#160;Consolidated 3Q 2020 EBT was $3,588 (34.2% of sales) compared to $4,448 (35.6% of sales) in 3Q 2019. &#160;Consolidated 9M 2020 EBT was $9,553 (31.7% of sales) compared to $13,150 (37.5% of sales) in 9M 2019. &#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>The EBT of Utah Medical Products, Inc. in the U.S. was $6,469 in 9M 2020 compared to $8,674 in 9M 2019. The EBT of Utah Medical Products, Ltd (Ireland) was EUR 2,393 in 9M 2020 compared to EUR 2,157 in 9M 2019. The EBT of Femcare Group Ltd (Femcare Ltd., UK and Femcare Australia Pty Ltd) was GBP (297) in 9M 2020 compared to GBP 1,449 in 9M 2019. The 9M 2020 EBT of Utah Medical Products Canada, Inc. (dba Femcare Canada) was CAD 565 in 9M 2020 compared to CAD 926 in 9M 2019. &#160;The EBT of UTMD&#8217;s manufacturing subsidiaries varies as a result of intercompany shipments which are eliminated in the consolidation of results. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>14</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><a href='#a2' style='text-decoration:none'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'>Table of Contents</span></a></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0'>EBITDA is a non-US GAAP metric that UTMD management believes is of interest to investors because it provides meaningful supplemental information to both management and investors that represents profitability performance without factoring in effects of financing, accounting decisions regarding non-cash expenses, capital expenditures or tax environments. Although the U.S. Securities and Exchange Commission advises that EBITDA is a non-GAAP metric, UTMD&#8217;s non-US GAAP EBITDA is the sum of the following elements in the table below, each of which is a US GAAP number:</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:171.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>Component of EBITDA</span></p>
</td><td valign='top' style='width:47.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>3Q 2020</span></p>
</td><td valign='top' style='width:47.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>3Q 2019</span></p>
</td><td valign='top' style='width:50.4pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>Change</span></p>
</td><td valign='top' style='width:50.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>9M 2020</span></p>
</td><td valign='top' style='width:50.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>9M 2019</span></p>
</td><td valign='top' style='width:50.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'><span style='border-bottom:1px solid #000000'>Change</span></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:171.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>EBT</p>
</td><td valign='top' style='background-color:#CCEEFF;width:47.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;3,588</p>
</td><td valign='top' style='background-color:#CCEEFF;width:47.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ &#160;4,448</p>
</td><td valign='top' style='background-color:#CCEEFF;width:50.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(19.3%)</p>
</td><td valign='top' style='background-color:#CCEEFF;width:50.75pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 9,553</p>
</td><td valign='top' style='background-color:#CCEEFF;width:50.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$13,150</p>
</td><td valign='top' style='background-color:#CCEEFF;width:50.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(27.4%)</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='width:171.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Depreciation of fixed assets</p>
</td><td valign='top' style='width:47.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>160</p>
</td><td valign='top' style='width:47.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>171</p>
</td><td valign='top' style='width:50.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:50.75pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>495</p>
</td><td valign='top' style='width:50.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>526</p>
</td><td valign='top' style='width:50.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF;width:171.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Amortization of patent expenses</p>
</td><td valign='top' style='background-color:#CCEEFF;width:47.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>13</p>
</td><td valign='top' style='background-color:#CCEEFF;width:47.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>13</p>
</td><td valign='top' style='background-color:#CCEEFF;width:50.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:50.75pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'> 37</p>
</td><td valign='top' style='background-color:#CCEEFF;width:50.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> 41</p>
</td><td valign='top' style='background-color:#CCEEFF;width:50.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='width:171.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Amortization of Femcare IIA</p>
</td><td valign='top' style='width:47.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> 516</p>
</td><td valign='top' style='width:47.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> 492</p>
</td><td valign='top' style='width:50.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:50.75pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>1,523</p>
</td><td valign='top' style='width:50.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>1,524</p>
</td><td valign='top' style='width:50.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF;width:171.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Amortization of CSI distribution agreement &#160;IIA</p>
</td><td valign='top' style='background-color:#CCEEFF;width:47.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> 1,105</p>
</td><td valign='top' style='background-color:#CCEEFF;width:47.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> 1,105</p>
</td><td valign='top' style='background-color:#CCEEFF;width:50.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:50.75pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>3,316</p>
</td><td valign='top' style='background-color:#CCEEFF;width:50.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>2,947</p>
</td><td valign='top' style='background-color:#CCEEFF;width:50.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='width:171.25pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0'>Stock option compensation expense</p>
</td><td valign='top' style='width:47.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> 49</p>
</td><td valign='top' style='width:47.65pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'> 29</p>
</td><td valign='top' style='width:50.4pt;padding-right:5.75pt;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='width:50.75pt;padding-right:5.75pt;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>121</p>
</td><td valign='top' style='width:50.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>85</p>
</td><td valign='top' style='width:50.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='background-color:#CCEEFF;width:171.25pt;padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0'>Remeasured currency (gains) or losses</p>
</td><td valign='top' style='background-color:#CCEEFF;width:47.65pt;padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>2</p>
</td><td valign='top' style='background-color:#CCEEFF;width:47.65pt;padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(3)</p>
</td><td valign='top' style='background-color:#CCEEFF;width:50.4pt;padding-right:5.75pt;border-bottom:3px double #000000;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:50.75pt;padding-right:5.75pt;border-left:0.5pt solid #000000;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(41)</p>
</td><td valign='top' style='background-color:#CCEEFF;width:50.75pt;padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>44</p>
</td><td valign='top' style='background-color:#CCEEFF;width:50.75pt;padding-right:5.75pt;border-bottom:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>&#160;</p>
</td></tr>
<tr style='height:11.5pt'><td valign='top' style='width:171.25pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0'>Adjusted Consolidated EBITDA:</p>
</td><td valign='top' style='width:47.65pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 5,433</p>
</td><td valign='top' style='width:47.65pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$ 6,255</p>
</td><td valign='top' style='width:50.4pt;padding-right:5.75pt;border-top:3px double #000000;border-right:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(13.2%)</p>
</td><td valign='top' style='width:50.75pt;padding-right:5.75pt;border-top:3px double #000000;border-left:0.5pt solid #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$15,004</p>
</td><td valign='top' style='width:50.75pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>$18,317</p>
</td><td valign='top' style='width:50.75pt;padding-right:5.75pt;border-top:3px double #000000'><p style='font:10pt Times New Roman;margin:0;text-align:right'>(18.1%)</p>
</td></tr>
</table>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Management believes that the non-US GAAP EBITDA decline is more indicative of the COVID-19 negative impact on UTMD&#8217;s 2020 operating results than the change represented by EBT.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:9pt'>g)</kbd><kbd style='margin-left:22.5pt'></kbd>Net Income&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Net Income is EBT minus a provision for income taxes. &#160;Net Income in 3Q 2020 was $2,933 (28.0% of sales) compared to $3,705 (29.7% of sales) in 3Q 2019. &#160;&#160;&#160;The average consolidated income tax provision (as a % of EBT) in 3Q 2020 was 18.3% compared to 16.7% in 3Q 2019. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Net Income in 9M 2020 was $7,386 (24.5% of sales) compared to Net Income of $10,369 (29.6% of sales) in 9M 2019. &#160;Net Income in 9M 2020 included a 2Q 2020 unfavorable $225 tax provision increase for a future UK income tax increase on non-deductible IIA amortization expense over the next six years. &#160;The average consolidated income tax provisions (as a % of EBT) in 9M 2020 and 9M 2019 were 22.7% and 21.1%, respectively. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:9pt'>h)</kbd><kbd style='margin-left:22.5pt'></kbd>Earnings Per Share (EPS)&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>EPS are consolidated Net Income divided by the number of shares of stock outstanding (diluted to take into consideration stock option awards which are &#8220;in the money,&#8221; i.e., have exercise prices below the applicable period&#8217;s weighted average market value). </p>
<p style='font:10pt Times New Roman;margin:0'> &#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Diluted EPS in 3Q 2020 were $.803 compared to $.991 in 3Q 2019. &#160;Diluted EPS in 9M 2020 were $2.008 compared to $2.774 in 9M 2019. &#160;According to U.S. GAAP, the UK tax law change in 2Q 2020 which increased UTMD&#8217;s deferred tax liability, to be amortized over the next six years, was recognized as an income tax provision increase in the 2Q 2020 income statement. Without the 2Q 2020 $225 tax provision adjustment, 9M 2020 EPS were $2.069. &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Diluted shares were 3,653,500 in 3Q 2020 compared to 3,737,335 in 3Q 2019, and 3,678,210 in 9M 2020 compared to 3,738,056 in 9M 2019. &#160;The lower diluted shares in 9M 2020 were the combined result of 80,000 shares repurchased in 1Q 2020, 7,000 shares repurchased in 3Q 2020, 5,614 employee option exercises in 9M 2020 and an employee option award of 26,300 shares in March 2020. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Outstanding shares at the end of 3Q 2020 were 3,640,371 compared to 3,721,757 at the end of calendar year 2019. The difference was due to employee option exercises of 5,614 during 9M 2020 offset by 87,000 shares repurchased in the open market. Outstanding shares were 3,720,344 one year ago at the end of 3Q 2019. The number of shares used for calculating diluted EPS was higher than ending shares because of a time-weighted calculation of average outstanding shares plus dilution from unexercised employee and director options. &#160;The total number of outstanding unexercised employee and outside director options at September 30, 2020 was 71,700 at an average exercise price of $65.80, including shares awarded but not yet vested. &#160;This compares to 51,690 unexercised option shares at the end of 2019 at an average exercise price of $58.50/ share, including shares awarded but not yet vested.</p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>15</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><a href='#a2' style='text-decoration:none'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'>Table of Contents</span></a></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0'>The number of shares added as a dilution factor in 3Q 2020 was 11,130 compared to 17,588 in 3Q 2019. The number of shares added as a dilution factor in 9M 2020 was 14,514 compared to 16,435 in 9M 2019. &#160;In March 2020, 26,300 option shares were awarded to 48 employees at an exercise price of $77.05 per share. No options were awarded in 2019. &#160;UTMD paid $1,020 ($0.280/share) in dividends to stockholders in 3Q 2020 compared to $1,028 ($0.275/ share) paid in 3Q 2019. Dividends paid to stockholders during 3Q 2020 were 35% of 3Q 2020 Net Income. &#160;UTMD paid $3,097 ($0.280/share) in dividends to stockholders in 9M 2020 compared to $3,083 ($0.275/ share) paid in 9M 2019. Dividends paid to stockholders during 9M 2020 were 41% of 9M 2020 Net Income. &#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:12pt Times New Roman;margin:0'><span style='font-size:10pt'>In March 2020, UTMD repurchased 80,000 of its shares in the open market at $80.32/ share. In September 2020, UTMD repurchased 7,000 of its shares in the open market at $78.67/ share. &#160;The total 87,000 shares repurchased in 9M 2020 were at an average price of $80.19/ share. &#160;In May 2019, UTMD repurchased 5,000 shares at $79.52/ share. No other shares were repurchased in 2019. The Company retains the strong desire and financial ability for repurchasing its shares at a price it believes is attractive for remaining stockholders.</span> </p>
<p style='font:12pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:9pt'>i) </kbd><kbd style='margin-left:22.5pt'></kbd>Return on Stockholder Equity (ROE) and Stock Value&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>ROE is the portion of Net Income retained by UTMD to internally finance its growth, divided by the average accumulated stockholders&#8217; equity for the applicable time period. &#160;After payment of cash dividends to stockholders, annualized ROE in 9M 2020 was 6% compared to annualized ROE of 11% in 9M 2019. Before the payment of dividends, annualized ROE in 9M 2020 was 10% compared to 15% in 9M 2019.  The lower ROE before dividends in 9M 2020 was due to an 8% increase in average accumulated stockholders&#8217; equity together with a 29% decrease in Net Income. Targeting a high ROE of 20% (before dividends) remains a key financial objective for UTMD management. &#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>UTMD&#8217;s closing share price at the end of 3Q 2020 was $79.87, down 26% from the $107.90 closing price at the end of 2019. &#160;The closing share price at the end of 3Q 2019 was $95.84. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Liquidity and Capital Resources</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:9pt'>j)</kbd><kbd style='margin-left:22.5pt'></kbd>Cash flows&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Net cash provided by operating activities, including adjustments for depreciation and amortization and other non-cash expenses along with changes in working capital, totaled $14,359 in 9M 2020 compared to $11,415 in 9M 2019. &#160;The $2,944 higher cash provided by operating activities in 9M 2020 was due primarily to a $6,187 difference from 1) 1,184 decreased trade accounts receivable and inventories compared to a $2,588 increase in 9M 2019, yielding a significant $3,772 working capital change difference in the two periods, 2) a $651 increase in accrued expenses compared to a $1,023 decrease in 9M 2019, yielding another $1,674 working capital change difference in the two periods, 3) $363 higher intangible asset amortization expense, and 4) $378 lower decrease in deferred income taxes, minus 1) $2,983 lower net income and 2) $251 higher decrease in accounts payable. &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Capital expenditures for property and equipment (PP&amp;E) were $806 in 9M 2020 compared to $251 in 9M 2019.  &#160;The higher capital expenditures were due to a new roof on the Midvale facility and investment in new manufacturing capabilities in Ireland. &#160;There were no capital expenditures for intangible assets in 9M 2020 compared to $21,000 in 9M 2019 for the purchase of the remaining life of CSI&#8217;s exclusive U.S.distribution rights for the Filshie Clip System.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>UTMD made cash dividend payments of $3,097 in 9M 2020 compared to $3,083 in 9M 2019. &#160;The Company used $6,976 of its cash to repurchase 87,000 of its own shares in 9M 2020 compared to using $398 of its cash to repurchase 5,000 of its own shares during 9M 2019. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>In 9M 2020, UTMD received $282 and issued 5,614 shares of its stock upon the exercise of employee and director stock options. Option exercises in 9M 2020 were at an average price of $50.15 per share. &#160;In comparison, in 9M 2019 the Company received $222 and issued 5,629 shares of stock on the exercise of employee and director stock options. Option exercises in 9M 2019 were at an average price of $39.53 per share. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Management believes that current cash balances, income from operations and effective management of working capital will provide the liquidity needed to finance internal growth plans. The Company may utilize cash not needed to support normal operations in one or a combination of the following: &#160;1) in general, to continue to invest at an opportune time in ways that will enhance future profitability; 2) to make additional investments in new technology and/or processes; and/or 3) to acquire a product line or company that will augment revenue and EPS growth and better utilize UTMD&#8217;s existing infrastructure. &#160;If there are no better strategic uses for UTMD&#8217;s cash, the Company will continue to return cash to stockholders in the form of dividends and share repurchases when the stock appears undervalued. </p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>16</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><a href='#a2' style='text-decoration:none'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'>Table of Contents</span></a></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:9pt'>k)</kbd><kbd style='margin-left:22.5pt'></kbd>Assets and Liabilities&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>September 30, 2020 total consolidated assets were $107,072, a net decrease of $2,715 from December 31, 2019. &#160;&#160;Net intangible assets declined by $5,397, inventories declined by $609 and receivables declined by $466. &#160;Offsetting that combined $6,472 asset decline was a $3,507 increase in cash and a $308 increase in PP&amp;E net of $495 in depreciation. &#160;As a result of the increase in cash, consolidated current assets increased $2,375.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>UTMD&#8217;s Ireland subsidiary EUR-denominated assets and liabilities on September 30, 2020 were translated into USD at an FX rate 4.4% higher (stronger EUR relative to the USD) than the FX rate at the end of 2019. UTMD&#8217;s UK subsidiary GBP-denominated assets were translated into USD at an FX rate 2.6% lower (weaker GBP) than the FX rate at the end of 2019. &#160;UTMD&#8217;s Australia subsidiary AUD-denominated assets were translated into USD at an FX rate 1.9% higher (stronger AUD) than the FX rate at the end of 2019. &#160;UTMD&#8217;s Canada subsidiary CAD-denominated assets were translated into USD at an FX rate 2.7% lower (weaker CAD) than the FX rate at the end of 2019. &#160;The net book value of consolidated property, plant and equipment increased $308 at September 30, 2020 from the end of 2019 due to period-ending changed FX rates, $806 in new asset purchases and $495 in depreciation. &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Working capital (current assets minus current liabilities) was $53,632 at September 30, 2020 compared to $51,438 at December 31, 2019. Consolidated receivables and inventories declined $466 and $609, respectively, but cash increased $3,507. &#160;Accrued liabilities increased $649, primarily from $550 higher income taxes payable as UTMD had over-accrued income taxes payable by $514 at the end of 2019, and $244 higher customer deposits as a result of the timing of international distributor shipments in 4Q 2020 requiring prepayment. &#160;UTMD management believes that its working capital remains sufficient to meet normal operating needs, new capital expenditures and continued cash dividend payments to stockholders.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>September 30, 2020 net intangible assets (goodwill plus other intangible assets less amortization) declined $5,397 from the end of 2019. &#160;No new intangible assets were acquired in 9M 2020. &#160;At September 30, 2020, net intangible assets including goodwill were 36% of total consolidated assets compared to 40% at year-end 2019, and 42% at September 30, 2019. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>The long term deferred tax liability (DTL) balance for Femcare IIA ($9,084 on the date of the acquisition) was $2,132 (&#163;1,650) at September 30, 2020, compared to $2,239 (&#163;1,688) at December 31, 2019, and $2,170 (&#163;1,764) at September 30, 2019. &#160;Reduction of the DTL occurs as the book/tax difference of IIA amortization is eliminated over the remaining useful life of the Femcare IIA (because the amortization expense is not tax deductible in the UK). The DTL only declined $107 at September 30, 2020 from December 31, 2019, despite 9M 2020 amortization expense of $1,523, which reduced the DTL balance by $289. &#160;The difference was due to a 2Q 2020 UK tax law change which increased the DTL balance by $225 (&#163;182) plus the change in ending FX rates. The UK decided to not reduce its corporate income tax rate from 19% to 17% beginning in 2Q 2020, as previously enacted. (The $225 increase in deferred UK taxes over the following six years was also booked in the 2Q 2020 tax provision, reducing 9M 2020 net income $225.)</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>UTMD&#8217;s total debt ratio (total liabilities/ total assets) as of September 30, 2020 was 8%, including a remaining $2,074 REPAT tax liability payable over another five years. &#160;The total debt ratio as of December 31, 2019 was also 8%, and as of September 30, 2019 was 9%. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>The $2,715 decrease in total liabilities and equity (same as total assets) was primarily due to a $2,677 September 30, 2020 ending decrease in stockholders&#8217; equity compared to December 31, 2019. Stockholders&#8217; equity was reduced during 9M 2020 by $10,074 from share repurchases and dividends paid to stockholders, offset by $7,386 net profit accumulated during 9M 2020.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:9pt'>l)</kbd><kbd style='margin-left:22.5pt'></kbd>Management's Outlook&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>As outlined in its December 31, 2019 SEC 10-K report, UTMD&#8217;s general plan for 2020 was to</p>
<p style='font:10pt Times New Roman;margin:0;text-indent:1.2pt;margin-left:21.3pt'>1) &#160;exploit distribution and manufacturing synergies by further integrating capabilities and resources in its multinational operations; &#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:22.5pt'></kbd>2) &#160;focus on effective direct marketing of the benefits of the Filshie Clip System in the U.S;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:22.5pt'></kbd>3) &#160;introduce additional products helpful to clinicians through internal new product development;&#160;</p>
<p style='font:10pt Times New Roman;margin:0;margin-left:7.2pt'><kbd style='margin-left:15.3pt'></kbd>4) &#160;continue to achieve excellent overall financial operating performance; &#160;</p>
<p style='font:10pt Times New Roman;margin:0;margin-left:22.5pt'>5) &#160;utilize positive cash generation to continue providing cash dividends to stockholders and make open market share repurchases if/when the UTMD share price seems undervalued; and</p>
<p style='font:10pt Times New Roman;margin:0;margin-left:22.5pt'>6) &#160;be vigilant for accretive acquisition opportunities which may be brought about by difficult burdens on small, innovative companies. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>Although not on its plan relative to specific financial numbers due to the COVID-19 pandemic, the Company continues to effectively execute its general plan outlined above. </p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>17</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><a href='#a2' style='text-decoration:none'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'>Table of Contents</span></a></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:9pt'>m)</kbd><kbd style='margin-left:22.5pt'></kbd>Accounting Policy Changes&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;color:#000000'>None</p>
<p style='font:10pt Times New Roman;margin:0;color:#000000'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><b>Forward-Looking Information</b>. &#160;This report contains certain forward-looking statements and information relating to the Company that are based on the beliefs of management as well as assumptions made by management based on information currently available. &#160;When used in this document, the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;project,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend&#8221; and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. &#160;Such statements reflect the current view of the Company respecting future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties stated throughout the document. &#160;Although the Company has attempted to identify important factors that could cause the actual results to differ materially, there may be other factors that cause the forward statement not to come true as anticipated, believed, projected, expected, or intended. &#160;Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may differ materially from those described herein as anticipated, believed, projected, estimated, expected or intended. &#160;Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results, and the Company assumes no obligation to update or disclose revisions to those estimates.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<a id='a10'></a><p style='font:10pt Times New Roman;margin:0'><b>Item 3.</b> <b>Quantitative and Qualitative Disclosures about Market Risk</b></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>UTMD has manufacturing and trading operations, including related assets, in the U.S. denominated in the U.S. Dollar (USD), in Ireland denominated in the Euro (EUR), in England denominated in the British Pound (GBP), in Australia denominated in the Australia Dollar (AUD), and, starting in 2017, in Canada denominated in the Canadian Dollar (CAD). &#160;The currencies are subject to exchange rate fluctuations that are beyond the control of UTMD. &#160;The exchange rates were .8529, .8907 and .9169 EUR per USD as of September 30, 2020, December 31, 2019 and September 30, 2019, respectively. &#160;Exchange rates were .7741, .7537 and .8129 GBP per USD as of September 30, 2020, December 31, 2019 and September 30, 2019, respectively. &#160;Exchange rates were 1.3964, 1.4226 and 1.4823 AUD per USD on September 30, 2020, December 31, 2019, and September 30, 2019, respectively. &#160;Exchange rates were 1.3323, 1.2962, and 1.3242 CAD per USD on September 30, 2020, December 31, 2019, and September 30, 2019, respectively. UTMD manages its foreign currency risk without separate hedging transactions by either invoicing customers in the local currency where costs of production were incurred, by converting currencies as transactions occur, and by optimizing global account structures through liquidity management accounts.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<a id='a11'></a><p style='font:10pt Times New Roman;margin:0'><b>Item 4. Controls and Procedures</b></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>The Company&#8217;s management, under the supervision and with the participation of the Chief Executive Officer and the Principal Financial Officer, evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended) as of September 30, 2020. Based on this evaluation, the Chief Executive Officer and Principal Financial Officer concluded that, as of September 30, 2020, the Company&#8217;s disclosure controls and procedures were effective. </p>
<p style='font:10pt Times New Roman;margin:0;text-indent:24.5pt'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>There were no changes in the Company&#8217;s internal controls over financial reporting that occurred during the nine months ended September 30, 2020, that have materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal controls over financial reporting. </p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>18</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><a href='#a2' style='text-decoration:none'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'>Table of Contents</span></a></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><a id='a12'></a><p style='font:10pt Times New Roman;margin:0;text-align:center'>PART II - OTHER INFORMATION</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<a id='a13'></a><p style='font:10pt Times New Roman;margin:0'><b>Item 1. Legal Proceedings</b></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>The Company may be a party from time to time in litigation incidental to its business. Presently, there is no litigation. </p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<a id='a14'></a><p style='font:10pt Times New Roman;margin:0'><b>Item 1A. Risk Factors</b></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><span style='color:#333333'>In addition to the other information set forth in this report, investors should carefully consider the factors discussed in Part I, &#8220;Item 1A. Risk Factors&#8221; in UTMD&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019, which could materially affect its business, financial condition or future results. &#160;The risks described in the Annual Report on Form 10-K are not the only risks facing the Company. &#160;Additional risks and uncertainties not currently known to UTMD or currently deemed to be immaterial also may materially adversely affect the Company&#8217;s business, financial condition and/or operating results.</span></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>Legislative or executive order healthcare reform in the United States</span>, particularly as suggested by leading candidates in a presidential election year, have the potential to render the U.S. medical device marketplace unpredictable. A fully government-run healthcare system would likely eliminate healthcare consumer choice as well as commercial incentives for innovation. &#160;Government-mandated shutdowns of &#8220;nonessential&#8221; medical procedures with the intent of protecting the public from a virus have the potential to substantially reduce demand for UTMD&#8217;s medical devices. &#160;&#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>Increasing regulatory burdens, including premarketing approval delays, may result in significant loss of revenue, unpredictable costs and loss of management focus on developing and marketing products that improve the quality of healthcare: </span></p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:7.2pt'></kbd>Thousands of small focused medical device manufacturers including UTMD that do not have the overhead structure that the few large medical device companies can afford are increasingly burdened with bureaucratic and underqualified regulator demands that are not reasonably related to assuring the safety or effectiveness of the devices that they provide. &#160;Premarketing submission administrative burdens, and substantial &#8220;user fees&#8221; or notified body review fees, represent a significant non-clinical and/or non-scientific barrier to new product introduction, resulting in lack of investment or delays to revenues from new or improved devices. &#160;The risks associated with such circumstances relate not only to substantial out-of-pocket costs, including potential litigation in millions of dollars, but also loss of business and a diversion of attention of key employees for an extended period of time from managing their normal responsibilities, particularly in new product development and routine quality assurance activities. &#160;&#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>The dominance of Group Purchasing Organizations (GPOs) adds non-productive costs, typically weakens the Company&#8217;s marketing and sales efforts and may result in lower revenues:</span> &#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:7.2pt'></kbd>GPOs, theoretically acting as bargaining agents for member hospitals, but actually collecting revenues from the companies that they are negotiating with, have made a concerted effort to turn medical devices that convey special patient safety advantages and better health outcomes, like UTMD&#8217;s, into undifferentiated commodities. GPOs have been granted an antitrust exemption by the U.S. Congress. Their business model based on &#8220;kickbacks&#8221; would be a violation of law in any other industry. These bureaucratic entities do not recognize or understand the overall cost of care as it relates to safety and effectiveness of devices, and they create a substantial administrative burden that is primarily driven by collection of administrative fees. &#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>The Company&#8217;s business strategy may not be successful in the future:</span></p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:8.55pt'></kbd>As the level of complexity and uncertainty in the medical device industry increases, evidenced, for example, by the unpredictable regulatory environment, the Company&#8217;s views of the future and product/ market strategy may not yield financial results consistent with the past.&#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>As the healthcare industry becomes increasingly bureaucratic, it puts smaller companies like UTMD at a competitive disadvantage: &#160;</span></p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:7.2pt'></kbd>An aging population is placing greater burdens on healthcare systems, particularly hospitals. The length of time and number of administrative steps required in adopting new products for use in hospitals has grown substantially in recent years. &#160;Smaller companies like UTMD typically do not have the administrative resources to deal with broad new administrative requirements, resulting in either loss of revenue or increased costs. &#160;As UTMD introduces new products it believes are safer and more effective, it may find itself excluded from certain clinical users because of the existence of long term supply agreements for preexisting products, particularly from competitors which offer hospitals a broader range of products and services. &#160;Restrictions used by hospital administrators to limit clinician involvement in device purchasing decisions makes communicating UTMD&#8217;s clinical advantages much more difficult. &#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>19</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><a href='#a2' style='text-decoration:none'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'>Table of Contents</span></a></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>A product liability lawsuit could result in significant legal expenses and a large award against the Company: </span></p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:7.2pt'></kbd>UTMD&#8217;s devices are frequently used in inherently risky situations to help physicians achieve a more positive outcome than what might otherwise be the case. &#160;In any lawsuit where an individual plaintiff suffered permanent physical injury, the possibility of a large award for damages exists whether or not a causal relationship exists. &#160;&#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>The Company&#8217;s reliance on third party distributors in some markets may result in less predictable revenues:</span></p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:7.2pt'></kbd>UTMD&#8217;s distributors have varying expertise in marketing and distributing specialty medical devices. &#160;They also sell other devices that may result in less focus on the Company&#8217;s products. &#160;In some countries, notably China, Pakistan and India not subject to similarly rigorous standards, a distributor of UTMD&#8217;s products may eventually become a competitor with a cheaper but lower quality version of UTMD&#8217;s devices. &#160;&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>The loss of one or more key employees could negatively affect UTMD performance:</span></p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:7.2pt'></kbd>In a small company with limited resources, the distraction or loss of key personnel at any point in time may be disruptive to performance. &#160;The Company&#8217;s benefits programs are key to recruiting and retaining talented employees. &#160;An increase in UTMD&#8217;s employee healthcare plan costs, for example, may cause the Company to have to reduce coverages which in turn represents a risk to retaining key employees.&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>Fluctuations in foreign currencies relative to the USD can result in significant differences in period to period financial results:</span></p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:7.2pt'></kbd>Since a significant portion of UTMD&#8217;s sales are invoiced in foreign currencies and consolidated financial results are reported in USD terms, a stronger USD can have negative revenue effects. Conversely, a weaker USD would increase foreign subsidiary operating costs in USD terms. For the portion of sales to foreign entities made in fixed USD terms, a stronger USD makes the devices more expensive and weakens demand. &#160;For the portion invoiced in a foreign currency, not only USD-denominated sales are reduced, but also gross profits may be reduced because finished distributed devices and/or U.S. made raw materials and components are likely being purchased in fixed USD.&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<a id='a15'></a><p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt Times New Roman;margin-left:0pt'><b>Item 2.</b></kbd><kbd style='margin-left:37.8pt'></kbd><b>Unregistered Sales of Equity Securities and Use of Proceeds</b>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>During 9M 2020, UTMD purchased 87,000 of its shares in the open market for $6,977 including commissions and fees. During 9M 2019 UTMD purchased 5,000 of its shares in the open market for $398 including commissions and fees.</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<a id='a17'></a><p style='font:10pt Times New Roman;margin:0'><b>Item 6. &#160;Exhibits </b></p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr style='height:14.4pt'><td valign='bottom' style='width:113.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='border-bottom:1px solid #000000'>Exhibit #</span></p>
</td><td valign='bottom' style='width:358.55pt'><p style='font:10pt Times New Roman;margin:0'><span style='border-bottom:1px solid #000000'>Title of Document</span></p>
</td></tr>
<tr style='height:3.6pt'><td valign='top' style='width:113.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:358.55pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:113.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>31.1</p>
</td><td valign='top' style='background-color:#CCEEFF;width:358.55pt'><p style='font:10pt Times New Roman;margin:0'><a href='utmd_ex31z1.htm' style='text-decoration:none'><span style='color:#0000FF;border-bottom:1px solid #0000FF'>Certification of CEO pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p>
</td></tr>
<tr><td valign='top' style='width:113.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:358.55pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:113.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>31.2</p>
</td><td valign='top' style='background-color:#CCEEFF;width:358.55pt'><p style='font:10pt Times New Roman;margin:0'><a href='utmd_ex31z2.htm' style='text-decoration:none'><span style='color:#0000FF;border-bottom:1px solid #0000FF'>Certification of Principal Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p>
</td></tr>
<tr><td valign='top' style='width:113.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:358.55pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:113.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>32.1</p>
</td><td valign='top' style='background-color:#CCEEFF;width:358.55pt'><p style='font:10pt Times New Roman;margin:0'><a href='utmd_ex32z1.htm' style='text-decoration:none'><span style='color:#0000FF;border-bottom:1px solid #0000FF'>Certification of CEO pursuant to 18 U.S.C. &#167;1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p>
</td></tr>
<tr><td valign='top' style='width:113.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:358.55pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:113.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>32.2</p>
</td><td valign='top' style='background-color:#CCEEFF;width:358.55pt'><p style='font:10pt Times New Roman;margin:0'><a href='utmd_ex32z2.htm' style='text-decoration:none'><span style='color:#0000FF;border-bottom:1px solid #0000FF'>Certification of Principal Financial Officer pursuant to 18 U.S.C. &#167;1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p>
</td></tr>
<tr><td valign='top' style='width:113.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:358.55pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:113.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>101</p>
</td><td valign='top' style='background-color:#CCEEFF;width:358.55pt'><p style='font:10pt Times New Roman;margin:0'>The following financial information from the Utah Medical Products, Inc. quarterly report on Form 10-Q for the quarter ended September 30, 2020, formatted in Inline Extensible Business Reporting Language (iXBRL): &#160;(i) Consolidated Condensed Balance Sheets, (ii) Consolidated Condensed Statements of Income, (iii) Consolidated Condensed Statements of Cash Flows, (iv) Consolidated Statements of Stockholders&#8217; Equity, and (v) related Notes to the Consolidated Condensed Financial Statements, tagged in detail.</p>
</td></tr>
<tr><td valign='top' style='width:113.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:358.55pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:113.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'>104</p>
</td><td valign='top' style='background-color:#CCEEFF;width:358.55pt'><p style='font:10pt Times New Roman;margin:0'>Cover Page Interactive Data File (embedded within the Inline XBRL document)</p>
</td></tr>
</table>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>20</span></p>
<hr style='page-break-after:always;border:0;height:1.5pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<p style='font:10pt CG Times;margin:0'><a href='#a2' style='text-decoration:none'><span style='font-family:Times New Roman;color:#0000FF;border-bottom:1px solid #0000FF'>Table of Contents</span></a></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<a id='a18'></a><p style='font:10pt Times New Roman;margin:0;text-align:center'>SIGNATURES</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:28.8pt'></kbd>Pursuant to the requirements of the Securities Exchanges Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:204.2pt'></kbd><span style='border-bottom:1px solid #000000'>UTAH MEDICAL PRODUCTS, INC.</span>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:204.2pt'></kbd>REGISTRANT&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt Times New Roman;margin-left:0pt'>Date: <span style='border-bottom:1px solid #000000'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;11/6/20 &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></kbd><kbd style='margin-left:204.2pt'></kbd>By: <span style='border-bottom:1px solid #000000'> &#160;&#160;&#160;&#160;&#160;&#160;/s/ Kevin L. Cornwell &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:55.4pt'> &#160;&#160;&#160;&#160;</kbd><kbd style='margin-left:219.1pt'></kbd>Kevin L. Cornwell&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:55.4pt'> &#160;&#160;&#160;&#160;</kbd><kbd style='margin-left:219.1pt'></kbd>CEO&#160;</p>
<p style='font:10pt Times New Roman;margin:0'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt Times New Roman;margin-left:0pt'>Date: <span style='border-bottom:1px solid #000000'> &#160;&#160;&#160;&#160;&#160;&#160;&#160;11/6/20 &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></kbd><kbd style='margin-left:204.2pt'></kbd>By: <span style='border-bottom:1px solid #000000'> &#160;&#160;&#160;&#160;&#160;&#160;/s/ Brian L. Koopman &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='position:absolute;font:10pt CG Times;margin-left:55.4pt'> &#160;&#160;&#160;&#160;</kbd><kbd style='margin-left:219.1pt'></kbd>Brian L. Koopman&#160;</p>
<p style='font:10pt Times New Roman;margin:0'><kbd style='margin-left:219.1pt'></kbd>Principal Financial Officer&#160;</p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:10pt CG Times;margin:0;text-align:center'><span style='font-family:Times New Roman'>21</span></p>
<p style='font:10pt CG Times;margin:0'>&#160;</p>
</div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>utmd_ex31z1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2020 [PPXK9NDL3JZWVJX3H04L]. www.edgarsuite.com -->
<HEAD>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><P align=right style='font:10pt Times New Roman;margin:0;margin-left:36pt'><B>Exhibit 31.1</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>CERTIFICATION OF CEO </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>PURSUANT TO RULE 13a-14(a) AS ADOPTED PURSUANT TO </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>I, Kevin L. Cornwell, certify that:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>1.</KBD><KBD style=margin-left:18pt></KBD>I have reviewed this quarterly report on Form 10-Q of Utah Medical Products, Inc.; &nbsp;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>2.</KBD><KBD style=margin-left:18pt></KBD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>3.</KBD><KBD style=margin-left:18pt></KBD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>4.</KBD><KBD style=margin-left:18pt></KBD>The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt CG Times;margin-left:-15.3pt'>(a)</KBD>designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-36pt;margin-left:33.3pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(b)</KBD>designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(c)</KBD>evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and &nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(d)</KBD>disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>5.</KBD><KBD style=margin-left:18pt></KBD>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent functions):&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(a)</KBD>all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-36pt;margin-left:33.3pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(b)</KBD>any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>Date: November 6, 2020</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;/s/ Kevin L. Cornwell &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>Kevin L. Cornwell</P>
<P style='font:10pt Times New Roman;margin:0'>Chief Executive Officer</P>
<P style='font:10pt CG Times;margin:0'>&nbsp;</P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>utmd_ex31z2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2020 [PPXK9NDL3JZWVJX3H04L]. www.edgarsuite.com -->
<HEAD>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><P align=right style='font:10pt Times New Roman;margin:0'><B>Exhibit 31.2</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>PURSUANT TO RULE 13a-14(a) AS ADOPTED PURSUANT TO </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>I, Brian L. Koopman, certify that:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>1.</KBD><KBD style=margin-left:18pt></KBD>I have reviewed this quarterly report on Form 10-Q of Utah Medical Products, Inc.; &nbsp;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>2.</KBD><KBD style=margin-left:18pt></KBD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>3.</KBD><KBD style=margin-left:18pt></KBD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>4.</KBD><KBD style=margin-left:18pt></KBD>The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(a)</KBD>designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-15.3pt;margin-left:33.3pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(b)</KBD>designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(c)</KBD>evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and &nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(d)</KBD>disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt CG Times;margin-left:0.05pt'>5.</KBD><KBD style=margin-left:18pt></KBD>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent functions):&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(a)</KBD>all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-36pt;margin-left:33.3pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:33.3pt'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:-15.3pt'>(b)</KBD>any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>Date: November 6, 2020</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ Brian L. Koopman &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>Brian L. Koopman</P>
<P style='font:10pt Times New Roman;margin:0'>Principal Financial Officer</P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>utmd_ex32z1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2020 [PPXK9NDL3JZWVJX3H04L]. www.edgarsuite.com -->
<HEAD>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><P align=right style='font:10pt Times New Roman;margin:0'><B>Exhibit 32.1</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>CERTIFICATION PURSUANT TO</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>18 U.S.C. SECTION 1350,</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>AS ADOPTED PURSUANT TO</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>In connection with the Quarterly Report of Utah Medical Products, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending September 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Kevin L. Cornwell, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:10pt CG Times;margin-left:-34.2pt'>(1)</KBD>the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and &nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:10pt CG Times;margin-left:-34.2pt'>(2)</KBD>the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-73.8pt;margin-left:73.8pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp;&nbsp;&nbsp;/s/ Kevin L. Cornwell &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>Kevin L. Cornwell</P>
<P style='font:10pt Times New Roman;margin:0'>Chief Executive Officer</P>
<P style='font:10pt Times New Roman;margin:0'>November 6, 2020</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt CG Times;margin:0'><FONT style='font-family:Times New Roman'><I>A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</I></FONT></P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>utmd_ex32z2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2020 [PPXK9NDL3JZWVJX3H04L]. www.edgarsuite.com -->
<HEAD>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Exhibit 32.2</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>CERTIFICATION PURSUANT TO</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>18 U.S.C. SECTION 1350,</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>AS ADOPTED PURSUANT TO</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>In connection with the Quarterly Report of Utah Medical Products, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending September 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Brian L. Koopman, Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:10pt CG Times;margin-left:-34.2pt'>(1)</KBD>the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and &nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:10pt CG Times;margin-left:-34.2pt'>(2)</KBD>the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'> &nbsp;&nbsp; &nbsp;/s/ Brian L. Koopman</FONT></P>
<P style='font:10pt Times New Roman;margin:0'>Brian L. Koopman</P>
<P style='font:10pt Times New Roman;margin:0'>Principal Financial Officer</P>
<P style='font:10pt Times New Roman;margin:0'>November 6, 2020</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt CG Times;margin:0'><FONT style='font-family:Times New Roman'><I>A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</I></FONT></P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>utmd-20200930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2020 [PPXK9NDL3JZWVJK4T7A6]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.utahmed.com/20200930"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent' xlink:label='us-gaap_AssetsCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:label='us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AssetsCurrent' xlink:to='us-gaap_CashAndCashEquivalentsAtCarryingValue' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent' xlink:label='us-gaap_AccountsReceivableNetCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AssetsCurrent' xlink:to='us-gaap_AccountsReceivableNetCurrent' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AssetsCurrent' xlink:to='us-gaap_InventoryNet' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent' xlink:label='us-gaap_OtherAssetsCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AssetsCurrent' xlink:to='us-gaap_OtherAssetsCurrent' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets' xlink:label='us-gaap_Assets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_AssetsCurrent' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet' xlink:label='us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_PropertyPlantAndEquipmentNet' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset' xlink:label='us-gaap_OperatingLeaseRightOfUseAsset'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_OperatingLeaseRightOfUseAsset' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill' xlink:label='us-gaap_Goodwill'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_Goodwill' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:label='us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_IntangibleAssetsNetExcludingGoodwill' use='optional' order='5.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross' xlink:label='us-gaap_FiniteLivedIntangibleAssetsGross'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:to='us-gaap_FiniteLivedIntangibleAssetsGross' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:to='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent' xlink:label='us-gaap_LiabilitiesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent' xlink:label='us-gaap_AccountsPayableCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesCurrent' xlink:to='us-gaap_AccountsPayableCurrent' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent' xlink:label='us-gaap_AccruedLiabilitiesCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesCurrent' xlink:to='us-gaap_AccruedLiabilitiesCurrent' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities' xlink:label='us-gaap_Liabilities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_LiabilitiesCurrent' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:label='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent' xlink:label='us-gaap_OtherLiabilitiesNoncurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_OtherLiabilitiesNoncurrent' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent' xlink:label='us-gaap_OperatingLeaseLiabilityNoncurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_OperatingLeaseLiabilityNoncurrent' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:label='us-gaap_DeferredIncomeTaxLiabilitiesNet'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_DeferredIncomeTaxLiabilitiesNet' use='optional' order='5.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity' xlink:label='us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesAndStockholdersEquity' xlink:to='us-gaap_Liabilities' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesAndStockholdersEquity' xlink:to='us-gaap_StockholdersEquity' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue' xlink:label='us-gaap_PreferredStockValue'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_StockholdersEquity' xlink:to='us-gaap_PreferredStockValue' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue' xlink:label='us-gaap_CommonStockValue'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_StockholdersEquity' xlink:to='us-gaap_CommonStockValue' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:label='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_StockholdersEquity' xlink:to='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock' xlink:label='us-gaap_AdditionalPaidInCapitalCommonStock'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_StockholdersEquity' xlink:to='us-gaap_AdditionalPaidInCapitalCommonStock' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit' xlink:label='us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_StockholdersEquity' xlink:to='us-gaap_RetainedEarningsAccumulatedDeficit' use='optional' order='5.0' weight='1.0'/>
	</link:calculationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_GrossProfit' xlink:to='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold' xlink:label='us-gaap_CostOfGoodsAndServicesSold'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_GrossProfit' xlink:to='us-gaap_CostOfGoodsAndServicesSold' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingIncomeLoss' xlink:to='us-gaap_GrossProfit' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses' xlink:label='us-gaap_OperatingExpenses'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingIncomeLoss' xlink:to='us-gaap_OperatingExpenses' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense' xlink:label='us-gaap_SellingGeneralAndAdministrativeExpense'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingExpenses' xlink:to='us-gaap_SellingGeneralAndAdministrativeExpense' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense' xlink:label='us-gaap_ResearchAndDevelopmentExpense'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingExpenses' xlink:to='us-gaap_ResearchAndDevelopmentExpense' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments' xlink:label='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments' xlink:to='us-gaap_OperatingIncomeLoss' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense' xlink:label='us-gaap_OtherNonoperatingIncomeExpense'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments' xlink:to='us-gaap_OtherNonoperatingIncomeExpense' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_ProfitLoss' xlink:to='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit' xlink:label='us-gaap_IncomeTaxExpenseBenefit'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_ProfitLoss' xlink:to='us-gaap_IncomeTaxExpenseBenefit' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax' xlink:label='us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_ComprehensiveIncomeNetOfTax' xlink:to='us-gaap_ProfitLoss' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_ComprehensiveIncomeNetOfTax' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' use='optional' order='2.0' weight='1.0'/>
	</link:calculationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_ProfitLoss' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation' xlink:label='us-gaap_Depreciation'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_Depreciation' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentForAmortization' xlink:label='us-gaap_AdjustmentForAmortization'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_AdjustmentForAmortization' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts' xlink:label='us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_ProvisionForDoubtfulAccounts' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_OperatingLeaseRightOfUseAssetAmortization' xlink:label='fil_OperatingLeaseRightOfUseAssetAmortization'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='fil_OperatingLeaseRightOfUseAssetAmortization' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets' xlink:label='us-gaap_GainLossOnDispositionOfAssets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_GainLossOnDispositionOfAssets' use='optional' order='5.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:label='us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_DeferredIncomeTaxExpenseBenefit' use='optional' order='6.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation' xlink:label='us-gaap_ShareBasedCompensation'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_ShareBasedCompensation' use='optional' order='7.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:label='us-gaap_DeferredTaxExpenseFromStockOptionsExercised'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_DeferredTaxExpenseFromStockOptionsExercised' use='optional' order='8.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable' xlink:label='us-gaap_IncreaseDecreaseInAccountsReceivable'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInAccountsReceivable' use='optional' order='9.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories' xlink:label='us-gaap_IncreaseDecreaseInInventories'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInInventories' use='optional' order='10.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:label='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' use='optional' order='11.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable' xlink:label='us-gaap_IncreaseDecreaseInAccountsPayable'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInAccountsPayable' use='optional' order='12.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:label='us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='us-gaap_IncreaseDecreaseInAccruedLiabilities' use='optional' order='13.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='us-gaap_NetCashProvidedByUsedInOperatingActivities' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='us-gaap_NetCashProvidedByUsedInInvestingActivities' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='us-gaap_NetCashProvidedByUsedInFinancingActivities' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:label='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:to='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' use='optional' order='1.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets' xlink:label='us-gaap_PaymentsToAcquireIntangibleAssets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:to='us-gaap_PaymentsToAcquireIntangibleAssets' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:label='us-gaap_ProceedsFromIssuanceOfCommonStock'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:to='us-gaap_ProceedsFromIssuanceOfCommonStock' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:label='us-gaap_PaymentsForRepurchaseOfCommonStock'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:to='us-gaap_PaymentsForRepurchaseOfCommonStock' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividends' xlink:label='us-gaap_PaymentsOfDividends'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:to='us-gaap_PaymentsOfDividends' use='optional' order='3.0' weight='-1.0'/>
	</link:calculationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves' xlink:label='us-gaap_InventoryFinishedGoodsNetOfReserves'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_InventoryNet' xlink:to='us-gaap_InventoryFinishedGoodsNetOfReserves' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess' xlink:label='us-gaap_InventoryWorkInProcess'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_InventoryNet' xlink:to='us-gaap_InventoryWorkInProcess' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials' xlink:label='us-gaap_InventoryRawMaterials'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_InventoryNet' xlink:to='us-gaap_InventoryRawMaterials' use='optional' order='3.0' weight='1.0'/>
	</link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>utmd-20200930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2020 [PPXK9NDL3JZWVJK4T7A6]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.utahmed.com/20200930"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DocumentDocumentAndEntityInformation"/>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET"/>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEETParenthetical" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEETParenthetical"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEETParenthetical"/>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME"/>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOMEParenthetical" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOMEParenthetical"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOMEParenthetical"/>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis' xlink:label='us-gaap_StatementEquityComponentsAxis'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/hypercube-dimension' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementEquityComponentsAxis' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-domain' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_EquityComponentDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain_1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-default' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_EquityComponentDomain_1' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember' xlink:label='us-gaap_CommonStockMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_CommonStockMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember' xlink:label='us-gaap_AdditionalPaidInCapitalMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_AdditionalPaidInCapitalMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeMember' xlink:label='us-gaap_ComprehensiveIncomeMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_ComprehensiveIncomeMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember' xlink:label='us-gaap_RetainedEarningsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_RetainedEarningsMember' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:label='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_SharesOutstanding' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionPlanExpense' xlink:label='us-gaap_StockOptionPlanExpense'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockOptionPlanExpense' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStockCash' xlink:label='us-gaap_DividendsCommonStockCash'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_DividendsCommonStockCash' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_ProfitLoss' use='optional' order='12.0'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:closed='true' xbrldt:contextElement='segment' use='optional'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW"/>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureBasisOfPresentation" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureBasisOfPresentation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureBasisOfPresentation"/>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples"/>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureInventories" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureInventories"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureInventories"/>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureStockBasedCompensation" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureStockBasedCompensation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureStockBasedCompensation"/>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureWarrantyReserve" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureWarrantyReserve"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureWarrantyReserve"/>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureRevenueRecognition" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureRevenueRecognition"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureRevenueRecognition"/>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureLeases" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureLeases"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureLeases"/>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureCSIDistributionAgreementPurchaseDisclosure" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureCSIDistributionAgreementPurchaseDisclosure"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureCSIDistributionAgreementPurchaseDisclosure"/>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureEarningsPerShare" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureEarningsPerShare"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureEarningsPerShare"/>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureSubsequentEvents" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureSubsequentEvents"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureSubsequentEvents"/>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies"/>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureInventoriesScheduleOfInventoryCurrentTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables"/>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables"/>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLeaseCostTables" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureLeasesLeaseCostTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLeaseCostTables"/>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTables" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTables"/>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesReconciliationOfOperatingLeaseLiabilitiesTables" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureLeasesReconciliationOfOperatingLeaseLiabilitiesTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesReconciliationOfOperatingLeaseLiabilitiesTables"/>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLesseeOperatingLeaseLiabilityMaturityTables" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureLeasesLesseeOperatingLeaseLiabilityMaturityTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLesseeOperatingLeaseLiabilityMaturityTables"/>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables"/>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails"/>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureStockBasedCompensationDetails" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureStockBasedCompensationDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureStockBasedCompensationDetails"/>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureWarrantyReserveDetails" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureWarrantyReserveDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureWarrantyReserveDetails"/>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis' xlink:label='srt_StatementGeographicalAxis'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/hypercube-dimension' xlink:from='us-gaap_StatementTable' xlink:to='srt_StatementGeographicalAxis' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain' xlink:label='srt_SegmentGeographicalDomain'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-domain' xlink:from='srt_StatementGeographicalAxis' xlink:to='srt_SegmentGeographicalDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain' xlink:label='srt_SegmentGeographicalDomain_1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-default' xlink:from='srt_StatementGeographicalAxis' xlink:to='srt_SegmentGeographicalDomain_1' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_DomesticUsMember' xlink:label='fil_DomesticUsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_SegmentGeographicalDomain' xlink:to='fil_DomesticUsMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_OutsideUsMember' xlink:label='fil_OutsideUsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_SegmentGeographicalDomain' xlink:to='fil_OutsideUsMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis' xlink:label='srt_ProductOrServiceAxis'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/hypercube-dimension' xlink:from='us-gaap_StatementTable' xlink:to='srt_ProductOrServiceAxis' use='optional' order='2.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain' xlink:label='srt_ProductsAndServicesDomain'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-domain' xlink:from='srt_ProductOrServiceAxis' xlink:to='srt_ProductsAndServicesDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain' xlink:label='srt_ProductsAndServicesDomain_1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-default' xlink:from='srt_ProductOrServiceAxis' xlink:to='srt_ProductsAndServicesDomain_1' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_ObstetricsMember' xlink:label='fil_ObstetricsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_ProductsAndServicesDomain' xlink:to='fil_ObstetricsMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_NeonatalMember' xlink:label='fil_NeonatalMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_ProductsAndServicesDomain' xlink:to='fil_NeonatalMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_GynecologyElectrosurgeryUrologyMember' xlink:label='fil_GynecologyElectrosurgeryUrologyMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_ProductsAndServicesDomain' xlink:to='fil_GynecologyElectrosurgeryUrologyMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_BloodPressureMonitoringAndAccessoriesMember' xlink:label='fil_BloodPressureMonitoringAndAccessoriesMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='srt_ProductsAndServicesDomain' xlink:to='fil_BloodPressureMonitoringAndAccessoriesMember' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' use='optional' order='1.0'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:closed='true' xbrldt:contextElement='segment' use='optional'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesDetails" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureLeasesDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesDetails"/>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLeaseCostDetails" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureLeasesLeaseCostDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLeaseCostDetails"/>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails"/>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesReconciliationOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureLeasesReconciliationOfOperatingLeaseLiabilitiesDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesReconciliationOfOperatingLeaseLiabilitiesDetails"/>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLesseeOperatingLeaseLiabilityMaturityDetails" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureLeasesLesseeOperatingLeaseLiabilityMaturityDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLesseeOperatingLeaseLiabilityMaturityDetails"/>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureCSIDistributionAgreementPurchaseDisclosureDetails" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureCSIDistributionAgreementPurchaseDisclosureDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureCSIDistributionAgreementPurchaseDisclosureDetails">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_DistributionRightsAcquisitionAxis' xlink:label='fil_DistributionRightsAcquisitionAxis'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/hypercube-dimension' xlink:from='us-gaap_StatementTable' xlink:to='fil_DistributionRightsAcquisitionAxis' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_DistributionRightsAcquisitionDomain' xlink:label='fil_DistributionRightsAcquisitionDomain'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-domain' xlink:from='fil_DistributionRightsAcquisitionAxis' xlink:to='fil_DistributionRightsAcquisitionDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_DistributionRightsAcquisitionDomain' xlink:label='fil_DistributionRightsAcquisitionDomain_1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-default' xlink:from='fil_DistributionRightsAcquisitionAxis' xlink:to='fil_DistributionRightsAcquisitionDomain_1' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_CoopersurgicalIncMember' xlink:label='fil_CoopersurgicalIncMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='fil_DistributionRightsAcquisitionDomain' xlink:to='fil_CoopersurgicalIncMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1' xlink:label='us-gaap_FinitelivedIntangibleAssetsAcquired1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_FinitelivedIntangibleAssetsAcquired1' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' xlink:label='fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' use='optional' order='2.0'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:closed='true' xbrldt:contextElement='segment' use='optional'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>utmd-20200930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2020 [PPXK9NDL3JZWVJK4T7A6]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.utahmed.com/20200930"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
	<link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' xlink:label='fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Remaining years of exclusive U.S. distribution rights for Femcare&apos;s Filshie Clip System</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Remaining years of exclusive U.S. distribution rights for Femcare&apos;s Filshie Clip System, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' xlink:to='lab_fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_ObstetricsMember' xlink:label='fil_ObstetricsMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ObstetricsMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Obstetrics</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ObstetricsMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Obstetrics, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ObstetricsMember' xlink:to='lab_fil_ObstetricsMember'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain' xlink:label='srt_SegmentGeographicalDomain'/>
		<link:label xlink:type='resource' xlink:label='lab_srt_SegmentGeographicalDomain' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Geographical</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='srt_SegmentGeographicalDomain' xlink:to='lab_srt_SegmentGeographicalDomain'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:label='us-gaap_IntangibleAssetsDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CSI Distribution Agreement Purchase Disclosure</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:to='lab_us-gaap_IntangibleAssetsDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis' xlink:label='us-gaap_StatementEquityComponentsAxis'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementEquityComponentsAxis' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Equity Components [Axis]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='lab_us-gaap_StatementEquityComponentsAxis'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract' xlink:label='us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other comprehensive income (loss):</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract' xlink:to='lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:label='us-gaap_DeferredIncomeTaxLiabilitiesNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:to='lab_us-gaap_DeferredIncomeTaxLiabilitiesNet'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets' xlink:label='us-gaap_Assets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Assets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Assets' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Assets' xlink:to='lab_us-gaap_Assets'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:label='us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other intangible assets, net</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Other intangible assets, net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:to='lab_us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressAddressLine1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Address Line One</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressAddressLine1' xlink:to='lab_dei_EntityAddressAddressLine1'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityExTransitionPeriod' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Ex Transition Period</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityExTransitionPeriod' xlink:to='lab_dei_EntityExTransitionPeriod'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears' xlink:label='us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears' xlink:to='lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability' xlink:label='us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability' xlink:to='lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain' xlink:label='srt_ProductsAndServicesDomain'/>
		<link:label xlink:type='resource' xlink:label='lab_srt_ProductsAndServicesDomain' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Product and Service</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='srt_ProductsAndServicesDomain' xlink:to='lab_srt_ProductsAndServicesDomain'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' xlink:label='us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stock-Based Compensation</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' xlink:to='lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock' xlink:label='us-gaap_InventoryDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventories {2}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Inventories</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryDisclosureTextBlock' xlink:to='lab_us-gaap_InventoryDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_OperatingLeaseRightOfUseAssetAmortization' xlink:label='fil_OperatingLeaseRightOfUseAssetAmortization'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OperatingLeaseRightOfUseAssetAmortization' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amortization of Right of Use Assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OperatingLeaseRightOfUseAssetAmortization' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Operating Lease, Right of Use Asset Amortization.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OperatingLeaseRightOfUseAssetAmortization' xlink:to='lab_fil_OperatingLeaseRightOfUseAssetAmortization'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock issued upon exercise of employee stock options</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:to='lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeMember' xlink:label='us-gaap_ComprehensiveIncomeMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ComprehensiveIncomeMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Comprehensive Income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ComprehensiveIncomeMember' xlink:to='lab_us-gaap_ComprehensiveIncomeMember'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProfitLoss' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net income</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProfitLoss' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProfitLoss' xlink:to='lab_us-gaap_ProfitLoss'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_GrossProfit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Gross profit</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_GrossProfit' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Gross profit</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_GrossProfit' xlink:to='lab_us-gaap_GrossProfit'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized' xlink:label='us-gaap_CommonStockSharesAuthorized'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockSharesAuthorized' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock, Shares Authorized</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockSharesAuthorized' xlink:to='lab_us-gaap_CommonStockSharesAuthorized'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total stockholders&apos; equity</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total stockholders&apos; equity</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockholdersEquity' xlink:to='lab_us-gaap_StockholdersEquity'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:label='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accumulated other comprehensive income (loss)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:to='lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract' xlink:label='us-gaap_LiabilitiesCurrentAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesCurrentAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current liabilities:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='lab_us-gaap_LiabilitiesCurrentAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset' xlink:label='us-gaap_OperatingLeaseRightOfUseAsset'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingLeaseRightOfUseAsset' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating lease - right of use assets, net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingLeaseRightOfUseAsset' xlink:to='lab_us-gaap_OperatingLeaseRightOfUseAsset'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus' xlink:label='dei_DocumentFiscalYearFocus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentFiscalYearFocus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Fiscal Year Focus</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentFiscalYearFocus' xlink:to='lab_dei_DocumentFiscalYearFocus'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_NeonatalMember' xlink:label='fil_NeonatalMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NeonatalMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Neonatal</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NeonatalMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Neonatal, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NeonatalMember' xlink:to='lab_fil_NeonatalMember'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' xlink:label='us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>New Accounting Pronouncements, Policy</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' xlink:to='lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock' xlink:label='us-gaap_RevenueRecognitionPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RevenueRecognitionPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Revenue Recognition</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RevenueRecognitionPolicyTextBlock' xlink:to='lab_us-gaap_RevenueRecognitionPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable' xlink:label='us-gaap_IncreaseDecreaseInAccountsPayable'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsPayable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts payable {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsPayable' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Accounts payable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccountsPayable' xlink:to='lab_us-gaap_IncreaseDecreaseInAccountsPayable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets' xlink:label='us-gaap_GainLossOnDispositionOfAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_GainLossOnDispositionOfAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>(Gain) loss on disposal of assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_GainLossOnDispositionOfAssets' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>(Gain) loss on disposal of assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_GainLossOnDispositionOfAssets' xlink:to='lab_us-gaap_GainLossOnDispositionOfAssets'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember' xlink:label='us-gaap_CommonStockMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockMember' xlink:to='lab_us-gaap_CommonStockMember'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' xlink:to='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract' xlink:label='us-gaap_OperatingExpensesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingExpensesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='lab_us-gaap_OperatingExpensesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued' xlink:label='us-gaap_PreferredStockSharesIssued'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PreferredStockSharesIssued' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Preferred Stock, Shares Issued</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PreferredStockSharesIssued' xlink:to='lab_us-gaap_PreferredStockSharesIssued'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_LocalPhoneNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Local Phone Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_LocalPhoneNumber' xlink:to='lab_dei_LocalPhoneNumber'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' xlink:label='us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Dilutive effect of stock options</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' xlink:to='lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent' xlink:label='us-gaap_OperatingLeaseLiabilityCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingLeaseLiabilityCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating Lease, Liability, Current</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingLeaseLiabilityCurrent' xlink:to='lab_us-gaap_OperatingLeaseLiabilityCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaid' xlink:label='us-gaap_InterestPaid'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InterestPaid' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash paid during the period for interest</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InterestPaid' xlink:to='lab_us-gaap_InterestPaid'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Effect of exchange rate changes on cash</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:to='lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total adjustments</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total adjustments</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:to='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation' xlink:label='us-gaap_ShareBasedCompensation'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ShareBasedCompensation' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stock-based compensation expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ShareBasedCompensation' xlink:to='lab_us-gaap_ShareBasedCompensation'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Sales, net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:to='lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized' xlink:label='us-gaap_PreferredStockSharesAuthorized'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PreferredStockSharesAuthorized' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Preferred Stock, Shares Authorized</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PreferredStockSharesAuthorized' xlink:to='lab_us-gaap_PreferredStockSharesAuthorized'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity' xlink:label='us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesAndStockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total liabilities and stockholders&apos; equity</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesAndStockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total liabilities and stockholders&apos; equity</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesAndStockholdersEquity' xlink:to='lab_us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract' xlink:label='us-gaap_StockholdersEquityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stockholders&apos; equity:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='lab_us-gaap_StockholdersEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent' xlink:label='us-gaap_AccountsPayableCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccountsPayableCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts payable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccountsPayableCurrent' xlink:to='lab_us-gaap_AccountsPayableCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCurrentReportingStatus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Current Reporting Status</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCurrentReportingStatus' xlink:to='lab_dei_EntityCurrentReportingStatus'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_DomesticUsMember' xlink:label='fil_DomesticUsMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DomesticUsMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>DomesticUsMember</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_DomesticUsMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the DomesticUsMember, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DomesticUsMember' xlink:to='lab_fil_DomesticUsMember'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DisclosureTextBlockAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Notes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='lab_us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividends' xlink:label='us-gaap_PaymentsOfDividends'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsOfDividends' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Payment of dividends</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsOfDividends' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Payment of dividends</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PaymentsOfDividends' xlink:to='lab_us-gaap_PaymentsOfDividends'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories' xlink:label='us-gaap_IncreaseDecreaseInInventories'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInInventories' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventories {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInInventories' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Inventories</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInInventories' xlink:to='lab_us-gaap_IncreaseDecreaseInInventories'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation' xlink:label='us-gaap_Depreciation'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Depreciation' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Depreciation</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Depreciation' xlink:to='lab_us-gaap_Depreciation'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Foreign currency translation adjustment</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Foreign currency translation net of taxes of $0 in all periods</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:to='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:label='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Weighted average shares, basic</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Shares outstanding - basic</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:to='lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent' xlink:label='us-gaap_LiabilitiesCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total current liabilities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesCurrent' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total current liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesCurrent' xlink:to='lab_us-gaap_LiabilitiesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressPostalZipCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Postal Zip Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressPostalZipCode' xlink:to='lab_dei_EntityAddressPostalZipCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport' xlink:label='dei_DocumentQuarterlyReport'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentQuarterlyReport' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Quarterly Report</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentQuarterlyReport' xlink:to='lab_dei_DocumentQuarterlyReport'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentDescription' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Description</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentDescription' xlink:to='lab_dei_AmendmentDescription'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityShellCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Shell Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityShellCompany' xlink:to='lab_dei_EntityShellCompany'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_CoopersurgicalIncMember' xlink:label='fil_CoopersurgicalIncMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CoopersurgicalIncMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CooperSurgical Inc</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CoopersurgicalIncMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the CooperSurgical Inc, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CoopersurgicalIncMember' xlink:to='lab_fil_CoopersurgicalIncMember'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive' xlink:label='us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive' xlink:to='lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves' xlink:label='us-gaap_InventoryFinishedGoodsNetOfReserves'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryFinishedGoodsNetOfReserves' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Finished goods</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryFinishedGoodsNetOfReserves' xlink:to='lab_us-gaap_InventoryFinishedGoodsNetOfReserves'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionPlanExpense' xlink:label='us-gaap_StockOptionPlanExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockOptionPlanExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stock option compensation expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockOptionPlanExpense' xlink:to='lab_us-gaap_StockOptionPlanExpense'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:label='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Equity Balance, value</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:role='http://www.xbrl.org/2003/role/periodStartLabel' xml:lang='en-US'>Equity Balance, value</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:role='http://www.xbrl.org/2003/role/periodEndLabel' xml:lang='en-US'>Equity Balance, value</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:to='lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense' xlink:label='us-gaap_OtherNonoperatingIncomeExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherNonoperatingIncomeExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other income (expense)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherNonoperatingIncomeExpense' xlink:to='lab_us-gaap_OtherNonoperatingIncomeExpense'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold' xlink:label='us-gaap_CostOfGoodsAndServicesSold'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CostOfGoodsAndServicesSold' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cost of goods sold</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CostOfGoodsAndServicesSold' xlink:to='lab_us-gaap_CostOfGoodsAndServicesSold'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue' xlink:label='us-gaap_PreferredStockValue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PreferredStockValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Preferred stock - $.01 par value; authorized - 5,000 shares; no shares issued or outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PreferredStockValue' xlink:to='lab_us-gaap_PreferredStockValue'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract' xlink:label='us-gaap_AssetsCurrentAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsCurrentAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current assets:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='lab_us-gaap_AssetsCurrentAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressCityOrTown' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, City or Town</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressCityOrTown' xlink:to='lab_dei_EntityAddressCityOrTown'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis' xlink:label='srt_ProductOrServiceAxis'/>
		<link:label xlink:type='resource' xlink:label='lab_srt_ProductOrServiceAxis' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Product and Service [Axis]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='srt_ProductOrServiceAxis' xlink:to='lab_srt_ProductOrServiceAxis'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_ReconciliationOfOperatingLeaseLiabilitiesTableTextBlock' xlink:label='fil_ReconciliationOfOperatingLeaseLiabilitiesTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ReconciliationOfOperatingLeaseLiabilitiesTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Reconciliation of operating lease liabilities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ReconciliationOfOperatingLeaseLiabilitiesTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Reconciliation of operating lease liabilities/ payments to operating lease liabilities.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ReconciliationOfOperatingLeaseLiabilitiesTableTextBlock' xlink:to='lab_fil_ReconciliationOfOperatingLeaseLiabilitiesTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_ScheduleOfRevenuesByProductCategoryTextBlock' xlink:label='fil_ScheduleOfRevenuesByProductCategoryTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ScheduleOfRevenuesByProductCategoryTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule Of Revenues By Product Category</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ScheduleOfRevenuesByProductCategoryTextBlock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the textual narrative disclosure of Schedule Of Revenues By Product Category, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ScheduleOfRevenuesByProductCategoryTextBlock' xlink:to='lab_fil_ScheduleOfRevenuesByProductCategoryTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net cash provided by operating activities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net cash provided by operating activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='lab_us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember' xlink:label='us-gaap_AdditionalPaidInCapitalMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdditionalPaidInCapitalMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Additional Paid-in Capital</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdditionalPaidInCapitalMember' xlink:to='lab_us-gaap_AdditionalPaidInCapitalMember'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax' xlink:label='us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ComprehensiveIncomeNetOfTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total comprehensive income</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ComprehensiveIncomeNetOfTax' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total comprehensive income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ComprehensiveIncomeNetOfTax' xlink:to='lab_us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments' xlink:label='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Income before provision for income taxes</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Income before provision for income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments' xlink:to='lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent' xlink:label='us-gaap_OtherLiabilitiesNoncurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherLiabilitiesNoncurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other long term liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherLiabilitiesNoncurrent' xlink:to='lab_us-gaap_OtherLiabilitiesNoncurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:label='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred tax liability - Femcare IIA</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:to='lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet' xlink:label='us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PropertyPlantAndEquipmentNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Property and equipment, net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PropertyPlantAndEquipmentNet' xlink:to='lab_us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle' xlink:label='dei_Security12bTitle'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_Security12bTitle' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Title of 12(b) Security</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_Security12bTitle' xlink:to='lab_dei_Security12bTitle'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityEmergingGrowthCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Emerging Growth Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityEmergingGrowthCompany' xlink:to='lab_dei_EntityEmergingGrowthCompany'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive' xlink:label='us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive' xlink:to='lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears' xlink:label='us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears' xlink:to='lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent' xlink:label='us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent' xlink:to='lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_BloodPressureMonitoringAndAccessoriesMember' xlink:label='fil_BloodPressureMonitoringAndAccessoriesMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BloodPressureMonitoringAndAccessoriesMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Blood Pressure Monitoring and Accessories</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BloodPressureMonitoringAndAccessoriesMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Blood Pressure Monitoring and Accessories, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BloodPressureMonitoringAndAccessoriesMember' xlink:to='lab_fil_BloodPressureMonitoringAndAccessoriesMember'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductWarrantyAccrual' xlink:label='us-gaap_ProductWarrantyAccrual'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProductWarrantyAccrual' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Standard and Extended Product Warranty Accrual</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProductWarrantyAccrual' xlink:to='lab_us-gaap_ProductWarrantyAccrual'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' xlink:label='us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>New Accounting Pronouncements and Changes in Accounting Principles</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' xlink:to='lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' xlink:label='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Basis of Presentation</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' xlink:to='lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid' xlink:label='us-gaap_IncomeTaxesPaid'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxesPaid' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash paid during the period for income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeTaxesPaid' xlink:to='lab_us-gaap_IncomeTaxesPaid'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net cash used in investing activities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net cash used in investing activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:to='lab_us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets' xlink:label='us-gaap_PaymentsToAcquireIntangibleAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsToAcquireIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Intangible assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsToAcquireIntangibleAssets' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Intangible assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PaymentsToAcquireIntangibleAssets' xlink:to='lab_us-gaap_PaymentsToAcquireIntangibleAssets'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:label='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Changes in operating assets and liabilities:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:label='us-gaap_DeferredTaxExpenseFromStockOptionsExercised'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Tax benefit attributable to exercise of stock options</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:to='lab_us-gaap_DeferredTaxExpenseFromStockOptionsExercised'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:label='us-gaap_LiabilitiesAndStockholdersEquityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>LIABILITIES AND STOCKHOLDERS&apos; EQUITY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventories</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryNet' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryNet' xlink:to='lab_us-gaap_InventoryNet'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressStateOrProvince' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, State or Province</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressStateOrProvince' xlink:to='lab_dei_EntityAddressStateOrProvince'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport' xlink:label='dei_DocumentTransitionReport'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentTransitionReport' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Transition Report</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentTransitionReport' xlink:to='lab_dei_DocumentTransitionReport'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter' xlink:label='us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter' xlink:to='lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears' xlink:label='us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears' xlink:to='lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1' xlink:label='us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating Lease, Weighted Average Remaining Lease Term</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1' xlink:to='lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_LesseeOperatingLeaseForAutomobileTermOfContract' xlink:label='fil_LesseeOperatingLeaseForAutomobileTermOfContract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_LesseeOperatingLeaseForAutomobileTermOfContract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Lessee Operating Lease for Automobile Term of Contract</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_LesseeOperatingLeaseForAutomobileTermOfContract' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Lessee Operating Lease for Automobile Term of Contract, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_LesseeOperatingLeaseForAutomobileTermOfContract' xlink:to='lab_fil_LesseeOperatingLeaseForAutomobileTermOfContract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess' xlink:label='us-gaap_InventoryWorkInProcess'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryWorkInProcess' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Work-in-process</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryWorkInProcess' xlink:to='lab_us-gaap_InventoryWorkInProcess'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock' xlink:label='us-gaap_LeaseCostTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LeaseCostTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Lease, Cost {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LeaseCostTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Lease, Cost</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LeaseCostTableTextBlock' xlink:to='lab_us-gaap_LeaseCostTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net decrease in cash and cash equivalents</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net decrease in cash and cash equivalents</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:to='lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:label='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Property and equipment</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Property and equipment</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:to='lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:label='us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accrued expenses {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Accrued expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:to='lab_us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock purchased and retired, shares</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:to='lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock issued upon exercise of employee stock options, shares</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:to='lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityInteractiveDataCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Interactive Data Current</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityInteractiveDataCurrent' xlink:to='lab_dei_EntityInteractiveDataCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityTaxIdentificationNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Tax Identification Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityTaxIdentificationNumber' xlink:to='lab_dei_EntityTaxIdentificationNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCentralIndexKey' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Central Index Key</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCentralIndexKey' xlink:to='lab_dei_EntityCentralIndexKey'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths' xlink:label='us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths' xlink:to='lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_GynecologyElectrosurgeryUrologyMember' xlink:label='fil_GynecologyElectrosurgeryUrologyMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_GynecologyElectrosurgeryUrologyMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Gynecology/Electrosurgery/Urology</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_GynecologyElectrosurgeryUrologyMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Gynecology/Electrosurgery/Urology, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_GynecologyElectrosurgeryUrologyMember' xlink:to='lab_fil_GynecologyElectrosurgeryUrologyMember'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:label='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Prepaid expenses and other current assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Prepaid expenses and other current assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:to='lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock received and retired upon exercise of stock options, shares</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Common stock received and retired upon exercise of stock options, shares (number of shares), during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:to='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense' xlink:label='us-gaap_ResearchAndDevelopmentExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ResearchAndDevelopmentExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Research &amp; development</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ResearchAndDevelopmentExpense' xlink:to='lab_us-gaap_ResearchAndDevelopmentExpense'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities' xlink:label='us-gaap_Liabilities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Liabilities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total liabilities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Liabilities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Liabilities' xlink:to='lab_us-gaap_Liabilities'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent' xlink:label='us-gaap_OperatingLeaseLiabilityNoncurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingLeaseLiabilityNoncurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating lease liability</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingLeaseLiabilityNoncurrent' xlink:to='lab_us-gaap_OperatingLeaseLiabilityNoncurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross' xlink:label='us-gaap_FiniteLivedIntangibleAssetsGross'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FiniteLivedIntangibleAssetsGross' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other intangible assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_FiniteLivedIntangibleAssetsGross' xlink:to='lab_us-gaap_FiniteLivedIntangibleAssetsGross'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityWellKnownSeasonedIssuer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Well-known Seasoned Issuer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityWellKnownSeasonedIssuer' xlink:to='lab_dei_EntityWellKnownSeasonedIssuer'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_DistributionRightsAcquisitionAxis' xlink:label='fil_DistributionRightsAcquisitionAxis'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DistributionRightsAcquisitionAxis' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Distribution Rights Acquisition [Axis]</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_DistributionRightsAcquisitionAxis' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the description of Distribution Rights Acquisition, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DistributionRightsAcquisitionAxis' xlink:to='lab_fil_DistributionRightsAcquisitionAxis'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock' xlink:label='us-gaap_EarningsPerShareTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Earnings Per Share</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerShareTextBlock' xlink:to='lab_us-gaap_EarningsPerShareTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock' xlink:label='us-gaap_LesseeOperatingLeasesTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LesseeOperatingLeasesTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Leases</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LesseeOperatingLeasesTextBlock' xlink:to='lab_us-gaap_LesseeOperatingLeasesTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductWarrantyDisclosureTextBlock' xlink:label='us-gaap_ProductWarrantyDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProductWarrantyDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Warranty Reserve</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProductWarrantyDisclosureTextBlock' xlink:to='lab_us-gaap_ProductWarrantyDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStockCash' xlink:label='us-gaap_DividendsCommonStockCash'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DividendsCommonStockCash' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock dividends</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DividendsCommonStockCash' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Common stock dividends</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DividendsCommonStockCash' xlink:to='lab_us-gaap_DividendsCommonStockCash'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock received and retired upon exercise of stock options</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the monetary amount of Common stock received and retired upon exercise of stock options, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:to='lab_fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit' xlink:label='us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RetainedEarningsAccumulatedDeficit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Retained earnings</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RetainedEarningsAccumulatedDeficit' xlink:to='lab_us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CityAreaCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>City Area Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CityAreaCode' xlink:to='lab_dei_CityAreaCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFilerCategory' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Filer Category</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFilerCategory' xlink:to='lab_dei_EntityFilerCategory'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCommonStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Common Stock, Shares Outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCommonStockSharesOutstanding' xlink:to='lab_dei_EntityCommonStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_DistributionRightsAcquisitionDomain' xlink:label='fil_DistributionRightsAcquisitionDomain'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DistributionRightsAcquisitionDomain' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Distribution Rights Acquisition</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_DistributionRightsAcquisitionDomain' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Distribution Rights Acquisition, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DistributionRightsAcquisitionDomain' xlink:to='lab_fil_DistributionRightsAcquisitionDomain'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue' xlink:label='us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Lessee, Operating Lease, Liability, to be Paid</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue' xlink:to='lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost' xlink:label='us-gaap_OperatingLeaseCost'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingLeaseCost' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating Lease, Cost</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingLeaseCost' xlink:to='lab_us-gaap_OperatingLeaseCost'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_LesseeOperatingLeaseForParkingLotTermOfContract' xlink:label='fil_LesseeOperatingLeaseForParkingLotTermOfContract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_LesseeOperatingLeaseForParkingLotTermOfContract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Lessee Operating Lease for Parking Lot Term of Contract</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_LesseeOperatingLeaseForParkingLotTermOfContract' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the Lessee Operating Lease for Parking Lot Term of Contract, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_LesseeOperatingLeaseForParkingLotTermOfContract' xlink:to='lab_fil_LesseeOperatingLeaseForParkingLotTermOfContract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials' xlink:label='us-gaap_InventoryRawMaterials'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryRawMaterials' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Raw materials</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryRawMaterials' xlink:to='lab_us-gaap_InventoryRawMaterials'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_TableTextBlockSupplementAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Tables/Schedules</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='lab_us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PolicyTextBlockAbstract' xlink:label='us-gaap_PolicyTextBlockAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PolicyTextBlockAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Policies</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PolicyTextBlockAbstract' xlink:to='lab_us-gaap_PolicyTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Adjustments to reconcile net income to net cash provided by operating activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Equity Balance, shares</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/periodStartLabel' xml:lang='en-US'>Equity Balance, shares</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/periodEndLabel' xml:lang='en-US'>Equity Balance, shares</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SharesOutstanding' xlink:to='lab_us-gaap_SharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic' xlink:label='us-gaap_EarningsPerShareBasic'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareBasic' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Earnings per share, basic</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareBasic' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Earnings per common share (basic)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerShareBasic' xlink:to='lab_us-gaap_EarningsPerShareBasic'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock' xlink:label='us-gaap_AdditionalPaidInCapitalCommonStock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdditionalPaidInCapitalCommonStock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Additional paid-in capital</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdditionalPaidInCapitalCommonStock' xlink:to='lab_us-gaap_AdditionalPaidInCapitalCommonStock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent' xlink:label='us-gaap_OtherAssetsCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherAssetsCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other current assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherAssetsCurrent' xlink:to='lab_us-gaap_OtherAssetsCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus' xlink:label='dei_DocumentFiscalPeriodFocus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentFiscalPeriodFocus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Fiscal Period Focus</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentFiscalPeriodFocus' xlink:to='lab_dei_DocumentFiscalPeriodFocus'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentType' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Type</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentType' xlink:to='lab_dei_DocumentType'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_TextBlockAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Details</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_TextBlockAbstract' xlink:to='lab_us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:label='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule of Earnings Per Share, Basic and Diluted</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:to='lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:label='us-gaap_ProceedsFromIssuanceOfCommonStock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Proceeds from issuance of common stock - options</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:to='lab_us-gaap_ProceedsFromIssuanceOfCommonStock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable' xlink:label='us-gaap_IncreaseDecreaseInAccountsReceivable'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsReceivable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts receivable and other receivables</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsReceivable' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Accounts receivable and other receivables</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccountsReceivable' xlink:to='lab_us-gaap_IncreaseDecreaseInAccountsReceivable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:label='us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred income taxes {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Deferred income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:to='lab_us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementTable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Statement</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementTable' xlink:to='lab_us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingIncomeLoss' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating income</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingIncomeLoss' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Operating income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingIncomeLoss' xlink:to='lab_us-gaap_OperatingIncomeLoss'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses' xlink:label='us-gaap_OperatingExpenses'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingExpenses' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total operating expenses</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingExpenses' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total operating expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingExpenses' xlink:to='lab_us-gaap_OperatingExpenses'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare' xlink:label='us-gaap_CommonStockParOrStatedValuePerShare'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockParOrStatedValuePerShare' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock, Par or Stated Value Per Share</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockParOrStatedValuePerShare' xlink:to='lab_us-gaap_CommonStockParOrStatedValuePerShare'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue' xlink:label='us-gaap_CommonStockValue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock - $.01 par value; authorized - 50,000 shares; issued - September 30, 2020, 3,640 shares and December 31, 2019, 3,722 shares</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockValue' xlink:to='lab_us-gaap_CommonStockValue'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent' xlink:label='us-gaap_AccruedLiabilitiesCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccruedLiabilitiesCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accrued expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccruedLiabilitiesCurrent' xlink:to='lab_us-gaap_AccruedLiabilitiesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill' xlink:label='us-gaap_Goodwill'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Goodwill' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Goodwill</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Goodwill' xlink:to='lab_us-gaap_Goodwill'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_SecurityExchangeName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Security Exchange Name</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_SecurityExchangeName' xlink:to='lab_dei_SecurityExchangeName'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityPublicFloat' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Public Float</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityPublicFloat' xlink:to='lab_dei_EntityPublicFloat'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_TradingSymbol' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trading Symbol</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_TradingSymbol' xlink:to='lab_dei_TradingSymbol'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CurrentFiscalYearEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current Fiscal Year End Date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CurrentFiscalYearEndDate' xlink:to='lab_dei_CurrentFiscalYearEndDate'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis' xlink:label='srt_StatementGeographicalAxis'/>
		<link:label xlink:type='resource' xlink:label='lab_srt_StatementGeographicalAxis' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Geographical [Axis]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='srt_StatementGeographicalAxis' xlink:to='lab_srt_StatementGeographicalAxis'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock' xlink:label='us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule of Future Minimum Rental Payments for Operating Leases</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock' xlink:to='lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net cash used in financing activities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net cash used in financing activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:to='lab_us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementLineItems' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Statement [Line Items]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementLineItems' xlink:to='lab_us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted' xlink:label='us-gaap_EarningsPerShareDiluted'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareDiluted' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Earnings per share, diluted</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareDiluted' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Earnings per common share (diluted)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerShareDiluted' xlink:to='lab_us-gaap_EarningsPerShareDiluted'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit' xlink:label='us-gaap_IncomeTaxExpenseBenefit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxExpenseBenefit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Provision for income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeTaxExpenseBenefit' xlink:to='lab_us-gaap_IncomeTaxExpenseBenefit'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense' xlink:label='us-gaap_SellingGeneralAndAdministrativeExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SellingGeneralAndAdministrativeExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Selling, general and administrative</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SellingGeneralAndAdministrativeExpense' xlink:to='lab_us-gaap_SellingGeneralAndAdministrativeExpense'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:label='us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash &amp; investments</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:role='http://www.xbrl.org/2003/role/periodStartLabel' xml:lang='en-US'>Cash at beginning of period</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:role='http://www.xbrl.org/2003/role/periodEndLabel' xml:lang='en-US'>Cash at end of period</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:to='lab_us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFileNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity File Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFileNumber' xlink:to='lab_dei_EntityFileNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityRegistrantName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Registrant Name</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityRegistrantName' xlink:to='lab_dei_EntityRegistrantName'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1' xlink:label='us-gaap_FinitelivedIntangibleAssetsAcquired1'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FinitelivedIntangibleAssetsAcquired1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Finite-lived Intangible Assets Acquired</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_FinitelivedIntangibleAssetsAcquired1' xlink:to='lab_us-gaap_FinitelivedIntangibleAssetsAcquired1'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour' xlink:label='us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour' xlink:to='lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent' xlink:label='us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating Lease, Weighted Average Discount Rate, Percent</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent' xlink:to='lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock' xlink:label='us-gaap_SubsequentEventsTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SubsequentEventsTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Subsequent Events</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SubsequentEventsTextBlock' xlink:to='lab_us-gaap_SubsequentEventsTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentForAmortization' xlink:label='us-gaap_AdjustmentForAmortization'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdjustmentForAmortization' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amortization</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdjustmentForAmortization' xlink:to='lab_us-gaap_AdjustmentForAmortization'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock purchased and retired</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:to='lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding' xlink:label='us-gaap_CommonStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock, Shares, Outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockSharesOutstanding' xlink:to='lab_us-gaap_CommonStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent' xlink:label='us-gaap_AssetsCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total current assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsCurrent' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Total current assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AssetsCurrent' xlink:to='lab_us-gaap_AssetsCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntitySmallBusiness' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Small Business</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntitySmallBusiness' xlink:to='lab_dei_EntitySmallBusiness'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree' xlink:label='us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree' xlink:to='lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount' xlink:label='us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount' xlink:to='lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:label='us-gaap_ScheduleOfInventoryCurrentTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule of Inventory, Current</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:to='lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EquityComponentDomain' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Equity Component</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EquityComponentDomain' xlink:to='lab_us-gaap_EquityComponentDomain'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember' xlink:label='us-gaap_RetainedEarningsMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RetainedEarningsMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Retained Earnings</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RetainedEarningsMember' xlink:to='lab_us-gaap_RetainedEarningsMember'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:label='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Diluted shares</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/verboseLabel' xml:lang='en-US'>Shares outstanding - diluted</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:to='lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued' xlink:label='us-gaap_CommonStockSharesIssued'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockSharesIssued' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock, Shares, Issued</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockSharesIssued' xlink:to='lab_us-gaap_CommonStockSharesIssued'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare' xlink:label='us-gaap_PreferredStockParOrStatedValuePerShare'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PreferredStockParOrStatedValuePerShare' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Preferred Stock, Par or Stated Value Per Share</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PreferredStockParOrStatedValuePerShare' xlink:to='lab_us-gaap_PreferredStockParOrStatedValuePerShare'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract' xlink:label='us-gaap_AssetsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>ASSETS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AssetsAbstract' xlink:to='lab_us-gaap_AssetsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityIncorporationStateCountryCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Incorporation, State or Country Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityIncorporationStateCountryCode' xlink:to='lab_dei_EntityIncorporationStateCountryCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityVoluntaryFilers' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Voluntary filer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityVoluntaryFilers' xlink:to='lab_dei_EntityVoluntaryFilers'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentPeriodEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Period End Date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentPeriodEndDate' xlink:to='lab_dei_DocumentPeriodEndDate'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo' xlink:label='us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo' xlink:to='lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears' xlink:label='us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears' xlink:to='lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_OutsideUsMember' xlink:label='fil_OutsideUsMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OutsideUsMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>OutsideUsMember</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OutsideUsMember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Represents the OutsideUsMember, during the indicated time period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OutsideUsMember' xlink:to='lab_fil_OutsideUsMember'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense' xlink:label='us-gaap_AllocatedShareBasedCompensationExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AllocatedShareBasedCompensationExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Allocated Share-based Compensation Expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AllocatedShareBasedCompensationExpense' xlink:to='lab_us-gaap_AllocatedShareBasedCompensationExpense'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock' xlink:label='us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Lessee, Operating Lease, Liability, Maturity</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock' xlink:to='lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:label='us-gaap_PaymentsForRepurchaseOfCommonStock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock purchased and retired {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Common stock purchased and retired</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:to='lab_us-gaap_PaymentsForRepurchaseOfCommonStock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:to='lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts' xlink:label='us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProvisionForDoubtfulAccounts' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Provision for (recovery of) losses on accounts receivable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProvisionForDoubtfulAccounts' xlink:to='lab_us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding' xlink:label='us-gaap_PreferredStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PreferredStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Preferred Stock, Shares Outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PreferredStockSharesOutstanding' xlink:to='lab_us-gaap_PreferredStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other intangible assets - accumulated amortization</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Other intangible assets - accumulated amortization</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:to='lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent' xlink:label='us-gaap_AccountsReceivableNetCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccountsReceivableNetCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts &amp; other receivables, net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccountsReceivableNetCurrent' xlink:to='lab_us-gaap_AccountsReceivableNetCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentFlag' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Flag</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentFlag' xlink:to='lab_dei_AmendmentFlag'/>
	</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>utmd-20200930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2020 [PPXK9NDL3JZWVJK4T7A6]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.utahmed.com/20200930"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DocumentDocumentAndEntityInformation">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityRegistrantName' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCentralIndexKey' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentType' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentPeriodEndDate' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CurrentFiscalYearEndDate' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_TradingSymbol' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityTaxIdentificationNumber' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCommonStockSharesOutstanding' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityPublicFloat' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFilerCategory' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCurrentReportingStatus' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityVoluntaryFilers' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityWellKnownSeasonedIssuer' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityShellCompany' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntitySmallBusiness' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityEmergingGrowthCompany' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityExTransitionPeriod' use='optional' order='17.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentDescription' use='optional' order='18.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport' xlink:label='dei_DocumentQuarterlyReport'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentQuarterlyReport' use='optional' order='19.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport' xlink:label='dei_DocumentTransitionReport'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentTransitionReport' use='optional' order='20.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFileNumber' use='optional' order='21.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityIncorporationStateCountryCode' use='optional' order='22.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressAddressLine1' use='optional' order='23.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressCityOrTown' use='optional' order='24.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressStateOrProvince' use='optional' order='25.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressPostalZipCode' use='optional' order='26.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CityAreaCode' use='optional' order='27.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_LocalPhoneNumber' use='optional' order='28.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle' xlink:label='dei_Security12bTitle'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_Security12bTitle' use='optional' order='29.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_SecurityExchangeName' use='optional' order='30.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityInteractiveDataCurrent' use='optional' order='31.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentFlag' use='optional' order='32.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus' xlink:label='dei_DocumentFiscalYearFocus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentFiscalYearFocus' use='optional' order='33.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus' xlink:label='dei_DocumentFiscalPeriodFocus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentFiscalPeriodFocus' use='optional' order='34.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract' xlink:label='us-gaap_AssetsAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_AssetsAbstract' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract' xlink:label='us-gaap_AssetsCurrentAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_AssetsCurrentAbstract' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:label='us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_CashAndCashEquivalentsAtCarryingValue' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent' xlink:label='us-gaap_AccountsReceivableNetCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_AccountsReceivableNetCurrent' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_InventoryNet' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent' xlink:label='us-gaap_OtherAssetsCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_OtherAssetsCurrent' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent' xlink:label='us-gaap_AssetsCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OtherAssetsCurrent' xlink:to='us-gaap_AssetsCurrent' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet' xlink:label='us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_PropertyPlantAndEquipmentNet' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset' xlink:label='us-gaap_OperatingLeaseRightOfUseAsset'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_OperatingLeaseRightOfUseAsset' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill' xlink:label='us-gaap_Goodwill'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_Goodwill' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross' xlink:label='us-gaap_FiniteLivedIntangibleAssetsGross'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_FiniteLivedIntangibleAssetsGross' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' use='optional' order='7.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:label='us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:to='us-gaap_IntangibleAssetsNetExcludingGoodwill' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets' xlink:label='us-gaap_Assets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_Assets' use='optional' order='8.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:label='us-gaap_LiabilitiesAndStockholdersEquityAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_LiabilitiesAndStockholdersEquityAbstract' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract' xlink:label='us-gaap_LiabilitiesCurrentAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_LiabilitiesCurrentAbstract' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent' xlink:label='us-gaap_AccountsPayableCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_AccountsPayableCurrent' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent' xlink:label='us-gaap_AccruedLiabilitiesCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_AccruedLiabilitiesCurrent' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent' xlink:label='us-gaap_LiabilitiesCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_LiabilitiesCurrent' use='optional' order='13.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' xlink:label='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent' xlink:label='us-gaap_OtherLiabilitiesNoncurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_OtherLiabilitiesNoncurrent' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent' xlink:label='us-gaap_OperatingLeaseLiabilityNoncurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_OperatingLeaseLiabilityNoncurrent' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet' xlink:label='us-gaap_DeferredIncomeTaxLiabilitiesNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_DeferredIncomeTaxLiabilitiesNet' use='optional' order='17.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities' xlink:label='us-gaap_Liabilities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_Liabilities' use='optional' order='18.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract' xlink:label='us-gaap_StockholdersEquityAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_StockholdersEquityAbstract' use='optional' order='19.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue' xlink:label='us-gaap_PreferredStockValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_PreferredStockValue' use='optional' order='20.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue' xlink:label='us-gaap_CommonStockValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_CommonStockValue' use='optional' order='21.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' xlink:label='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1' use='optional' order='22.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock' xlink:label='us-gaap_AdditionalPaidInCapitalCommonStock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_AdditionalPaidInCapitalCommonStock' use='optional' order='23.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit' xlink:label='us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_RetainedEarningsAccumulatedDeficit' use='optional' order='24.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_StockholdersEquity' use='optional' order='25.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity' xlink:label='us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_LiabilitiesAndStockholdersEquity' use='optional' order='26.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEETParenthetical" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEETParenthetical"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEETParenthetical">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare' xlink:label='us-gaap_PreferredStockParOrStatedValuePerShare'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_PreferredStockParOrStatedValuePerShare' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized' xlink:label='us-gaap_PreferredStockSharesAuthorized'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_PreferredStockSharesAuthorized' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued' xlink:label='us-gaap_PreferredStockSharesIssued'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_PreferredStockSharesIssued' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding' xlink:label='us-gaap_PreferredStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_PreferredStockSharesOutstanding' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare' xlink:label='us-gaap_CommonStockParOrStatedValuePerShare'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_CommonStockParOrStatedValuePerShare' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized' xlink:label='us-gaap_CommonStockSharesAuthorized'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_CommonStockSharesAuthorized' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued' xlink:label='us-gaap_CommonStockSharesIssued'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_CommonStockSharesIssued' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding' xlink:label='us-gaap_CommonStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_CommonStockSharesOutstanding' use='optional' order='8.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold' xlink:label='us-gaap_CostOfGoodsAndServicesSold'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_CostOfGoodsAndServicesSold' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_GrossProfit' use='optional' order='3.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract' xlink:label='us-gaap_OperatingExpensesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_OperatingExpensesAbstract' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense' xlink:label='us-gaap_SellingGeneralAndAdministrativeExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_SellingGeneralAndAdministrativeExpense' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense' xlink:label='us-gaap_ResearchAndDevelopmentExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_ResearchAndDevelopmentExpense' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses' xlink:label='us-gaap_OperatingExpenses'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_OperatingExpenses' use='optional' order='7.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_OperatingIncomeLoss' use='optional' order='8.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense' xlink:label='us-gaap_OtherNonoperatingIncomeExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_OtherNonoperatingIncomeExpense' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments' xlink:label='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments' use='optional' order='10.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit' xlink:label='us-gaap_IncomeTaxExpenseBenefit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_IncomeTaxExpenseBenefit' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_ProfitLoss' use='optional' order='12.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic' xlink:label='us-gaap_EarningsPerShareBasic'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_EarningsPerShareBasic' use='optional' order='13.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted' xlink:label='us-gaap_EarningsPerShareDiluted'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_EarningsPerShareDiluted' use='optional' order='14.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:label='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' use='optional' order='15.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:label='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' use='optional' order='16.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract' xlink:label='us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract' use='optional' order='17.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' use='optional' order='18.0' preferredLabel='http://www.xbrl.org/2003/role/verboseLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax' xlink:label='us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_ComprehensiveIncomeNetOfTax' use='optional' order='19.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOMEParenthetical" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOMEParenthetical"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOMEParenthetical">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis' xlink:label='us-gaap_StatementEquityComponentsAxis'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementEquityComponentsAxis' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember' xlink:label='us-gaap_CommonStockMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_CommonStockMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember' xlink:label='us-gaap_AdditionalPaidInCapitalMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_AdditionalPaidInCapitalMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeMember' xlink:label='us-gaap_ComprehensiveIncomeMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_ComprehensiveIncomeMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember' xlink:label='us-gaap_RetainedEarningsMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_RetainedEarningsMember' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_EquityComponentDomain' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:label='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/periodStartLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_SharesOutstanding' use='optional' order='2.0' preferredLabel='http://www.xbrl.org/2003/role/periodStartLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' xlink:label='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' xlink:label='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionPlanExpense' xlink:label='us-gaap_StockOptionPlanExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockOptionPlanExpense' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockRepurchasedAndRetiredDuringPeriodValue' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' xlink:label='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockRepurchasedAndRetiredDuringPeriodShares' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStockCash' xlink:label='us-gaap_DividendsCommonStockCash'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_DividendsCommonStockCash' use='optional' order='11.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_ProfitLoss' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest' xlink:label='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1' use='optional' order='13.0' preferredLabel='http://www.xbrl.org/2003/role/periodEndLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding_1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_SharesOutstanding_1' use='optional' order='14.0' preferredLabel='http://www.xbrl.org/2003/role/periodEndLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_ProfitLoss' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation' xlink:label='us-gaap_Depreciation'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_Depreciation' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentForAmortization' xlink:label='us-gaap_AdjustmentForAmortization'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_AdjustmentForAmortization' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts' xlink:label='us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_ProvisionForDoubtfulAccounts' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_OperatingLeaseRightOfUseAssetAmortization' xlink:label='fil_OperatingLeaseRightOfUseAssetAmortization'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='fil_OperatingLeaseRightOfUseAssetAmortization' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets' xlink:label='us-gaap_GainLossOnDispositionOfAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_GainLossOnDispositionOfAssets' use='optional' order='5.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:label='us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_DeferredIncomeTaxExpenseBenefit' use='optional' order='4.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation' xlink:label='us-gaap_ShareBasedCompensation'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_ShareBasedCompensation' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxExpenseFromStockOptionsExercised' xlink:label='us-gaap_DeferredTaxExpenseFromStockOptionsExercised'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_DeferredTaxExpenseFromStockOptionsExercised' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:label='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable' xlink:label='us-gaap_IncreaseDecreaseInAccountsReceivable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccountsReceivable' use='optional' order='8.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories' xlink:label='us-gaap_IncreaseDecreaseInInventories'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_IncreaseDecreaseInInventories' use='optional' order='9.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' xlink:label='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets' use='optional' order='10.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable' xlink:label='us-gaap_IncreaseDecreaseInAccountsPayable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccountsPayable' use='optional' order='11.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:label='us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccruedLiabilities' use='optional' order='12.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities' use='optional' order='13.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInOperatingActivities' use='optional' order='14.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:label='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' use='optional' order='16.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets' xlink:label='us-gaap_PaymentsToAcquireIntangibleAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_PaymentsToAcquireIntangibleAssets' use='optional' order='17.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInInvestingActivities' use='optional' order='18.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' use='optional' order='19.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock' xlink:label='us-gaap_ProceedsFromIssuanceOfCommonStock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_ProceedsFromIssuanceOfCommonStock' use='optional' order='20.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock' xlink:label='us-gaap_PaymentsForRepurchaseOfCommonStock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_PaymentsForRepurchaseOfCommonStock' use='optional' order='21.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividends' xlink:label='us-gaap_PaymentsOfDividends'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_PaymentsOfDividends' use='optional' order='22.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInFinancingActivities' use='optional' order='23.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' xlink:label='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents' use='optional' order='24.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' xlink:label='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect' use='optional' order='25.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:label='us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_CashAndCashEquivalentsAtCarryingValue' use='optional' order='26.0' preferredLabel='http://www.xbrl.org/2003/role/periodStartLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:label='us-gaap_CashAndCashEquivalentsAtCarryingValue_1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_CashAndCashEquivalentsAtCarryingValue_1' use='optional' order='27.0' preferredLabel='http://www.xbrl.org/2003/role/periodEndLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid' xlink:label='us-gaap_IncomeTaxesPaid'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_IncomeTaxesPaid' use='optional' order='28.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaid' xlink:label='us-gaap_InterestPaid'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_InterestPaid' use='optional' order='29.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureBasisOfPresentation" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureBasisOfPresentation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureBasisOfPresentation">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' xlink:label='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' xlink:label='us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureInventories" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureInventories"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureInventories">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock' xlink:label='us-gaap_InventoryDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_InventoryDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureStockBasedCompensation" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureStockBasedCompensation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureStockBasedCompensation">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' xlink:label='us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureWarrantyReserve" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureWarrantyReserve"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureWarrantyReserve">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductWarrantyDisclosureTextBlock' xlink:label='us-gaap_ProductWarrantyDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_ProductWarrantyDisclosureTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureRevenueRecognition" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureRevenueRecognition"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureRevenueRecognition">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock' xlink:label='us-gaap_RevenueRecognitionPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_RevenueRecognitionPolicyTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureLeases" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureLeases"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureLeases">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock' xlink:label='us-gaap_LesseeOperatingLeasesTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_LesseeOperatingLeasesTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureCSIDistributionAgreementPurchaseDisclosure" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureCSIDistributionAgreementPurchaseDisclosure"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureCSIDistributionAgreementPurchaseDisclosure">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:label='us-gaap_IntangibleAssetsDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_IntangibleAssetsDisclosureTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureEarningsPerShare" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureEarningsPerShare"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureEarningsPerShare">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock' xlink:label='us-gaap_EarningsPerShareTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_EarningsPerShareTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureSubsequentEvents" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureSubsequentEvents"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureSubsequentEvents">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract' xlink:label='us-gaap_DisclosureTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock' xlink:label='us-gaap_SubsequentEventsTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_DisclosureTextBlockAbstract' xlink:to='us-gaap_SubsequentEventsTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PolicyTextBlockAbstract' xlink:label='us-gaap_PolicyTextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' xlink:label='us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_PolicyTextBlockAbstract' xlink:to='us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureInventoriesScheduleOfInventoryCurrentTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:label='us-gaap_ScheduleOfInventoryCurrentTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='us-gaap_ScheduleOfInventoryCurrentTableTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_ScheduleOfRevenuesByProductCategoryTextBlock' xlink:label='fil_ScheduleOfRevenuesByProductCategoryTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='fil_ScheduleOfRevenuesByProductCategoryTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLeaseCostTables" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureLeasesLeaseCostTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLeaseCostTables">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock' xlink:label='us-gaap_LeaseCostTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='us-gaap_LeaseCostTableTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTables" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTables">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock' xlink:label='us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesReconciliationOfOperatingLeaseLiabilitiesTables" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureLeasesReconciliationOfOperatingLeaseLiabilitiesTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesReconciliationOfOperatingLeaseLiabilitiesTables">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_ReconciliationOfOperatingLeaseLiabilitiesTableTextBlock' xlink:label='fil_ReconciliationOfOperatingLeaseLiabilitiesTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='fil_ReconciliationOfOperatingLeaseLiabilitiesTableTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLesseeOperatingLeaseLiabilityMaturityTables" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureLeasesLesseeOperatingLeaseLiabilityMaturityTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLesseeOperatingLeaseLiabilityMaturityTables">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock' xlink:label='us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlockSupplementAbstract' xlink:label='us-gaap_TableTextBlockSupplementAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:label='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TableTextBlockSupplementAbstract' xlink:to='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves' xlink:label='us-gaap_InventoryFinishedGoodsNetOfReserves'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_InventoryFinishedGoodsNetOfReserves' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess' xlink:label='us-gaap_InventoryWorkInProcess'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_InventoryWorkInProcess' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials' xlink:label='us-gaap_InventoryRawMaterials'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_InventoryRawMaterials' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_InventoryNet' use='optional' order='4.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureStockBasedCompensationDetails" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureStockBasedCompensationDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureStockBasedCompensationDetails">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense' xlink:label='us-gaap_AllocatedShareBasedCompensationExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_AllocatedShareBasedCompensationExpense' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureWarrantyReserveDetails" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureWarrantyReserveDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureWarrantyReserveDetails">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductWarrantyAccrual' xlink:label='us-gaap_ProductWarrantyAccrual'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_ProductWarrantyAccrual' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis' xlink:label='srt_StatementGeographicalAxis'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='srt_StatementGeographicalAxis' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain' xlink:label='srt_SegmentGeographicalDomain'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_StatementGeographicalAxis' xlink:to='srt_SegmentGeographicalDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_DomesticUsMember' xlink:label='fil_DomesticUsMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_StatementGeographicalAxis' xlink:to='fil_DomesticUsMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_OutsideUsMember' xlink:label='fil_OutsideUsMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_StatementGeographicalAxis' xlink:to='fil_OutsideUsMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis' xlink:label='srt_ProductOrServiceAxis'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='srt_ProductOrServiceAxis' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain' xlink:label='srt_ProductsAndServicesDomain'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='srt_ProductsAndServicesDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_ObstetricsMember' xlink:label='fil_ObstetricsMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='fil_ObstetricsMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_GynecologyElectrosurgeryUrologyMember' xlink:label='fil_GynecologyElectrosurgeryUrologyMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='fil_GynecologyElectrosurgeryUrologyMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_NeonatalMember' xlink:label='fil_NeonatalMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='fil_NeonatalMember' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_BloodPressureMonitoringAndAccessoriesMember' xlink:label='fil_BloodPressureMonitoringAndAccessoriesMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='srt_ProductOrServiceAxis' xlink:to='fil_BloodPressureMonitoringAndAccessoriesMember' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' xlink:label='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesDetails" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureLeasesDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesDetails">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_LesseeOperatingLeaseForParkingLotTermOfContract' xlink:label='fil_LesseeOperatingLeaseForParkingLotTermOfContract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='fil_LesseeOperatingLeaseForParkingLotTermOfContract' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_LesseeOperatingLeaseForAutomobileTermOfContract' xlink:label='fil_LesseeOperatingLeaseForAutomobileTermOfContract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='fil_LesseeOperatingLeaseForAutomobileTermOfContract' use='optional' order='2.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLeaseCostDetails" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureLeasesLeaseCostDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLeaseCostDetails">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost' xlink:label='us-gaap_OperatingLeaseCost'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_OperatingLeaseCost' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability' xlink:label='us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1' xlink:label='us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent' xlink:label='us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent' use='optional' order='4.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent' xlink:label='us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears' xlink:label='us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears' xlink:label='us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears' xlink:label='us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears' xlink:label='us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter' xlink:label='us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter' use='optional' order='6.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesReconciliationOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureLeasesReconciliationOfOperatingLeaseLiabilitiesDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesReconciliationOfOperatingLeaseLiabilitiesDetails">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue' xlink:label='us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent' xlink:label='us-gaap_OperatingLeaseLiabilityCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_OperatingLeaseLiabilityCurrent' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent' xlink:label='us-gaap_OperatingLeaseLiabilityNoncurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_OperatingLeaseLiabilityNoncurrent' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount' xlink:label='us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount' use='optional' order='4.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLesseeOperatingLeaseLiabilityMaturityDetails" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureLeasesLesseeOperatingLeaseLiabilityMaturityDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLesseeOperatingLeaseLiabilityMaturityDetails">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths' xlink:label='us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo' xlink:label='us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree' xlink:label='us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour' xlink:label='us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive' xlink:label='us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive' xlink:label='us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive' use='optional' order='6.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureCSIDistributionAgreementPurchaseDisclosureDetails" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureCSIDistributionAgreementPurchaseDisclosureDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureCSIDistributionAgreementPurchaseDisclosureDetails">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_DistributionRightsAcquisitionAxis' xlink:label='fil_DistributionRightsAcquisitionAxis'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='fil_DistributionRightsAcquisitionAxis' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_DistributionRightsAcquisitionDomain' xlink:label='fil_DistributionRightsAcquisitionDomain'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DistributionRightsAcquisitionAxis' xlink:to='fil_DistributionRightsAcquisitionDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_CoopersurgicalIncMember' xlink:label='fil_CoopersurgicalIncMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DistributionRightsAcquisitionAxis' xlink:to='fil_CoopersurgicalIncMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1' xlink:label='us-gaap_FinitelivedIntangibleAssetsAcquired1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_FinitelivedIntangibleAssetsAcquired1' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='utmd-20200930.xsd#fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' xlink:label='fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' use='optional' order='2.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails" xlink:type="simple" xlink:href="utmd-20200930.xsd#idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.utahmed.com/20200930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_ProfitLoss' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:label='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' xlink:label='us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:label='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic' xlink:label='us-gaap_EarningsPerShareBasic'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_EarningsPerShareBasic' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted' xlink:label='us-gaap_EarningsPerShareDiluted'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='us-gaap_EarningsPerShareDiluted' use='optional' order='6.0'/>
	</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>utmd-20200930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2020 [PPXK9NDL3JZWVJK4T7A6]. www.edgarsuite.com -->
<schema xmlns:nonnum='http://www.xbrl.org/dtr/type/non-numeric' xmlns='http://www.w3.org/2001/XMLSchema' xmlns:us-gaap='http://fasb.org/us-gaap/2020-01-31' xmlns:srt='http://fasb.org/srt/2020-01-31' xmlns:fil='http://www.utahmed.com/20200930' xmlns:dei='http://xbrl.sec.gov/dei/2020-01-31' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:xbrldt='http://xbrl.org/2005/xbrldt' targetNamespace='http://www.utahmed.com/20200930' xmlns:link='http://www.xbrl.org/2003/linkbase' xmlns:xbrli='http://www.xbrl.org/2003/instance' elementFormDefault='qualified' attributeFormDefault='unqualified'>
	<annotation>
		<appinfo>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20200930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20200930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20200930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20200930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:roleType roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails" id="idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails">
				<link:definition>000360 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies" id="idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies">
				<link:definition>000180 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureEarningsPerShare" id="idr_DisclosureEarningsPerShare">
				<link:definition>000160 - Disclosure - Earnings Per Share</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureCSIDistributionAgreementPurchaseDisclosure" id="idr_DisclosureCSIDistributionAgreementPurchaseDisclosure">
				<link:definition>000150 - Disclosure - CSI Distribution Agreement Purchase Disclosure</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLesseeOperatingLeaseLiabilityMaturityTables" id="idr_DisclosureLeasesLesseeOperatingLeaseLiabilityMaturityTables">
				<link:definition>000240 - Disclosure - Leases: Lessee, Operating Lease, Liability, Maturity (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW" id="idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW">
				<link:definition>000070 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables" id="idr_DisclosureInventoriesScheduleOfInventoryCurrentTables">
				<link:definition>000190 - Disclosure - Inventories: Schedule of Inventory, Current (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLeaseCostDetails" id="idr_DisclosureLeasesLeaseCostDetails">
				<link:definition>000310 - Disclosure - Leases: Lease, Cost (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureInventories" id="idr_DisclosureInventories">
				<link:definition>000100 - Disclosure - Inventories</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureStockBasedCompensationDetails" id="idr_DisclosureStockBasedCompensationDetails">
				<link:definition>000270 - Disclosure - Stock-Based Compensation (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEETParenthetical" id="idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEETParenthetical">
				<link:definition>000030 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureWarrantyReserve" id="idr_DisclosureWarrantyReserve">
				<link:definition>000120 - Disclosure - Warranty Reserve</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureRevenueRecognition" id="idr_DisclosureRevenueRecognition">
				<link:definition>000130 - Disclosure - Revenue Recognition</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureLeases" id="idr_DisclosureLeases">
				<link:definition>000140 - Disclosure - Leases</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTables" id="idr_DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTables">
				<link:definition>000220 - Disclosure - Leases: Schedule of Future Minimum Rental Payments for Operating Leases (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME" id="idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME">
				<link:definition>000040 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureWarrantyReserveDetails" id="idr_DisclosureWarrantyReserveDetails">
				<link:definition>000280 - Disclosure - Warranty Reserve (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" id="idr_DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails">
				<link:definition>000320 - Disclosure - Leases: Schedule of Future Minimum Rental Payments for Operating Leases (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOMEParenthetical" id="idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOMEParenthetical">
				<link:definition>000050 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLeaseCostTables" id="idr_DisclosureLeasesLeaseCostTables">
				<link:definition>000210 - Disclosure - Leases: Lease, Cost (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails" id="idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails">
				<link:definition>000260 - Disclosure - Inventories: Schedule of Inventory, Current (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLesseeOperatingLeaseLiabilityMaturityDetails" id="idr_DisclosureLeasesLesseeOperatingLeaseLiabilityMaturityDetails">
				<link:definition>000340 - Disclosure - Leases: Lessee, Operating Lease, Liability, Maturity (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureStockBasedCompensation" id="idr_DisclosureStockBasedCompensation">
				<link:definition>000110 - Disclosure - Stock-Based Compensation</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20200930/role/idr_DocumentDocumentAndEntityInformation" id="idr_DocumentDocumentAndEntityInformation">
				<link:definition>000010 - Document - Document and Entity Information</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" id="idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY">
				<link:definition>000060 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS&apos; EQUITY</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureBasisOfPresentation" id="idr_DisclosureBasisOfPresentation">
				<link:definition>000080 - Disclosure - Basis of Presentation</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables" id="idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables">
				<link:definition>000250 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples" id="idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples">
				<link:definition>000090 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesReconciliationOfOperatingLeaseLiabilitiesTables" id="idr_DisclosureLeasesReconciliationOfOperatingLeaseLiabilitiesTables">
				<link:definition>000230 - Disclosure - Leases: Reconciliation of operating lease liabilities (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesDetails" id="idr_DisclosureLeasesDetails">
				<link:definition>000300 - Disclosure - Leases (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails" id="idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails">
				<link:definition>000290 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET" id="idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET">
				<link:definition>000020 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureCSIDistributionAgreementPurchaseDisclosureDetails" id="idr_DisclosureCSIDistributionAgreementPurchaseDisclosureDetails">
				<link:definition>000350 - Disclosure - CSI Distribution Agreement Purchase Disclosure (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables" id="idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables">
				<link:definition>000200 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureLeasesReconciliationOfOperatingLeaseLiabilitiesDetails" id="idr_DisclosureLeasesReconciliationOfOperatingLeaseLiabilitiesDetails">
				<link:definition>000330 - Disclosure - Leases: Reconciliation of operating lease liabilities (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.utahmed.com/20200930/role/idr_DisclosureSubsequentEvents" id="idr_DisclosureSubsequentEvents">
				<link:definition>000170 - Disclosure - Subsequent Events</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
		</appinfo>
	</annotation>
	<import schemaLocation='http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd' namespace='http://www.xbrl.org/2003/instance'/>
	<import schemaLocation='http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd' namespace='http://www.xbrl.org/dtr/type/numeric'/>
	<import schemaLocation='http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd' namespace='http://www.xbrl.org/dtr/type/non-numeric'/>
	<import schemaLocation='http://www.xbrl.org/2005/xbrldt-2005.xsd' namespace='http://xbrl.org/2005/xbrldt'/>
	<import namespace='http://fasb.org/us-gaap/2020-01-31' schemaLocation='http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd' />
	<import namespace='http://xbrl.sec.gov/dei/2020-01-31' schemaLocation='https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_OperatingLeaseRightOfUseAssetAmortization' name='OperatingLeaseRightOfUseAssetAmortization' />
	<element abstract='true' nillable='true' type='nonnum:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_DomesticUsMember' name='DomesticUsMember' />
	<element abstract='true' nillable='true' type='nonnum:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_OutsideUsMember' name='OutsideUsMember' />
	<element abstract='true' nillable='true' type='nonnum:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ObstetricsMember' name='ObstetricsMember' />
	<element abstract='true' nillable='true' type='nonnum:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_NeonatalMember' name='NeonatalMember' />
	<element abstract='true' nillable='true' type='nonnum:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_GynecologyElectrosurgeryUrologyMember' name='GynecologyElectrosurgeryUrologyMember' />
	<element abstract='true' nillable='true' type='nonnum:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_BloodPressureMonitoringAndAccessoriesMember' name='BloodPressureMonitoringAndAccessoriesMember' />
	<element nillable='true' type='nonnum:textBlockItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ScheduleOfRevenuesByProductCategoryTextBlock' name='ScheduleOfRevenuesByProductCategoryTextBlock' />
	<element nillable='true' type='nonnum:textBlockItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ReconciliationOfOperatingLeaseLiabilitiesTableTextBlock' name='ReconciliationOfOperatingLeaseLiabilitiesTableTextBlock' />
	<element nillable='true' type='xbrli:durationItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_LesseeOperatingLeaseForParkingLotTermOfContract' name='LesseeOperatingLeaseForParkingLotTermOfContract' />
	<element nillable='true' type='xbrli:durationItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_LesseeOperatingLeaseForAutomobileTermOfContract' name='LesseeOperatingLeaseForAutomobileTermOfContract' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrldt:dimensionItem' xbrli:periodType='duration' id='fil_DistributionRightsAcquisitionAxis' name='DistributionRightsAcquisitionAxis' />
	<element abstract='true' nillable='true' type='nonnum:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_DistributionRightsAcquisitionDomain' name='DistributionRightsAcquisitionDomain' />
	<element abstract='true' nillable='true' type='nonnum:domainItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_CoopersurgicalIncMember' name='CoopersurgicalIncMember' />
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' name='RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions' name='CommonStockReceivedAndRetiredUponExerciseOfStockOptions' />
	<element nillable='true' type='xbrli:sharesItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' name='CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares' />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>utmd-20200930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:fil="http://www.utahmed.com/20200930"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="utmd-20200930.xsd" xlink:type="simple"/>
    <context id="D200101_200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="E20Q3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="E19Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="I201105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2020-11-05</instant>
        </period>
    </context>
    <context id="D200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2020-09-30</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="E19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Y20Q3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Y19Q3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="D190101_190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="E18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="E19Q3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="D200101_200930_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="D200101_200930_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="D200101_200930_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="D200101_200930_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="E20Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="E20Q2_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="E20Q2_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="E20Q2_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="E20Q2_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="Y20Q3_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Y20Q3_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Y20Q3_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Y20Q3_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="E20Q3_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="E20Q3_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="E20Q3_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="E20Q3_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="E19_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="E19_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="E19_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="E19_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="E19Q2_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="E19Q2_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="E19Q2_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="E19Q2_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="Y19Q3_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Y19Q3_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Y19Q3_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Y19Q3_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="E19Q3_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="E19Q3_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="E19Q3_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="E19Q3_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="E18_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="E18_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="E18_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="E18_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="D190101_190930_StEqComps-CommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="D190101_190930_StEqComps-AddPaidInCap">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="D190101_190930_StEqComps-ComprIncome">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="D190101_190930_StEqComps-RetainedEarnings">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Y18Q3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="D180101_180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="D200101_200930_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="D200101_200930_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="D200101_200930_ProductOrService-Obstetrics">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Y20Q3_ProductOrService-Obstetrics_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Y20Q3_ProductOrService-Obstetrics_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Y20Q3_ProductOrService-Obstetrics">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="D200101_200930_ProductOrService-GynecologyElectrosurgeryUrology">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Y20Q3_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Y20Q3_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Y20Q3_ProductOrService-GynecologyElectrosurgeryUrology">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="D200101_200930_ProductOrService-Neonatal">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Y20Q3_ProductOrService-Neonatal_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Y20Q3_ProductOrService-Neonatal_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Y20Q3_ProductOrService-Neonatal">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="D200101_200930_ProductOrService-BloodPressureMonitoringAndAccessories">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Y20Q3_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Y20Q3_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Y20Q3_ProductOrService-BloodPressureMonitoringAndAccessories">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Y20Q3_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Y20Q3_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="D200101_200930_ProductOrService-Obstetrics_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="D200101_200930_ProductOrService-Obstetrics_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:ObstetricsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="D200101_200930_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="D200101_200930_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:GynecologyElectrosurgeryUrologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="D200101_200930_ProductOrService-Neonatal_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="D200101_200930_ProductOrService-Neonatal_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:NeonatalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="D200101_200930_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:DomesticUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="D200101_200930_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">fil:BloodPressureMonitoringAndAccessoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fil:OutsideUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="D190101_190930_DistributionRightsAcquisition-CoopersurgicalInc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
            <segment>
                <xbrldi:explicitMember dimension="fil:DistributionRightsAcquisitionAxis">fil:CoopersurgicalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="UsdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="D200101_200930" id="fact1">0000706698</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="D200101_200930" id="fact2">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCurrentReportingStatus contextRef="D200101_200930" id="fact3">Yes</dei:EntityCurrentReportingStatus>
    <dei:AmendmentFlag contextRef="D200101_200930" id="fact4">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="D200101_200930" id="fact5">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="D200101_200930" id="fact6">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentType contextRef="D200101_200930">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="D200101_200930">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="D200101_200930">2020-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="D200101_200930">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="D200101_200930">001-12575</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="D200101_200930">UTAH MEDICAL PRODUCTS INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="D200101_200930">UT</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="D200101_200930">87-0342734</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="D200101_200930">7043 South 300 West</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="D200101_200930">Midvale</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="D200101_200930">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="D200101_200930">84047</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="D200101_200930">801</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="D200101_200930">566-1200</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="D200101_200930">Common stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="D200101_200930">UTMD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="D200101_200930">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityInteractiveDataCurrent contextRef="D200101_200930">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="D200101_200930">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="D200101_200930">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="D200101_200930">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="D200101_200930">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="I201105" decimals="INF" unitRef="Shares">3640403</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="E20Q3" decimals="-3" unitRef="USD">46294000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="E19" decimals="-3" unitRef="USD">42787000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="E20Q3" decimals="-3" unitRef="USD">4277000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="E19" decimals="-3" unitRef="USD">4742000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="E20Q3" decimals="-3" unitRef="USD">6304000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="E19" decimals="-3" unitRef="USD">6913000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent contextRef="E20Q3" decimals="-3" unitRef="USD">385000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="E19" decimals="-3" unitRef="USD">444000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="E20Q3" decimals="-3" unitRef="USD">57260000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="E19" decimals="-3" unitRef="USD">54886000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="E20Q3" decimals="-3" unitRef="USD">10650000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="E19" decimals="-3" unitRef="USD">10314000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="E20Q3" decimals="-3" unitRef="USD">386000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="E19" decimals="-3" unitRef="USD">414000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill contextRef="E20Q3" decimals="-3" unitRef="USD">13783000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="E19" decimals="-3" unitRef="USD">13961000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="E20Q3" decimals="-3" unitRef="USD">54362000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="E19" decimals="-3" unitRef="USD">55205000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="E20Q3" decimals="-3" unitRef="USD">29369000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="E19" decimals="-3" unitRef="USD">24993000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="E20Q3" decimals="-3" unitRef="USD">24993000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="E19" decimals="-3" unitRef="USD">30212000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Assets contextRef="E20Q3" decimals="-3" unitRef="USD">107072000</us-gaap:Assets>
    <us-gaap:Assets contextRef="E19" decimals="-3" unitRef="USD">109787000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="E20Q3" decimals="-3" unitRef="USD">651000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="E19" decimals="-3" unitRef="USD">1098000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="E20Q3" decimals="-3" unitRef="USD">2976000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="E19" decimals="-3" unitRef="USD">2350000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="E20Q3" decimals="-3" unitRef="USD">3627000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="E19" decimals="-3" unitRef="USD">3448000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="E20Q3" decimals="-3" unitRef="USD">1995000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="E19" decimals="-3" unitRef="USD">2110000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="E20Q3" decimals="-3" unitRef="USD">2132000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="E19" decimals="-3" unitRef="USD">2239000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="E20Q3" decimals="-3" unitRef="USD">346000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="E19" decimals="-3" unitRef="USD">376000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="E20Q3" decimals="-3" unitRef="USD">557000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="E19" decimals="-3" unitRef="USD">521000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:Liabilities contextRef="E20Q3" decimals="-3" unitRef="USD">8657000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="E19" decimals="-3" unitRef="USD">8694000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="E20Q3" decimals="INF" unitRef="UsdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="E19" decimals="INF" unitRef="UsdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="E20Q3" decimals="-3" unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="E19" decimals="-3" unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="E20Q3" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="E19" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="E20Q3" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="E19" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="E20Q3" decimals="-3" unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="E19" decimals="-3" unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="E20Q3" decimals="INF" unitRef="UsdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="E19" decimals="INF" unitRef="UsdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="E20Q3" decimals="-3" unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="E19" decimals="-3" unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="E20Q3" decimals="-3" unitRef="Shares">3640000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="E20Q3" decimals="-3" unitRef="Shares">3640000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="E19" decimals="-3" unitRef="Shares">3722000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="E19" decimals="-3" unitRef="Shares">3722000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="E20Q3" decimals="-3" unitRef="USD">36000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="E19" decimals="-3" unitRef="USD">37000</us-gaap:CommonStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1 contextRef="E20Q3" decimals="-3" unitRef="USD">-10199000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1 contextRef="E19" decimals="-3" unitRef="USD">-9782000</us-gaap:AccumulatedOtherComprehensiveIncomeLossBeforeTax1>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="E20Q3" decimals="-3" unitRef="USD">0</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="E19" decimals="-3" unitRef="USD">18000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="E20Q3" decimals="-3" unitRef="USD">108578000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="E19" decimals="-3" unitRef="USD">110820000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="E20Q3" decimals="-3" unitRef="USD">98415000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="E19" decimals="-3" unitRef="USD">101093000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="E20Q3" decimals="-3" unitRef="USD">107072000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="E19" decimals="-3" unitRef="USD">109787000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="Y20Q3" decimals="-3" unitRef="USD">10479000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="Y19Q3" decimals="-3" unitRef="USD">12494000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D200101_200930" decimals="-3" unitRef="USD">30168000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D190101_190930" decimals="-3" unitRef="USD">35073000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="Y20Q3" decimals="-3" unitRef="USD">3982000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="Y19Q3" decimals="-3" unitRef="USD">5115000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="D200101_200930" decimals="-3" unitRef="USD">11885000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="D190101_190930" decimals="-3" unitRef="USD">13421000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="Y20Q3" decimals="-3" unitRef="USD">6497000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="Y19Q3" decimals="-3" unitRef="USD">7379000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="D200101_200930" decimals="-3" unitRef="USD">18283000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="D190101_190930" decimals="-3" unitRef="USD">21652000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="Y20Q3" decimals="-3" unitRef="USD">2785000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="Y19Q3" decimals="-3" unitRef="USD">2878000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="D200101_200930" decimals="-3" unitRef="USD">8480000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="D190101_190930" decimals="-3" unitRef="USD">8341000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="Y20Q3" decimals="-3" unitRef="USD">125000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="Y19Q3" decimals="-3" unitRef="USD">130000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="D200101_200930" decimals="-3" unitRef="USD">375000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="D190101_190930" decimals="-3" unitRef="USD">357000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses contextRef="Y20Q3" decimals="-3" unitRef="USD">2910000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="Y19Q3" decimals="-3" unitRef="USD">3008000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="D200101_200930" decimals="-3" unitRef="USD">8855000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="D190101_190930" decimals="-3" unitRef="USD">8698000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="Y20Q3" decimals="-3" unitRef="USD">3587000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="Y19Q3" decimals="-3" unitRef="USD">4371000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="D200101_200930" decimals="-3" unitRef="USD">9428000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="D190101_190930" decimals="-3" unitRef="USD">12954000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="Y20Q3" decimals="-3" unitRef="USD">1000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="Y19Q3" decimals="-3" unitRef="USD">76000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="D200101_200930" decimals="-3" unitRef="USD">125000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="D190101_190930" decimals="-3" unitRef="USD">196000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="Y20Q3" decimals="-3" unitRef="USD">3588000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="Y19Q3" decimals="-3" unitRef="USD">4447000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="D200101_200930" decimals="-3" unitRef="USD">9553000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="D190101_190930" decimals="-3" unitRef="USD">13150000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="Y20Q3" decimals="-3" unitRef="USD">655000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="Y19Q3" decimals="-3" unitRef="USD">742000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="D200101_200930" decimals="-3" unitRef="USD">2167000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="D190101_190930" decimals="-3" unitRef="USD">2781000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="Y20Q3" decimals="-3" unitRef="USD">2933000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="Y19Q3" decimals="-3" unitRef="USD">3705000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="D200101_200930" decimals="-3" unitRef="USD">7386000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="D190101_190930" decimals="-3" unitRef="USD">10369000</us-gaap:ProfitLoss>
    <us-gaap:EarningsPerShareBasic contextRef="Y20Q3" decimals="INF" unitRef="UsdPerShare">0.81</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="Y19Q3" decimals="INF" unitRef="UsdPerShare">1.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="D200101_200930"
      decimals="INF"
      unitRef="UsdPerShare">2.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="D190101_190930"
      decimals="INF"
      unitRef="UsdPerShare">2.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted contextRef="Y20Q3" decimals="INF" unitRef="UsdPerShare">0.80</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted contextRef="Y19Q3" decimals="INF" unitRef="UsdPerShare">0.99</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="D200101_200930"
      decimals="INF"
      unitRef="UsdPerShare">2.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="D190101_190930"
      decimals="INF"
      unitRef="UsdPerShare">2.77</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Y20Q3" decimals="-3" unitRef="Shares">3642000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Y19Q3" decimals="-3" unitRef="Shares">3720000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="D200101_200930" decimals="-3" unitRef="Shares">3664000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="D190101_190930" decimals="-3" unitRef="Shares">3722000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Y20Q3" decimals="-3" unitRef="Shares">3653000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Y19Q3" decimals="-3" unitRef="Shares">3737000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="D200101_200930" decimals="-3" unitRef="Shares">3678000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="D190101_190930" decimals="-3" unitRef="Shares">3738000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="Y20Q3" decimals="INF" unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="Y19Q3" decimals="INF" unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="D200101_200930" decimals="INF" unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="D190101_190930" decimals="INF" unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="Y20Q3" decimals="-3" unitRef="USD">1511000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="Y19Q3" decimals="-3" unitRef="USD">-1683000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="D200101_200930" decimals="-3" unitRef="USD">-416000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="D190101_190930" decimals="-3" unitRef="USD">-1200000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="Y20Q3" decimals="-3" unitRef="USD">4444000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="Y19Q3" decimals="-3" unitRef="USD">2022000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="D200101_200930" decimals="-3" unitRef="USD">6970000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="D190101_190930" decimals="-3" unitRef="USD">9169000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ProfitLoss contextRef="D200101_200930" decimals="-3" unitRef="USD">7386000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="D190101_190930" decimals="-3" unitRef="USD">10369000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation contextRef="D200101_200930" decimals="-3" unitRef="USD">495000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="D190101_190930" decimals="-3" unitRef="USD">526000</us-gaap:Depreciation>
    <us-gaap:AdjustmentForAmortization contextRef="D200101_200930" decimals="-3" unitRef="USD">4875000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization contextRef="D190101_190930" decimals="-3" unitRef="USD">4512000</us-gaap:AdjustmentForAmortization>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="D200101_200930" decimals="-3" unitRef="USD">-4000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="D190101_190930" decimals="-3" unitRef="USD">-2000</us-gaap:ProvisionForDoubtfulAccounts>
    <fil:OperatingLeaseRightOfUseAssetAmortization contextRef="D200101_200930" decimals="-3" unitRef="USD">29000</fil:OperatingLeaseRightOfUseAssetAmortization>
    <fil:OperatingLeaseRightOfUseAssetAmortization contextRef="D190101_190930" decimals="-3" unitRef="USD">29000</fil:OperatingLeaseRightOfUseAssetAmortization>
    <us-gaap:GainLossOnDispositionOfAssets contextRef="D200101_200930" decimals="-3" unitRef="USD">-1000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets contextRef="D190101_190930" decimals="-3" unitRef="USD">0</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="D200101_200930" decimals="-3" unitRef="USD">-20000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="D190101_190930" decimals="-3" unitRef="USD">-398000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation contextRef="D200101_200930" decimals="-3" unitRef="USD">121000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="D190101_190930" decimals="-3" unitRef="USD">85000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredTaxExpenseFromStockOptionsExercised contextRef="D200101_200930" decimals="-3" unitRef="USD">7000</us-gaap:DeferredTaxExpenseFromStockOptionsExercised>
    <us-gaap:DeferredTaxExpenseFromStockOptionsExercised contextRef="D190101_190930" decimals="-3" unitRef="USD">20000</us-gaap:DeferredTaxExpenseFromStockOptionsExercised>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="D200101_200930" decimals="-3" unitRef="USD">-442000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="D190101_190930" decimals="-3" unitRef="USD">1139000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="D200101_200930" decimals="-3" unitRef="USD">-757000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="D190101_190930" decimals="-3" unitRef="USD">1449000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="D200101_200930" decimals="-3" unitRef="USD">-58000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="D190101_190930" decimals="-3" unitRef="USD">-73000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="D200101_200930" decimals="-3" unitRef="USD">-439000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="D190101_190930" decimals="-3" unitRef="USD">-188000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="D200101_200930" decimals="-3" unitRef="USD">651000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="D190101_190930" decimals="-3" unitRef="USD">-1023000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities contextRef="D200101_200930" decimals="-3" unitRef="USD">6973000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities contextRef="D190101_190930" decimals="-3" unitRef="USD">1046000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="D200101_200930" decimals="-3" unitRef="USD">14359000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="D190101_190930" decimals="-3" unitRef="USD">11415000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="D200101_200930" decimals="-3" unitRef="USD">806000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="D190101_190930" decimals="-3" unitRef="USD">252000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="D200101_200930" decimals="-3" unitRef="USD">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="D190101_190930" decimals="-3" unitRef="USD">21000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="D200101_200930" decimals="-3" unitRef="USD">-806000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="D190101_190930" decimals="-3" unitRef="USD">-21252000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="D200101_200930" decimals="-3" unitRef="USD">282000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="D190101_190930" decimals="-3" unitRef="USD">223000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="D200101_200930" decimals="-3" unitRef="USD">6977000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="D190101_190930" decimals="-3" unitRef="USD">398000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfDividends contextRef="D200101_200930" decimals="-3" unitRef="USD">3097000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends contextRef="D190101_190930" decimals="-3" unitRef="USD">3083000</us-gaap:PaymentsOfDividends>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="D200101_200930" decimals="-3" unitRef="USD">-9792000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="D190101_190930" decimals="-3" unitRef="USD">-3258000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="D200101_200930" decimals="-3" unitRef="USD">-254000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="D190101_190930" decimals="-3" unitRef="USD">-624000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="D200101_200930" decimals="-3" unitRef="USD">3507000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="D190101_190930" decimals="-3" unitRef="USD">-13719000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="E19" decimals="-3" unitRef="USD">42787000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="E18" decimals="-3" unitRef="USD">51112000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="E20Q3" decimals="-3" unitRef="USD">46294000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="E19Q3" decimals="-3" unitRef="USD">37393000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:IncomeTaxesPaid contextRef="D200101_200930" decimals="-3" unitRef="USD">2153000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="D190101_190930" decimals="-3" unitRef="USD">3957000</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaid contextRef="D200101_200930" decimals="-3" unitRef="USD">0</us-gaap:InterestPaid>
    <us-gaap:InterestPaid contextRef="D190101_190930" decimals="-3" unitRef="USD">0</us-gaap:InterestPaid>
    <us-gaap:SharesOutstanding
      contextRef="E20Q2_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">3643000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E20Q2_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E20Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">80000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E20Q2_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">-11710000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E20Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">106881000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="E20Q2" decimals="-3" unitRef="USD">95288000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Y20Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">4000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y20Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y20Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">202000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y20Q3_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y20Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Y20Q3" decimals="-3" unitRef="USD">202000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y20Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y20Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y20Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">49000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y20Q3_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y20Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense contextRef="Y20Q3" decimals="-3" unitRef="USD">49000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="Y20Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">-7000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y20Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y20Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">-332000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y20Q3_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y20Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">-219000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="Y20Q3" decimals="-3" unitRef="USD">-551000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y20Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y20Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y20Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y20Q3_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">1511000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y20Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="Y20Q3" decimals="-3" unitRef="USD">1511000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y20Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y20Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y20Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y20Q3_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y20Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">1018000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="Y20Q3" decimals="-3" unitRef="USD">1018000</us-gaap:DividendsCommonStockCash>
    <us-gaap:ProfitLoss
      contextRef="Y20Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y20Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y20Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y20Q3_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y20Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">2933000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="Y20Q3" decimals="-3" unitRef="USD">2933000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="E20Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">3640000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E20Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E20Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E20Q3_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">-10199000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E20Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">108578000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="E20Q3" decimals="-3" unitRef="USD">98415000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="E19_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">3722000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E19_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">37000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E19_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">18000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E19_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">-9783000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E19_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">110820000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="E19" decimals="-3" unitRef="USD">101092000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="D200101_200930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">6000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="D200101_200930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="D200101_200930_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">282000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="D200101_200930_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="D200101_200930_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="D200101_200930" decimals="-3" unitRef="USD">282000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockOptionPlanExpense
      contextRef="D200101_200930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="D200101_200930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="D200101_200930_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">121000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="D200101_200930_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="D200101_200930_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense contextRef="D200101_200930" decimals="-3" unitRef="USD">121000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="D200101_200930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">-87000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="D200101_200930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">-1000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="D200101_200930_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">-421000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="D200101_200930_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="D200101_200930_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">-6555000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="D200101_200930" decimals="-3" unitRef="USD">-6976000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D200101_200930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D200101_200930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D200101_200930_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D200101_200930_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">-416000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D200101_200930_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="D200101_200930" decimals="-3" unitRef="USD">-416000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="D200101_200930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="D200101_200930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="D200101_200930_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="D200101_200930_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="D200101_200930_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">3074000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="D200101_200930" decimals="-3" unitRef="USD">3074000</us-gaap:DividendsCommonStockCash>
    <us-gaap:ProfitLoss
      contextRef="D200101_200930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D200101_200930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D200101_200930_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D200101_200930_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D200101_200930_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">7386000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="D200101_200930" decimals="-3" unitRef="USD">7386000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="E20Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">3640000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E20Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E20Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E20Q3_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">-10199000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E20Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">108578000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="E20Q3" decimals="-3" unitRef="USD">98415000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="E19Q2_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">3719000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E19Q2_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">37000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E19Q2_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E19Q2_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">-10807000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E19Q2_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">104682000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="E19Q2" decimals="-3" unitRef="USD">93912000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Y19Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">1000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y19Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y19Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">52000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y19Q3_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Y19Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Y19Q3" decimals="-3" unitRef="USD">52000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y19Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y19Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y19Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">29000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y19Q3_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Y19Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense contextRef="Y19Q3" decimals="-3" unitRef="USD">29000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="Y19Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y19Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y19Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">-81000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y19Q3_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="Y19Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">81000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="Y19Q3" decimals="-3" unitRef="USD">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y19Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y19Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y19Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y19Q3_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">-1683000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Y19Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="Y19Q3" decimals="-3" unitRef="USD">-1683000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y19Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y19Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y19Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y19Q3_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="Y19Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">1029000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="Y19Q3" decimals="-3" unitRef="USD">1029000</us-gaap:DividendsCommonStockCash>
    <us-gaap:ProfitLoss
      contextRef="Y19Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y19Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y19Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y19Q3_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Y19Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">3705000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="Y19Q3" decimals="-3" unitRef="USD">3705000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="E19Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">3720000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E19Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">37000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E19Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E19Q3_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">-12490000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E19Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">107439000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="E19Q3" decimals="-3" unitRef="USD">94986000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="E18_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">3720000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E18_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">37000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E18_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">121000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E18_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">-11290000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E18_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">100123000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="E18" decimals="-3" unitRef="USD">88992000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="D190101_190930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">5000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="D190101_190930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="D190101_190930_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">222000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="D190101_190930_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="D190101_190930_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="D190101_190930" decimals="-3" unitRef="USD">222000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockOptionPlanExpense
      contextRef="D190101_190930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="D190101_190930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="D190101_190930_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">85000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="D190101_190930_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="D190101_190930_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense contextRef="D190101_190930" decimals="-3" unitRef="USD">85000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="D190101_190930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">-5000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="D190101_190930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="D190101_190930_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">-429000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="D190101_190930_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="D190101_190930_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">31000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="D190101_190930" decimals="-3" unitRef="USD">-398000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D190101_190930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D190101_190930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D190101_190930_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D190101_190930_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">-1200000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D190101_190930_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="D190101_190930" decimals="-3" unitRef="USD">-1200000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="D190101_190930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="D190101_190930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="D190101_190930_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="D190101_190930_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="D190101_190930_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">3084000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="D190101_190930" decimals="-3" unitRef="USD">3084000</us-gaap:DividendsCommonStockCash>
    <us-gaap:ProfitLoss
      contextRef="D190101_190930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D190101_190930_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D190101_190930_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D190101_190930_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D190101_190930_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">10369000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="D190101_190930" decimals="-3" unitRef="USD">10369000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="E19Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="Shares">3720000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E19Q3_StEqComps-CommonStock"
      decimals="-3"
      unitRef="USD">37000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E19Q3_StEqComps-AddPaidInCap"
      decimals="-3"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E19Q3_StEqComps-ComprIncome"
      decimals="-3"
      unitRef="USD">-12490000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="E19Q3_StEqComps-RetainedEarnings"
      decimals="-3"
      unitRef="USD">107439000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="E19Q3" decimals="-3" unitRef="USD">94986000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="D200101_200930">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(1) The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States. &#160;These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the Company") annual report on Form 10-K for the year ended December 31, 2019. &#160;In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. &#160;Currency amounts are in thousands except per-share amounts and where noted.&lt;/p&gt;
</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="D200101_200930">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(2) Recent Accounting Standards. &lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;p style="font:10pt CG Times;margin:0"&gt;&lt;span style="font-family:Times New Roman"&gt;The Company has determined that other recently issued accounting standards will either have no material impact on its consolidated financial position, results of operations or cash flows, or will not apply to its operations.&lt;/span&gt;&lt;/p&gt;
</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="D200101_200930">&lt;span style="font-family:Times New Roman"&gt;The Company has determined that other recently issued accounting standards will either have no material impact on its consolidated financial position, results of operations or cash flows, or will not apply to its operations.&lt;/span&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InventoryDisclosureTextBlock contextRef="D200101_200930">&lt;p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:6pt"&gt;(3) Inventories at September 30, 2020, and December 31, 2019, consisted of the following:&lt;/p&gt;
&lt;table style="margin:0 auto;border-collapse:collapse;width:100%"&gt;&lt;tr&gt;&lt;td style="width:144pt" valign="top"/&gt;&lt;td style="width:6.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:108pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt; September 30, 2020&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:6.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:101pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;December 31, 2019&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:144pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Finished goods&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:6.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:108pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,446&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:6.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:101pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,708&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:144pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Work-in-process&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:6.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:108pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,387&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:6.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:101pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,022&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:144pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Raw materials&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:6.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:108pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,471&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:6.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:101pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;4,183&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:144pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:6.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:108pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;6,304&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:6.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:101pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;6,913&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="D200101_200930">&lt;table style="margin:0 auto;border-collapse:collapse;width:100%"&gt;&lt;tr&gt;&lt;td style="width:144pt" valign="top"/&gt;&lt;td style="width:6.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:108pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt; September 30, 2020&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:6.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:101pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;December 31, 2019&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:144pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Finished goods&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:6.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:108pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,446&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:6.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:101pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,708&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:144pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Work-in-process&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:6.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:108pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,387&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:6.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:101pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,022&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:144pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Raw materials&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:6.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:108pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,471&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:6.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:101pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;4,183&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:144pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:6.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:108pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;6,304&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:6.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;$&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:101pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;6,913&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="E19Q3" decimals="-3" unitRef="USD">1446000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="E18" decimals="-3" unitRef="USD">1708000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryWorkInProcess contextRef="E19Q3" decimals="-3" unitRef="USD">1387000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess contextRef="E18" decimals="-3" unitRef="USD">1022000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryRawMaterials contextRef="E19Q3" decimals="-3" unitRef="USD">3471000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="E18" decimals="-3" unitRef="USD">4183000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryNet contextRef="E19Q3" decimals="-3" unitRef="USD">6304000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="E18" decimals="-3" unitRef="USD">6913000</us-gaap:InventoryNet>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="D200101_200930">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(4) Stock-Based Compensation. At September 30, 2020, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors. &#160;The Company accounts for stock compensation under FASB Accounting Standards Codification (&#x201c;ASC&#x201d;) 718, &lt;i&gt;Compensation - Stock Compensation&lt;/i&gt;. &#160;This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors. &#160;In the quarters ended September 30, 2020, and 2019, the Company recognized $49 and $29, respectively, in stock based compensation cost. &#160;In the nine months ended September 30, 2020, and 2019, the Company recognized $121 and $85, respectively, in stock based compensation cost.&lt;/p&gt;
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Y19Q3" decimals="-3" unitRef="USD">49000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Y18Q3" decimals="-3" unitRef="USD">29000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="D190101_190930" decimals="-3" unitRef="USD">121000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="D180101_180930" decimals="-3" unitRef="USD">85000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ProductWarrantyDisclosureTextBlock contextRef="D200101_200930">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(5) Warranty Reserve. &#160;The Company&#x2019;s published warranty is: &#x201c;UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment. &#160;During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price.&#x201d; &lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt"&gt;UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2019, or September 30, 2020. &lt;/p&gt;
</us-gaap:ProductWarrantyDisclosureTextBlock>
    <us-gaap:ProductWarrantyAccrual contextRef="E19" decimals="INF" unitRef="USD">0</us-gaap:ProductWarrantyAccrual>
    <us-gaap:ProductWarrantyAccrual contextRef="E20Q3" decimals="INF" unitRef="USD">0</us-gaap:ProductWarrantyAccrual>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="D200101_200930">&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;(6) Global 3Q 2020 revenues (USD) by product category:&lt;/p&gt;
&lt;table style="margin:0 auto;border-collapse:collapse;width:100%"&gt;&lt;tr&gt;&lt;td style="width:180pt" valign="top"/&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Domestic&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Outside US&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Obstetrics&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,032&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;247&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,279&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Gynecology/Electrosurgery/Urology&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;2,847&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;2,202&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;5,049&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Neonatal&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,151&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;348&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,499&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Blood Pressure Monitoring and Accessories&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;1,920&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;732&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;2,652&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-indent:-19.8pt;margin-left:19.8pt"&gt;&lt;span style="font-family:Times New Roman"&gt;Total&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;6,950&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,529&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;10,479&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;&#160;&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;Global 9M 2020 revenues (USD) by product category:&lt;/p&gt;
&lt;table style="margin:0 auto;border-collapse:collapse;width:100%"&gt;&lt;tr&gt;&lt;td style="width:180pt" valign="top"/&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Domestic&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Outside US&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Obstetrics&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,739&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;612&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,351&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Gynecology/Electrosurgery/Urology&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;7,686&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;6,945&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;14,631&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Neonatal&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,266&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,169&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;4,435&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Blood Pressure Monitoring and Accessories&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;5,215&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;2,536&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;7,751&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-indent:-19.8pt;margin-left:19.8pt"&gt;&lt;span style="font-family:Times New Roman"&gt;Total&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;18,906&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;11,262&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;30,168&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font:12pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
</us-gaap:RevenueRecognitionPolicyTextBlock>
    <fil:ScheduleOfRevenuesByProductCategoryTextBlock contextRef="D200101_200930">&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;(6) Global 3Q 2020 revenues (USD) by product category:&lt;/p&gt;
&lt;table style="margin:0 auto;border-collapse:collapse;width:100%"&gt;&lt;tr&gt;&lt;td style="width:180pt" valign="top"/&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Domestic&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Outside US&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Obstetrics&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,032&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;247&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,279&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Gynecology/Electrosurgery/Urology&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;2,847&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;2,202&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;5,049&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Neonatal&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,151&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;348&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,499&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Blood Pressure Monitoring and Accessories&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;1,920&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;732&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;2,652&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-indent:-19.8pt;margin-left:19.8pt"&gt;&lt;span style="font-family:Times New Roman"&gt;Total&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;6,950&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,529&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;10,479&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;&#160;&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;Global 9M 2020 revenues (USD) by product category:&lt;/p&gt;
&lt;table style="margin:0 auto;border-collapse:collapse;width:100%"&gt;&lt;tr&gt;&lt;td style="width:180pt" valign="top"/&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Domestic&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Outside US&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Total&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Obstetrics&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,739&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;612&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,351&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Gynecology/Electrosurgery/Urology&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;7,686&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;6,945&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;14,631&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Neonatal&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,266&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1,169&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;4,435&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Blood Pressure Monitoring and Accessories&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;5,215&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;2,536&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;7,751&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-indent:-19.8pt;margin-left:19.8pt"&gt;&lt;span style="font-family:Times New Roman"&gt;Total&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;18,906&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;11,262&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt CG Times;margin:0;text-align:right"&gt;&lt;span style="font-family:Times New Roman"&gt;$&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;30,168&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font:12pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
</fil:ScheduleOfRevenuesByProductCategoryTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y20Q3_ProductOrService-Obstetrics_StGeo-DomesticUs"
      decimals="-3"
      unitRef="USD">1032000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y20Q3_ProductOrService-Obstetrics_StGeo-OutsideUs"
      decimals="-3"
      unitRef="USD">247000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y20Q3_ProductOrService-Obstetrics"
      decimals="-3"
      unitRef="USD">1279000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y20Q3_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs"
      decimals="-3"
      unitRef="USD">2847000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y20Q3_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs"
      decimals="-3"
      unitRef="USD">2202000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y20Q3_ProductOrService-GynecologyElectrosurgeryUrology"
      decimals="-3"
      unitRef="USD">5049000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y20Q3_ProductOrService-Neonatal_StGeo-DomesticUs"
      decimals="-3"
      unitRef="USD">1151000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y20Q3_ProductOrService-Neonatal_StGeo-OutsideUs"
      decimals="-3"
      unitRef="USD">348000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y20Q3_ProductOrService-Neonatal"
      decimals="-3"
      unitRef="USD">1499000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y20Q3_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs"
      decimals="-3"
      unitRef="USD">1920000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y20Q3_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs"
      decimals="-3"
      unitRef="USD">732000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y20Q3_ProductOrService-BloodPressureMonitoringAndAccessories"
      decimals="-3"
      unitRef="USD">2652000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y20Q3_StGeo-DomesticUs"
      decimals="-3"
      unitRef="USD">6950000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Y20Q3_StGeo-OutsideUs"
      decimals="-3"
      unitRef="USD">3529000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="Y20Q3" decimals="-3" unitRef="USD">10479000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D200101_200930_ProductOrService-Obstetrics_StGeo-DomesticUs"
      decimals="-3"
      unitRef="USD">2739000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D200101_200930_ProductOrService-Obstetrics_StGeo-OutsideUs"
      decimals="-3"
      unitRef="USD">612000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D200101_200930_ProductOrService-Obstetrics"
      decimals="-3"
      unitRef="USD">3351000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D200101_200930_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-DomesticUs"
      decimals="-3"
      unitRef="USD">7686000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D200101_200930_ProductOrService-GynecologyElectrosurgeryUrology_StGeo-OutsideUs"
      decimals="-3"
      unitRef="USD">6945000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D200101_200930_ProductOrService-GynecologyElectrosurgeryUrology"
      decimals="-3"
      unitRef="USD">14631000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D200101_200930_ProductOrService-Neonatal_StGeo-DomesticUs"
      decimals="-3"
      unitRef="USD">3266000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D200101_200930_ProductOrService-Neonatal_StGeo-OutsideUs"
      decimals="-3"
      unitRef="USD">1169000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D200101_200930_ProductOrService-Neonatal"
      decimals="-3"
      unitRef="USD">4435000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D200101_200930_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-DomesticUs"
      decimals="-3"
      unitRef="USD">5215000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D200101_200930_ProductOrService-BloodPressureMonitoringAndAccessories_StGeo-OutsideUs"
      decimals="-3"
      unitRef="USD">2536000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D200101_200930_ProductOrService-BloodPressureMonitoringAndAccessories"
      decimals="-3"
      unitRef="USD">7751000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D200101_200930_StGeo-DomesticUs"
      decimals="-3"
      unitRef="USD">18906000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D200101_200930_StGeo-OutsideUs"
      decimals="-3"
      unitRef="USD">11262000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="D200101_200930" decimals="-3" unitRef="USD">30168000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="D200101_200930">&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;(7) Leases&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;&#160;&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;UTMD has operating leases for a portion of its parking lot at its Midvale facility and an automobile at its Ireland facility. &#160;The remaining lease term on the parking lot is 11 years and on the automobile it is 16 months. &#160;There are no options to extend or terminate the leases. &#160;UTMD has no other leases yet to commence. &#160;As neither lease contains implicit rates, UTMD&#x2019;s incremental borrowing rate, based on information available at adoption date, was used to determine the present value of the leases.&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;p style="font:10pt Arial Narrow;margin:0;color:#339966"/&gt;
&lt;table style="border-collapse:collapse;width:100%"&gt;&lt;tr style="height:23.85pt"&gt;&lt;td style="width:311.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;The components of lease cost were as follows:&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:112.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;Three Months Ended September 30, 2020&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:311.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Operating Lease Cost (&lt;i&gt;in thousands&lt;/i&gt;)&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:112.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$15&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:311.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Right of Use Assets obtained in exchange for new operating lease Obligations&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:112.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$0&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:311.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:112.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"/&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:311.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Other Information&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:112.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;Three Months Ended September 30, 2020&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:311.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Weighted Average Remaining Lease Term &#160;- Operating Leases&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:112.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;11 years&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:311.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Weighted Average Discount Rate &#x2013;&#160;Operating Leases&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:112.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5.4%&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;table style="border-collapse:collapse;width:100%"&gt;&lt;tr style="height:23.85pt"&gt;&lt;td style="width:239.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Operating lease liabilities/ payments (&lt;i&gt;in thousands&lt;/i&gt;)&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:72pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:239.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Operating lease payments, 2020&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:72pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$60&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:239.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Operating lease payments, 2021&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:72pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$60&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:239.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Operating lease payments, 2022&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:72pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$45&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:239.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Operating lease payments, 2023&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:72pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$45&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:239.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Operating lease payments, 2024&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:72pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$45&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:239.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Thereafter&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:72pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$299&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:10pt"&gt;&#160;&lt;/p&gt;
&lt;table style="border-collapse:collapse;width:100%"&gt;&lt;tr style="height:23.85pt"&gt;&lt;td style="width:311.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Reconciliation of operating lease liabilities/ payments to operating lease liabilities&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:99pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt; (&lt;i&gt;in thousands&lt;/i&gt;)&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:311.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Total operating lease liabilities/ payments&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:99pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$528&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:311.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Operating lease liabilities &#x2013;&#160;current (included in Accrued Expenses)&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:99pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$40&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:311.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Operating lease liabilities &#x2013;&#160;long term&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:99pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;$346&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:311.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Present value adjustment&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:99pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$142&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:10pt"&gt;&#160;&lt;/p&gt;
&lt;span style="font-family:Times New Roman;color:#000000"&gt;&lt;b&gt;Maturities of lease liabilities were as follows:&lt;/b&gt;&lt;/span&gt;(&lt;i&gt;in thousands&lt;/i&gt;)&lt;br/&gt;&lt;p style="font:10pt Arial Narrow;margin-top:0pt;margin-bottom:10pt;color:#339966"/&gt;
&lt;table style="border-collapse:collapse;width:100%"&gt;&lt;tr&gt;&lt;td style="width:239.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Maturities of lease liabilities were as follows:&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:90pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;(&lt;i&gt;in thousands&lt;/i&gt;)&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:239.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Year ending December 31,&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:90pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:239.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;2020&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:90pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$38&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:239.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;2021&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:90pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$40&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:239.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;2022&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:90pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$27&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:239.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;2023&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:90pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$29&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:239.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;2024&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:90pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$30&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:239.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Thereafter&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:90pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$248&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font:12pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
</us-gaap:LesseeOperatingLeasesTextBlock>
    <fil:LesseeOperatingLeaseForParkingLotTermOfContract contextRef="D200930">P11Y</fil:LesseeOperatingLeaseForParkingLotTermOfContract>
    <fil:LesseeOperatingLeaseForAutomobileTermOfContract contextRef="D200930">P16M</fil:LesseeOperatingLeaseForAutomobileTermOfContract>
    <us-gaap:LeaseCostTableTextBlock contextRef="D200101_200930">&lt;p style="font:10pt Arial Narrow;margin:0;color:#339966"/&gt;
&lt;table style="border-collapse:collapse;width:100%"&gt;&lt;tr style="height:23.85pt"&gt;&lt;td style="width:311.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;The components of lease cost were as follows:&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:112.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;Three Months Ended September 30, 2020&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:311.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Operating Lease Cost (&lt;i&gt;in thousands&lt;/i&gt;)&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:112.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$15&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:311.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Right of Use Assets obtained in exchange for new operating lease Obligations&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:112.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$0&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:311.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:112.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"/&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:311.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Other Information&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:112.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;Three Months Ended September 30, 2020&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:311.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Weighted Average Remaining Lease Term &#160;- Operating Leases&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:112.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;11 years&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:311.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Weighted Average Discount Rate &#x2013;&#160;Operating Leases&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:112.5pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;5.4%&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="Y20Q3" decimals="-3" unitRef="USD">15000</us-gaap:OperatingLeaseCost>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="Y20Q3" decimals="-3" unitRef="USD">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="E20Q3">P11Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="E20Q3" decimals="INF" unitRef="Pure">0.054</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="D200101_200930">&lt;table style="border-collapse:collapse;width:100%"&gt;&lt;tr style="height:23.85pt"&gt;&lt;td style="width:239.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Operating lease liabilities/ payments (&lt;i&gt;in thousands&lt;/i&gt;)&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:72pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:239.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Operating lease payments, 2020&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:72pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$60&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:239.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Operating lease payments, 2021&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:72pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$60&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:239.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Operating lease payments, 2022&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:72pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$45&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:239.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Operating lease payments, 2023&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:72pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$45&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:239.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Operating lease payments, 2024&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:72pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$45&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:239.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Thereafter&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:72pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$299&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="E19" decimals="-3" unitRef="USD">60000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="E19" decimals="-3" unitRef="USD">60000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="E19" decimals="-3" unitRef="USD">45000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="E19" decimals="-3" unitRef="USD">45000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="E19" decimals="-3" unitRef="USD">45000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="E19" decimals="-3" unitRef="USD">299000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
    <fil:ReconciliationOfOperatingLeaseLiabilitiesTableTextBlock contextRef="D200101_200930">&lt;p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:10pt"&gt;&#160;&lt;/p&gt;
&lt;table style="border-collapse:collapse;width:100%"&gt;&lt;tr style="height:23.85pt"&gt;&lt;td style="width:311.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Reconciliation of operating lease liabilities/ payments to operating lease liabilities&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:99pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt; (&lt;i&gt;in thousands&lt;/i&gt;)&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:311.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Total operating lease liabilities/ payments&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:99pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$528&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:311.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Operating lease liabilities &#x2013;&#160;current (included in Accrued Expenses)&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:99pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$40&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:311.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Operating lease liabilities &#x2013;&#160;long term&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:99pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&lt;span style="border-bottom:1px solid #000000"&gt;$346&lt;/span&gt;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:311.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Present value adjustment&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:99pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$142&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</fil:ReconciliationOfOperatingLeaseLiabilitiesTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="E20Q3" decimals="-3" unitRef="USD">528000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="E20Q3" decimals="-3" unitRef="USD">40000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="E20Q3" decimals="-3" unitRef="USD">346000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="E20Q3" decimals="-3" unitRef="USD">142000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="D200101_200930">&lt;p style="font:10pt Arial Narrow;margin-top:0pt;margin-bottom:10pt;color:#339966"/&gt;
&lt;table style="border-collapse:collapse;width:100%"&gt;&lt;tr&gt;&lt;td style="width:239.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Maturities of lease liabilities were as follows:&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:90pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;(&lt;i&gt;in thousands&lt;/i&gt;)&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:239.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Year ending December 31,&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:90pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:239.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;2020&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:90pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$38&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:239.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;2021&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:90pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$40&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:239.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;2022&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:90pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$27&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:239.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;2023&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:90pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$29&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="background-color:#CCEEFF;width:239.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;2024&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:90pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$30&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td style="width:239.4pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Thereafter&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:90pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;$248&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font:12pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="E19" decimals="-3" unitRef="USD">38000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="E19" decimals="-3" unitRef="USD">40000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="E19" decimals="-3" unitRef="USD">27000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="E19" decimals="-3" unitRef="USD">29000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="E19" decimals="-3" unitRef="USD">30000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="E19" decimals="-3" unitRef="USD">248000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="D200101_200930">&lt;p style="font:12pt Times New Roman;margin:0;color:#000000"&gt;&lt;span style="font-size:10pt"&gt;(8) Distribution Agreement Purchase. UTMD completed the purchase of exclusive U.S. distribution rights for the Filshie Clip System from CooperSurgical, Inc. (CSI) on February 1, 2019. The $21,000 purchase price represented an identifiable intangible asset which is being straight-line amortized and recognized as part of G&amp;amp;A expenses over a remaining 3.08 year life as of September 30, 2020 of the prior CSI distribution agreement with Femcare.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font:12pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="D190101_190930_DistributionRightsAcquisition-CoopersurgicalInc"
      decimals="-3"
      unitRef="USD">21000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <fil:RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem
      contextRef="D190101_190930_DistributionRightsAcquisition-CoopersurgicalInc"
      decimals="INF"
      unitRef="Pure">3.08</fil:RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem>
    <us-gaap:EarningsPerShareTextBlock contextRef="D200101_200930">&lt;p style="font:10pt Times New Roman;margin:0"&gt;(9) Earnings Per Share. Basic earnings per share is calculated by dividing net income attributable to the common stockholders of the company by the weighted average number of common shares outstanding during the period. &#160;Diluted earnings per share is calculated by assuming the exercise of stock options at the closing price of stock at the end of 3&lt;span style="vertical-align:super"&gt;rd&lt;/span&gt; quarter 2020.&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;p style="font:10pt Times New Roman;margin:0"&gt; The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:&lt;/p&gt;
&lt;table style="border-collapse:collapse;width:100%"&gt;&lt;tr style="height:12.5pt"&gt;&lt;td style="width:257.15pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;(&lt;i&gt;in thousands&lt;/i&gt;)&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:269.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Three months ended&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:36.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:313.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Nine months ended&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:257.15pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:269.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;September 30,&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:36.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:313.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;September 30,&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:257.15pt;padding-right:5.75pt" valign="top"/&gt;&lt;td style="width:109.35pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2020&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:31.3pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:128.9pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2019&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:36.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:147.35pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2020&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:27.6pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:138.1pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2019&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:257.15pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;b&gt;Numerator&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:109.35pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:31.3pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:128.9pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:36.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:147.35pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:27.6pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:138.1pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.2pt"&gt;&lt;td style="width:257.15pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Net income&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:109.35pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,933&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:31.3pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:128.9pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,705&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:36.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:147.35pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;7,386&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:27.6pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:138.1pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;10,369&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:257.15pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:109.35pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:31.3pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:128.9pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:36.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:147.35pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:27.6pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:138.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12pt"&gt;&lt;td style="width:257.15pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;b&gt;Denominator&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:109.35pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:31.3pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:128.9pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:36.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:147.35pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:27.6pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:138.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:257.15pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Weighted average shares, basic&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:109.35pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,642&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:31.3pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:128.9pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,720&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:36.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:147.35pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,664&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:27.6pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:138.1pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,722&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:257.15pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Dilutive effect of stock options&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:109.35pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;11&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:31.3pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:128.9pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;17&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:36.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:147.35pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;14&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:27.6pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:138.1pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;16&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:257.15pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Diluted shares&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:109.35pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,653&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:31.3pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:128.9pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,737&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:36.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:147.35pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,678&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:27.6pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:138.1pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,738&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:257.15pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:109.35pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:31.3pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:128.9pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:36.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:147.35pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:27.6pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:138.1pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:257.15pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Earnings per share, basic&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:109.35pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;0.81&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:31.3pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:128.9pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1.00&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:36.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:147.35pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2.02&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:27.6pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:138.1pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2.79&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:257.15pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Earnings per share, diluted&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:109.35pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;0.80&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:31.3pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:128.9pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;0.99&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:36.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:147.35pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2.01&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:27.6pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:138.1pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2.77&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font:12pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="D200101_200930">&lt;p style="font:10pt Times New Roman;margin:0"&gt; The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:&lt;/p&gt;
&lt;table style="border-collapse:collapse;width:100%"&gt;&lt;tr style="height:12.5pt"&gt;&lt;td style="width:257.15pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;(&lt;i&gt;in thousands&lt;/i&gt;)&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:269.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Three months ended&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:36.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:313.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;Nine months ended&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:257.15pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:269.55pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;September 30,&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:36.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td colspan="3" style="width:313.05pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;September 30,&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:257.15pt;padding-right:5.75pt" valign="top"/&gt;&lt;td style="width:109.35pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2020&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:31.3pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:128.9pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2019&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:36.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:147.35pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2020&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:27.6pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:138.1pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:center"&gt;2019&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:257.15pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;b&gt;Numerator&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:109.35pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:31.3pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:128.9pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:36.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:147.35pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:27.6pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:138.1pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:11.2pt"&gt;&lt;td style="width:257.15pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Net income&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:109.35pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2,933&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:31.3pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:128.9pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,705&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:36.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:147.35pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;7,386&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:27.6pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:138.1pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;10,369&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:257.15pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:109.35pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:31.3pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:128.9pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:36.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:147.35pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:27.6pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:138.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12pt"&gt;&lt;td style="width:257.15pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&lt;b&gt;Denominator&lt;/b&gt;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:109.35pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:31.3pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:128.9pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:36.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:147.35pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:27.6pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:138.1pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:257.15pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Weighted average shares, basic&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:109.35pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,642&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:31.3pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:128.9pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,720&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:36.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:147.35pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,664&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:27.6pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:138.1pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,722&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:257.15pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Dilutive effect of stock options&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:109.35pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;11&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:31.3pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:128.9pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;17&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:36.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:147.35pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;14&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:27.6pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:138.1pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;16&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:257.15pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Diluted shares&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:109.35pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,653&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:31.3pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:128.9pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,737&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:36.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:147.35pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,678&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:27.6pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:138.1pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;3,738&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:257.15pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:109.35pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:31.3pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:128.9pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:36.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:147.35pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:27.6pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:138.1pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="background-color:#CCEEFF;width:257.15pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Earnings per share, basic&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:109.35pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;0.81&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:31.3pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:128.9pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;1.00&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:36.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:147.35pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2.02&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:27.6pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="background-color:#CCEEFF;width:138.1pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2.79&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="height:12.5pt"&gt;&lt;td style="width:257.15pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0"&gt;Earnings per share, diluted&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:109.35pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;0.80&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:31.3pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:128.9pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;0.99&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:36.85pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:147.35pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2.01&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:27.6pt;padding-right:5.75pt" valign="top"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;&#160;&lt;/p&gt;
&lt;/td&gt;&lt;td style="width:138.1pt;padding-right:5.75pt" valign="middle"&gt;&lt;p style="font:10pt Times New Roman;margin:0;text-align:right"&gt;2.77&lt;/p&gt;
&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font:12pt Times New Roman;margin:0"&gt;&#160;&lt;/p&gt;
</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ProfitLoss contextRef="Y20Q3" decimals="-3" unitRef="USD">2933000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="Y19Q3" decimals="-3" unitRef="USD">3705000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="D200101_200930" decimals="-3" unitRef="USD">7386000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="D190101_190930" decimals="-3" unitRef="USD">10369000</us-gaap:ProfitLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Y20Q3" decimals="-3" unitRef="Shares">3642000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Y19Q3" decimals="-3" unitRef="Shares">3720000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="D200101_200930" decimals="-3" unitRef="Shares">3664000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="D190101_190930" decimals="-3" unitRef="Shares">3722000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="Y20Q3" decimals="-3" unitRef="Shares">11000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="Y19Q3" decimals="-3" unitRef="Shares">17000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="D200101_200930" decimals="-3" unitRef="Shares">14000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="D190101_190930" decimals="-3" unitRef="Shares">16000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Y20Q3" decimals="-3" unitRef="Shares">3653000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Y19Q3" decimals="-3" unitRef="Shares">3737000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="D200101_200930" decimals="-3" unitRef="Shares">3678000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="D190101_190930" decimals="-3" unitRef="Shares">3738000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic contextRef="Y20Q3" decimals="INF" unitRef="UsdPerShare">0.81</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="Y19Q3" decimals="INF" unitRef="UsdPerShare">1.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="D200101_200930"
      decimals="INF"
      unitRef="UsdPerShare">2.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="D190101_190930"
      decimals="INF"
      unitRef="UsdPerShare">2.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted contextRef="Y20Q3" decimals="INF" unitRef="UsdPerShare">0.80</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted contextRef="Y19Q3" decimals="INF" unitRef="UsdPerShare">0.99</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="D200101_200930"
      decimals="INF"
      unitRef="UsdPerShare">2.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="D190101_190930"
      decimals="INF"
      unitRef="UsdPerShare">2.77</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SubsequentEventsTextBlock contextRef="D200101_200930">&lt;p style="font:10pt Times New Roman;margin:0;color:#000000"&gt;(10) Subsequent Events.&lt;b&gt; &#160;&lt;/b&gt;UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its financial statements.&lt;/p&gt;
</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139817332901912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Nov. 05, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">UTAH MEDICAL PRODUCTS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000706698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">UTMD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0342734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,640,403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-12575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">UT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7043 South 300 West<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Midvale<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">566-1200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.01 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139817332629928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; investments</a></td>
<td class="nump">$ 46,294<span></span>
</td>
<td class="nump">$ 42,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts &amp; other receivables, net</a></td>
<td class="nump">4,277<span></span>
</td>
<td class="nump">4,742<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">6,304<span></span>
</td>
<td class="nump">6,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">385<span></span>
</td>
<td class="nump">444<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">57,260<span></span>
</td>
<td class="nump">54,886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">10,650<span></span>
</td>
<td class="nump">10,314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease - right of use assets, net</a></td>
<td class="nump">386<span></span>
</td>
<td class="nump">414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">13,783<span></span>
</td>
<td class="nump">13,961<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Other intangible assets</a></td>
<td class="nump">54,362<span></span>
</td>
<td class="nump">55,205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Other intangible assets - accumulated amortization</a></td>
<td class="num">(29,369)<span></span>
</td>
<td class="num">(24,993)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other intangible assets, net</a></td>
<td class="nump">24,993<span></span>
</td>
<td class="nump">30,212<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">107,072<span></span>
</td>
<td class="nump">109,787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">651<span></span>
</td>
<td class="nump">1,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">2,976<span></span>
</td>
<td class="nump">2,350<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,627<span></span>
</td>
<td class="nump">3,448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Deferred tax liability - Femcare IIA</a></td>
<td class="nump">1,995<span></span>
</td>
<td class="nump">2,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long term liabilities</a></td>
<td class="nump">2,132<span></span>
</td>
<td class="nump">2,239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability</a></td>
<td class="nump">346<span></span>
</td>
<td class="nump">376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes</a></td>
<td class="nump">557<span></span>
</td>
<td class="nump">521<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">8,657<span></span>
</td>
<td class="nump">8,694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock - $.01 par value; authorized - 5,000 shares; no shares issued or outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - $.01 par value; authorized - 50,000 shares; issued - September 30, 2020, 3,640 shares and December 31, 2019, 3,722 shares</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(10,199)<span></span>
</td>
<td class="num">(9,782)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">108,578<span></span>
</td>
<td class="nump">110,820<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">98,415<span></span>
</td>
<td class="nump">101,093<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 107,072<span></span>
</td>
<td class="nump">$ 109,787<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of increase (decrease) in accumulated equity from transactions and other events and circumstances from non-owner sources, including portion attributable to noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners (distributions to owners).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139817336578840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">3,640,000<span></span>
</td>
<td class="nump">3,722,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">3,640,000<span></span>
</td>
<td class="nump">3,722,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139817330640632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">$ 10,479<span></span>
</td>
<td class="nump">$ 12,494<span></span>
</td>
<td class="nump">$ 30,168<span></span>
</td>
<td class="nump">$ 35,073<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">3,982<span></span>
</td>
<td class="nump">5,115<span></span>
</td>
<td class="nump">11,885<span></span>
</td>
<td class="nump">13,421<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">6,497<span></span>
</td>
<td class="nump">7,379<span></span>
</td>
<td class="nump">18,283<span></span>
</td>
<td class="nump">21,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">2,785<span></span>
</td>
<td class="nump">2,878<span></span>
</td>
<td class="nump">8,480<span></span>
</td>
<td class="nump">8,341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research &amp; development</a></td>
<td class="nump">125<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="nump">375<span></span>
</td>
<td class="nump">357<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">2,910<span></span>
</td>
<td class="nump">3,008<span></span>
</td>
<td class="nump">8,855<span></span>
</td>
<td class="nump">8,698<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">3,587<span></span>
</td>
<td class="nump">4,371<span></span>
</td>
<td class="nump">9,428<span></span>
</td>
<td class="nump">12,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before provision for income taxes</a></td>
<td class="nump">3,588<span></span>
</td>
<td class="nump">4,447<span></span>
</td>
<td class="nump">9,553<span></span>
</td>
<td class="nump">13,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">655<span></span>
</td>
<td class="nump">742<span></span>
</td>
<td class="nump">2,167<span></span>
</td>
<td class="nump">2,781<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 2,933<span></span>
</td>
<td class="nump">$ 3,705<span></span>
</td>
<td class="nump">$ 7,386<span></span>
</td>
<td class="nump">$ 10,369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per common share (basic)</a></td>
<td class="nump">$ 0.81<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 2.02<span></span>
</td>
<td class="nump">$ 2.79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per common share (diluted)</a></td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="nump">$ 0.99<span></span>
</td>
<td class="nump">$ 2.01<span></span>
</td>
<td class="nump">$ 2.77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares outstanding - basic</a></td>
<td class="nump">3,642<span></span>
</td>
<td class="nump">3,720<span></span>
</td>
<td class="nump">3,664<span></span>
</td>
<td class="nump">3,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares outstanding - diluted</a></td>
<td class="nump">3,653<span></span>
</td>
<td class="nump">3,737<span></span>
</td>
<td class="nump">3,678<span></span>
</td>
<td class="nump">3,738<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation net of taxes of $0 in all periods</a></td>
<td class="nump">$ 1,511<span></span>
</td>
<td class="num">$ (1,683)<span></span>
</td>
<td class="num">$ (416)<span></span>
</td>
<td class="num">$ (1,200)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive income</a></td>
<td class="nump">$ 4,444<span></span>
</td>
<td class="nump">$ 2,022<span></span>
</td>
<td class="nump">$ 6,970<span></span>
</td>
<td class="nump">$ 9,169<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139817339718248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32262-110900<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30755-110894<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139817331513336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Comprehensive Income</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Dec. 31, 2018</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 121<span></span>
</td>
<td class="num">$ (11,290)<span></span>
</td>
<td class="nump">$ 100,123<span></span>
</td>
<td class="nump">$ 88,992<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Dec. 31, 2018</a></td>
<td class="nump">3,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options, shares</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Common stock purchased and retired</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(429)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="num">(398)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Common stock purchased and retired, shares</a></td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,200)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,084)<span></span>
</td>
<td class="num">(3,084)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,369<span></span>
</td>
<td class="nump">10,369<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Sep. 30, 2019</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(12,490)<span></span>
</td>
<td class="nump">107,439<span></span>
</td>
<td class="nump">94,986<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Sep. 30, 2019</a></td>
<td class="nump">3,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Jun. 30, 2019</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(10,807)<span></span>
</td>
<td class="nump">104,682<span></span>
</td>
<td class="nump">93,912<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Jun. 30, 2019</a></td>
<td class="nump">3,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options, shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Common stock purchased and retired</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(81)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Common stock purchased and retired, shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,683)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,683)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,029)<span></span>
</td>
<td class="num">(1,029)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,705<span></span>
</td>
<td class="nump">3,705<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Sep. 30, 2019</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(12,490)<span></span>
</td>
<td class="nump">107,439<span></span>
</td>
<td class="nump">94,986<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Sep. 30, 2019</a></td>
<td class="nump">3,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Dec. 31, 2019</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="num">(9,783)<span></span>
</td>
<td class="nump">110,820<span></span>
</td>
<td class="nump">101,092<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Dec. 31, 2019</a></td>
<td class="nump">3,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">282<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options, shares</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Common stock purchased and retired</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(421)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,555)<span></span>
</td>
<td class="num">(6,976)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Common stock purchased and retired, shares</a></td>
<td class="num">(87)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(416)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(416)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,074)<span></span>
</td>
<td class="num">(3,074)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,386<span></span>
</td>
<td class="nump">7,386<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Sep. 30, 2020</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(10,199)<span></span>
</td>
<td class="nump">108,578<span></span>
</td>
<td class="nump">98,415<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Sep. 30, 2020</a></td>
<td class="nump">3,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Jun. 30, 2020</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="num">(11,710)<span></span>
</td>
<td class="nump">106,881<span></span>
</td>
<td class="nump">95,288<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Jun. 30, 2020</a></td>
<td class="nump">3,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of employee stock options, shares</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Common stock purchased and retired</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(332)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(219)<span></span>
</td>
<td class="num">(551)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Common stock purchased and retired, shares</a></td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,511<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,018)<span></span>
</td>
<td class="num">(1,018)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,933<span></span>
</td>
<td class="nump">2,933<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity Balance, value at Sep. 30, 2020</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (10,199)<span></span>
</td>
<td class="nump">$ 108,578<span></span>
</td>
<td class="nump">$ 98,415<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity Balance, shares at Sep. 30, 2020</a></td>
<td class="nump">3,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139817330703448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 7,386<span></span>
</td>
<td class="nump">$ 10,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">495<span></span>
</td>
<td class="nump">526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">4,875<span></span>
</td>
<td class="nump">4,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for (recovery of) losses on accounts receivable</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OperatingLeaseRightOfUseAssetAmortization', window );">Amortization of Right of Use Assets</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">(Gain) loss on disposal of assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(398)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxExpenseFromStockOptionsExercised', window );">Tax benefit attributable to exercise of stock options</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable and other receivables</a></td>
<td class="nump">442<span></span>
</td>
<td class="num">(1,139)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">757<span></span>
</td>
<td class="num">(1,449)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(439)<span></span>
</td>
<td class="num">(188)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">651<span></span>
</td>
<td class="num">(1,023)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities', window );">Total adjustments</a></td>
<td class="nump">6,973<span></span>
</td>
<td class="nump">1,046<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">14,359<span></span>
</td>
<td class="nump">11,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(806)<span></span>
</td>
<td class="num">(252)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(21,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(806)<span></span>
</td>
<td class="num">(21,252)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock - options</a></td>
<td class="nump">282<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Common stock purchased and retired</a></td>
<td class="num">(6,977)<span></span>
</td>
<td class="num">(398)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Payment of dividends</a></td>
<td class="num">(3,097)<span></span>
</td>
<td class="num">(3,083)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(9,792)<span></span>
</td>
<td class="num">(3,258)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="num">(254)<span></span>
</td>
<td class="num">(624)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="nump">3,507<span></span>
</td>
<td class="num">(13,719)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash at beginning of period</a></td>
<td class="nump">42,787<span></span>
</td>
<td class="nump">51,112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash at end of period</a></td>
<td class="nump">46,294<span></span>
</td>
<td class="nump">37,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid during the period for income taxes</a></td>
<td class="nump">2,153<span></span>
</td>
<td class="nump">3,957<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid during the period for interest</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OperatingLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Right of Use Asset Amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_OperatingLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxExpenseFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax expense from write-off of the deferred tax asset related to deductible stock options at exercise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxExpenseFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139817334128520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(1) The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States. &#160;These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the Company") annual report on Form 10-K for the year ended December 31, 2019. &#160;In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. &#160;Currency amounts are in thousands except per-share amounts and where noted.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139817334231992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>New Accounting Pronouncements and Changes in Accounting Principles<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">New Accounting Pronouncements and Changes in Accounting Principles</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(2) Recent Accounting Standards. </p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt CG Times;margin:0"><span style="font-family:Times New Roman">The Company has determined that other recently issued accounting standards will either have no material impact on its consolidated financial position, results of operations or cash flows, or will not apply to its operations.</span></p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=112272810&amp;loc=SL108384541-122693<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=112272810&amp;loc=d3e31137-122693<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139817335818056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:6pt">(3) Inventories at September 30, 2020, and December 31, 2019, consisted of the following:</p>
<table style="margin:0 auto;border-collapse:collapse;width:100%"><tr><td style="width:144pt" valign="top"/><td style="width:6.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:108pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"> September 30, 2020</p>
</td><td style="width:8.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:6.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:101pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">December 31, 2019</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:144pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Finished goods</p>
</td><td style="background-color:#CCEEFF;width:6.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">$</p>
</td><td style="background-color:#CCEEFF;width:108pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,446</p>
</td><td style="background-color:#CCEEFF;width:8.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:6.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">$</p>
</td><td style="background-color:#CCEEFF;width:101pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,708</p>
</td></tr>
<tr><td style="width:144pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Work-in-process</p>
</td><td style="width:6.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:108pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,387</p>
</td><td style="width:8.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:6.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:101pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,022</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:144pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Raw materials</p>
</td><td style="background-color:#CCEEFF;width:6.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:108pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,471</p>
</td><td style="background-color:#CCEEFF;width:8.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:6.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:101pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,183</p>
</td></tr>
<tr><td style="width:144pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Total</p>
</td><td style="width:6.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">$</p>
</td><td style="width:108pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">6,304</p>
</td><td style="width:8.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:6.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">$</p>
</td><td style="width:101pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">6,913</p>
</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139817342655448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(4) Stock-Based Compensation. At September 30, 2020, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors. &#160;The Company accounts for stock compensation under FASB Accounting Standards Codification (&#8220;ASC&#8221;) 718, <i>Compensation - Stock Compensation</i>. &#160;This statement requires the Company to recognize compensation cost based on the grant date fair value of options granted to employees and directors. &#160;In the quarters ended September 30, 2020, and 2019, the Company recognized $49 and $29, respectively, in stock based compensation cost. &#160;In the nine months ended September 30, 2020, and 2019, the Company recognized $121 and $85, respectively, in stock based compensation cost.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139817334105272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warranty Reserve<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductWarrantyDisclosureTextBlock', window );">Warranty Reserve</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(5) Warranty Reserve. &#160;The Company&#8217;s published warranty is: &#8220;UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment. &#160;During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price.&#8221; </p>
<p style="font:10pt Times New Roman;margin-top:6pt;margin-bottom:0pt">UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2019, or September 30, 2020. </p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -URI http://asc.fasb.org/topic&amp;trid=2155896<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139817334268760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0;color:#000000">(6) Global 3Q 2020 revenues (USD) by product category:</p>
<table style="margin:0 auto;border-collapse:collapse;width:100%"><tr><td style="width:180pt" valign="top"/><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Domestic</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Outside US</p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Total</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Obstetrics</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,032</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">247</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,279</p>
</td></tr>
<tr><td style="width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Gynecology/Electrosurgery/Urology</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">2,847</span></p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">2,202</span></p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">5,049</span></p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,151</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">348</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,499</p>
</td></tr>
<tr><td style="width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Blood Pressure Monitoring and Accessories</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">1,920</span></p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">732</span></p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">2,652</span></p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-indent:-19.8pt;margin-left:19.8pt"><span style="font-family:Times New Roman">Total</span></p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">6,950</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,529</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">10,479</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Global 9M 2020 revenues (USD) by product category:</p>
<table style="margin:0 auto;border-collapse:collapse;width:100%"><tr><td style="width:180pt" valign="top"/><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Domestic</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Outside US</p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Total</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Obstetrics</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,739</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">612</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,351</p>
</td></tr>
<tr><td style="width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Gynecology/Electrosurgery/Urology</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">7,686</span></p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">6,945</span></p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">14,631</span></p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,266</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,169</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,435</p>
</td></tr>
<tr><td style="width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Blood Pressure Monitoring and Accessories</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">5,215</span></p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">2,536</span></p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">7,751</span></p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-indent:-19.8pt;margin-left:19.8pt"><span style="font-family:Times New Roman">Total</span></p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">18,906</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">11,262</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">30,168</p>
</td></tr>
</table>
<p style="font:12pt Times New Roman;margin:0">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139817335804264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0;color:#000000">(7) Leases</p>
<p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">UTMD has operating leases for a portion of its parking lot at its Midvale facility and an automobile at its Ireland facility. &#160;The remaining lease term on the parking lot is 11 years and on the automobile it is 16 months. &#160;There are no options to extend or terminate the leases. &#160;UTMD has no other leases yet to commence. &#160;As neither lease contains implicit rates, UTMD&#8217;s incremental borrowing rate, based on information available at adoption date, was used to determine the present value of the leases.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Arial Narrow;margin:0;color:#339966"/>
<table style="border-collapse:collapse;width:100%"><tr style="height:23.85pt"><td style="width:311.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">The components of lease cost were as follows:</p>
</td><td style="width:112.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">Three Months Ended September 30, 2020</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:311.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Operating Lease Cost (<i>in thousands</i>)</p>
</td><td style="background-color:#CCEEFF;width:112.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$15</p>
</td></tr>
<tr><td style="width:311.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Right of Use Assets obtained in exchange for new operating lease Obligations</p>
</td><td style="width:112.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$0</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:311.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:112.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right"/>
</td></tr>
<tr><td style="width:311.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Other Information</p>
</td><td style="width:112.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">Three Months Ended September 30, 2020</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:311.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Weighted Average Remaining Lease Term &#160;- Operating Leases</p>
</td><td style="background-color:#CCEEFF;width:112.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">11 years</p>
</td></tr>
<tr><td style="width:311.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Weighted Average Discount Rate &#8211;&#160;Operating Leases</p>
</td><td style="width:112.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5.4%</p>
</td></tr>
</table>
<table style="border-collapse:collapse;width:100%"><tr style="height:23.85pt"><td style="width:239.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Operating lease liabilities/ payments (<i>in thousands</i>)</p>
</td><td style="width:72pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:239.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Operating lease payments, 2020</p>
</td><td style="background-color:#CCEEFF;width:72pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$60</p>
</td></tr>
<tr><td style="width:239.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Operating lease payments, 2021</p>
</td><td style="width:72pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$60</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:239.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Operating lease payments, 2022</p>
</td><td style="background-color:#CCEEFF;width:72pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$45</p>
</td></tr>
<tr><td style="width:239.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Operating lease payments, 2023</p>
</td><td style="width:72pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$45</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:239.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Operating lease payments, 2024</p>
</td><td style="background-color:#CCEEFF;width:72pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$45</p>
</td></tr>
<tr><td style="width:239.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Thereafter</p>
</td><td style="width:72pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$299</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:10pt">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr style="height:23.85pt"><td style="width:311.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Reconciliation of operating lease liabilities/ payments to operating lease liabilities</p>
</td><td style="width:99pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right"> (<i>in thousands</i>)</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:311.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Total operating lease liabilities/ payments</p>
</td><td style="background-color:#CCEEFF;width:99pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$528</p>
</td></tr>
<tr><td style="width:311.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Operating lease liabilities &#8211;&#160;current (included in Accrued Expenses)</p>
</td><td style="width:99pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$40</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:311.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Operating lease liabilities &#8211;&#160;long term</p>
</td><td style="background-color:#CCEEFF;width:99pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">$346</span></p>
</td></tr>
<tr><td style="width:311.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Present value adjustment</p>
</td><td style="width:99pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$142</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:10pt">&#160;</p>
<span style="font-family:Times New Roman;color:#000000"><b>Maturities of lease liabilities were as follows:</b></span>(<i>in thousands</i>)<br/><p style="font:10pt Arial Narrow;margin-top:0pt;margin-bottom:10pt;color:#339966"/>
<table style="border-collapse:collapse;width:100%"><tr><td style="width:239.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Maturities of lease liabilities were as follows:</p>
</td><td style="width:90pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<i>in thousands</i>)</p>
</td></tr>
<tr><td style="width:239.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Year ending December 31,</p>
</td><td style="width:90pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:239.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">2020</p>
</td><td style="background-color:#CCEEFF;width:90pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$38</p>
</td></tr>
<tr><td style="width:239.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">2021</p>
</td><td style="width:90pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$40</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:239.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">2022</p>
</td><td style="background-color:#CCEEFF;width:90pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$27</p>
</td></tr>
<tr><td style="width:239.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">2023</p>
</td><td style="width:90pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$29</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:239.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">2024</p>
</td><td style="background-color:#CCEEFF;width:90pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$30</p>
</td></tr>
<tr><td style="width:239.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Thereafter</p>
</td><td style="width:90pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$248</p>
</td></tr>
</table>
<p style="font:12pt Times New Roman;margin:0">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139817335551032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CSI Distribution Agreement Purchase Disclosure<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">CSI Distribution Agreement Purchase Disclosure</a></td>
<td class="text"><p style="font:12pt Times New Roman;margin:0;color:#000000"><span style="font-size:10pt">(8) Distribution Agreement Purchase. UTMD completed the purchase of exclusive U.S. distribution rights for the Filshie Clip System from CooperSurgical, Inc. (CSI) on February 1, 2019. The $21,000 purchase price represented an identifiable intangible asset which is being straight-line amortized and recognized as part of G&amp;A expenses over a remaining 3.08 year life as of September 30, 2020 of the prior CSI distribution agreement with Femcare.</span></p>
<p style="font:12pt Times New Roman;margin:0">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139817334168616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0">(9) Earnings Per Share. Basic earnings per share is calculated by dividing net income attributable to the common stockholders of the company by the weighted average number of common shares outstanding during the period. &#160;Diluted earnings per share is calculated by assuming the exercise of stock options at the closing price of stock at the end of 3<span style="vertical-align:super">rd</span> quarter 2020.</p>
<p style="font:10pt Times New Roman;margin:0">&#160;</p>
<p style="font:10pt Times New Roman;margin:0"> The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:</p>
<table style="border-collapse:collapse;width:100%"><tr style="height:12.5pt"><td style="width:257.15pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">(<i>in thousands</i>)</p>
</td><td colspan="3" style="width:269.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Three months ended</p>
</td><td style="width:36.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td colspan="3" style="width:313.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Nine months ended</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:257.15pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td colspan="3" style="width:269.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">September 30,</p>
</td><td style="width:36.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td colspan="3" style="width:313.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">September 30,</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:257.15pt;padding-right:5.75pt" valign="top"/><td style="width:109.35pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center">2020</p>
</td><td style="width:31.3pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:128.9pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center">2019</p>
</td><td style="width:36.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:147.35pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center">2020</p>
</td><td style="width:27.6pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:138.1pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center">2019</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:257.15pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><b>Numerator</b></p>
</td><td style="background-color:#CCEEFF;width:109.35pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:31.3pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:128.9pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:36.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:147.35pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:27.6pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:138.1pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:11.2pt"><td style="width:257.15pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Net income</p>
</td><td style="width:109.35pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,933</p>
</td><td style="width:31.3pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:128.9pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,705</p>
</td><td style="width:36.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:147.35pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">7,386</p>
</td><td style="width:27.6pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:138.1pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">10,369</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:257.15pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:109.35pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:31.3pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:128.9pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:36.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:147.35pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:27.6pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:138.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:12pt"><td style="width:257.15pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><b>Denominator</b></p>
</td><td style="width:109.35pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:31.3pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:128.9pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:36.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:147.35pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:27.6pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:138.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:257.15pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Weighted average shares, basic</p>
</td><td style="background-color:#CCEEFF;width:109.35pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,642</p>
</td><td style="background-color:#CCEEFF;width:31.3pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:128.9pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,720</p>
</td><td style="background-color:#CCEEFF;width:36.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:147.35pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,664</p>
</td><td style="background-color:#CCEEFF;width:27.6pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:138.1pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,722</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:257.15pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Dilutive effect of stock options</p>
</td><td style="width:109.35pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">11</p>
</td><td style="width:31.3pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:128.9pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">17</p>
</td><td style="width:36.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:147.35pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">14</p>
</td><td style="width:27.6pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:138.1pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">16</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:257.15pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Diluted shares</p>
</td><td style="background-color:#CCEEFF;width:109.35pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,653</p>
</td><td style="background-color:#CCEEFF;width:31.3pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:128.9pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,737</p>
</td><td style="background-color:#CCEEFF;width:36.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:147.35pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,678</p>
</td><td style="background-color:#CCEEFF;width:27.6pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:138.1pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,738</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:257.15pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:109.35pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:31.3pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:128.9pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:36.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:147.35pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:27.6pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:138.1pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:257.15pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Earnings per share, basic</p>
</td><td style="background-color:#CCEEFF;width:109.35pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">0.81</p>
</td><td style="background-color:#CCEEFF;width:31.3pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:128.9pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.00</p>
</td><td style="background-color:#CCEEFF;width:36.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:147.35pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">2.02</p>
</td><td style="background-color:#CCEEFF;width:27.6pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:138.1pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">2.79</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:257.15pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Earnings per share, diluted</p>
</td><td style="width:109.35pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">0.80</p>
</td><td style="width:31.3pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:128.9pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">0.99</p>
</td><td style="width:36.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:147.35pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">2.01</p>
</td><td style="width:27.6pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:138.1pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">2.77</p>
</td></tr>
</table>
<p style="font:12pt Times New Roman;margin:0">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139817335799768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0;color:#000000">(10) Subsequent Events.<b> &#160;</b>UTMD has evaluated subsequent events through the date the financial statements were issued, and concluded there were no other events or transactions during this period that required recognition or disclosure in its financial statements.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139817335784440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PolicyTextBlockAbstract', window );"><strong>Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy</a></td>
<td class="text"><span style="font-family:Times New Roman">The Company has determined that other recently issued accounting standards will either have no material impact on its consolidated financial position, results of operations or cash flows, or will not apply to its operations.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139817350444024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories: Schedule of Inventory, Current (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlockSupplementAbstract', window );"><strong>Tables/Schedules</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current</a></td>
<td class="text"><table style="margin:0 auto;border-collapse:collapse;width:100%"><tr><td style="width:144pt" valign="top"/><td style="width:6.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:108pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center"> September 30, 2020</p>
</td><td style="width:8.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:6.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:101pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">December 31, 2019</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:144pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Finished goods</p>
</td><td style="background-color:#CCEEFF;width:6.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">$</p>
</td><td style="background-color:#CCEEFF;width:108pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,446</p>
</td><td style="background-color:#CCEEFF;width:8.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:6.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">$</p>
</td><td style="background-color:#CCEEFF;width:101pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,708</p>
</td></tr>
<tr><td style="width:144pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Work-in-process</p>
</td><td style="width:6.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:108pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,387</p>
</td><td style="width:8.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:6.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:101pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,022</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:144pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Raw materials</p>
</td><td style="background-color:#CCEEFF;width:6.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:108pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,471</p>
</td><td style="background-color:#CCEEFF;width:8.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:6.5pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:101pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,183</p>
</td></tr>
<tr><td style="width:144pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Total</p>
</td><td style="width:6.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">$</p>
</td><td style="width:108pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">6,304</p>
</td><td style="width:8.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:6.5pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">$</p>
</td><td style="width:101pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">6,913</p>
</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139817350773016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition: Schedule Of Revenues By Product Category (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlockSupplementAbstract', window );"><strong>Tables/Schedules</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ScheduleOfRevenuesByProductCategoryTextBlock', window );">Schedule Of Revenues By Product Category</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0;color:#000000">(6) Global 3Q 2020 revenues (USD) by product category:</p>
<table style="margin:0 auto;border-collapse:collapse;width:100%"><tr><td style="width:180pt" valign="top"/><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Domestic</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Outside US</p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Total</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Obstetrics</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,032</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">247</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,279</p>
</td></tr>
<tr><td style="width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Gynecology/Electrosurgery/Urology</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">2,847</span></p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">2,202</span></p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">5,049</span></p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,151</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">348</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,499</p>
</td></tr>
<tr><td style="width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Blood Pressure Monitoring and Accessories</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">1,920</span></p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">732</span></p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">2,652</span></p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-indent:-19.8pt;margin-left:19.8pt"><span style="font-family:Times New Roman">Total</span></p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">6,950</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,529</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">10,479</p>
</td></tr>
</table>
<p style="font:10pt Times New Roman;margin:0;color:#000000">&#160;</p>
<p style="font:10pt Times New Roman;margin:0">Global 9M 2020 revenues (USD) by product category:</p>
<table style="margin:0 auto;border-collapse:collapse;width:100%"><tr><td style="width:180pt" valign="top"/><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Domestic</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Outside US</p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Total</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Obstetrics</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,739</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">612</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,351</p>
</td></tr>
<tr><td style="width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Gynecology/Electrosurgery/Urology</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">7,686</span></p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">6,945</span></p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">14,631</span></p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Neonatal</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,266</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">1,169</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">4,435</p>
</td></tr>
<tr><td style="width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Blood Pressure Monitoring and Accessories</p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">5,215</span></p>
</td><td style="width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">2,536</span></p>
</td><td style="width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">7,751</span></p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:180pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-indent:-19.8pt;margin-left:19.8pt"><span style="font-family:Times New Roman">Total</span></p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">18,906</p>
</td><td style="background-color:#CCEEFF;width:23.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">11,262</p>
</td><td style="background-color:#CCEEFF;width:28.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:8.65pt;padding-right:5.75pt" valign="top"><p style="font:10pt CG Times;margin:0;text-align:right"><span style="font-family:Times New Roman">$</span></p>
</td><td style="background-color:#CCEEFF;width:54pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">30,168</p>
</td></tr>
</table>
<p style="font:12pt Times New Roman;margin:0">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ScheduleOfRevenuesByProductCategoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the textual narrative disclosure of Schedule Of Revenues By Product Category, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ScheduleOfRevenuesByProductCategoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139817335843048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases: Lease, Cost (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlockSupplementAbstract', window );"><strong>Tables/Schedules</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease, Cost</a></td>
<td class="text"><p style="font:10pt Arial Narrow;margin:0;color:#339966"/>
<table style="border-collapse:collapse;width:100%"><tr style="height:23.85pt"><td style="width:311.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">The components of lease cost were as follows:</p>
</td><td style="width:112.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">Three Months Ended September 30, 2020</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:311.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Operating Lease Cost (<i>in thousands</i>)</p>
</td><td style="background-color:#CCEEFF;width:112.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$15</p>
</td></tr>
<tr><td style="width:311.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Right of Use Assets obtained in exchange for new operating lease Obligations</p>
</td><td style="width:112.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$0</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:311.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:112.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right"/>
</td></tr>
<tr><td style="width:311.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Other Information</p>
</td><td style="width:112.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">Three Months Ended September 30, 2020</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:311.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Weighted Average Remaining Lease Term &#160;- Operating Leases</p>
</td><td style="background-color:#CCEEFF;width:112.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">11 years</p>
</td></tr>
<tr><td style="width:311.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Weighted Average Discount Rate &#8211;&#160;Operating Leases</p>
</td><td style="width:112.5pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">5.4%</p>
</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139817334222520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases: Schedule of Future Minimum Rental Payments for Operating Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlockSupplementAbstract', window );"><strong>Tables/Schedules</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Rental Payments for Operating Leases</a></td>
<td class="text"><table style="border-collapse:collapse;width:100%"><tr style="height:23.85pt"><td style="width:239.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Operating lease liabilities/ payments (<i>in thousands</i>)</p>
</td><td style="width:72pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:239.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Operating lease payments, 2020</p>
</td><td style="background-color:#CCEEFF;width:72pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$60</p>
</td></tr>
<tr><td style="width:239.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Operating lease payments, 2021</p>
</td><td style="width:72pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$60</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:239.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Operating lease payments, 2022</p>
</td><td style="background-color:#CCEEFF;width:72pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$45</p>
</td></tr>
<tr><td style="width:239.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Operating lease payments, 2023</p>
</td><td style="width:72pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$45</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:239.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Operating lease payments, 2024</p>
</td><td style="background-color:#CCEEFF;width:72pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$45</p>
</td></tr>
<tr><td style="width:239.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Thereafter</p>
</td><td style="width:72pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$299</p>
</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139817335815816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases: Reconciliation of operating lease liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlockSupplementAbstract', window );"><strong>Tables/Schedules</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ReconciliationOfOperatingLeaseLiabilitiesTableTextBlock', window );">Reconciliation of operating lease liabilities</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:10pt">&#160;</p>
<table style="border-collapse:collapse;width:100%"><tr style="height:23.85pt"><td style="width:311.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Reconciliation of operating lease liabilities/ payments to operating lease liabilities</p>
</td><td style="width:99pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right"> (<i>in thousands</i>)</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:311.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Total operating lease liabilities/ payments</p>
</td><td style="background-color:#CCEEFF;width:99pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$528</p>
</td></tr>
<tr><td style="width:311.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Operating lease liabilities &#8211;&#160;current (included in Accrued Expenses)</p>
</td><td style="width:99pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$40</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:311.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Operating lease liabilities &#8211;&#160;long term</p>
</td><td style="background-color:#CCEEFF;width:99pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right"><span style="border-bottom:1px solid #000000">$346</span></p>
</td></tr>
<tr><td style="width:311.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Present value adjustment</p>
</td><td style="width:99pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$142</p>
</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ReconciliationOfOperatingLeaseLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reconciliation of operating lease liabilities/ payments to operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ReconciliationOfOperatingLeaseLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139817335866936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases: Lessee, Operating Lease, Liability, Maturity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlockSupplementAbstract', window );"><strong>Tables/Schedules</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity</a></td>
<td class="text"><p style="font:10pt Arial Narrow;margin-top:0pt;margin-bottom:10pt;color:#339966"/>
<table style="border-collapse:collapse;width:100%"><tr><td style="width:239.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Maturities of lease liabilities were as follows:</p>
</td><td style="width:90pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">(<i>in thousands</i>)</p>
</td></tr>
<tr><td style="width:239.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Year ending December 31,</p>
</td><td style="width:90pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:239.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">2020</p>
</td><td style="background-color:#CCEEFF;width:90pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$38</p>
</td></tr>
<tr><td style="width:239.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">2021</p>
</td><td style="width:90pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$40</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:239.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">2022</p>
</td><td style="background-color:#CCEEFF;width:90pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$27</p>
</td></tr>
<tr><td style="width:239.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">2023</p>
</td><td style="width:90pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$29</p>
</td></tr>
<tr><td style="background-color:#CCEEFF;width:239.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">2024</p>
</td><td style="background-color:#CCEEFF;width:90pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$30</p>
</td></tr>
<tr><td style="width:239.4pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Thereafter</p>
</td><td style="width:90pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">$248</p>
</td></tr>
</table>
<p style="font:12pt Times New Roman;margin:0">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139817334155784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlockSupplementAbstract', window );"><strong>Tables/Schedules</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><p style="font:10pt Times New Roman;margin:0"> The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share:</p>
<table style="border-collapse:collapse;width:100%"><tr style="height:12.5pt"><td style="width:257.15pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">(<i>in thousands</i>)</p>
</td><td colspan="3" style="width:269.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Three months ended</p>
</td><td style="width:36.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td colspan="3" style="width:313.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">Nine months ended</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:257.15pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td colspan="3" style="width:269.55pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">September 30,</p>
</td><td style="width:36.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td colspan="3" style="width:313.05pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">September 30,</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:257.15pt;padding-right:5.75pt" valign="top"/><td style="width:109.35pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center">2020</p>
</td><td style="width:31.3pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:128.9pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center">2019</p>
</td><td style="width:36.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:147.35pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center">2020</p>
</td><td style="width:27.6pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:center">&#160;</p>
</td><td style="width:138.1pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:center">2019</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:257.15pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><b>Numerator</b></p>
</td><td style="background-color:#CCEEFF;width:109.35pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:31.3pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:128.9pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:36.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:147.35pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:27.6pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:138.1pt;padding-right:5.75pt;border-top:0.5pt solid #000000" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:11.2pt"><td style="width:257.15pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Net income</p>
</td><td style="width:109.35pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">2,933</p>
</td><td style="width:31.3pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:128.9pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,705</p>
</td><td style="width:36.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:147.35pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">7,386</p>
</td><td style="width:27.6pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:138.1pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">10,369</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:257.15pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:109.35pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:31.3pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:128.9pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:36.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:147.35pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:27.6pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="background-color:#CCEEFF;width:138.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:12pt"><td style="width:257.15pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0"><b>Denominator</b></p>
</td><td style="width:109.35pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:31.3pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:128.9pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:36.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:147.35pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:27.6pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:138.1pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:257.15pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Weighted average shares, basic</p>
</td><td style="background-color:#CCEEFF;width:109.35pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,642</p>
</td><td style="background-color:#CCEEFF;width:31.3pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:128.9pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,720</p>
</td><td style="background-color:#CCEEFF;width:36.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:147.35pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,664</p>
</td><td style="background-color:#CCEEFF;width:27.6pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:138.1pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,722</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:257.15pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Dilutive effect of stock options</p>
</td><td style="width:109.35pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">11</p>
</td><td style="width:31.3pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:128.9pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">17</p>
</td><td style="width:36.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:147.35pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">14</p>
</td><td style="width:27.6pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:138.1pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">16</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:257.15pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Diluted shares</p>
</td><td style="background-color:#CCEEFF;width:109.35pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,653</p>
</td><td style="background-color:#CCEEFF;width:31.3pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:128.9pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,737</p>
</td><td style="background-color:#CCEEFF;width:36.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:147.35pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,678</p>
</td><td style="background-color:#CCEEFF;width:27.6pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:138.1pt;padding-right:5.75pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">3,738</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:257.15pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">&#160;</p>
</td><td style="width:109.35pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:31.3pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:128.9pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:36.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:147.35pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:27.6pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:138.1pt;padding-right:5.75pt;border-top:3px double #000000" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td></tr>
<tr style="height:12.5pt"><td style="background-color:#CCEEFF;width:257.15pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Earnings per share, basic</p>
</td><td style="background-color:#CCEEFF;width:109.35pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">0.81</p>
</td><td style="background-color:#CCEEFF;width:31.3pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:128.9pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">1.00</p>
</td><td style="background-color:#CCEEFF;width:36.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:147.35pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">2.02</p>
</td><td style="background-color:#CCEEFF;width:27.6pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="background-color:#CCEEFF;width:138.1pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">2.79</p>
</td></tr>
<tr style="height:12.5pt"><td style="width:257.15pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0">Earnings per share, diluted</p>
</td><td style="width:109.35pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">0.80</p>
</td><td style="width:31.3pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:128.9pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">0.99</p>
</td><td style="width:36.85pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:147.35pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">2.01</p>
</td><td style="width:27.6pt;padding-right:5.75pt" valign="top"><p style="font:10pt Times New Roman;margin:0;text-align:right">&#160;</p>
</td><td style="width:138.1pt;padding-right:5.75pt" valign="middle"><p style="font:10pt Times New Roman;margin:0;text-align:right">2.77</p>
</td></tr>
</table>
<p style="font:12pt Times New Roman;margin:0">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139817333988040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories: Schedule of Inventory, Current (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,446<span></span>
</td>
<td class="nump">$ 1,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,387<span></span>
</td>
<td class="nump">1,022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,471<span></span>
</td>
<td class="nump">4,183<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="nump">$ 6,304<span></span>
</td>
<td class="nump">$ 6,913<span></span>
</td>
<td class="nump">$ 6,304<span></span>
</td>
<td class="nump">$ 6,913<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139817336405880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">$ 121<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139817335601704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warranty Reserve (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrual', window );">Standard and Extended Product Warranty Accrual</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139817332751032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition: Schedule Of Revenues By Product Category (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">$ 10,479<span></span>
</td>
<td class="nump">$ 12,494<span></span>
</td>
<td class="nump">$ 30,168<span></span>
</td>
<td class="nump">$ 35,073<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fil_ObstetricsMember', window );">Obstetrics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">1,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fil_GynecologyElectrosurgeryUrologyMember', window );">Gynecology/Electrosurgery/Urology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">5,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fil_NeonatalMember', window );">Neonatal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">1,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=fil_BloodPressureMonitoringAndAccessoriesMember', window );">Blood Pressure Monitoring and Accessories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">2,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">6,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember | Obstetrics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">1,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember | Gynecology/Electrosurgery/Urology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">2,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember | Neonatal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">1,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_DomesticUsMember', window );">DomesticUsMember | Blood Pressure Monitoring and Accessories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">1,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">3,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember | Obstetrics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember | Gynecology/Electrosurgery/Urology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">2,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember | Neonatal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fil_OutsideUsMember', window );">OutsideUsMember | Blood Pressure Monitoring and Accessories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales, net</a></td>
<td class="nump">$ 732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fil_ObstetricsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fil_ObstetricsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fil_GynecologyElectrosurgeryUrologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fil_GynecologyElectrosurgeryUrologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fil_NeonatalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fil_NeonatalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=fil_BloodPressureMonitoringAndAccessoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=fil_BloodPressureMonitoringAndAccessoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=fil_DomesticUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=fil_DomesticUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=fil_OutsideUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=fil_OutsideUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139817335636488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_LesseeOperatingLeaseForParkingLotTermOfContract', window );">Lessee Operating Lease for Parking Lot Term of Contract</a></td>
<td class="text">11 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_LesseeOperatingLeaseForAutomobileTermOfContract', window );">Lessee Operating Lease for Automobile Term of Contract</a></td>
<td class="text">16 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_LesseeOperatingLeaseForAutomobileTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the Lessee Operating Lease for Automobile Term of Contract, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_LesseeOperatingLeaseForAutomobileTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_LesseeOperatingLeaseForParkingLotTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the Lessee Operating Lease for Parking Lot Term of Contract, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_LesseeOperatingLeaseForParkingLotTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139817339392840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases: Lease, Cost (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating Lease, Cost</a></td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating Lease, Weighted Average Remaining Lease Term</a></td>
<td class="text">11 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating Lease, Weighted Average Discount Rate, Percent</a></td>
<td class="nump">5.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139817339479432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases: Schedule of Future Minimum Rental Payments for Operating Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">Operating Leases, Future Minimum Payments Due, Next Twelve Months</a></td>
<td class="nump">$ 60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">Operating Leases, Future Minimum Payments, Due in Two Years</a></td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">Operating Leases, Future Minimum Payments, Due in Three Years</a></td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">Operating Leases, Future Minimum Payments, Due in Four Years</a></td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">Operating Leases, Future Minimum Payments, Due in Five Years</a></td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Operating Leases, Future Minimum Payments, Due Thereafter</a></td>
<td class="nump">$ 299<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139817339369720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases: Reconciliation of operating lease liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Lessee, Operating Lease, Liability, to be Paid</a></td>
<td class="nump">$ 528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating Lease, Liability, Current</a></td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability</a></td>
<td class="nump">346<span></span>
</td>
<td class="nump">$ 376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</a></td>
<td class="nump">$ 142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139817339460392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases: Lessee, Operating Lease, Liability, Maturity (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Lessee, Operating Lease, Liability, to be Paid, Year One</a></td>
<td class="nump">$ 38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Lessee, Operating Lease, Liability, to be Paid, Year Two</a></td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">Lessee, Operating Lease, Liability, to be Paid, Year Three</a></td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">Lessee, Operating Lease, Liability, to be Paid, Year Four</a></td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">Lessee, Operating Lease, Liability, to be Paid, Year Five</a></td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Lessee, Operating Lease, Liability, to be Paid, after Year Five</a></td>
<td class="nump">$ 248<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139817349115432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CSI Distribution Agreement Purchase Disclosure (Details) - CooperSurgical Inc<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-lived Intangible Assets Acquired</a></td>
<td class="nump">$ 21,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem', window );">Remaining years of exclusive U.S. distribution rights for Femcare's Filshie Clip System</a></td>
<td class="nump">3.08<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the Remaining years of exclusive U.S. distribution rights for Femcare's Filshie Clip System, during the indicated time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DistributionRightsAcquisitionAxis=fil_CoopersurgicalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_DistributionRightsAcquisitionAxis=fil_CoopersurgicalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139817339595992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 2,933<span></span>
</td>
<td class="nump">$ 3,705<span></span>
</td>
<td class="nump">$ 7,386<span></span>
</td>
<td class="nump">$ 10,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares, basic</a></td>
<td class="nump">3,642<span></span>
</td>
<td class="nump">3,720<span></span>
</td>
<td class="nump">3,664<span></span>
</td>
<td class="nump">3,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive effect of stock options</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted shares</a></td>
<td class="nump">3,653<span></span>
</td>
<td class="nump">3,737<span></span>
</td>
<td class="nump">3,678<span></span>
</td>
<td class="nump">3,738<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share, basic</a></td>
<td class="nump">$ 0.81<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 2.02<span></span>
</td>
<td class="nump">$ 2.79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share, diluted</a></td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="nump">$ 0.99<span></span>
</td>
<td class="nump">$ 2.01<span></span>
</td>
<td class="nump">$ 2.77<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>48
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M@'S$/Y'8ZKUC8J?R(N6K/9D%%QUJ&8E8^,9"</AY$U,1QQ8)>/Q7@G:J9]K
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MC$SRPU#P0"@[ .ZOI#2[$_N :EMU_#]02P,$%     @ QGUF44[Q=%SO!0
M'A<  !@   !X;"]W;W)K<VAE971S+W-H965T,BYX;6R=6-MNVS@0_17"*'9;
M((E%ZF:U3@#73ML ;1/$R>XS(],Q44ET22J7?OV.9$6R18H)]B61Y,/1F=',
MG"&GCT+^4AO&-'K*LT*=CC9:;S^.QRK=L)RJ$[%E!?RR%C*G&F[E_5AM):.K
M>E&>C8GG1>.<\F)T-JV?7<FSJ2AUQ@MV)9$J\YS*Y\\L$X^G(SQZ>7#-[S>Z
M>C ^FV[I/5LR?;N]DG W;JVL>,X*Q46!)%N?CF;XX]RO%]2(?SA[5'O7J'+E
M3HA?U<W%ZG3D58Q8QE)=F:#P[X'-6995EH#'[\;HJ'UGM7#_^L7ZE]IY<.:.
M*C87V;]\I3>GH\D(K=B:EIF^%H_?6.-06-E+1:;JO^BQP7HCE)9*B[Q9# QR
M7NS^TZ<F$'L+<#"P@#0+R%L7^,T"OW9TQZQV:T$U/9M*\8ADA09KU44=FWHU
M>,.+ZC,NM81?.:S39[<WLV_HQ_GB8C[[CJZN+Q>W\YOE$;KX.3]!\\N?R\OO
M%XO9S?D"?9Y]G_V<GZ/EM_/S&W2,;I<+]/[=!_0.\0+=;$2I:+%2T[$&4I7I
M<=H0^+PC0 8(+-GV!/G>$2(>\2S+Y^[E"Y;"<EPMQ\GA\C&$HHT':>-!:GO^
M@+UY*24K-*)*,:T^.BSZK46_MA@,6:1J@_ZB^?831.J!*0U%H*V!VMF):CM5
M^3V<!1%)@NGX83\>%A2))W&+.B 9M"0#)\E9FHH2:#5$A=XP"56:,OY [S*F
MCE#!M(WSSFQXR";N4;: XH#8&8<MX]#)^ )B66@A.;/&,C1>&?E>/Y064()]
M.Z^HY14Y>5W6H4L/TLA&,#+>[4_"'C\3$P2!G5[<THN=]&Z$IMD;Z,7&J\.8
M1%Z/H 453":1G>*DI3AQ4KR2(%)2/R-H*(C]+OFVJIC!#)P8'+ 7A7VF-I2/
M!X*9M$P3][<&GE3SXAYE#*0$NJ*L5 .)-2KA=A?=0>*))0.B'FT3$PR1QE[7
M\CTG[:]"K!YYEEF;M6<&RH\G?H^7%99$>(#:GAKA-U0/+S0M[CDT'D>&-I8.
MD\^/2)^I!182+QQ@VND$)O^'*>0 3=,R+S.JV0K17$C-_]!J9+$Z00QVQR3Q
MHZ3OA0T7),E L\*=.&&W.@VX,9BTC;E](H<\&KXFS/<('NCYN),I[-:I7?MR
M)(4I-=B+O=C("ALN&911W*D2#M\T/V2<WO&,:Y GUQ"!.UG!;EUI%7I+GRM)
MMGIO"D84XK[K)@A<GPPXWND*=@L+\),E9#Q[@AV&LHLR-O6")'&_Y]E0_EY#
M/R38J0IVR\JA\NU]'RM34R^@M?3G&ALJ"(9"V:D*=LO*@JT9L%PA39]:HL_0
M6;ZP/*62H8N+F96TJ18X2?I#A05%,!X(+^E$A;A%9==(,@%BJ)G,7PLP,06$
M8+]?IC84\9,!KIW*D%=4IJ?;;8RM3$T!\8-^SMI \< <1/;V(FZ-:1.!%ZG(
M694/ ]$TY2$,^]EJ Y$!Q2:=@!"W@.S*ZK6O;<K!)#()VE#)P+A#.LT@@;,E
M+[5(?VU$MF)2_5T/E/K9U9-)U^R)>P]R)5\^D*K> 17Z[L3#T*$E>J!9R3XA
M6NH-[%'^ .08A4>>YR&U@1)6GU AFDO$E:HZIY!(E%J!$J\@-:UA-#<L_3G7
M"3ETLY,>XI:>N<AS4;S11^_ R<:U8P3;?,WR.V@1+WO](^0?1<$+M![V83/?
M8)H-?86)"6DPUI!8]E%&<5HP T)/.KTCK^I=.^7MMLM0HEO)-M41UP-[*=GW
MF5#J@Y6Y*7/'&'SNCWXV'$PJ Z,4Z?20N/5PMEKQ:BR%ZMU2OCKF!4KIED,U
M6]F:4F>DGF6/-:"%I--"XM;":Z8I/(*Y@LH"RL*>!!;A\R9A/.DSM.  2 8J
MQ._$SW>+WZX)*DNCL9[SF*J63 +<%VH+#/+#&YKY_4[^?+?\&2V[+KXWL\?&
M 91UQ+;B+"/V>._PLCHY_D'E/2\42/,:%GHG,01 [@YC=S=:;.OSS#NAM<CK
MRPVC0+L"P.]K(?3+375$VAZ)G_T'4$L#!!0    ( ,9]9E%%]BK<QP(  %T)
M   8    >&PO=V]R:W-H965T<R]S:&5E=#,N>&ULG9;;;N(P$(9?Q8KVDB4G
MCE6(1 .K(K4E:FCWVDT&8C6)6=LI[3[]VB;-0AL.A0OB<>;_^688<+P-92\\
M!1#H+<\*/C)2(=97ILGC%'+,VW0-A;RSI"S'0H9L9?(U YQH49Z9CF7US!R3
MPO ]O1<RWZ.ER$@!(4.\S'/,WJ\AHYN181L?&P]DE0JU8?K>&J\@ O&X#IF,
MS-HE(3D4G- ",5B.C+%]%=B6$NB,)P(;OK-&JI1G2E]4,$M&AJ6(((-8* LL
M+Z\00)8I)\GQIS(UZL]4PMWUA_LO7;PLYAES"&CVFR0B'1D# R6PQ&4F'NCF
M!JJ"NLHOIAG7[VA3Y5H&BDLN:%Z))4%.BNT5OU6-V!'8G0,"IQ(XYPK<2N#J
M0K=DNJP)%MCW&-T@IK*EFUKHWFBUK(84ZFN,!)-WB=0)_W$QOD%WT\DL&-^B
M\&$^>0P640O-[H,V"N;WT?QV-ADOIA-T/;X=WP=3%-U,IPOT$X6802%2$"3&
MF8Q_(!/Q5&YRSQ023-F;<05QO85P#D!$L&XCUVHAQW*L!GEP7#Z!6,IM);>'
M^W)3MJ/NB5/WQ-%^[D$_@4G&CSBYM9.KG3H'G$(YD\ 8)"@2-'YIJ:XARF2$
MA=Q\PED)* 2YH3K7U+BM?U_[JY_DJV^U+=LS7W?;<R)I#[U3HW>^AZX1.1J7
M(J6,_(6D"7?KV=TAZ5KZ]8GX=-X>=+>&[EX$/>.\; ;N?@'YC'HL8P^R5T/V
M+H*<EX(+7"2D6#61]DZ2'LO8(^W7I/VCI '-<_E7>^GL]L^9W1-)>]R#FGOP
M#>ZS!G=P:" _-_F,Q#WF8<T\_#9SZ\C@#K]PN+U. V]#7M]Q#N+:UO^#P[H
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M65NPD8W@=S[]\8V@\J7R>(8VK%#>,Z3.310GZMA/A:QZ.S HGK[)S]-G.@1
MOJ>M_,@$^;:/M7 "(,L>6#)!QSP89?[$!(O+U1;]%N>[WU6F/R@)LU."!%Q
M@3GM5.<+8"R-261B+$_?(0#&\6"R!/=)%X_277*I9I?K2PC.D=B<N8!H5$(
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M7\7E4C;$3%==L-4%4!+!DM@@P0[U0M4%2-9W01(7/A&Y9GPM:,+9TD1H=.@
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M$[8EA?IEQ?@FD>J6/W;$EI,D,XTV>0=%4:^S26C1NC@SS^;\XHSM9$X+,N=
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MR>N7&81^2O>+Z-LT&3<^\IQ-GS47(@8!\/G6L\S#0AP,3^7R#U!+ P04
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M:4.-$HTWH/-*TR_8+_P%0^M=_@502P,$%     @ QGUF4=WDQ\J\ P  \@<
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MMJ^@9%61T)JQ@E>>9,)RSW+J277SVWO"V2SSA<J4A[(9"?KOGLQ8.2\]V;R
M-&=EEOYH2L9X6?K6E!7D+,^*_]&6@O&T($Y%5E*-&7%Y;$PZ9U52>H/>6QFX
M)E1B#C_[GN,GDZ!'HN[GG85:C\I-0^&\>QZI5],D^1$^S>,;85JI+'2XH]3D
M8E9$8*89-SE.#V&N;+6C*17,/?T6T/@ .M]ING4GQQ<X_VA6WP%02P,$%
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MOHQ-PQWD!1YN<C.FE^XD%K@@TT[[=!"!#K>C\&)5X6\D<V7I&^(?5W2A1.T
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M32\H6G8@^]'0A!H4WF!ZDW?_ E!+ P04    " #&?691[Q:%_.<!  !5!
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M$6J6H&;_\T>.U7RIA*=A?RB$-;6=L =0PG/G!G3<4%A!4"( !86.QTQR&',
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MN&6ML$^J^X5#/1>.KU#"^"]TO>]%&D#1&JOJ 4P9U%SV)WL?^G  F$5' ,D
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M/'>\;Q0L:P7I&0436&E%A86/*L/LS_S8N>DLI:VE97J1<(ME'X;)6TB3-+G
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M:-Q_?\' M'NC59RNPZPNM:/)#V))JQ:-=R#[2FNW5WR ;GEG?P%02P,$%
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MP"YK,^K)I:/9)'$8%(GDV<3+25<<&BF 94DSQE63VC5_ M6X@6,@CB'.()Y
M/!LZI8-V.%.?5YHY.9M[>?[Z'(;+.V41C><$-XZ([3A*:,D6[UJ?RD#V$2V+
MA;./G7T&[[W=\&QVT 4>_(0TD*M6VFZ,#-IA"%]TL^?5O)O@-TP?./$66))K
M-,ZF >AN*G8;JQH_B?;*TESS8D4_$M3.@,Y+I>QIXP(,OZ;-7U!+ P04
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M+/5/#X0)T.LKSM5V8KK>\!M-_P%02P,$%     @ QGUF488W.P=? @  B 8
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M\X DFHADF(A=XS\"B$0#D8P!8AU\_C[G=_XZ&$3@DO:SPCK;%,FH6MSE;I1
M$2MR>7K?;4:;':_[:I^G-;[ MP_8,+[$MZO3?I9.?]I>>PSY-LD%2NE&367?
M^.HF\M..U>E$LGVU)?/&I&19=;BC84QY*5#7-XS)CY-R@F;?</XO4$L#!!0
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M TI6V)Q#%$P@#,)@!#X_#E]@8>!3"Y]^?@OWC2>#,>%@3.CXHH-\KL(C3-'
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MZ94'F1"028>0]XD'F1*0:9>0J0>Y3T#N=PFY[T$>$) '74(>>) # G+0)>3
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MM[Q3;Q\>I?-CSW.-^[^3ZM"_Z\;MA^7SYN0;'W"V<.:[_P502P,$%     @
MQGUF4>N(NN65 0  @A8  !,   !;0V]N=&5N=%]4>7!E<UTN>&ULS9C-;L(P
M$(1?)<H5$6.[I3\"+FVO+8>^@)ML2$026[:A\/9UPH_4BD8@*G4NL1+OSHR]
MTG?(Y'UKR$6;NFK<-"Z\-X^,N;2@6KE$&VK"3JYMK7QXM0MF5+I4"V)B-!JS
M5#>>&C_TK48\FSQ3KE:5CUXVX;,K=3.-+54NCIYVA:W7-%;&5&6J?-AGZR;[
MX3+<.R2ALZMQ16G<(!3$[*1#N_.[P;[O;4W6EAE%<V7]JZI#%=M4S/EM12[I
MESB14>=YF5*FTU4=6A)G+*G,%42^KI*=Z*#?V8<;IMV37^W?R?09ALJYU<:%
MB5FZW.XPDK9[:((065_V'_'H&*2O/A^UT\XH.],[7.^GMLMN'HYUR_5W_'W&
M1_T+<PB0'!(DQPU(CEN0'&.0''<@.>Y!<CR Y. CE" H1.4H2.4H3.4H4.4H
M5.4H6.4H7.4H8.4H9!4H9!4H9!4H9!4H9!4H9!4H9!4H9!4H9!4H9!4H9)4H
M9)4H9)4H9)4H9)4H9)4H9)7_2=8/K9=__5>T79-:E<W!GW6_GF=?4$L! A0#
M%     @ QGUF40=!36*!    L0   !               ( !     &1O8U!R
M;W!S+V%P<"YX;6Q02P$"% ,4    " #&?691:@?%\NX    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #&?691
MF5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( ,9]9E$R0-KG, 4  &(5   8              "
M@0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #&?691
M3O%T7.\%   >%P  &               @(%S#0  >&PO=V]R:W-H965T<R]S
M:&5E=#(N>&UL4$L! A0#%     @ QGUF447V*MS' @  70D  !@
M     ("!F!,  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (
M ,9]9E% 'FPSM04  -,6   8              " @946  !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6Q02P$"% ,4    " #&?691,8"<394"  ##!@  &
M            @(& '   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#
M%     @ QGUF49T>%=0'"   +C(  !@              ("!2Q\  'AL+W=O
M<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( ,9]9E'"]B16Q@8  "(:
M   8              " @8@G  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q0
M2P$"% ,4    " #&?691T$>JTE<#   V!P  &               @(&$+@
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ QGUF47QG5N=V
M @  BP4  !@              ("!$3(  'AL+W=O<FMS:&5E=',O<VAE970Y
M+GAM;%!+ 0(4 Q0    ( ,9]9E%D-E@'2P(   4%   9              "
M@;TT  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ QGUF
M4>9)7A%S @  A@4  !D              ("!/S<  'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6Q02P$"% ,4    " #&?691W>3'RKP#  #R!P  &0
M        @('I.0  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0
M   ( ,9]9E%B'G-1\ (  '0&   9              " @=P]  !X;"]W;W)K
M<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ QGUF436]'.9#!   K@H
M !D              ("! T$  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q0
M2P$"% ,4    " #&?691\7Z3X^<"   X!@  &0              @(%]10
M>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( ,9]9E'JR\Q-
M7@,  )\'   9              " @9M(  !X;"]W;W)K<VAE971S+W-H965T
M,38N>&UL4$L! A0#%     @ QGUF4>\6A?SG 0  500  !D
M ("!,$P  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " #&
M?6918BVKLW<"  ""!0  &0              @(%.3@  >&PO=V]R:W-H965T
M<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( ,9]9E$I8N7K50(   @%   9
M          " @?Q0  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#
M%     @ QGUF49C V@$2 P  QP8  !D              ("!B%,  'AL+W=O
M<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " #&?691W,"'RY("  "Z
M!0  &0              @('15@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM
M;%!+ 0(4 Q0    ( ,9]9E$7F+N/0 (  ),%   9              " @9I9
M  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ QGUF4?\V
MA0YP @  R 4  !D              ("!$5P  'AL+W=O<FMS:&5E=',O<VAE
M970R,RYX;6Q02P$"% ,4    " #&?691M^SK66 "   E!0  &0
M    @(&X7@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (
M ,9]9E%L/;[E_@(  *8&   9              " @4]A  !X;"]W;W)K<VAE
M971S+W-H965T,C4N>&UL4$L! A0#%     @ QGUF4:U_IH.( @  4@<  !D
M             ("!A&0  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"
M% ,4    " #&?691AC<[!U\"  "(!@  &0              @(%#9P  >&PO
M=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( ,9]9E'8[G.0] $
M % $   9              " @=EI  !X;"]W;W)K<VAE971S+W-H965T,C@N
M>&UL4$L! A0#%     @ QGUF4710V49L!   0Q0  !D              ("!
M!&P  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " #&?691
M=PG26^D!  !_!   &0              @(&G<   >&PO=V]R:W-H965T<R]S
M:&5E=#,P+GAM;%!+ 0(4 Q0    ( ,9]9E'8K5N:>0(  % &   9
M      " @<=R  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%
M  @ QGUF4;P$R!EI @  /0<  !D              ("!=W4  'AL+W=O<FMS
M:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " #&?691W@['PV@"   V!@
M&0              @($7>   >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+
M 0(4 Q0    ( ,9]9E%]<)-\50(  !L'   9              " @;9Z  !X
M;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ QGUF40F1-MIL
M @  ^P0  !D              ("!0GT  'AL+W=O<FMS:&5E=',O<VAE970S
M-2YX;6Q02P$"% ,4    " #&?691'J8(R& #  !\"P  &0
M@('E?P  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( ,9]
M9E&:ZBQ]*P(  'T)   -              "  7R#  !X;"]S='EL97,N>&UL
M4$L! A0#%     @ QGUF49>*NQS     $P(   L              ( !TH4
M %]R96QS+RYR96QS4$L! A0#%     @ QGUF42[^W\%W P  =!@   \
M         ( !NX8  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( ,9]9E'6
M^OFQ> $   ,6   :              "  5^*  !X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( ,9]9E'KB+KEE0$  ((6   3
M      "  0^,  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     L "P ZPL
' -6-      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>83</ContextCount>
  <ElementCount>229</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>11</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="utmd-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000010 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20200930/role/idr_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="utmd-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>000020 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="utmd-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>000030 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEETParenthetical</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="utmd-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>000040 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="utmd-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>000050 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOMEParenthetical</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="utmd-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>000060 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="utmd-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>000070 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW</Role>
      <ShortName>UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="utmd-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>000080 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20200930/role/idr_DisclosureBasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="utmd-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>000090 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20200930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples</Role>
      <ShortName>New Accounting Pronouncements and Changes in Accounting Principles</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="utmd-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>000100 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20200930/role/idr_DisclosureInventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="utmd-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>000110 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20200930/role/idr_DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="utmd-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>000120 - Disclosure - Warranty Reserve</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20200930/role/idr_DisclosureWarrantyReserve</Role>
      <ShortName>Warranty Reserve</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="utmd-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>000130 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20200930/role/idr_DisclosureRevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="utmd-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>000140 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20200930/role/idr_DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="utmd-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>000150 - Disclosure - CSI Distribution Agreement Purchase Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20200930/role/idr_DisclosureCSIDistributionAgreementPurchaseDisclosure</Role>
      <ShortName>CSI Distribution Agreement Purchase Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="utmd-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>000160 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20200930/role/idr_DisclosureEarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="utmd-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>000170 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20200930/role/idr_DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="utmd-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>000180 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20200930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies</Role>
      <ShortName>New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.utahmed.com/20200930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="utmd-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>000190 - Disclosure - Inventories: Schedule of Inventory, Current (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20200930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables</Role>
      <ShortName>Inventories: Schedule of Inventory, Current (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="utmd-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>000200 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20200930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables</Role>
      <ShortName>Revenue Recognition: Schedule Of Revenues By Product Category (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="utmd-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>000210 - Disclosure - Leases: Lease, Cost (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLeaseCostTables</Role>
      <ShortName>Leases: Lease, Cost (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="utmd-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>000220 - Disclosure - Leases: Schedule of Future Minimum Rental Payments for Operating Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20200930/role/idr_DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTables</Role>
      <ShortName>Leases: Schedule of Future Minimum Rental Payments for Operating Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="utmd-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>000230 - Disclosure - Leases: Reconciliation of operating lease liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20200930/role/idr_DisclosureLeasesReconciliationOfOperatingLeaseLiabilitiesTables</Role>
      <ShortName>Leases: Reconciliation of operating lease liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="utmd-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>000240 - Disclosure - Leases: Lessee, Operating Lease, Liability, Maturity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLesseeOperatingLeaseLiabilityMaturityTables</Role>
      <ShortName>Leases: Lessee, Operating Lease, Liability, Maturity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="utmd-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>000250 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20200930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables</Role>
      <ShortName>Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="utmd-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>000260 - Disclosure - Inventories: Schedule of Inventory, Current (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20200930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails</Role>
      <ShortName>Inventories: Schedule of Inventory, Current (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20200930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="utmd-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>000270 - Disclosure - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20200930/role/idr_DisclosureStockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20200930/role/idr_DisclosureStockBasedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="utmd-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>000280 - Disclosure - Warranty Reserve (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20200930/role/idr_DisclosureWarrantyReserveDetails</Role>
      <ShortName>Warranty Reserve (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20200930/role/idr_DisclosureWarrantyReserve</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="utmd-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>000290 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20200930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails</Role>
      <ShortName>Revenue Recognition: Schedule Of Revenues By Product Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20200930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="utmd-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>000300 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20200930/role/idr_DisclosureLeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLeaseCostTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="utmd-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>000310 - Disclosure - Leases: Lease, Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLeaseCostDetails</Role>
      <ShortName>Leases: Lease, Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLeaseCostTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="utmd-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>000320 - Disclosure - Leases: Schedule of Future Minimum Rental Payments for Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20200930/role/idr_DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails</Role>
      <ShortName>Leases: Schedule of Future Minimum Rental Payments for Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20200930/role/idr_DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="utmd-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>000330 - Disclosure - Leases: Reconciliation of operating lease liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20200930/role/idr_DisclosureLeasesReconciliationOfOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Leases: Reconciliation of operating lease liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20200930/role/idr_DisclosureLeasesReconciliationOfOperatingLeaseLiabilitiesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="utmd-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>000340 - Disclosure - Leases: Lessee, Operating Lease, Liability, Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLesseeOperatingLeaseLiabilityMaturityDetails</Role>
      <ShortName>Leases: Lessee, Operating Lease, Liability, Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLesseeOperatingLeaseLiabilityMaturityTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="utmd-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>000350 - Disclosure - CSI Distribution Agreement Purchase Disclosure (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20200930/role/idr_DisclosureCSIDistributionAgreementPurchaseDisclosureDetails</Role>
      <ShortName>CSI Distribution Agreement Purchase Disclosure (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20200930/role/idr_DisclosureCSIDistributionAgreementPurchaseDisclosure</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="utmd-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>000360 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.utahmed.com/20200930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails</Role>
      <ShortName>Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.utahmed.com/20200930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="utmd-20200930.htm">utmd-20200930.htm</File>
    <File>utmd-20200930.xsd</File>
    <File>utmd-20200930_cal.xml</File>
    <File>utmd-20200930_def.xml</File>
    <File>utmd-20200930_lab.xml</File>
    <File>utmd-20200930_pre.xml</File>
    <File>utmd_ex31z1.htm</File>
    <File>utmd_ex31z2.htm</File>
    <File>utmd_ex32z1.htm</File>
    <File>utmd_ex32z2.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>53
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "utmd-20200930.htm": {
   "axisCustom": 1,
   "axisStandard": 3,
   "contextCount": 83,
   "dts": {
    "calculationLink": {
     "local": [
      "utmd-20200930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "utmd-20200930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "utmd-20200930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "utmd-20200930_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "utmd-20200930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "utmd-20200930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 207,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 6,
    "total": 6
   },
   "keyCustom": 6,
   "keyStandard": 223,
   "memberCustom": 7,
   "memberStandard": 4,
   "nsprefix": "fil",
   "nsuri": "http://www.utahmed.com/20200930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D200101_200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000010 - Document - Document and Entity Information",
     "role": "http://www.utahmed.com/20200930/role/idr_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D200101_200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D200101_200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000100 - Disclosure - Inventories",
     "role": "http://www.utahmed.com/20200930/role/idr_DisclosureInventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D200101_200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D200101_200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000110 - Disclosure - Stock-Based Compensation",
     "role": "http://www.utahmed.com/20200930/role/idr_DisclosureStockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D200101_200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D200101_200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProductWarrantyDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000120 - Disclosure - Warranty Reserve",
     "role": "http://www.utahmed.com/20200930/role/idr_DisclosureWarrantyReserve",
     "shortName": "Warranty Reserve",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D200101_200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProductWarrantyDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D200101_200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRecognitionPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000130 - Disclosure - Revenue Recognition",
     "role": "http://www.utahmed.com/20200930/role/idr_DisclosureRevenueRecognition",
     "shortName": "Revenue Recognition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D200101_200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRecognitionPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D200101_200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000140 - Disclosure - Leases",
     "role": "http://www.utahmed.com/20200930/role/idr_DisclosureLeases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D200101_200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D200101_200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000150 - Disclosure - CSI Distribution Agreement Purchase Disclosure",
     "role": "http://www.utahmed.com/20200930/role/idr_DisclosureCSIDistributionAgreementPurchaseDisclosure",
     "shortName": "CSI Distribution Agreement Purchase Disclosure",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D200101_200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D200101_200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000160 - Disclosure - Earnings Per Share",
     "role": "http://www.utahmed.com/20200930/role/idr_DisclosureEarningsPerShare",
     "shortName": "Earnings Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D200101_200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D200101_200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000170 - Disclosure - Subsequent Events",
     "role": "http://www.utahmed.com/20200930/role/idr_DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D200101_200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D200101_200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000180 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)",
     "role": "http://www.utahmed.com/20200930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies",
     "shortName": "New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D200101_200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D200101_200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000190 - Disclosure - Inventories: Schedule of Inventory, Current (Tables)",
     "role": "http://www.utahmed.com/20200930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables",
     "shortName": "Inventories: Schedule of Inventory, Current (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D200101_200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "E20Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000020 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET",
     "role": "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "E20Q3",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D200101_200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fil:ScheduleOfRevenuesByProductCategoryTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000200 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Tables)",
     "role": "http://www.utahmed.com/20200930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables",
     "shortName": "Revenue Recognition: Schedule Of Revenues By Product Category (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D200101_200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fil:ScheduleOfRevenuesByProductCategoryTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D200101_200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000210 - Disclosure - Leases: Lease, Cost (Tables)",
     "role": "http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLeaseCostTables",
     "shortName": "Leases: Lease, Cost (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D200101_200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D200101_200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000220 - Disclosure - Leases: Schedule of Future Minimum Rental Payments for Operating Leases (Tables)",
     "role": "http://www.utahmed.com/20200930/role/idr_DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTables",
     "shortName": "Leases: Schedule of Future Minimum Rental Payments for Operating Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D200101_200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D200101_200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fil:ReconciliationOfOperatingLeaseLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000230 - Disclosure - Leases: Reconciliation of operating lease liabilities (Tables)",
     "role": "http://www.utahmed.com/20200930/role/idr_DisclosureLeasesReconciliationOfOperatingLeaseLiabilitiesTables",
     "shortName": "Leases: Reconciliation of operating lease liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D200101_200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fil:ReconciliationOfOperatingLeaseLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D200101_200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000240 - Disclosure - Leases: Lessee, Operating Lease, Liability, Maturity (Tables)",
     "role": "http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLesseeOperatingLeaseLiabilityMaturityTables",
     "shortName": "Leases: Lessee, Operating Lease, Liability, Maturity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D200101_200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D200101_200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000250 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)",
     "role": "http://www.utahmed.com/20200930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables",
     "shortName": "Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D200101_200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "E19Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000260 - Disclosure - Inventories: Schedule of Inventory, Current (Details)",
     "role": "http://www.utahmed.com/20200930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails",
     "shortName": "Inventories: Schedule of Inventory, Current (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "E19Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "Y19Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000270 - Disclosure - Stock-Based Compensation (Details)",
     "role": "http://www.utahmed.com/20200930/role/idr_DisclosureStockBasedCompensationDetails",
     "shortName": "Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "Y19Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ProductWarrantyAccrual",
       "p",
       "us-gaap:ProductWarrantyDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "E20Q3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProductWarrantyAccrual",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000280 - Disclosure - Warranty Reserve (Details)",
     "role": "http://www.utahmed.com/20200930/role/idr_DisclosureWarrantyReserveDetails",
     "shortName": "Warranty Reserve (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ProductWarrantyAccrual",
       "p",
       "us-gaap:ProductWarrantyDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "E20Q3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProductWarrantyAccrual",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "Y20Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000290 - Disclosure - Revenue Recognition: Schedule Of Revenues By Product Category (Details)",
     "role": "http://www.utahmed.com/20200930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails",
     "shortName": "Revenue Recognition: Schedule Of Revenues By Product Category (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "fil:ScheduleOfRevenuesByProductCategoryTextBlock",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "Y20Q3_ProductOrService-Obstetrics",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "E20Q3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "UsdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000030 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical",
     "role": "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEETParenthetical",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "E20Q3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "UsdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fil:LesseeOperatingLeaseForParkingLotTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000300 - Disclosure - Leases (Details)",
     "role": "http://www.utahmed.com/20200930/role/idr_DisclosureLeasesDetails",
     "shortName": "Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fil:LesseeOperatingLeaseForParkingLotTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "Y20Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000310 - Disclosure - Leases: Lease, Cost (Details)",
     "role": "http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLeaseCostDetails",
     "shortName": "Leases: Lease, Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "Y20Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "E19",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000320 - Disclosure - Leases: Schedule of Future Minimum Rental Payments for Operating Leases (Details)",
     "role": "http://www.utahmed.com/20200930/role/idr_DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails",
     "shortName": "Leases: Schedule of Future Minimum Rental Payments for Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "E19",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "fil:ReconciliationOfOperatingLeaseLiabilitiesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "E20Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000330 - Disclosure - Leases: Reconciliation of operating lease liabilities (Details)",
     "role": "http://www.utahmed.com/20200930/role/idr_DisclosureLeasesReconciliationOfOperatingLeaseLiabilitiesDetails",
     "shortName": "Leases: Reconciliation of operating lease liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "fil:ReconciliationOfOperatingLeaseLiabilitiesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "E20Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "E19",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000340 - Disclosure - Leases: Lessee, Operating Lease, Liability, Maturity (Details)",
     "role": "http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLesseeOperatingLeaseLiabilityMaturityDetails",
     "shortName": "Leases: Lessee, Operating Lease, Liability, Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "E19",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D190101_190930_DistributionRightsAcquisition-CoopersurgicalInc",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000350 - Disclosure - CSI Distribution Agreement Purchase Disclosure (Details)",
     "role": "http://www.utahmed.com/20200930/role/idr_DisclosureCSIDistributionAgreementPurchaseDisclosureDetails",
     "shortName": "CSI Distribution Agreement Purchase Disclosure (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D190101_190930_DistributionRightsAcquisition-CoopersurgicalInc",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "Y20Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000360 - Disclosure - Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details)",
     "role": "http://www.utahmed.com/20200930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
     "shortName": "Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "Y20Q3",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "Y20Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000040 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME",
     "role": "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "Y20Q3",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "Y20Q3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000050 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical",
     "role": "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOMEParenthetical",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "Y20Q3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "E18_StEqComps-CommonStock",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000060 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY",
     "role": "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "E18_StEqComps-CommonStock",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D200101_200930",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000070 - Statement - UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW",
     "role": "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW",
     "shortName": "UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D200101_200930",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D200101_200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000080 - Disclosure - Basis of Presentation",
     "role": "http://www.utahmed.com/20200930/role/idr_DisclosureBasisOfPresentation",
     "shortName": "Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D200101_200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D200101_200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000090 - Disclosure - New Accounting Pronouncements and Changes in Accounting Principles",
     "role": "http://www.utahmed.com/20200930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples",
     "shortName": "New Accounting Pronouncements and Changes in Accounting Principles",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20200930.htm",
      "contextRef": "D200101_200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 11,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Voluntary filer"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "fil_BloodPressureMonitoringAndAccessoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the Blood Pressure Monitoring and Accessories, during the indicated time period.",
        "label": "Blood Pressure Monitoring and Accessories"
       }
      }
     },
     "localname": "BloodPressureMonitoringAndAccessoriesMember",
     "nsuri": "http://www.utahmed.com/20200930",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the monetary amount of Common stock received and retired upon exercise of stock options, during the indicated time period.",
        "label": "Common stock received and retired upon exercise of stock options"
       }
      }
     },
     "localname": "CommonStockReceivedAndRetiredUponExerciseOfStockOptions",
     "nsuri": "http://www.utahmed.com/20200930",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fil_CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the Common stock received and retired upon exercise of stock options, shares (number of shares), during the indicated time period.",
        "label": "Common stock received and retired upon exercise of stock options, shares"
       }
      }
     },
     "localname": "CommonStockReceivedAndRetiredUponExerciseOfStockOptionsShares",
     "nsuri": "http://www.utahmed.com/20200930",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "fil_CoopersurgicalIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the CooperSurgical Inc, during the indicated time period.",
        "label": "CooperSurgical Inc"
       }
      }
     },
     "localname": "CoopersurgicalIncMember",
     "nsuri": "http://www.utahmed.com/20200930",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureCSIDistributionAgreementPurchaseDisclosureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fil_DistributionRightsAcquisitionAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the description of Distribution Rights Acquisition, during the indicated time period.",
        "label": "Distribution Rights Acquisition [Axis]"
       }
      }
     },
     "localname": "DistributionRightsAcquisitionAxis",
     "nsuri": "http://www.utahmed.com/20200930",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureCSIDistributionAgreementPurchaseDisclosureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "fil_DistributionRightsAcquisitionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the Distribution Rights Acquisition, during the indicated time period.",
        "label": "Distribution Rights Acquisition"
       }
      }
     },
     "localname": "DistributionRightsAcquisitionDomain",
     "nsuri": "http://www.utahmed.com/20200930",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureCSIDistributionAgreementPurchaseDisclosureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fil_DomesticUsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the DomesticUsMember, during the indicated time period.",
        "label": "DomesticUsMember"
       }
      }
     },
     "localname": "DomesticUsMember",
     "nsuri": "http://www.utahmed.com/20200930",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fil_GynecologyElectrosurgeryUrologyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the Gynecology/Electrosurgery/Urology, during the indicated time period.",
        "label": "Gynecology/Electrosurgery/Urology"
       }
      }
     },
     "localname": "GynecologyElectrosurgeryUrologyMember",
     "nsuri": "http://www.utahmed.com/20200930",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fil_LesseeOperatingLeaseForAutomobileTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the Lessee Operating Lease for Automobile Term of Contract, during the indicated time period.",
        "label": "Lessee Operating Lease for Automobile Term of Contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseForAutomobileTermOfContract",
     "nsuri": "http://www.utahmed.com/20200930",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "fil_LesseeOperatingLeaseForParkingLotTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the Lessee Operating Lease for Parking Lot Term of Contract, during the indicated time period.",
        "label": "Lessee Operating Lease for Parking Lot Term of Contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseForParkingLotTermOfContract",
     "nsuri": "http://www.utahmed.com/20200930",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "fil_NeonatalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the Neonatal, during the indicated time period.",
        "label": "Neonatal"
       }
      }
     },
     "localname": "NeonatalMember",
     "nsuri": "http://www.utahmed.com/20200930",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fil_ObstetricsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the Obstetrics, during the indicated time period.",
        "label": "Obstetrics"
       }
      }
     },
     "localname": "ObstetricsMember",
     "nsuri": "http://www.utahmed.com/20200930",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fil_OperatingLeaseRightOfUseAssetAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW": {
       "order": 4.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Lease, Right of Use Asset Amortization.",
        "label": "Amortization of Right of Use Assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortization",
     "nsuri": "http://www.utahmed.com/20200930",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fil_OutsideUsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the OutsideUsMember, during the indicated time period.",
        "label": "OutsideUsMember"
       }
      }
     },
     "localname": "OutsideUsMember",
     "nsuri": "http://www.utahmed.com/20200930",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fil_ReconciliationOfOperatingLeaseLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reconciliation of operating lease liabilities/ payments to operating lease liabilities.",
        "label": "Reconciliation of operating lease liabilities"
       }
      }
     },
     "localname": "ReconciliationOfOperatingLeaseLiabilitiesTableTextBlock",
     "nsuri": "http://www.utahmed.com/20200930",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureLeasesReconciliationOfOperatingLeaseLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fil_RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the Remaining years of exclusive U.S. distribution rights for Femcare's Filshie Clip System, during the indicated time period.",
        "label": "Remaining years of exclusive U.S. distribution rights for Femcare's Filshie Clip System"
       }
      }
     },
     "localname": "RemainingYearsOfExclusiveUSDistributionRightsForFemcaresFilshieClipSystem",
     "nsuri": "http://www.utahmed.com/20200930",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureCSIDistributionAgreementPurchaseDisclosureDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "fil_ScheduleOfRevenuesByProductCategoryTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the textual narrative disclosure of Schedule Of Revenues By Product Category, during the indicated time period.",
        "label": "Schedule Of Revenues By Product Category"
       }
      }
     },
     "localname": "ScheduleOfRevenuesByProductCategoryTextBlock",
     "nsuri": "http://www.utahmed.com/20200930",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r112",
      "r144",
      "r145",
      "r216",
      "r235",
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r112",
      "r144",
      "r145",
      "r216",
      "r235",
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r113",
      "r114",
      "r144",
      "r146",
      "r237",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r113",
      "r114",
      "r144",
      "r146",
      "r237",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r12",
      "r116",
      "r117"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts &amp; other receivables, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossBeforeTax1": {
     "auth_ref": [],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of increase (decrease) in accumulated equity from transactions and other events and circumstances from non-owner sources, including portion attributable to noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners (distributions to owners).",
        "label": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossBeforeTax1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r65",
      "r66",
      "r67",
      "r154",
      "r155",
      "r156"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r56",
      "r132"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW": {
       "order": 2.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.",
        "label": "Total adjustments",
        "totalLabel": "Total adjustments"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to reconcile net income to net cash provided by operating activities"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r151",
      "r153",
      "r159"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r62",
      "r101",
      "r104",
      "r110",
      "r119",
      "r181",
      "r185",
      "r191",
      "r222",
      "r228"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Total assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r33",
      "r62",
      "r119",
      "r181",
      "r185",
      "r191"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Total current assets",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r22",
      "r58"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash &amp; investments",
        "periodEndLabel": "Cash at end of period",
        "periodStartLabel": "Cash at beginning of period"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET",
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r52",
      "r193"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Net decrease in cash and cash equivalents",
        "totalLabel": "Net decrease in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r65",
      "r66"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEETParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEETParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEETParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r11",
      "r141"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEETParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock - $.01 par value; authorized - 50,000 shares; issued - September 30, 2020, 3,640 shares and December 31, 2019, 3,722 shares"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income"
       }
      }
     },
     "localname": "ComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r37",
      "r39",
      "r40",
      "r41",
      "r225",
      "r232"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Total comprehensive income",
        "totalLabel": "Total comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r45",
      "r216"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r56",
      "r63",
      "r167",
      "r174",
      "r175",
      "r176"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW": {
       "order": 6.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred income taxes {1}",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r162",
      "r163"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxExpenseFromStockOptionsExercised": {
     "auth_ref": [],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW": {
       "order": 8.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax expense from write-off of the deferred tax asset related to deductible stock options at exercise.",
        "label": "Tax benefit attributable to exercise of stock options"
       }
      }
     },
     "localname": "DeferredTaxExpenseFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r165",
      "r166"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred tax liability - Femcare IIA"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r56",
      "r135"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW": {
       "order": 1.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Notes"
       }
      }
     },
     "localname": "DisclosureTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r142"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Common stock dividends",
        "negatedLabel": "Common stock dividends"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r42",
      "r74",
      "r75",
      "r76",
      "r77",
      "r78",
      "r85",
      "r87",
      "r88",
      "r89",
      "r90",
      "r94",
      "r95",
      "r226",
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings per share, basic",
        "verboseLabel": "Earnings per common share (basic)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r42",
      "r74",
      "r75",
      "r76",
      "r77",
      "r78",
      "r87",
      "r88",
      "r89",
      "r90",
      "r94",
      "r95",
      "r226",
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings per share, diluted",
        "verboseLabel": "Earnings per common share (diluted)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r91",
      "r92",
      "r93",
      "r96"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureEarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r193"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of exchange rate changes on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r65",
      "r66",
      "r67",
      "r71",
      "r79",
      "r81",
      "r97",
      "r120",
      "r141",
      "r142",
      "r154",
      "r155",
      "r156",
      "r168",
      "r169",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r200",
      "r238",
      "r239",
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r131"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Other intangible assets - accumulated amortization",
        "negatedLabel": "Other intangible assets - accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r131",
      "r220"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Other intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r129"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-lived Intangible Assets Acquired"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureCSIDistributionAgreementPurchaseDisclosureDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "auth_ref": [
      "r56",
      "r134",
      "r137"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW": {
       "order": 5.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.",
        "label": "(Gain) loss on disposal of assets",
        "negatedLabel": "(Gain) loss on disposal of assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r126",
      "r127",
      "r221"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r44",
      "r62",
      "r101",
      "r103",
      "r106",
      "r109",
      "r111",
      "r119",
      "r191"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r64",
      "r101",
      "r103",
      "r106",
      "r109",
      "r111"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income before provision for income taxes",
        "totalLabel": "Income before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r63",
      "r80",
      "r81",
      "r100",
      "r164",
      "r173",
      "r177",
      "r234"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r53",
      "r59"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Cash paid during the period for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW": {
       "order": 12.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Accounts payable {1}",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW": {
       "order": 9.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Accounts receivable and other receivables",
        "negatedLabel": "Accounts receivable and other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW": {
       "order": 13.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Accrued expenses {1}",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW": {
       "order": 10.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Inventories {1}",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW": {
       "order": 11.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Prepaid expenses and other current assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "CSI Distribution Agreement Purchase Disclosure"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureCSIDistributionAgreementPurchaseDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r128",
      "r130"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Other intangible assets, net",
        "totalLabel": "Other intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaid": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.",
        "label": "Cash paid during the period for interest"
       }
      }
     },
     "localname": "InterestPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventories {2}",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureInventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r18",
      "r124"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r31"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventories",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails",
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost {1}",
        "terseLabel": "Lease, Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLeaseCostTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLesseeOperatingLeaseLiabilityMaturityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r211"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureLeasesReconciliationOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r211"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLesseeOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r211"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLesseeOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r211"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLesseeOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r211"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLesseeOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r211"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLesseeOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r211"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLesseeOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r211"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureLeasesReconciliationOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r24",
      "r62",
      "r105",
      "r119",
      "r182",
      "r185",
      "r186",
      "r191"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Total liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r17",
      "r62",
      "r119",
      "r191",
      "r223",
      "r230"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Total liabilities and stockholders' equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r26",
      "r62",
      "r119",
      "r182",
      "r185",
      "r186",
      "r191"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Total current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net cash used in financing activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net cash used in investing activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r52",
      "r54",
      "r57"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net cash provided by operating activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r68",
      "r69",
      "r72",
      "r73",
      "r82",
      "r83",
      "r84",
      "r121",
      "r122",
      "r147",
      "r148",
      "r149",
      "r150",
      "r157",
      "r170",
      "r171",
      "r172",
      "r217",
      "r218",
      "r219",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "New Accounting Pronouncements and Changes in Accounting Principles"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciples"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureNewAccountingPronouncementsAndChangesInAccountingPrinciplesNewAccountingPronouncementsPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Total operating expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating expense"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r101",
      "r103",
      "r106",
      "r109",
      "r111"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating income",
        "totalLabel": "Operating income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r206",
      "r212"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r205"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureLeasesReconciliationOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r205"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureLeasesReconciliationOfOperatingLeaseLiabilitiesDetails",
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r204"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating lease - right of use assets, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r209",
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLeaseCostDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r208",
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLeaseCostDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r201",
      "r202"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": {
     "auth_ref": [
      "r201",
      "r202"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Five Years"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r201",
      "r202"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r201",
      "r202"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r201",
      "r202"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Two Years"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": {
     "auth_ref": [
      "r201",
      "r202"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due Thereafter"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Foreign currency translation adjustment",
        "verboseLabel": "Foreign currency translation net of taxes of $0 in all periods"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME",
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "auth_ref": [
      "r34",
      "r35",
      "r192",
      "r199"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOMEParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other long term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Common stock purchased and retired {1}",
        "negatedLabel": "Common stock purchased and retired"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividends": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.",
        "label": "Payment of dividends",
        "negatedLabel": "Payment of dividends"
       }
      }
     },
     "localname": "PaymentsOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Intangible assets",
        "negatedLabel": "Intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Property and equipment",
        "negatedLabel": "Property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PolicyTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Policies"
       }
      }
     },
     "localname": "PolicyTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEETParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEETParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEETParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEETParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred stock - $.01 par value; authorized - 5,000 shares; no shares issued or outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from issuance of common stock - options"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductWarrantyAccrual": {
     "auth_ref": [
      "r138",
      "r139",
      "r224"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.",
        "label": "Standard and Extended Product Warranty Accrual"
       }
      }
     },
     "localname": "ProductWarrantyAccrual",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureWarrantyReserveDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductWarrantyDisclosureTextBlock": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period.",
        "label": "Warranty Reserve"
       }
      }
     },
     "localname": "ProductWarrantyDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureWarrantyReserve"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r36",
      "r38",
      "r51",
      "r62",
      "r70",
      "r80",
      "r81",
      "r101",
      "r103",
      "r106",
      "r109",
      "r111",
      "r119",
      "r180",
      "r183",
      "r184",
      "r188",
      "r189",
      "r191",
      "r227"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net income",
        "totalLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW",
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME",
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r8",
      "r9",
      "r136",
      "r231"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r43",
      "r123"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW": {
       "order": 3.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Provision for (recovery of) losses on accounts receivable"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r161",
      "r256"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research &amp; development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r14",
      "r142",
      "r158",
      "r229",
      "r241",
      "r245"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r65",
      "r66",
      "r67",
      "r71",
      "r79",
      "r81",
      "r120",
      "r154",
      "r155",
      "r156",
      "r168",
      "r169",
      "r238",
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r98",
      "r99",
      "r102",
      "r107",
      "r108",
      "r112",
      "r113",
      "r115",
      "r143",
      "r144",
      "r216"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Sales, net"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails",
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r60",
      "r61"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureRevenueRecognition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r207",
      "r212"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureLeasesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureLeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r7",
      "r19",
      "r20",
      "r21"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureInventoriesScheduleOfInventoryCurrentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW": {
       "order": 7.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDCONDENSEDSTATEMENTOFCASHFLOW"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Equity Balance, shares",
        "periodEndLabel": "Equity Balance, shares",
        "periodStartLabel": "Equity Balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r28",
      "r65",
      "r66",
      "r67",
      "r71",
      "r79",
      "r81",
      "r97",
      "r120",
      "r141",
      "r142",
      "r154",
      "r155",
      "r156",
      "r168",
      "r169",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r200",
      "r238",
      "r239",
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureCSIDistributionAgreementPurchaseDisclosureDetails",
      "http://www.utahmed.com/20200930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails",
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r65",
      "r66",
      "r67",
      "r97",
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureCSIDistributionAgreementPurchaseDisclosureDetails",
      "http://www.utahmed.com/20200930/role/idr_DisclosureRevenueRecognitionScheduleOfRevenuesByProductCategoryDetails",
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r10",
      "r11",
      "r141",
      "r142",
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Common stock issued upon exercise of employee stock options, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r28",
      "r141",
      "r142"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Common stock issued upon exercise of employee stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionPlanExpense": {
     "auth_ref": [
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for option under share-based payment arrangement.",
        "label": "Stock option compensation expense"
       }
      }
     },
     "localname": "StockOptionPlanExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r10",
      "r11",
      "r141",
      "r142"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Common stock purchased and retired, shares"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "auth_ref": [
      "r10",
      "r11",
      "r141",
      "r142"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).",
        "label": "Common stock purchased and retired"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r11",
      "r15",
      "r16",
      "r62",
      "r118",
      "r119",
      "r191"
     ],
     "calculation": {
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Total stockholders' equity",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r62",
      "r65",
      "r66",
      "r67",
      "r71",
      "r79",
      "r119",
      "r120",
      "r142",
      "r154",
      "r155",
      "r156",
      "r168",
      "r169",
      "r178",
      "r179",
      "r187",
      "r191",
      "r194",
      "r195",
      "r200",
      "r239",
      "r240"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Equity Balance, value",
        "periodEndLabel": "Equity Balance, value",
        "periodStartLabel": "Equity Balance, value"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r214",
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TableTextBlockSupplementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Tables/Schedules"
       }
      }
     },
     "localname": "TableTextBlockSupplementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Details"
       }
      }
     },
     "localname": "TextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Dilutive effect of stock options"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r86",
      "r90"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Diluted shares",
        "verboseLabel": "Shares outstanding - diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r85",
      "r90"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted average shares, basic",
        "verboseLabel": "Shares outstanding - basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.utahmed.com/20200930/role/idr_DisclosureEarningsPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
      "http://www.utahmed.com/20200930/role/idr_UTAHMEDICALPRODUCTSINCCONSOLIDATEDSTATEMENTOFINCOME"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(5)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "460",
   "URI": "http://asc.fasb.org/topic&trid=2155896"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30755-110894"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r257": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r258": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r259": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r261": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r262": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r263": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=d3e31137-122693"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=SL108384541-122693"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>54
<FILENAME>0001811884-20-000015-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001811884-20-000015-xbrl.zip
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M!?'+#'7VQ":Z8>T']E WQM3ZY4(!^("2NN[KNMJGJJI;??T=@52OEBJ?-Q&
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M/M&'9+%L0DUB3M@ W5&9*!I1+),,1ESK?3H1]&'86.4@&/D 4K'7D $J@J)
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MF*'<4L5GJ79*':)1AU3GU '_!$0=Y4R^NEF%*6)D+)%Q9__6:PJ<%#@I<!(
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M46<($.( BM P*O@<V_B!K*)3T!6TA;0?70F*HEQ^HXIFFSEHY,B*.=%-JJ+
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MC=R$$*D[ZY%$_B/ZR:>5A$7P!9A)LM?Y"/"T0*92*W[POM3G/>8H33 D*\%
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MJDA--L_BW U,7BY5N$ E9N.58 CJG-3FI)3<EO.>Y:J;L%U*+,I=T^D+<':
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MD419,D+Y,$E4T>A.4Z>3"269B&R0[00<F\H9W4$B53P_1U4;/QF,@7 \@^5
MVJ:<7\&(,C6DGNC+&@6?LQ-H/L$\1J?SEN/@I60]A&6B5$=3+) ;<5H=OMF,
MNP%H#@,8G=CW02!,P&DB1N3T)%J&E_DOMK$NM\_!N!,(YC% @43_?6U=W[;\
M_"Q;F@=#^?.FV1EVK^5?NC?-[>UKWFS*D,W-FX*5LQE"+5_V&!UINT^4HJR>
M/P/BP;7L,W5*!$.V^(S%N.YQ(8<AMEK/4Z4_^4]5#;6AH/B32HX-"0#%@\(3
M;&-XDLQ%=Z1JO?[T#-@,V\ ',CIJTV4M@]G8I6EJ]EKRJDCXF EFE4,CE"6C
MDB)\;)=5%#RC>\Q*H>9\*A-T[4+?)MUN()&@G]G=8P"NJ_:7 )&"J^4JRYE@
M@KE0:LP@4$-7,,O'; ITZSX7JYKEM(/1O:L/'*1EU.FBAAQL7>KO1D[',)UG
M%Z#+T-KHTLYC- G3(DP\J6^@."5!V6*U7 +\!A/*Y+RK100PX,)?8HX^93DM
MNP$QIHXZ+,.%LH<NTCZG!*5OL'MV8R>.#=$AQ.AXXI?3.I30N.3I 26#Z87[
M0(9%C0Y6RPPS)8..$)0,\Z:H\5WOS^@$1O?PE8:!!U[)_$=?7]%1[P#8"2J:
MG9@GK&)T0,[!]16C-(Z2$<JAS-K!NA6@1G>?M/6F:QE \#U9[OZT%T.&"$>V
M;W;B^)\"$)S_>LM@D8'OEAK;+=?8EL4+#+PEKD;(_S>:G4&L)%^W!I^NV]W/
MVUN82&W5D#6*5!E+B0WJ@@C$QS*6S;#4_&IQR]6VM]4LP)*>.4O;[%[@ =_S
MP8PH4QR,G1R/'B,;'](^V)38V+^JY#%(#NG7>>4W;6*GO>+;&MOHF5\#Y'AK
MX[3SEC&2LL\[;Z$;Q#<Q1\VQ(Q%!9D<YCLWJZ?<<TQ1#&=TU?775Y9)2[ ;U
M[L3(<\-#FOIA6<^RYS"GFVM+^P(W$^\1=M,O)DGIJL5X]Q3/@@8T>KO@1X2)
M,D27-#"?4NYO?NR.4H]5IO/L*>@Y#99C9V&)A;V-$U"Y2J]97'N.>*;1DC'_
MV8P./A@C!E<R1CFJ<B7E3LO -,1[#K#.1,FX_F(&KI&SWX$_JI4@?XMTUQ>9
M-^? ;"RURNC6>9ZPYQY0R)C);O'.#+>0!F$J(VG \G>+;%X?JU]ARV;=<T?(
M9[YD#S@W9)#?U"&\ME9?64OG>7&@QPRFJ;$<&PMWC\$482<,:D%$LX@3N3<W
MMQ_D>MB+<Y!\)M9XSHFQGK-VPU;A@2+D>W'^L&$X#?2&%.X2%5B[MZL(^.NL
M+Q'_#?-I7,"0D[Y*_;770/2!"X9M 4[PFHCX%Q'*'C"LMIJMFR$X1=6<VV-$
M[J&/!#1'([!UE85G%J+L[2:EF#SJN$46'8U>6M(HLMS\^!4;')(>\-UK"AC;
MZ/4JC2+7F" Y0CS=:Y(>\-UK"AC;Z#LQEBIV1U&UN^2K#*QQKVVT].+]<"OP
M&;VF)R<A0>YKV5)H!MJ7A>@6Z?,_P,Q=5"EY0&Q!OH"A<J1#)4[E-S3)>4-N
M-M]^ ?RD"W#+Q)51&\#Q3_FT./?4^S2[H^SKF++YS,0U)15;VTF391:CIR^A
M7UY3UH>IQ^3(Q//AFLVXV\#F,(SA/3;0H#MJ8&4!XF3%WBCE7H 74SU':E_=
M^NF6!N:V2[FG!H#5RHYZ ;3CN=*]5J]U#*[+;Z@KQ%S^U%,M3VSM64ZS/%&V
MDJK43WY[:!E2JG?A<&E(_Z8B_W27NAV"S5)*Z=F<I1]9WX0@\86H:<H;/12O
M-/A,V1>UL"<S"^VA(@WQKH"TIJ+1M;J5T'WT<".G[ PC-Q.6&.VNH!)7L$ I
M3#=<!M^K'W<R??KP^O]02P,$%     @ QGUF4?#",5*>"@  KH   !4   !U
M=&UD+3(P,C P.3,P7V1E9BYX;6SM76UWVC@6_MS^"K;S@=US2LC+9*;)F70.
M!=(R)<  F<[LGCT]PA:@K;&H)"?AW\^5P<%@RQ@LO]#M%P*V?/7<YY&EJVM9
M^>77IYE5>L",$VK?E,].3LLE;!O4)/;DIDPXK;QY<WE5.2O_^O;E+_^H5$H]
M1DW'P&9IM"@U&^]K?>X0@4N<CL4C8OAUJ68^(%L6J-/9W!&8E5JV31^0@ KX
M:_AAG+R&<_,%(Y.I*/VS_J_2^>GIF\KYZ?EIZ3^]WI\?KSJ-]L5O__[TQV\?
M?QS^7/OIOR>EQ\?'$VQ.$'-K.S'HK%2I "*+V%^NY<<(<5P"5VQ^\VHJQ/RZ
M6I77/(V8=4+9I I57%2]@J]>OGCAEKU^XF2C_..%5_JL^N==>V!,\0Q5B,V%
M],F]CI-K[AYN4\-U*D:%)64)^:OB%:O(0Y6S\\K%V<D3-]<PQ\3:J,41:#K#
MIN2A*GD[O;HX79>6YO9C(7#%BH>SJZNKJGO65QB,F>*YM-_V975Y<K,PB<#R
MS.S;ER^68B)F,&KA/AZ75E_O^ZU@;<0659/,JJLR5619KTHNTFNQF..;5YS,
MYA;VCDT9'BMA>+ E_9>2^!^DM6I22%/ P0QGA"MP%-OR!M,(,<QZ8LC/IBHF
M'B/'$AH!!VWKA$MGB.BD-V Z.5C73F6&9R/,="+=L+N&Z6'<!JCJ/ZHN2F*R
MSPUJ.."]\/[6;+-I"R(6+7M,V<SM]'8[X(B96?&,NTACVUX[ 4V%V$0>;,//
MC3KQD\"VB4VO5@E?MY,ZV+P?UC[<-1NM>JW=ZW<;]_7AH-6IU[N=0;?=:M2&
MS<:[6KO6J3<''YK-X:&\[EE+%@P?#"DKKGL0K]ABB@4Q4(S10P?QFU463P45
MOC0E&0SA\Z[9&79OX4SWKIF>%,&JBB%!%*Y,J<_HEMA1;T%%R?GF& R[]8\?
MNNU&LS]H_G[?&OZ5B4 AU19.GQ", '&%T:*&'UC9DO,VRLI^HLK^Z&V,^,B-
MMQQ>F2 T=]%5L26X=\2EM')ZMIJH_; Z_'D@D, RFABBD86]&BPTPM9-65&H
MFB_2YE>842_D7)W:\)/7G@C?!3ST&I\?ZU918YL>03#L&5_%Q9L.Q9Q'>3;&
MC,Z4Q'H5T[@>E!P.<.A< D=6N429B=DJ)[*,NJ\-:@MHV$W+M7)3YG@BO^0D
MXI87#7<FH! OO&QJHFW/GW8H%M4*_0(J/%8+=Z3"?#[+1)KE1#Q-;<"1H[NM
MP(49M0>"&E_NW%FU0KE@N?0T\T_RP_6*;'-^G4+<*]K]4S--L@330\1LV74T
M)P)9D6I$7W,4RNQP.URE\]Q4DAXQ/)6=R0-NV1#'X5WWBZ+\4:@3X6ZX,A>Y
M*=/' IS 9A,QF]@3'BF+HO!1:*)R-%R0'W,3Y'DPA6D2;L'7G3'VNF!>B&%\
MF%(+B.-+.:#)6XY\+MBCS&T+0C R@ED<!-M#VJ&V',5!88 R:<%XSC 72B^U
M&,^SB:H5W9QPZ&&Q: /T8(H 6-<1\O&=]$8E=*#<$6@6]*UH(Z_;K%J<.]AL
M.$PV)LP(-?] EH/=<UT7*V\^P<R9<&Q&W8=[V3D"^?;GIFC#M\*%9</4H&^4
MH:,5.)(=??% ,*,Z)I9_3M7'!H8 T:S9)D0GA&'S'J(8#TMW[$>X)5L22\75
M+1$_X<)=YBW<LK'IDV]E[YL4T>,J7,J?\NUEEQA[%@+P<YC:J9/VH86+*]@N
M+\/5^#E?-?IX[C!CBKB_905&\2B)8EHX$MWB\A$NYIN"BQG:B1YDXEN1,[JK
MO,I-SZZ88A:2_VI3SF\IPV1BUQW&L&TLA@S9'!FN +;I_K+<Q50U\W\.%Y*H
M#A;=\1 ]*91/J;+BMY&T6%8D#TYS:TX-\D!,;)O<%U'4$9\J&H2R>/$E57NJ
M$"6_E$Z/T3$1LJTI9/ 5*#[Q?F\45&^E;_0Z@BPKV7"QN91AA?GTY'+]S-2B
M,([<E 5S(Z+H!ZE;'+@+>*I;;@.@+YFL:8+OC69GL+&"IUX;?+AM=S^EMZ0I
MLM9BK&B*"3'!RF["9;-Q&'Z'..'=<0_"#6@?R99T1QK-9"UW3 0ZB.O@QYIA
M4,<6,FICU(:OAGNW<1B)ZU-D3S!OV?XRQ#8(<,F3$YRD\FR%T(-4AV M^P%J
MI8SH$,!O+%M"PVO609 ;E+R3DQ(9>T+@J:DW4-C-EK:=('0P^ DQB,#%H@^]
M#GO R:G;-I@M9^K:=9#5Q]"0'?ACT,G2D^1\A=C,EK)( #I8:V-HPQHZL)6=
M;-D)5*J#D?J@!3^6#\]ET#YAV!U?>JL4R[ID<M;VJ"M;9@\"IH-];\%-#S,W
M:96<XX#%;)F,J%[+(.N,./[JR.6T<AS7<"<'+&8\L*JKSSG,CKBT1RUB+-Q/
M+>%@)BB/)G _Q"7-$;[<L,%T+-P=>P<7RY3I,I&B=P:PL[+<9@A[($LGI%L#
M6)WC[Q;+G4-$'0D\ 4"Z!$E2>=Y!XB%(]463[F>=<FWW1KC9/&)--09]]*W%
MNW4$'+T#WV;.K"\33U8/+=R.[Y:R[APS)+O$Y65ZR4X&(@]I="'6)Z2\(6$(
MLXB;&^B.-VMN$S2"<X+HEF[?:O,0ZW",.KLISC$.KWEQAZ -P5_=75C\*O/I
MW@[!E\:\;WTW;Y^1J7@#0L8&L1R!35T")060[ZSR<+29!<H-^4J-E56D[-56
MP% Y""V];+LVTJ/-%R'WG@ZM6SEK;7PJ[.::D$^'P8-F)]IX3E3[$4SC/*C_
M7]N2<"9\*.'7-D(XM*[X/:83AN93N;U.R#8DT66+O/W(#B]SWA\AGDC+&OW@
M0W>UB"Z;TW8CL5K9LU!J3U-^"S,[(7+<7D2/%MEN*Q+^ZA @P5P0XS[\]?K0
M(GDLG(S5:KQW?().Z6OTX33*%VV)B2-8W"Y1>!(#+J7\_G"LCF,5D'39 &)(
M8F#%"!M:K.B#:[AO:M:+,ZZND,MG:ROL7-F=J\OF.*Y&-:LM><*<+,*0JD6#
MG(?41#(4833MCKC @A$C8AS8+I+70+"SP3P/! &GTAY-.Q@,J[;*"BE0> JW
M'=(WE(83^'YAP\3>HI,%-'1#,#GEGV"VN&?N026O\:XK/-TQW=>W8T:X"N\L
M2DVYBE\F7.XH\$3E6Y( OV8 =NZF;I5:['-UX179BXKO^UXEWSK-S>#=@E!U
MN1,3,L0G(J9UAPN8&K'FTVK[IAKG\B&<J7Z/]1!+Q7^Q[B!^8HUZWU_ (UI>
MP-M^6*PM1[]I+H_GWND\^=A:,J29KX#=7-=#I<G@@2M[-/.=$,41+8E*4\O8
M"W\TJ[=WO85>%95N?Q5C#9#VOFR/.@N[,"H=5>*_BJ--E/VK+.K;2=_\XW'%
M(R0?.WWY[S!YS?CJ$+Z,@H,)^GC7%#E;']/KO+.1D1!#D\-QK\HI5;]7:XLE
ME/X,?L92Y)BQ3TN-(B3RZY1"+R'3AO(!:<LVE&DZ5<D\DB![MK3UEI@*9PNW
M8??1)>)NI?#8DKN,MF >9$\(#"4RJ[22A6'S3.%#K$N+GVJ+QT#:_6\?2W<@
MF/X+(\:[8S?#)S>GNQ\$;QB8I-[BF2%W,;R%>&Y*<-TB\\&"@X\A/8 ^V\55
M4S.'L9Y_?4^EZDZE'OPBA[;)7F($1_+FBP_N2E;Y(?]A_=N7?P-02P,$%
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M.%OE%W>)0S_1]%Q'U_HU'69\0:+#SA0GO6<!\"$4H3/ 0&] 'A6,_92LIE0
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M-W_<K54P\8RR +O9]]!?>%B+LY?*9%;OD?JJDQM<J\.CA!7TH+1:Q$%?,V+
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MBU7Y6K'1S@*G!]E-&NF)L?OJ*!>A;("IWUZWO;2V4A\M-ZFFU(2^"OE5$F_
MGWS]LK:W1@:HO.TU-_>&6RAO*#*HOIB3U1E^P 'AWAKY4BY8$^7O0)<_+8D@
MWXF" ?J=L]E^A[P]$TO V4H3U95,?W!&R<DCNJ\SZ%-CV'4FJW&O5V%W(%'5
MJ4XLK@BLX08SOK>+X+9075%:^9[9F%2)9&:"4 /NU+PKRVL9EK25(0\L58W3
M<+B[\$,_H?(\X%JIW_<1$8:C*5^#HDY7+A#H^(V*;WFZ4EU-5!'7:HAZMLA^
MQD'P8T@>PR5%/PFI1,R316S;%[6'6V@5DH B'BGIZ2^,-BJ(HXRZ)8C2UD+=
M9JLS(-WO),[\.$MPR3(!L9#[F'MW9ZF!9D]^T[V#^AW(W8*V1*"\3B4F*.."
M2FS03XS1WPS=#ACM4<L;  _';N3SPR<[O"OZ_;(.]=IZ+1_<VX%WN-W N1.Q
M_!8LRHE?$JBBB\7MH>N_4A*03TU.'%'JB).W!%#:O:\N]GH#,:YWC;(PF.*E
M/CQES!;SRDA:AB6];NOXL(Q>1*M2(4^_+);&BX9+(/94NFI7\)#=ND76E3O7
M5X*B^*$]E:7.?&:@"[VX=-G.+'<"I F;@]//*^0P9LCR"D8&KQU!PNOY3+3N
MPQCS0Z6'6O9['30-;@LV9P4>P_YK@^5W7(MOCR<]*@Y.G.@9.1M6@C/+0@8U
M_[ZDXR!P2 Q8=T>SZR:.'V*O.(G,7 J<-&!C=897ONN++!@:+\(MO+JRP<R\
M&1>$<S:6P+*]%NHFWE9#U-ME\BE+,A]AYY1X3:4!#OX,N2INX@-:+GCB?TH0
M,8J6P$+4T?+EKU"C/=L++OP 1Z<47_<D$L=O';:"VP8:N1J(W>)T44'8HN&7
M=+MN A!KN^]POOTZF'DN+=(D3N@&@GZ*A-B0OF0@T$]#)A-1?]G>B?.99#>5
M,2JQL@Y+.GIIB C4':R>3$QGA"5V;FMDRM_JS<QT*%6/AJ8A+$SM.]/RY/'_
MQZATJ$IMLU(#7.V+MFUA&6A\?:AH6C/6@C;1LY:@LZNBNL;(6N&.QS+A"I#9
MT-"LPUV9MQD/.WNS%(M[+G>GJZG=>"6&:R?ZA?U*DJZ5&(04>JC$H)(6_M5J
M+$&0LT64[\"E&$QTV%PI!ID>7M8^I*.Z-6HQ:$V'$6HQW#B/'^B(1+X3*$LQ
M'+0U5HFA20+0M:3SB#8%04NPI=5I814&H=Z'P\MA7OQENMT&F'T\%,&]RM>@
M*-*5"Q2?PGC$1TMWC;TTL,[?15<%57BU&IL!?5Y(X+O/.[D4 !.U!GNWR*4
M97A@I.V+&E+TN.:_HJ'XX4 S\_XGC9,\4_8-9MWU WR%DWGHD@V^)#%];B9?
M02^LH'#ML_\0K)?D8D?[J) ,A3BANT$F&WO.?N.E'+:Y>.CN&9'=3M/9R6;9
MG.E3[=4)USON!LP4K+!JB-N!\_SV8KOX>\IL%^\<^M3%!I,<&)$Z.V0M$R=*
M+E]P!\Y#H2=<:_''^%0HK4-ZH!\O-.*=$_NN8*(VMS4=$G$@@9%P" JM#"T3
M=,>(&X0\6/@''-T1<8V&@SZXN<L98X2^XEWYVC+\2_6ABNZHXVG(K:7'S4E.
MP*P2\_#4V?J)$Y1,N,*-HO)%^+9/5S;8)J[@@E@VLBDOP,49688Q?774-U>M
MQFI N\P^T5MSDGE)0[!=1L@;'H1N=5H_<<=K9AFYUGMS%#K+[^XO_-BEF.4[
MI OZK'J%*V\+<0M22@#RW\B)HXPZRL@C3M\2K&CIH.SYHS<,O2/FEM*5@(3_
MV00NRGR,0($1M'#LR_UL&NZ:0@>\L]>\0S5_>]K+O>D9<\JVSJ*C?6%JRU5I
M8<98K!IWV2RKF1^D"?:TRFUWI0:^R('U H+#@C6S<M<#ZR>("\#C?7(1+$,L
M4'6U^PH#"!@THMK%V(LOJ$I82A=V8\2,\:K#G/H] _'4>I*!;$\Y$\0@P4N.
M,38,R6XY:FVJ$;<W4KBUGHX:HJU;#-_(U5-9(&&<1<"Q*2/TRM!XM9?JJ0+Y
M0%<,.=4\7M+AR<EV.>#W#_O->M^Q;WKQVB:Z.([+BKZ:M*JMRC Z8)J#/*=^
M9CV[=9[R!*[O<(A7PMA-U5O@I =Z4L&VT1F+G?G5>3)>K=A@-Z2%BAO[8MG\
MT=1%+1-""Z0-6>.5?N+XL5:R,E4:P6NS-O$$[> +BI9!I;FG]<JH0O6.$"^P
M]SX074PWM#06,5#G;B9D(/N>&/PB B66YJ-N(?:H00[UK@NC' 18&0'?^6=7
MB>Y=.V/8KG(&N;#RE.5[CZJBT%(?".\BMT:^]5;"CXKSJ@*$*&_$S' 8+QU_
MKYUH$?&%Q?OD!"DNKG $J-=Y$SH/6DAG(+-1'G%..5'<H(P7XLRLS9G90D%5
M!+8=OU$PR<51 S!K9A!M!WP-0*NX4OOMZ^,3M*4 >V ,OD-.FJQ)Y/]*@39%
M?SB>'!\?YZYKW_&;.?Y\24' BSFB;XXGB"EM@KZ9_/'W1=/LGID>IK,V)ZS-
MR5O6YM_>O+'3$TZD:@E(ZV,\H/^/ZT9T+$H5,^2.&.+V8&\?E23 &SA&W-;%
M5=GWFD>/UC ,!Z/WA'B/?A (4+/[,Q0D53X03!2T+,-"M8O5H6_496^.%4OL
MII&?/)\_N6NJ/'SE;)H<+!J;01PM9'Q!ER,Y75001HRR)1!0=;SL@:'4>,]I
MG*[3N\!W+P+B5)>*YC;P)$T-'$'&0DX.<7H6C;^PK_4\2R+U]C;RMY'#7/:7
MSYL[4OW4U_\.&?%&3J K@HP@RBA:--Z-/2V/M5BI_25FS/82F2_?7[$3G8?>
M&3U#-0RYL"DH8:."/^C8DKOFYKZ7C#HZ9Z<,2M\B6*A4<)#646<,.N\%XR@I
M[0/I;U7$T$?[6_OWF-Q'SG;M4U$:2OW(VW;%C)8$H*UBB::ZCL^06-'J>@$6
M?>V/X;!WD29IA#_XH;])-S<L=4M09(ZZ(%&U=D4[]ST(;7/.? 9Z:,JU+Q,%
MY;*@3!A42,/SWE1RX=AV9C:J5K';GRGD##>C!+7H+_S0"=V#0&G!M&E! #HW
MVLL*F0!712!^&G.O"K0J^.@%X=O1.ZDU"=K%,69R>S55IVM'Q([@67+IAWA.
M?Q3-O8:&QCQ,:KR->)F@GQA=Q G;LBM2=UWH=M*L]_$"TW/W<@%<1*U-!Z=7
MI# =GNXI0PE&Z$#W$/6\.[8'J5=TH@I3;\+6H+[D+3Q9^_)@[=%SE2]>,4MW
MS3;?%KM\MG3UM,S%$P>4YOU[*D1$S[VA-_,V=&_/8M;H%@'G,HH69[V7P0MV
M*QEAUA#.:8+N,U[<WNX<<+,,?.UT4UOEVP_@@,XA= =+16+_L)P_#T[ #IDS
MNK.-HF<JM=1C1.M=L!M)&PE!E[3L!/,[9[/]CGX('W">&,S@]L!X3S3R4/%.
M.0FZP_=^R%96=@^3O6=_SR0)JHI^81;NH]&C4;QRVFBEYJK3>G(-4$_I*F4^
M44+3:ZF)F4I*A_Q !X!]&2644;4$++(.-Q=0:M!PST-_0S\>;+D*$X$G1F,S
M. 2:^1J P9ZP;9X8LH[7X2#1^'!;B NZF4EPP&I+SL.$:MN_"W"6P(>7CHFP
M=R+806B]"MU M)$/@JV,SY0S0GM.*&.%"EZ6@*V+=JIK5.OALZ]8$+-<7U $
M"0#:FLQ0Q8.J<D. VZZ(T"1S7V#,+8-R5]UUK2O4..ACU1?ZC%FQ+NS-'NC3
M>WSFQSPJ_,9)6/R!*\ERUY:,V=I$^G*;"4/,H5VP13E?5#!&C/,$Y;PM0WA7
MU<E+'[4<\P'OS=*[&/\]I0*</_ DW2K7"V%[\.V82A+0A=B..,JH6X8Z9>=K
M-UY:XS!&*8,+$LTV)$K\7XL234TX$K<W5U1 ( DHWJ1$SS((*?LM3LTO&X(A
M;>D4OC=X2\=W33^9WBST;G#"=KAGO!97EGQ2=EO:A@+<^MY:6F-1>3NF_%X_
MRMA:!L<.^JG;[KL-YRAQG[K5(7JI>-U&'G-AQQF+B865KMOH0Q+ :4M1 YU,
MVF:3:!O/GYUE0]#.GSV8O!HI'*Q.^JV5[WN$5-_9Y>ERXP3!NS3V0US+M"-J
M!;_3;N1JX$J;TT4%84N H.AV_4);K&T[KPYO*6-HP?$]G2$O#P\D'_SVD'.W
M!*1@[4'N#^L#;PG0/](]178/A+WS)Y<VI:>P5+C"=Z/5*^!5/>@;]&7^*!,
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ME[5G0%!0(D@L>5S8M";WBBA"6R&7<(P^T!Y\_]WK9N.'CCZ&IMSC_8YA<\X
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MZ(9QF%B((GE.HPC9'C(:(#P>I]B&PBP(F(>Q(9C&JO(S -<4"_"?)$.B$ZY
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M6IG,+C*,W8&>8H3#I0<70DCDQL'4&(^8Q"1'C*.5,/PU31(687B(9^"J%!W
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MQQ4PM'",)DF@D/C$\(G-SNO4QMT':JGA:=M<JK-WK?Q?X6]02P$"% ,4
M" #&?691DMMU\B.P  !3Q @ $0              @ $     =71M9"TR,#(P
M,#DS,"YH=&U02P$"% ,4    " #&?691!9#/&]D)  "*6@  $0
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M7V5X,S%Z,BYH=&U02P$"% ,4    " #&?691[=[$UF@$  !*#   #P
M        @ '_)@$ =71M9%]E>#,R>C$N:'1M4$L! A0#%     @ QGUF4;6,
M 3Y/!   ,PP   \              ( !E"L! '5T;61?97@S,GHR+FAT;5!+
4!08     "@ * 'X"   0, $    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
